id	sid	tid	token	lemma	pos
10_1101-2020_09_23_308239	1	1	2599906	2599906	CD
10_1101-2020_09_23_308239	1	2	1	1	CD
10_1101-2020_09_23_308239	1	3	The	the	DT
10_1101-2020_09_23_308239	1	4	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	1	5	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	1	6	:	:	:
10_1101-2020_09_23_308239	1	7	A	a	DT
10_1101-2020_09_23_308239	1	8	method	method	NN
10_1101-2020_09_23_308239	1	9	for	for	IN
10_1101-2020_09_23_308239	1	10	the	the	DT
10_1101-2020_09_23_308239	1	11	rational	rational	JJ
10_1101-2020_09_23_308239	1	12	selection	selection	NN
10_1101-2020_09_23_308239	1	13	of	of	IN
10_1101-2020_09_23_308239	1	14	drug	drug	NN
10_1101-2020_09_23_308239	1	15	repurposing	repurposing	NN
10_1101-2020_09_23_308239	1	16	candidates	candidate	NNS
10_1101-2020_09_23_308239	1	17	from	from	IN
10_1101-2020_09_23_308239	1	18	multimodal	multimodal	JJ
10_1101-2020_09_23_308239	1	19	knowledge	knowledge	NN
10_1101-2020_09_23_308239	1	20	harmonization	harmonization	NN
10_1101-2020_09_23_308239	1	21	Bruce	Bruce	NNP
10_1101-2020_09_23_308239	1	22	Schultz1	Schultz1	NNP
10_1101-2020_09_23_308239	1	23	,	,	,
10_1101-2020_09_23_308239	1	24	Andrea	Andrea	NNP
10_1101-2020_09_23_308239	1	25	Zaliani2,3	zaliani2,3	CD
10_1101-2020_09_23_308239	1	26	,	,	,
10_1101-2020_09_23_308239	1	27	Christian	Christian	NNP
10_1101-2020_09_23_308239	1	28	Ebeling1	Ebeling1	NNP
10_1101-2020_09_23_308239	1	29	,	,	,
10_1101-2020_09_23_308239	1	30	Jeanette	Jeanette	NNP
10_1101-2020_09_23_308239	1	31	Reinshagen2,3	reinshagen2,3	CD
10_1101-2020_09_23_308239	1	32	,	,	,
10_1101-2020_09_23_308239	1	33	Denisa	Denisa	NNP
10_1101-2020_09_23_308239	1	34	Bojkova11	Bojkova11	NNP
10_1101-2020_09_23_308239	1	35	,	,	,
10_1101-2020_09_23_308239	1	36	Vanessa	Vanessa	NNP
10_1101-2020_09_23_308239	1	37	Lage	Lage	NNP
10_1101-2020_09_23_308239	1	38	-	-	HYPH
10_1101-2020_09_23_308239	1	39	Rupprecht1	Rupprecht1	NNP
10_1101-2020_09_23_308239	1	40	,	,	,
10_1101-2020_09_23_308239	1	41	Reagon	Reagon	NNP
10_1101-2020_09_23_308239	1	42	Karki1	Karki1	NNP
10_1101-2020_09_23_308239	1	43	,	,	,
10_1101-2020_09_23_308239	1	44	Sören	Sören	NNP
10_1101-2020_09_23_308239	1	45	Lukassen7	Lukassen7	NNP
10_1101-2020_09_23_308239	1	46	,	,	,
10_1101-2020_09_23_308239	1	47	Yojana	Yojana	NNP
10_1101-2020_09_23_308239	1	48	Gadiya1	Gadiya1	NNP
10_1101-2020_09_23_308239	1	49	,	,	,
10_1101-2020_09_23_308239	1	50	Neal	Neal	NNP
10_1101-2020_09_23_308239	1	51	G.	G.	NNP
10_1101-2020_09_23_308239	1	52	Ravindra8	Ravindra8	NNP
10_1101-2020_09_23_308239	1	53	,	,	,
10_1101-2020_09_23_308239	1	54	Sayoni	Sayoni	NNP
10_1101-2020_09_23_308239	1	55	Das4	Das4	NNP
10_1101-2020_09_23_308239	1	56	,	,	,
10_1101-2020_09_23_308239	1	57	Shounak	Shounak	NNP
10_1101-2020_09_23_308239	1	58	Baksi6	Baksi6	NNP
10_1101-2020_09_23_308239	1	59	,	,	,
10_1101-2020_09_23_308239	1	60	Daniel	Daniel	NNP
10_1101-2020_09_23_308239	1	61	Domingo	Domingo	NNP
10_1101-2020_09_23_308239	1	62	-	-	HYPH
10_1101-2020_09_23_308239	1	63	Fernández1	Fernández1	NNP
10_1101-2020_09_23_308239	1	64	,	,	,
10_1101-2020_09_23_308239	1	65	Manuel	Manuel	NNP
10_1101-2020_09_23_308239	1	66	Lentzen1	Lentzen1	NNP
10_1101-2020_09_23_308239	1	67	,	,	,
10_1101-2020_09_23_308239	1	68	Mark	Mark	NNP
10_1101-2020_09_23_308239	1	69	Strivens4	Strivens4	NNP
10_1101-2020_09_23_308239	1	70	,	,	,
10_1101-2020_09_23_308239	1	71	Tamara	Tamara	NNP
10_1101-2020_09_23_308239	1	72	Raschka1	Raschka1	NNP
10_1101-2020_09_23_308239	1	73	,	,	,
10_1101-2020_09_23_308239	1	74	Jindrich	Jindrich	NNP
10_1101-2020_09_23_308239	1	75	Cinatl11	Cinatl11	NNP
10_1101-2020_09_23_308239	1	76	,	,	,
10_1101-2020_09_23_308239	1	77	Lauren	Lauren	NNP
10_1101-2020_09_23_308239	1	78	Nicole	Nicole	NNP
10_1101-2020_09_23_308239	1	79	DeLong1	DeLong1	NNP
10_1101-2020_09_23_308239	1	80	,	,	,
10_1101-2020_09_23_308239	1	81	Phil	Phil	NNP
10_1101-2020_09_23_308239	1	82	Gribbon2,3	gribbon2,3	CD
10_1101-2020_09_23_308239	1	83	,	,	,
10_1101-2020_09_23_308239	1	84	Gerd	Gerd	NNP
10_1101-2020_09_23_308239	1	85	Geisslinger3,9,10	geisslinger3,9,10	NN
10_1101-2020_09_23_308239	1	86	,	,	,
10_1101-2020_09_23_308239	1	87	Sandra	Sandra	NNP
10_1101-2020_09_23_308239	1	88	Ciesek10,11,12	Ciesek10,11,12	NNP
10_1101-2020_09_23_308239	1	89	David	David	NNP
10_1101-2020_09_23_308239	1	90	van	van	NNP
10_1101-2020_09_23_308239	1	91	Dijk8	dijk8	NN
10_1101-2020_09_23_308239	1	92	,	,	,
10_1101-2020_09_23_308239	1	93	Steve	Steve	NNP
10_1101-2020_09_23_308239	1	94	Gardner4	Gardner4	NNP
10_1101-2020_09_23_308239	1	95	,	,	,
10_1101-2020_09_23_308239	1	96	Alpha	Alpha	NNP
10_1101-2020_09_23_308239	1	97	Tom	Tom	NNP
10_1101-2020_09_23_308239	1	98	Kodamullil1	Kodamullil1	NNP
10_1101-2020_09_23_308239	1	99	,	,	,
10_1101-2020_09_23_308239	1	100	Holger	Holger	NNP
10_1101-2020_09_23_308239	1	101	Fröhlich1	Fröhlich1	NNP
10_1101-2020_09_23_308239	1	102	,	,	,
10_1101-2020_09_23_308239	1	103	Manuel	Manuel	NNP
10_1101-2020_09_23_308239	1	104	Peitsch5	Peitsch5	NNP
10_1101-2020_09_23_308239	1	105	,	,	,
10_1101-2020_09_23_308239	1	106	Marc	Marc	NNP
10_1101-2020_09_23_308239	1	107	Jacobs1	Jacobs1	NNP
10_1101-2020_09_23_308239	1	108	,	,	,
10_1101-2020_09_23_308239	1	109	Julia	Julia	NNP
10_1101-2020_09_23_308239	1	110	Hoeng5	Hoeng5	NNP
10_1101-2020_09_23_308239	1	111	,	,	,
10_1101-2020_09_23_308239	1	112	Roland	Roland	NNP
10_1101-2020_09_23_308239	1	113	Eils7	eils7	NN
10_1101-2020_09_23_308239	1	114	,	,	,
10_1101-2020_09_23_308239	1	115	Carsten	Carsten	NNP
10_1101-2020_09_23_308239	1	116	Claussen2,3	claussen2,3	CD
10_1101-2020_09_23_308239	1	117	and	and	CC
10_1101-2020_09_23_308239	1	118	Martin	Martin	NNP
10_1101-2020_09_23_308239	1	119	Hofmann	Hofmann	NNP
10_1101-2020_09_23_308239	1	120	-	-	HYPH
10_1101-2020_09_23_308239	1	121	Apitius*1	Apitius*1	NNP
10_1101-2020_09_23_308239	1	122	1	1	CD
10_1101-2020_09_23_308239	1	123	Fraunhofer	Fraunhofer	NNP
10_1101-2020_09_23_308239	1	124	Institute	Institute	NNP
10_1101-2020_09_23_308239	1	125	for	for	IN
10_1101-2020_09_23_308239	1	126	Algorithms	Algorithms	NNP
10_1101-2020_09_23_308239	1	127	and	and	CC
10_1101-2020_09_23_308239	1	128	Scientific	Scientific	NNP
10_1101-2020_09_23_308239	1	129	Computing	Computing	NNP
10_1101-2020_09_23_308239	1	130	SCAI	SCAI	NNP
10_1101-2020_09_23_308239	1	131	,	,	,
10_1101-2020_09_23_308239	1	132	Department	Department	NNP
10_1101-2020_09_23_308239	1	133	of	of	IN
10_1101-2020_09_23_308239	1	134	Bioinformatics	Bioinformatics	NNP
10_1101-2020_09_23_308239	1	135	,	,	,
10_1101-2020_09_23_308239	1	136	Institutszentrum	Institutszentrum	NNP
10_1101-2020_09_23_308239	1	137	Birlinghoven	Birlinghoven	NNP
10_1101-2020_09_23_308239	1	138	,	,	,
10_1101-2020_09_23_308239	1	139	53754	53754	CD
10_1101-2020_09_23_308239	1	140	Sankt	Sankt	NNP
10_1101-2020_09_23_308239	1	141	Augustin	Augustin	NNP
10_1101-2020_09_23_308239	1	142	,	,	,
10_1101-2020_09_23_308239	1	143	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	144	2	2	CD
10_1101-2020_09_23_308239	1	145	Fraunhofer	Fraunhofer	NNP
10_1101-2020_09_23_308239	1	146	Institute	Institute	NNP
10_1101-2020_09_23_308239	1	147	for	for	IN
10_1101-2020_09_23_308239	1	148	Translational	Translational	NNP
10_1101-2020_09_23_308239	1	149	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	1	150	and	and	CC
10_1101-2020_09_23_308239	1	151	Pharmacology	Pharmacology	NNP
10_1101-2020_09_23_308239	1	152	ITMP	ITMP	NNP
10_1101-2020_09_23_308239	1	153	,	,	,
10_1101-2020_09_23_308239	1	154	ScreeningPort	ScreeningPort	NNP
10_1101-2020_09_23_308239	1	155	,	,	,
10_1101-2020_09_23_308239	1	156	22525	22525	CD
10_1101-2020_09_23_308239	1	157	Hamburg	Hamburg	NNP
10_1101-2020_09_23_308239	1	158	,	,	,
10_1101-2020_09_23_308239	1	159	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	160	3	3	CD
10_1101-2020_09_23_308239	1	161	Fraunhofer	Fraunhofer	NNP
10_1101-2020_09_23_308239	1	162	Cluster	Cluster	NNP
10_1101-2020_09_23_308239	1	163	of	of	IN
10_1101-2020_09_23_308239	1	164	Excellence	Excellence	NNP
10_1101-2020_09_23_308239	1	165	for	for	IN
10_1101-2020_09_23_308239	1	166	Immune	Immune	NNP
10_1101-2020_09_23_308239	1	167	Mediated	Mediated	NNP
10_1101-2020_09_23_308239	1	168	Diseases	Diseases	NNP
10_1101-2020_09_23_308239	1	169	,	,	,
10_1101-2020_09_23_308239	1	170	CIMD	CIMD	NNP
10_1101-2020_09_23_308239	1	171	,	,	,
10_1101-2020_09_23_308239	1	172	External	external	JJ
10_1101-2020_09_23_308239	1	173	partner	partner	NN
10_1101-2020_09_23_308239	1	174	site	site	NN
10_1101-2020_09_23_308239	1	175	,	,	,
10_1101-2020_09_23_308239	1	176	22525	22525	CD
10_1101-2020_09_23_308239	1	177	Hamburg	Hamburg	NNP
10_1101-2020_09_23_308239	1	178	,	,	,
10_1101-2020_09_23_308239	1	179	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	180	4	4	CD
10_1101-2020_09_23_308239	1	181	PrecisionLife	PrecisionLife	NNP
10_1101-2020_09_23_308239	1	182	Ltd.	Ltd.	NNP
10_1101-2020_09_23_308239	1	183	Unit	Unit	NNP
10_1101-2020_09_23_308239	1	184	8b	8b	NNP
10_1101-2020_09_23_308239	1	185	Bankside	Bankside	NNP
10_1101-2020_09_23_308239	1	186	,	,	,
10_1101-2020_09_23_308239	1	187	Hanborough	Hanborough	NNP
10_1101-2020_09_23_308239	1	188	Business	Business	NNP
10_1101-2020_09_23_308239	1	189	Park	Park	NNP
10_1101-2020_09_23_308239	1	190	,	,	,
10_1101-2020_09_23_308239	1	191	Long	Long	NNP
10_1101-2020_09_23_308239	1	192	Hanborough	Hanborough	NNP
10_1101-2020_09_23_308239	1	193	,	,	,
10_1101-2020_09_23_308239	1	194	Oxfordshire	Oxfordshire	NNP
10_1101-2020_09_23_308239	1	195	,	,	,
10_1101-2020_09_23_308239	1	196	OX29	OX29	NNP
10_1101-2020_09_23_308239	1	197	8LJ	8LJ	NNP
10_1101-2020_09_23_308239	1	198	,	,	,
10_1101-2020_09_23_308239	1	199	United	United	NNP
10_1101-2020_09_23_308239	1	200	Kingdom	Kingdom	NNP
10_1101-2020_09_23_308239	1	201	5	5	CD
10_1101-2020_09_23_308239	1	202	Philipp	Philipp	NNP
10_1101-2020_09_23_308239	1	203	Morris	Morris	NNP
10_1101-2020_09_23_308239	1	204	International	International	NNP
10_1101-2020_09_23_308239	1	205	R&D	r&d	NN
10_1101-2020_09_23_308239	1	206	,	,	,
10_1101-2020_09_23_308239	1	207	Biological	Biological	NNP
10_1101-2020_09_23_308239	1	208	Systems	Systems	NNPS
10_1101-2020_09_23_308239	1	209	Research	Research	NNP
10_1101-2020_09_23_308239	1	210	,	,	,
10_1101-2020_09_23_308239	1	211	R&D	R&D	NNP
10_1101-2020_09_23_308239	1	212	Innovation	Innovation	NNP
10_1101-2020_09_23_308239	1	213	Cube	Cube	NNP
10_1101-2020_09_23_308239	1	214	T1517.07	t1517.07	NN
10_1101-2020_09_23_308239	1	215	,	,	,
10_1101-2020_09_23_308239	1	216	Quai	Quai	NNP
10_1101-2020_09_23_308239	1	217	Jeanrenaud	Jeanrenaud	NNP
10_1101-2020_09_23_308239	1	218	5	5	CD
10_1101-2020_09_23_308239	1	219	,	,	,
10_1101-2020_09_23_308239	1	220	CH-2000	CH-2000	NNP
10_1101-2020_09_23_308239	1	221	Neuchatel	Neuchatel	NNP
10_1101-2020_09_23_308239	1	222	,	,	,
10_1101-2020_09_23_308239	1	223	Switzerland	Switzerland	NNP
10_1101-2020_09_23_308239	1	224	6	6	CD
10_1101-2020_09_23_308239	1	225	Causality	Causality	NNP
10_1101-2020_09_23_308239	1	226	BioModels	BioModels	NNP
10_1101-2020_09_23_308239	1	227	Pvt	Pvt	NNP
10_1101-2020_09_23_308239	1	228	Ltd.	Ltd.	NNP
10_1101-2020_09_23_308239	1	229	,	,	,
10_1101-2020_09_23_308239	1	230	Kinfra	Kinfra	NNP
10_1101-2020_09_23_308239	1	231	Hi	Hi	NNP
10_1101-2020_09_23_308239	1	232	-	-	HYPH
10_1101-2020_09_23_308239	1	233	Tech	Tech	NNP
10_1101-2020_09_23_308239	1	234	Park	Park	NNP
10_1101-2020_09_23_308239	1	235	,	,	,
10_1101-2020_09_23_308239	1	236	Kerala	Kerala	NNP
10_1101-2020_09_23_308239	1	237	technology	technology	NN
10_1101-2020_09_23_308239	1	238	Innovation	Innovation	NNP
10_1101-2020_09_23_308239	1	239	Zone-	Zone-	NNP
10_1101-2020_09_23_308239	1	240	KTIZ	KTIZ	NNP
10_1101-2020_09_23_308239	1	241	,	,	,
10_1101-2020_09_23_308239	1	242	Kalamassery	Kalamassery	NNP
10_1101-2020_09_23_308239	1	243	,	,	,
10_1101-2020_09_23_308239	1	244	Cochin	Cochin	NNP
10_1101-2020_09_23_308239	1	245	,	,	,
10_1101-2020_09_23_308239	1	246	683503-India	683503-India	NNP
10_1101-2020_09_23_308239	1	247	7	7	CD
10_1101-2020_09_23_308239	1	248	Center	Center	NNP
10_1101-2020_09_23_308239	1	249	for	for	IN
10_1101-2020_09_23_308239	1	250	Digital	Digital	NNP
10_1101-2020_09_23_308239	1	251	Health	Health	NNP
10_1101-2020_09_23_308239	1	252	,	,	,
10_1101-2020_09_23_308239	1	253	Charité	Charité	NNP
10_1101-2020_09_23_308239	1	254	Universitätsmedizin	Universitätsmedizin	NNP
10_1101-2020_09_23_308239	1	255	Berlin	Berlin	NNP
10_1101-2020_09_23_308239	1	256	&	&	CC
10_1101-2020_09_23_308239	1	257	Berlin	Berlin	NNP
10_1101-2020_09_23_308239	1	258	Institute	Institute	NNP
10_1101-2020_09_23_308239	1	259	of	of	IN
10_1101-2020_09_23_308239	1	260	Health	Health	NNP
10_1101-2020_09_23_308239	1	261	(	(	-LRB-
10_1101-2020_09_23_308239	1	262	BIH	BIH	NNP
10_1101-2020_09_23_308239	1	263	)	)	-RRB-
10_1101-2020_09_23_308239	1	264	8	8	CD
10_1101-2020_09_23_308239	1	265	Center	Center	NNP
10_1101-2020_09_23_308239	1	266	for	for	IN
10_1101-2020_09_23_308239	1	267	Biomedical	Biomedical	NNP
10_1101-2020_09_23_308239	1	268	Data	Data	NNP
10_1101-2020_09_23_308239	1	269	Science	Science	NNP
10_1101-2020_09_23_308239	1	270	,	,	,
10_1101-2020_09_23_308239	1	271	Yale	Yale	NNP
10_1101-2020_09_23_308239	1	272	School	School	NNP
10_1101-2020_09_23_308239	1	273	of	of	IN
10_1101-2020_09_23_308239	1	274	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	1	275	,	,	,
10_1101-2020_09_23_308239	1	276	Yale	Yale	NNP
10_1101-2020_09_23_308239	1	277	University	University	NNP
10_1101-2020_09_23_308239	1	278	,	,	,
10_1101-2020_09_23_308239	1	279	333	333	CD
10_1101-2020_09_23_308239	1	280	Cedar	Cedar	NNP
10_1101-2020_09_23_308239	1	281	Street	Street	NNP
10_1101-2020_09_23_308239	1	282	,	,	,
10_1101-2020_09_23_308239	1	283	New	New	NNP
10_1101-2020_09_23_308239	1	284	Haven	Haven	NNP
10_1101-2020_09_23_308239	1	285	,	,	,
10_1101-2020_09_23_308239	1	286	CT	CT	NNP
10_1101-2020_09_23_308239	1	287	06510	06510	CD
10_1101-2020_09_23_308239	1	288	,	,	,
10_1101-2020_09_23_308239	1	289	USA	USA	NNP
10_1101-2020_09_23_308239	1	290	9	9	CD
10_1101-2020_09_23_308239	1	291	Pharmazentrum	Pharmazentrum	NNP
10_1101-2020_09_23_308239	1	292	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	293	/	/	SYM
10_1101-2020_09_23_308239	1	294	ZAFES	ZAFES	NNP
10_1101-2020_09_23_308239	1	295	,	,	,
10_1101-2020_09_23_308239	1	296	Institut	Institut	NNP
10_1101-2020_09_23_308239	1	297	für	für	NN
10_1101-2020_09_23_308239	1	298	Klinische	Klinische	NNP
10_1101-2020_09_23_308239	1	299	Pharmakologie	Pharmakologie	NNP
10_1101-2020_09_23_308239	1	300	,	,	,
10_1101-2020_09_23_308239	1	301	Klinikum	Klinikum	NNP
10_1101-2020_09_23_308239	1	302	der	der	VBD
10_1101-2020_09_23_308239	1	303	Goethe	Goethe	NNP
10_1101-2020_09_23_308239	1	304	-	-	HYPH
10_1101-2020_09_23_308239	1	305	Universität	Universität	NNP
10_1101-2020_09_23_308239	1	306	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	307	,	,	,
10_1101-2020_09_23_308239	1	308	60590	60590	CD
10_1101-2020_09_23_308239	1	309	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	310	am	be	VBP
10_1101-2020_09_23_308239	1	311	Main	Main	NNP
10_1101-2020_09_23_308239	1	312	,	,	,
10_1101-2020_09_23_308239	1	313	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	314	10	10	CD
10_1101-2020_09_23_308239	1	315	Fraunhofer	Fraunhofer	NNP
10_1101-2020_09_23_308239	1	316	Institute	Institute	NNP
10_1101-2020_09_23_308239	1	317	for	for	IN
10_1101-2020_09_23_308239	1	318	Translational	Translational	NNP
10_1101-2020_09_23_308239	1	319	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	1	320	and	and	CC
10_1101-2020_09_23_308239	1	321	Pharmacology	Pharmacology	NNP
10_1101-2020_09_23_308239	1	322	ITMP	ITMP	NNP
10_1101-2020_09_23_308239	1	323	,	,	,
10_1101-2020_09_23_308239	1	324	,	,	,
10_1101-2020_09_23_308239	1	325	60596	60596	CD
10_1101-2020_09_23_308239	1	326	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	327	am	be	VBP
10_1101-2020_09_23_308239	1	328	Main	Main	NNP
10_1101-2020_09_23_308239	1	329	,	,	,
10_1101-2020_09_23_308239	1	330	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	331	11	11	CD
10_1101-2020_09_23_308239	1	332	Institute	Institute	NNP
10_1101-2020_09_23_308239	1	333	for	for	IN
10_1101-2020_09_23_308239	1	334	Medical	Medical	NNP
10_1101-2020_09_23_308239	1	335	Virology	Virology	NNP
10_1101-2020_09_23_308239	1	336	,	,	,
10_1101-2020_09_23_308239	1	337	University	University	NNP
10_1101-2020_09_23_308239	1	338	Hospital	Hospital	NNP
10_1101-2020_09_23_308239	1	339	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	340	,	,	,
10_1101-2020_09_23_308239	1	341	60590	60590	CD
10_1101-2020_09_23_308239	1	342	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	343	am	be	VBP
10_1101-2020_09_23_308239	1	344	Main	Main	NNP
10_1101-2020_09_23_308239	1	345	,	,	,
10_1101-2020_09_23_308239	1	346	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	347	12	12	CD
10_1101-2020_09_23_308239	1	348	DZIF	DZIF	NNP
10_1101-2020_09_23_308239	1	349	,	,	,
10_1101-2020_09_23_308239	1	350	German	german	JJ
10_1101-2020_09_23_308239	1	351	Centre	Centre	NNP
10_1101-2020_09_23_308239	1	352	for	for	IN
10_1101-2020_09_23_308239	1	353	Infection	Infection	NNP
10_1101-2020_09_23_308239	1	354	Research	Research	NNP
10_1101-2020_09_23_308239	1	355	,	,	,
10_1101-2020_09_23_308239	1	356	External	external	JJ
10_1101-2020_09_23_308239	1	357	partner	partner	NN
10_1101-2020_09_23_308239	1	358	site	site	NN
10_1101-2020_09_23_308239	1	359	,	,	,
10_1101-2020_09_23_308239	1	360	60596	60596	CD
10_1101-2020_09_23_308239	1	361	Frankfurt	Frankfurt	NNP
10_1101-2020_09_23_308239	1	362	am	be	VBP
10_1101-2020_09_23_308239	1	363	Main	Main	NNP
10_1101-2020_09_23_308239	1	364	,	,	,
10_1101-2020_09_23_308239	1	365	Germany	Germany	NNP
10_1101-2020_09_23_308239	1	366	*	*	NFP
10_1101-2020_09_23_308239	1	367	martin.hofmann-apitius@scai.fraunhofer.de	martin.hofmann-apitius@scai.fraunhofer.de	XX
10_1101-2020_09_23_308239	1	368	.CC	.CC	NFP
10_1101-2020_09_23_308239	1	369	-	-	:
10_1101-2020_09_23_308239	1	370	BY	by	IN
10_1101-2020_09_23_308239	1	371	-	-	HYPH
10_1101-2020_09_23_308239	1	372	NC	NC	NNP
10_1101-2020_09_23_308239	1	373	-	-	HYPH
10_1101-2020_09_23_308239	1	374	ND	ND	NNP
10_1101-2020_09_23_308239	1	375	4.0	4.0	CD
10_1101-2020_09_23_308239	1	376	International	international	JJ
10_1101-2020_09_23_308239	1	377	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	1	378	.	.	.
10_1101-2020_09_23_308239	2	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	2	2	is	be	VBZ
10_1101-2020_09_23_308239	2	3	made	make	VBN
10_1101-2020_09_23_308239	2	4	available	available	JJ
10_1101-2020_09_23_308239	2	5	under	under	IN
10_1101-2020_09_23_308239	2	6	a	a	DT
10_1101-2020_09_23_308239	2	7	preprint	preprint	NN
10_1101-2020_09_23_308239	2	8	(	(	-LRB-
10_1101-2020_09_23_308239	2	9	which	which	WDT
10_1101-2020_09_23_308239	2	10	was	be	VBD
10_1101-2020_09_23_308239	2	11	not	not	RB
10_1101-2020_09_23_308239	2	12	certified	certify	VBN
10_1101-2020_09_23_308239	2	13	by	by	IN
10_1101-2020_09_23_308239	2	14	peer	peer	NN
10_1101-2020_09_23_308239	2	15	review	review	NN
10_1101-2020_09_23_308239	2	16	)	)	-RRB-
10_1101-2020_09_23_308239	2	17	is	be	VBZ
10_1101-2020_09_23_308239	2	18	the	the	DT
10_1101-2020_09_23_308239	2	19	author	author	NN
10_1101-2020_09_23_308239	2	20	/	/	SYM
10_1101-2020_09_23_308239	2	21	funder	funder	NN
10_1101-2020_09_23_308239	2	22	,	,	,
10_1101-2020_09_23_308239	2	23	who	who	WP
10_1101-2020_09_23_308239	2	24	has	have	VBZ
10_1101-2020_09_23_308239	2	25	granted	grant	VBN
10_1101-2020_09_23_308239	2	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	2	27	a	a	DT
10_1101-2020_09_23_308239	2	28	license	license	NN
10_1101-2020_09_23_308239	2	29	to	to	TO
10_1101-2020_09_23_308239	2	30	display	display	VB
10_1101-2020_09_23_308239	2	31	the	the	DT
10_1101-2020_09_23_308239	2	32	preprint	preprint	NN
10_1101-2020_09_23_308239	2	33	in	in	IN
10_1101-2020_09_23_308239	2	34	The	the	DT
10_1101-2020_09_23_308239	2	35	copyright	copyright	NN
10_1101-2020_09_23_308239	2	36	holder	holder	NN
10_1101-2020_09_23_308239	2	37	for	for	IN
10_1101-2020_09_23_308239	2	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	2	39	version	version	NN
10_1101-2020_09_23_308239	2	40	posted	post	VBD
10_1101-2020_09_23_308239	2	41	February	February	NNP
10_1101-2020_09_23_308239	2	42	12	12	CD
10_1101-2020_09_23_308239	2	43	,	,	,
10_1101-2020_09_23_308239	2	44	2021	2021	CD
10_1101-2020_09_23_308239	2	45	.	.	.
10_1101-2020_09_23_308239	2	46	;	;	:
10_1101-2020_09_23_308239	2	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	2	48	:	:	:
10_1101-2020_09_23_308239	2	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	2	50	preprint	preprint	NN
10_1101-2020_09_23_308239	2	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	2	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	2	53	2	2	CD
10_1101-2020_09_23_308239	2	54	Abstract	Abstract	NNP
10_1101-2020_09_23_308239	2	55	The	the	DT
10_1101-2020_09_23_308239	2	56	SARS	SARS	NNP
10_1101-2020_09_23_308239	2	57	-	-	HYPH
10_1101-2020_09_23_308239	2	58	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	2	59	pandemic	pandemic	NN
10_1101-2020_09_23_308239	2	60	has	have	VBZ
10_1101-2020_09_23_308239	2	61	challenged	challenge	VBN
10_1101-2020_09_23_308239	2	62	researchers	researcher	NNS
10_1101-2020_09_23_308239	2	63	at	at	IN
10_1101-2020_09_23_308239	2	64	a	a	DT
10_1101-2020_09_23_308239	2	65	global	global	JJ
10_1101-2020_09_23_308239	2	66	scale	scale	NN
10_1101-2020_09_23_308239	2	67	.	.	.
10_1101-2020_09_23_308239	3	1	The	the	DT
10_1101-2020_09_23_308239	3	2	scientific	scientific	JJ
10_1101-2020_09_23_308239	3	3	community	community	NN
10_1101-2020_09_23_308239	3	4	’s	’s	POS
10_1101-2020_09_23_308239	3	5	massive	massive	JJ
10_1101-2020_09_23_308239	3	6	response	response	NN
10_1101-2020_09_23_308239	3	7	has	have	VBZ
10_1101-2020_09_23_308239	3	8	resulted	result	VBN
10_1101-2020_09_23_308239	3	9	in	in	IN
10_1101-2020_09_23_308239	3	10	a	a	DT
10_1101-2020_09_23_308239	3	11	flood	flood	NN
10_1101-2020_09_23_308239	3	12	of	of	IN
10_1101-2020_09_23_308239	3	13	experiments	experiment	NNS
10_1101-2020_09_23_308239	3	14	,	,	,
10_1101-2020_09_23_308239	3	15	analyses	analysis	NNS
10_1101-2020_09_23_308239	3	16	,	,	,
10_1101-2020_09_23_308239	3	17	hypotheses	hypothesis	NNS
10_1101-2020_09_23_308239	3	18	,	,	,
10_1101-2020_09_23_308239	3	19	and	and	CC
10_1101-2020_09_23_308239	3	20	publications	publication	NNS
10_1101-2020_09_23_308239	3	21	,	,	,
10_1101-2020_09_23_308239	3	22	especially	especially	RB
10_1101-2020_09_23_308239	3	23	in	in	IN
10_1101-2020_09_23_308239	3	24	the	the	DT
10_1101-2020_09_23_308239	3	25	field	field	NN
10_1101-2020_09_23_308239	3	26	of	of	IN
10_1101-2020_09_23_308239	3	27	drug	drug	NN
10_1101-2020_09_23_308239	3	28	repurposing	repurposing	NN
10_1101-2020_09_23_308239	3	29	.	.	.
10_1101-2020_09_23_308239	4	1	However	however	RB
10_1101-2020_09_23_308239	4	2	,	,	,
10_1101-2020_09_23_308239	4	3	many	many	JJ
10_1101-2020_09_23_308239	4	4	of	of	IN
10_1101-2020_09_23_308239	4	5	the	the	DT
10_1101-2020_09_23_308239	4	6	proposed	propose	VBN
10_1101-2020_09_23_308239	4	7	therapeutic	therapeutic	JJ
10_1101-2020_09_23_308239	4	8	compounds	compound	NNS
10_1101-2020_09_23_308239	4	9	obtained	obtain	VBN
10_1101-2020_09_23_308239	4	10	from	from	IN
10_1101-2020_09_23_308239	4	11	SARS	SARS	NNP
10_1101-2020_09_23_308239	4	12	-	-	HYPH
10_1101-2020_09_23_308239	4	13	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	4	14	specific	specific	NN
10_1101-2020_09_23_308239	4	15	assays	assay	NNS
10_1101-2020_09_23_308239	4	16	are	be	VBP
10_1101-2020_09_23_308239	4	17	not	not	RB
10_1101-2020_09_23_308239	4	18	in	in	IN
10_1101-2020_09_23_308239	4	19	agreement	agreement	NN
10_1101-2020_09_23_308239	4	20	and	and	CC
10_1101-2020_09_23_308239	4	21	thus	thus	RB
10_1101-2020_09_23_308239	4	22	demonstrate	demonstrate	VBP
10_1101-2020_09_23_308239	4	23	the	the	DT
10_1101-2020_09_23_308239	4	24	need	need	NN
10_1101-2020_09_23_308239	4	25	for	for	IN
10_1101-2020_09_23_308239	4	26	a	a	DT
10_1101-2020_09_23_308239	4	27	singular	singular	JJ
10_1101-2020_09_23_308239	4	28	source	source	NN
10_1101-2020_09_23_308239	4	29	of	of	IN
10_1101-2020_09_23_308239	4	30	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	4	31	related	related	JJ
10_1101-2020_09_23_308239	4	32	information	information	NN
10_1101-2020_09_23_308239	4	33	from	from	IN
10_1101-2020_09_23_308239	4	34	which	which	WDT
10_1101-2020_09_23_308239	4	35	a	a	DT
10_1101-2020_09_23_308239	4	36	rational	rational	JJ
10_1101-2020_09_23_308239	4	37	selection	selection	NN
10_1101-2020_09_23_308239	4	38	of	of	IN
10_1101-2020_09_23_308239	4	39	drug	drug	NN
10_1101-2020_09_23_308239	4	40	repurposing	repurposing	NN
10_1101-2020_09_23_308239	4	41	candidates	candidate	NNS
10_1101-2020_09_23_308239	4	42	can	can	MD
10_1101-2020_09_23_308239	4	43	be	be	VB
10_1101-2020_09_23_308239	4	44	made	make	VBN
10_1101-2020_09_23_308239	4	45	.	.	.
10_1101-2020_09_23_308239	5	1	In	in	IN
10_1101-2020_09_23_308239	5	2	this	this	DT
10_1101-2020_09_23_308239	5	3	paper	paper	NN
10_1101-2020_09_23_308239	5	4	,	,	,
10_1101-2020_09_23_308239	5	5	we	-PRON-	PRP
10_1101-2020_09_23_308239	5	6	present	present	VBP
10_1101-2020_09_23_308239	5	7	the	the	DT
10_1101-2020_09_23_308239	5	8	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	5	9	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	5	10	,	,	,
10_1101-2020_09_23_308239	5	11	a	a	DT
10_1101-2020_09_23_308239	5	12	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	5	13	drug	drug	NN
10_1101-2020_09_23_308239	5	14	-	-	HYPH
10_1101-2020_09_23_308239	5	15	target	target	NN
10_1101-2020_09_23_308239	5	16	-	-	HYPH
10_1101-2020_09_23_308239	5	17	mechanism	mechanism	NN
10_1101-2020_09_23_308239	5	18	graph	graph	NN
10_1101-2020_09_23_308239	5	19	generated	generate	VBN
10_1101-2020_09_23_308239	5	20	from	from	IN
10_1101-2020_09_23_308239	5	21	a	a	DT
10_1101-2020_09_23_308239	5	22	compilation	compilation	NN
10_1101-2020_09_23_308239	5	23	of	of	IN
10_1101-2020_09_23_308239	5	24	10	10	CD
10_1101-2020_09_23_308239	5	25	separate	separate	JJ
10_1101-2020_09_23_308239	5	26	disease	disease	NN
10_1101-2020_09_23_308239	5	27	maps	map	NNS
10_1101-2020_09_23_308239	5	28	and	and	CC
10_1101-2020_09_23_308239	5	29	sources	source	NNS
10_1101-2020_09_23_308239	5	30	of	of	IN
10_1101-2020_09_23_308239	5	31	experimental	experimental	JJ
10_1101-2020_09_23_308239	5	32	data	datum	NNS
10_1101-2020_09_23_308239	5	33	focused	focus	VBN
10_1101-2020_09_23_308239	5	34	on	on	IN
10_1101-2020_09_23_308239	5	35	SARS-	SARS-	NNP
10_1101-2020_09_23_308239	5	36	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	5	37	/	/	SYM
10_1101-2020_09_23_308239	5	38	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	5	39	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	5	40	.	.	.
10_1101-2020_09_23_308239	6	1	By	by	IN
10_1101-2020_09_23_308239	6	2	applying	apply	VBG
10_1101-2020_09_23_308239	6	3	our	-PRON-	PRP$
10_1101-2020_09_23_308239	6	4	systematic	systematic	JJ
10_1101-2020_09_23_308239	6	5	approach	approach	NN
10_1101-2020_09_23_308239	6	6	,	,	,
10_1101-2020_09_23_308239	6	7	we	-PRON-	PRP
10_1101-2020_09_23_308239	6	8	were	be	VBD
10_1101-2020_09_23_308239	6	9	able	able	JJ
10_1101-2020_09_23_308239	6	10	to	to	TO
10_1101-2020_09_23_308239	6	11	predict	predict	VB
10_1101-2020_09_23_308239	6	12	the	the	DT
10_1101-2020_09_23_308239	6	13	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	6	14	effect	effect	NN
10_1101-2020_09_23_308239	6	15	of	of	IN
10_1101-2020_09_23_308239	6	16	specific	specific	JJ
10_1101-2020_09_23_308239	6	17	drug	drug	NN
10_1101-2020_09_23_308239	6	18	pairs	pair	NNS
10_1101-2020_09_23_308239	6	19	,	,	,
10_1101-2020_09_23_308239	6	20	such	such	JJ
10_1101-2020_09_23_308239	6	21	as	as	IN
10_1101-2020_09_23_308239	6	22	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	6	23	and	and	CC
10_1101-2020_09_23_308239	6	24	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	6	25	or	or	CC
10_1101-2020_09_23_308239	6	26	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	6	27	and	and	CC
10_1101-2020_09_23_308239	6	28	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	6	29	,	,	,
10_1101-2020_09_23_308239	6	30	on	on	IN
10_1101-2020_09_23_308239	6	31	SARS	SARS	NNP
10_1101-2020_09_23_308239	6	32	-	-	HYPH
10_1101-2020_09_23_308239	6	33	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	6	34	infection	infection	NN
10_1101-2020_09_23_308239	6	35	.	.	.
10_1101-2020_09_23_308239	7	1	Experimental	experimental	JJ
10_1101-2020_09_23_308239	7	2	validation	validation	NN
10_1101-2020_09_23_308239	7	3	of	of	IN
10_1101-2020_09_23_308239	7	4	our	-PRON-	PRP$
10_1101-2020_09_23_308239	7	5	results	result	NNS
10_1101-2020_09_23_308239	7	6	demonstrate	demonstrate	VBP
10_1101-2020_09_23_308239	7	7	that	that	IN
10_1101-2020_09_23_308239	7	8	our	-PRON-	PRP$
10_1101-2020_09_23_308239	7	9	graph	graph	NN
10_1101-2020_09_23_308239	7	10	can	can	MD
10_1101-2020_09_23_308239	7	11	be	be	VB
10_1101-2020_09_23_308239	7	12	used	use	VBN
10_1101-2020_09_23_308239	7	13	to	to	TO
10_1101-2020_09_23_308239	7	14	not	not	RB
10_1101-2020_09_23_308239	7	15	only	only	RB
10_1101-2020_09_23_308239	7	16	explore	explore	VB
10_1101-2020_09_23_308239	7	17	the	the	DT
10_1101-2020_09_23_308239	7	18	involved	involved	JJ
10_1101-2020_09_23_308239	7	19	mechanistic	mechanistic	JJ
10_1101-2020_09_23_308239	7	20	pathways	pathway	NNS
10_1101-2020_09_23_308239	7	21	,	,	,
10_1101-2020_09_23_308239	7	22	but	but	CC
10_1101-2020_09_23_308239	7	23	also	also	RB
10_1101-2020_09_23_308239	7	24	to	to	TO
10_1101-2020_09_23_308239	7	25	identify	identify	VB
10_1101-2020_09_23_308239	7	26	novel	novel	JJ
10_1101-2020_09_23_308239	7	27	combinations	combination	NNS
10_1101-2020_09_23_308239	7	28	of	of	IN
10_1101-2020_09_23_308239	7	29	drug	drug	NN
10_1101-2020_09_23_308239	7	30	repurposing	repurposing	NN
10_1101-2020_09_23_308239	7	31	candidates	candidate	NNS
10_1101-2020_09_23_308239	7	32	.	.	.
10_1101-2020_09_23_308239	8	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	8	2	-	-	:
10_1101-2020_09_23_308239	8	3	BY	by	IN
10_1101-2020_09_23_308239	8	4	-	-	HYPH
10_1101-2020_09_23_308239	8	5	NC	NC	NNP
10_1101-2020_09_23_308239	8	6	-	-	HYPH
10_1101-2020_09_23_308239	8	7	ND	ND	NNP
10_1101-2020_09_23_308239	8	8	4.0	4.0	CD
10_1101-2020_09_23_308239	8	9	International	international	JJ
10_1101-2020_09_23_308239	8	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	8	11	.	.	.
10_1101-2020_09_23_308239	9	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	9	2	is	be	VBZ
10_1101-2020_09_23_308239	9	3	made	make	VBN
10_1101-2020_09_23_308239	9	4	available	available	JJ
10_1101-2020_09_23_308239	9	5	under	under	IN
10_1101-2020_09_23_308239	9	6	a	a	DT
10_1101-2020_09_23_308239	9	7	preprint	preprint	NN
10_1101-2020_09_23_308239	9	8	(	(	-LRB-
10_1101-2020_09_23_308239	9	9	which	which	WDT
10_1101-2020_09_23_308239	9	10	was	be	VBD
10_1101-2020_09_23_308239	9	11	not	not	RB
10_1101-2020_09_23_308239	9	12	certified	certify	VBN
10_1101-2020_09_23_308239	9	13	by	by	IN
10_1101-2020_09_23_308239	9	14	peer	peer	NN
10_1101-2020_09_23_308239	9	15	review	review	NN
10_1101-2020_09_23_308239	9	16	)	)	-RRB-
10_1101-2020_09_23_308239	9	17	is	be	VBZ
10_1101-2020_09_23_308239	9	18	the	the	DT
10_1101-2020_09_23_308239	9	19	author	author	NN
10_1101-2020_09_23_308239	9	20	/	/	SYM
10_1101-2020_09_23_308239	9	21	funder	funder	NN
10_1101-2020_09_23_308239	9	22	,	,	,
10_1101-2020_09_23_308239	9	23	who	who	WP
10_1101-2020_09_23_308239	9	24	has	have	VBZ
10_1101-2020_09_23_308239	9	25	granted	grant	VBN
10_1101-2020_09_23_308239	9	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	9	27	a	a	DT
10_1101-2020_09_23_308239	9	28	license	license	NN
10_1101-2020_09_23_308239	9	29	to	to	TO
10_1101-2020_09_23_308239	9	30	display	display	VB
10_1101-2020_09_23_308239	9	31	the	the	DT
10_1101-2020_09_23_308239	9	32	preprint	preprint	NN
10_1101-2020_09_23_308239	9	33	in	in	IN
10_1101-2020_09_23_308239	9	34	The	the	DT
10_1101-2020_09_23_308239	9	35	copyright	copyright	NN
10_1101-2020_09_23_308239	9	36	holder	holder	NN
10_1101-2020_09_23_308239	9	37	for	for	IN
10_1101-2020_09_23_308239	9	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	9	39	version	version	NN
10_1101-2020_09_23_308239	9	40	posted	post	VBD
10_1101-2020_09_23_308239	9	41	February	February	NNP
10_1101-2020_09_23_308239	9	42	12	12	CD
10_1101-2020_09_23_308239	9	43	,	,	,
10_1101-2020_09_23_308239	9	44	2021	2021	CD
10_1101-2020_09_23_308239	9	45	.	.	.
10_1101-2020_09_23_308239	9	46	;	;	:
10_1101-2020_09_23_308239	9	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	9	48	:	:	:
10_1101-2020_09_23_308239	9	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	9	50	preprint	preprint	NN
10_1101-2020_09_23_308239	9	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	9	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	9	53	3	3	CD
10_1101-2020_09_23_308239	9	54	Introduction	Introduction	NNP
10_1101-2020_09_23_308239	9	55	and	and	CC
10_1101-2020_09_23_308239	9	56	Motivation	Motivation	NNP
10_1101-2020_09_23_308239	9	57	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	9	58	is	be	VBZ
10_1101-2020_09_23_308239	9	59	the	the	DT
10_1101-2020_09_23_308239	9	60	term	term	NN
10_1101-2020_09_23_308239	9	61	coined	coin	VBN
10_1101-2020_09_23_308239	9	62	for	for	IN
10_1101-2020_09_23_308239	9	63	the	the	DT
10_1101-2020_09_23_308239	9	64	pandemic	pandemic	NN
10_1101-2020_09_23_308239	9	65	caused	cause	VBN
10_1101-2020_09_23_308239	9	66	by	by	IN
10_1101-2020_09_23_308239	9	67	SARS	SARS	NNP
10_1101-2020_09_23_308239	9	68	-	-	HYPH
10_1101-2020_09_23_308239	9	69	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	9	70	.	.	.
10_1101-2020_09_23_308239	10	1	Unprecedented	unprecedented	JJ
10_1101-2020_09_23_308239	10	2	in	in	IN
10_1101-2020_09_23_308239	10	3	the	the	DT
10_1101-2020_09_23_308239	10	4	history	history	NN
10_1101-2020_09_23_308239	10	5	of	of	IN
10_1101-2020_09_23_308239	10	6	science	science	NN
10_1101-2020_09_23_308239	10	7	,	,	,
10_1101-2020_09_23_308239	10	8	this	this	DT
10_1101-2020_09_23_308239	10	9	pandemic	pandemic	NN
10_1101-2020_09_23_308239	10	10	has	have	VBZ
10_1101-2020_09_23_308239	10	11	elicited	elicit	VBN
10_1101-2020_09_23_308239	10	12	a	a	DT
10_1101-2020_09_23_308239	10	13	worldwide	worldwide	JJ
10_1101-2020_09_23_308239	10	14	,	,	,
10_1101-2020_09_23_308239	10	15	collaborative	collaborative	JJ
10_1101-2020_09_23_308239	10	16	response	response	NN
10_1101-2020_09_23_308239	10	17	from	from	IN
10_1101-2020_09_23_308239	10	18	the	the	DT
10_1101-2020_09_23_308239	10	19	scientific	scientific	JJ
10_1101-2020_09_23_308239	10	20	community	community	NN
10_1101-2020_09_23_308239	10	21	.	.	.
10_1101-2020_09_23_308239	11	1	In	in	IN
10_1101-2020_09_23_308239	11	2	addition	addition	NN
10_1101-2020_09_23_308239	11	3	to	to	IN
10_1101-2020_09_23_308239	11	4	the	the	DT
10_1101-2020_09_23_308239	11	5	strong	strong	JJ
10_1101-2020_09_23_308239	11	6	focus	focus	NN
10_1101-2020_09_23_308239	11	7	on	on	IN
10_1101-2020_09_23_308239	11	8	the	the	DT
10_1101-2020_09_23_308239	11	9	epidemiology	epidemiology	NN
10_1101-2020_09_23_308239	11	10	of	of	IN
10_1101-2020_09_23_308239	11	11	the	the	DT
10_1101-2020_09_23_308239	11	12	virus1	virus1	NN
10_1101-2020_09_23_308239	11	13	2	2	CD
10_1101-2020_09_23_308239	11	14	3	3	CD
10_1101-2020_09_23_308239	11	15	,	,	,
10_1101-2020_09_23_308239	11	16	experiments	experiment	NNS
10_1101-2020_09_23_308239	11	17	aimed	aim	VBN
10_1101-2020_09_23_308239	11	18	at	at	IN
10_1101-2020_09_23_308239	11	19	understanding	understanding	NN
10_1101-2020_09_23_308239	11	20	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	11	21	underlying	underlie	VBG
10_1101-2020_09_23_308239	11	22	the	the	DT
10_1101-2020_09_23_308239	11	23	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	11	24	of	of	IN
10_1101-2020_09_23_308239	11	25	the	the	DT
10_1101-2020_09_23_308239	11	26	virus	virus	NN
10_1101-2020_09_23_308239	11	27	have	have	VBP
10_1101-2020_09_23_308239	11	28	led	lead	VBN
10_1101-2020_09_23_308239	11	29	to	to	IN
10_1101-2020_09_23_308239	11	30	new	new	JJ
10_1101-2020_09_23_308239	11	31	insights	insight	NNS
10_1101-2020_09_23_308239	11	32	in	in	IN
10_1101-2020_09_23_308239	11	33	a	a	DT
10_1101-2020_09_23_308239	11	34	comparably	comparably	RB
10_1101-2020_09_23_308239	11	35	short	short	JJ
10_1101-2020_09_23_308239	11	36	amount	amount	NN
10_1101-2020_09_23_308239	11	37	of	of	IN
10_1101-2020_09_23_308239	11	38	time4	time4	NN
10_1101-2020_09_23_308239	11	39	5	5	CD
10_1101-2020_09_23_308239	11	40	6	6	CD
10_1101-2020_09_23_308239	11	41	7	7	CD
10_1101-2020_09_23_308239	11	42	.	.	.
10_1101-2020_09_23_308239	12	1	In	in	IN
10_1101-2020_09_23_308239	12	2	the	the	DT
10_1101-2020_09_23_308239	12	3	field	field	NN
10_1101-2020_09_23_308239	12	4	of	of	IN
10_1101-2020_09_23_308239	12	5	computational	computational	JJ
10_1101-2020_09_23_308239	12	6	biology	biology	NN
10_1101-2020_09_23_308239	12	7	,	,	,
10_1101-2020_09_23_308239	12	8	several	several	JJ
10_1101-2020_09_23_308239	12	9	initiatives	initiative	NNS
10_1101-2020_09_23_308239	12	10	have	have	VBP
10_1101-2020_09_23_308239	12	11	started	start	VBN
10_1101-2020_09_23_308239	12	12	generating	generate	VBG
10_1101-2020_09_23_308239	12	13	disease	disease	NN
10_1101-2020_09_23_308239	12	14	maps	map	NNS
10_1101-2020_09_23_308239	12	15	that	that	WDT
10_1101-2020_09_23_308239	12	16	represent	represent	VBP
10_1101-2020_09_23_308239	12	17	the	the	DT
10_1101-2020_09_23_308239	12	18	current	current	JJ
10_1101-2020_09_23_308239	12	19	knowledge	knowledge	NN
10_1101-2020_09_23_308239	12	20	pertaining	pertain	VBG
10_1101-2020_09_23_308239	12	21	to	to	IN
10_1101-2020_09_23_308239	12	22	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	12	23	mechanisms8	mechanisms8	NN
10_1101-2020_09_23_308239	12	24	9	9	CD
10_1101-2020_09_23_308239	12	25	10	10	CD
10_1101-2020_09_23_308239	12	26	11	11	CD
10_1101-2020_09_23_308239	12	27	.	.	.
10_1101-2020_09_23_308239	13	1	Such	such	JJ
10_1101-2020_09_23_308239	13	2	disease	disease	NN
10_1101-2020_09_23_308239	13	3	maps	map	NNS
10_1101-2020_09_23_308239	13	4	have	have	VBP
10_1101-2020_09_23_308239	13	5	proven	prove	VBN
10_1101-2020_09_23_308239	13	6	valuable	valuable	JJ
10_1101-2020_09_23_308239	13	7	before	before	IN
10_1101-2020_09_23_308239	13	8	in	in	IN
10_1101-2020_09_23_308239	13	9	diverse	diverse	JJ
10_1101-2020_09_23_308239	13	10	areas	area	NNS
10_1101-2020_09_23_308239	13	11	of	of	IN
10_1101-2020_09_23_308239	13	12	research	research	NN
10_1101-2020_09_23_308239	13	13	such	such	JJ
10_1101-2020_09_23_308239	13	14	as	as	IN
10_1101-2020_09_23_308239	13	15	12	12	CD
10_1101-2020_09_23_308239	13	16	13	13	CD
10_1101-2020_09_23_308239	13	17	14	14	CD
10_1101-2020_09_23_308239	13	18	15	15	CD
10_1101-2020_09_23_308239	13	19	.	.	.
10_1101-2020_09_23_308239	14	1	When	when	WRB
10_1101-2020_09_23_308239	14	2	taken	take	VBN
10_1101-2020_09_23_308239	14	3	together	together	RB
10_1101-2020_09_23_308239	14	4	with	with	IN
10_1101-2020_09_23_308239	14	5	related	related	JJ
10_1101-2020_09_23_308239	14	6	work	work	NN
10_1101-2020_09_23_308239	14	7	including	include	VBG
10_1101-2020_09_23_308239	14	8	cause	cause	NN
10_1101-2020_09_23_308239	14	9	-	-	HYPH
10_1101-2020_09_23_308239	14	10	and	and	CC
10_1101-2020_09_23_308239	14	11	-	-	HYPH
10_1101-2020_09_23_308239	14	12	effect	effect	NN
10_1101-2020_09_23_308239	14	13	modeling8	modeling8	NN
10_1101-2020_09_23_308239	14	14	,	,	,
10_1101-2020_09_23_308239	14	15	entity	entity	NN
10_1101-2020_09_23_308239	14	16	relationship	relationship	NN
10_1101-2020_09_23_308239	14	17	graphs16	graphs16	NNS
10_1101-2020_09_23_308239	14	18	,	,	,
10_1101-2020_09_23_308239	14	19	and	and	CC
10_1101-2020_09_23_308239	14	20	pathways17	pathways17	NNPS
10_1101-2020_09_23_308239	14	21	;	;	:
10_1101-2020_09_23_308239	14	22	these	these	DT
10_1101-2020_09_23_308239	14	23	disease	disease	NN
10_1101-2020_09_23_308239	14	24	maps	map	NNS
10_1101-2020_09_23_308239	14	25	represent	represent	VBP
10_1101-2020_09_23_308239	14	26	a	a	DT
10_1101-2020_09_23_308239	14	27	considerable	considerable	JJ
10_1101-2020_09_23_308239	14	28	amount	amount	NN
10_1101-2020_09_23_308239	14	29	of	of	IN
10_1101-2020_09_23_308239	14	30	highly	highly	RB
10_1101-2020_09_23_308239	14	31	curated	curate	VBN
10_1101-2020_09_23_308239	14	32	“	"	``
10_1101-2020_09_23_308239	14	33	knowledge	knowledge	NN
10_1101-2020_09_23_308239	14	34	graphs	graphs	NN
10_1101-2020_09_23_308239	14	35	”	"	''
10_1101-2020_09_23_308239	14	36	which	which	WDT
10_1101-2020_09_23_308239	14	37	focus	focus	VBP
10_1101-2020_09_23_308239	14	38	primarily	primarily	RB
10_1101-2020_09_23_308239	14	39	on	on	IN
10_1101-2020_09_23_308239	14	40	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	14	41	biology	biology	NN
10_1101-2020_09_23_308239	14	42	.	.	.
10_1101-2020_09_23_308239	15	1	Here	here	RB
10_1101-2020_09_23_308239	15	2	,	,	,
10_1101-2020_09_23_308239	15	3	we	-PRON-	PRP
10_1101-2020_09_23_308239	15	4	use	use	VBP
10_1101-2020_09_23_308239	15	5	the	the	DT
10_1101-2020_09_23_308239	15	6	term	term	NN
10_1101-2020_09_23_308239	15	7	“	"	``
10_1101-2020_09_23_308239	15	8	mechanism	mechanism	NN
10_1101-2020_09_23_308239	15	9	”	"	''
10_1101-2020_09_23_308239	15	10	to	to	TO
10_1101-2020_09_23_308239	15	11	describe	describe	VB
10_1101-2020_09_23_308239	15	12	a	a	DT
10_1101-2020_09_23_308239	15	13	single	single	JJ
10_1101-2020_09_23_308239	15	14	,	,	,
10_1101-2020_09_23_308239	15	15	or	or	CC
10_1101-2020_09_23_308239	15	16	multiple	multiple	JJ
10_1101-2020_09_23_308239	15	17	cause	cause	NN
10_1101-2020_09_23_308239	15	18	-	-	HYPH
10_1101-2020_09_23_308239	15	19	and	and	CC
10_1101-2020_09_23_308239	15	20	-	-	HYPH
10_1101-2020_09_23_308239	15	21	effect	effect	NN
10_1101-2020_09_23_308239	15	22	relationships	relationship	NNS
10_1101-2020_09_23_308239	15	23	(	(	-LRB-
10_1101-2020_09_23_308239	15	24	i.e.	i.e.	FW
10_1101-2020_09_23_308239	16	1	a	a	DT
10_1101-2020_09_23_308239	16	2	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	16	3	)	)	-RRB-
10_1101-2020_09_23_308239	16	4	,	,	,
10_1101-2020_09_23_308239	16	5	“	"	``
10_1101-2020_09_23_308239	16	6	pathways	pathway	NNS
10_1101-2020_09_23_308239	16	7	”	"	''
10_1101-2020_09_23_308239	16	8	to	to	TO
10_1101-2020_09_23_308239	16	9	refer	refer	VB
10_1101-2020_09_23_308239	16	10	to	to	IN
10_1101-2020_09_23_308239	16	11	a	a	DT
10_1101-2020_09_23_308239	16	12	well	well	RB
10_1101-2020_09_23_308239	16	13	-	-	HYPH
10_1101-2020_09_23_308239	16	14	established	establish	VBN
10_1101-2020_09_23_308239	16	15	series	series	NN
10_1101-2020_09_23_308239	16	16	of	of	IN
10_1101-2020_09_23_308239	16	17	interactions	interaction	NNS
10_1101-2020_09_23_308239	16	18	resulting	result	VBG
10_1101-2020_09_23_308239	16	19	in	in	IN
10_1101-2020_09_23_308239	16	20	cellular	cellular	JJ
10_1101-2020_09_23_308239	16	21	change	change	NN
10_1101-2020_09_23_308239	16	22	or	or	CC
10_1101-2020_09_23_308239	16	23	a	a	DT
10_1101-2020_09_23_308239	16	24	defined	define	VBN
10_1101-2020_09_23_308239	16	25	product	product	NN
10_1101-2020_09_23_308239	16	26	,	,	,
10_1101-2020_09_23_308239	16	27	and	and	CC
10_1101-2020_09_23_308239	16	28	“	"	``
10_1101-2020_09_23_308239	16	29	models	model	NNS
10_1101-2020_09_23_308239	16	30	”	"	''
10_1101-2020_09_23_308239	16	31	for	for	IN
10_1101-2020_09_23_308239	16	32	describing	describe	VBG
10_1101-2020_09_23_308239	16	33	a	a	DT
10_1101-2020_09_23_308239	16	34	collection	collection	NN
10_1101-2020_09_23_308239	16	35	of	of	IN
10_1101-2020_09_23_308239	16	36	experimental	experimental	JJ
10_1101-2020_09_23_308239	16	37	data	datum	NNS
10_1101-2020_09_23_308239	16	38	or	or	CC
10_1101-2020_09_23_308239	16	39	known	know	VBN
10_1101-2020_09_23_308239	16	40	interactions	interaction	NNS
10_1101-2020_09_23_308239	16	41	defined	define	VBN
10_1101-2020_09_23_308239	16	42	in	in	IN
10_1101-2020_09_23_308239	16	43	the	the	DT
10_1101-2020_09_23_308239	16	44	context	context	NN
10_1101-2020_09_23_308239	16	45	of	of	IN
10_1101-2020_09_23_308239	16	46	a	a	DT
10_1101-2020_09_23_308239	16	47	particular	particular	JJ
10_1101-2020_09_23_308239	16	48	biological	biological	JJ
10_1101-2020_09_23_308239	16	49	process	process	NN
10_1101-2020_09_23_308239	16	50	or	or	CC
10_1101-2020_09_23_308239	16	51	pathology	pathology	NN
10_1101-2020_09_23_308239	16	52	.	.	.
10_1101-2020_09_23_308239	17	1	As	as	IN
10_1101-2020_09_23_308239	17	2	of	of	IN
10_1101-2020_09_23_308239	17	3	July	July	NNP
10_1101-2020_09_23_308239	17	4	2020	2020	CD
10_1101-2020_09_23_308239	17	5	,	,	,
10_1101-2020_09_23_308239	17	6	a	a	DT
10_1101-2020_09_23_308239	17	7	collection	collection	NN
10_1101-2020_09_23_308239	17	8	consisting	consist	VBG
10_1101-2020_09_23_308239	17	9	of	of	IN
10_1101-2020_09_23_308239	17	10	10	10	CD
10_1101-2020_09_23_308239	17	11	models	model	NNS
10_1101-2020_09_23_308239	17	12	representing	represent	VBG
10_1101-2020_09_23_308239	17	13	core	core	JJ
10_1101-2020_09_23_308239	17	14	knowledge	knowledge	NN
10_1101-2020_09_23_308239	17	15	about	about	IN
10_1101-2020_09_23_308239	17	16	the	the	DT
10_1101-2020_09_23_308239	17	17	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	17	18	of	of	IN
10_1101-2020_09_23_308239	17	19	SARS	SARS	NNP
10_1101-2020_09_23_308239	17	20	-	-	HYPH
10_1101-2020_09_23_308239	17	21	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	17	22	and	and	CC
10_1101-2020_09_23_308239	17	23	its	-PRON-	PRP$
10_1101-2020_09_23_308239	17	24	primary	primary	JJ
10_1101-2020_09_23_308239	17	25	target	target	NN
10_1101-2020_09_23_308239	17	26	,	,	,
10_1101-2020_09_23_308239	17	27	the	the	DT
10_1101-2020_09_23_308239	17	28	lung	lung	NN
10_1101-2020_09_23_308239	17	29	epithelium	epithelium	NN
10_1101-2020_09_23_308239	17	30	,	,	,
10_1101-2020_09_23_308239	17	31	was	be	VBD
10_1101-2020_09_23_308239	17	32	shared	share	VBN
10_1101-2020_09_23_308239	17	33	with	with	IN
10_1101-2020_09_23_308239	17	34	the	the	DT
10_1101-2020_09_23_308239	17	35	public	public	NN
10_1101-2020_09_23_308239	17	36	.	.	.
10_1101-2020_09_23_308239	18	1	With	with	IN
10_1101-2020_09_23_308239	18	2	the	the	DT
10_1101-2020_09_23_308239	18	3	rapidly	rapidly	RB
10_1101-2020_09_23_308239	18	4	increasing	increase	VBG
10_1101-2020_09_23_308239	18	5	generation	generation	NN
10_1101-2020_09_23_308239	18	6	of	of	IN
10_1101-2020_09_23_308239	18	7	data	datum	NNS
10_1101-2020_09_23_308239	18	8	(	(	-LRB-
10_1101-2020_09_23_308239	18	9	e.g.	e.g.	RB
10_1101-2020_09_23_308239	19	1	transcriptome18	transcriptome18	NNP
10_1101-2020_09_23_308239	19	2	,	,	,
10_1101-2020_09_23_308239	19	3	interactome19	interactome19	NNPS
10_1101-2020_09_23_308239	19	4	,	,	,
10_1101-2020_09_23_308239	19	5	and	and	CC
10_1101-2020_09_23_308239	19	6	proteome20	proteome20	NNP
10_1101-2020_09_23_308239	19	7	data	datum	NNS
10_1101-2020_09_23_308239	19	8	)	)	-RRB-
10_1101-2020_09_23_308239	19	9	,	,	,
10_1101-2020_09_23_308239	19	10	we	-PRON-	PRP
10_1101-2020_09_23_308239	19	11	are	be	VBP
10_1101-2020_09_23_308239	19	12	now	now	RB
10_1101-2020_09_23_308239	19	13	in	in	IN
10_1101-2020_09_23_308239	19	14	the	the	DT
10_1101-2020_09_23_308239	19	15	position	position	NN
10_1101-2020_09_23_308239	19	16	to	to	TO
10_1101-2020_09_23_308239	19	17	challenge	challenge	VB
10_1101-2020_09_23_308239	19	18	and	and	CC
10_1101-2020_09_23_308239	19	19	validate	validate	VB
10_1101-2020_09_23_308239	19	20	these	these	DT
10_1101-2020_09_23_308239	19	21	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	19	22	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	19	23	knowledge	knowledge	NN
10_1101-2020_09_23_308239	19	24	graphs	graph	NNS
10_1101-2020_09_23_308239	19	25	with	with	IN
10_1101-2020_09_23_308239	19	26	experimental	experimental	JJ
10_1101-2020_09_23_308239	19	27	data	datum	NNS
10_1101-2020_09_23_308239	19	28	.	.	.
10_1101-2020_09_23_308239	20	1	This	this	DT
10_1101-2020_09_23_308239	20	2	is	be	VBZ
10_1101-2020_09_23_308239	20	3	of	of	IN
10_1101-2020_09_23_308239	20	4	particular	particular	JJ
10_1101-2020_09_23_308239	20	5	interest	interest	NN
10_1101-2020_09_23_308239	20	6	as	as	IN
10_1101-2020_09_23_308239	20	7	.CC	.CC	NFP
10_1101-2020_09_23_308239	20	8	-	-	HYPH
10_1101-2020_09_23_308239	20	9	BY	by	IN
10_1101-2020_09_23_308239	20	10	-	-	HYPH
10_1101-2020_09_23_308239	20	11	NC	NC	NNP
10_1101-2020_09_23_308239	20	12	-	-	HYPH
10_1101-2020_09_23_308239	20	13	ND	ND	NNP
10_1101-2020_09_23_308239	20	14	4.0	4.0	CD
10_1101-2020_09_23_308239	20	15	International	international	JJ
10_1101-2020_09_23_308239	20	16	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	20	17	.	.	.
10_1101-2020_09_23_308239	21	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	21	2	is	be	VBZ
10_1101-2020_09_23_308239	21	3	made	make	VBN
10_1101-2020_09_23_308239	21	4	available	available	JJ
10_1101-2020_09_23_308239	21	5	under	under	IN
10_1101-2020_09_23_308239	21	6	a	a	DT
10_1101-2020_09_23_308239	21	7	preprint	preprint	NN
10_1101-2020_09_23_308239	21	8	(	(	-LRB-
10_1101-2020_09_23_308239	21	9	which	which	WDT
10_1101-2020_09_23_308239	21	10	was	be	VBD
10_1101-2020_09_23_308239	21	11	not	not	RB
10_1101-2020_09_23_308239	21	12	certified	certify	VBN
10_1101-2020_09_23_308239	21	13	by	by	IN
10_1101-2020_09_23_308239	21	14	peer	peer	NN
10_1101-2020_09_23_308239	21	15	review	review	NN
10_1101-2020_09_23_308239	21	16	)	)	-RRB-
10_1101-2020_09_23_308239	21	17	is	be	VBZ
10_1101-2020_09_23_308239	21	18	the	the	DT
10_1101-2020_09_23_308239	21	19	author	author	NN
10_1101-2020_09_23_308239	21	20	/	/	SYM
10_1101-2020_09_23_308239	21	21	funder	funder	NN
10_1101-2020_09_23_308239	21	22	,	,	,
10_1101-2020_09_23_308239	21	23	who	who	WP
10_1101-2020_09_23_308239	21	24	has	have	VBZ
10_1101-2020_09_23_308239	21	25	granted	grant	VBN
10_1101-2020_09_23_308239	21	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	21	27	a	a	DT
10_1101-2020_09_23_308239	21	28	license	license	NN
10_1101-2020_09_23_308239	21	29	to	to	TO
10_1101-2020_09_23_308239	21	30	display	display	VB
10_1101-2020_09_23_308239	21	31	the	the	DT
10_1101-2020_09_23_308239	21	32	preprint	preprint	NN
10_1101-2020_09_23_308239	21	33	in	in	IN
10_1101-2020_09_23_308239	21	34	The	the	DT
10_1101-2020_09_23_308239	21	35	copyright	copyright	NN
10_1101-2020_09_23_308239	21	36	holder	holder	NN
10_1101-2020_09_23_308239	21	37	for	for	IN
10_1101-2020_09_23_308239	21	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	21	39	version	version	NN
10_1101-2020_09_23_308239	21	40	posted	post	VBD
10_1101-2020_09_23_308239	21	41	February	February	NNP
10_1101-2020_09_23_308239	21	42	12	12	CD
10_1101-2020_09_23_308239	21	43	,	,	,
10_1101-2020_09_23_308239	21	44	2021	2021	CD
10_1101-2020_09_23_308239	21	45	.	.	.
10_1101-2020_09_23_308239	21	46	;	;	:
10_1101-2020_09_23_308239	21	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	21	48	:	:	:
10_1101-2020_09_23_308239	21	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	21	50	preprint	preprint	NN
10_1101-2020_09_23_308239	21	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	21	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	21	53	4	4	CD
10_1101-2020_09_23_308239	21	54	validation	validation	NN
10_1101-2020_09_23_308239	21	55	of	of	IN
10_1101-2020_09_23_308239	21	56	these	these	DT
10_1101-2020_09_23_308239	21	57	knowledge	knowledge	NN
10_1101-2020_09_23_308239	21	58	graphs	graphs	NN
10_1101-2020_09_23_308239	21	59	bears	bear	VBZ
10_1101-2020_09_23_308239	21	60	the	the	DT
10_1101-2020_09_23_308239	21	61	potential	potential	NN
10_1101-2020_09_23_308239	21	62	to	to	TO
10_1101-2020_09_23_308239	21	63	identify	identify	VB
10_1101-2020_09_23_308239	21	64	those	those	DT
10_1101-2020_09_23_308239	21	65	disease	disease	NN
10_1101-2020_09_23_308239	21	66	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	21	67	highly	highly	RB
10_1101-2020_09_23_308239	21	68	relevant	relevant	JJ
10_1101-2020_09_23_308239	21	69	for	for	IN
10_1101-2020_09_23_308239	21	70	targeting	target	VBG
10_1101-2020_09_23_308239	21	71	in	in	IN
10_1101-2020_09_23_308239	21	72	drug	drug	NN
10_1101-2020_09_23_308239	21	73	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	21	74	approaches	approach	NNS
10_1101-2020_09_23_308239	21	75	.	.	.
10_1101-2020_09_23_308239	22	1	The	the	DT
10_1101-2020_09_23_308239	22	2	concept	concept	NN
10_1101-2020_09_23_308239	22	3	of	of	IN
10_1101-2020_09_23_308239	22	4	drug	drug	NN
10_1101-2020_09_23_308239	22	5	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	22	6	(	(	-LRB-
10_1101-2020_09_23_308239	22	7	the	the	DT
10_1101-2020_09_23_308239	22	8	secondary	secondary	JJ
10_1101-2020_09_23_308239	22	9	use	use	NN
10_1101-2020_09_23_308239	22	10	of	of	IN
10_1101-2020_09_23_308239	22	11	already	already	RB
10_1101-2020_09_23_308239	22	12	developed	develop	VBN
10_1101-2020_09_23_308239	22	13	drugs	drug	NNS
10_1101-2020_09_23_308239	22	14	for	for	IN
10_1101-2020_09_23_308239	22	15	therapeutic	therapeutic	JJ
10_1101-2020_09_23_308239	22	16	uses	use	NNS
10_1101-2020_09_23_308239	22	17	other	other	JJ
10_1101-2020_09_23_308239	22	18	than	than	IN
10_1101-2020_09_23_308239	22	19	those	those	DT
10_1101-2020_09_23_308239	22	20	they	-PRON-	PRP
10_1101-2020_09_23_308239	22	21	were	be	VBD
10_1101-2020_09_23_308239	22	22	designed	design	VBN
10_1101-2020_09_23_308239	22	23	for	for	IN
10_1101-2020_09_23_308239	22	24	)	)	-RRB-
10_1101-2020_09_23_308239	22	25	is	be	VBZ
10_1101-2020_09_23_308239	22	26	not	not	RB
10_1101-2020_09_23_308239	22	27	new	new	JJ
10_1101-2020_09_23_308239	22	28	.	.	.
10_1101-2020_09_23_308239	23	1	The	the	DT
10_1101-2020_09_23_308239	23	2	major	major	JJ
10_1101-2020_09_23_308239	23	3	advantage	advantage	NN
10_1101-2020_09_23_308239	23	4	of	of	IN
10_1101-2020_09_23_308239	23	5	drug	drug	NN
10_1101-2020_09_23_308239	23	6	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	23	7	over	over	IN
10_1101-2020_09_23_308239	23	8	conventional	conventional	JJ
10_1101-2020_09_23_308239	23	9	drug	drug	NN
10_1101-2020_09_23_308239	23	10	development	development	NN
10_1101-2020_09_23_308239	23	11	is	be	VBZ
10_1101-2020_09_23_308239	23	12	the	the	DT
10_1101-2020_09_23_308239	23	13	massive	massive	JJ
10_1101-2020_09_23_308239	23	14	decrease	decrease	NN
10_1101-2020_09_23_308239	23	15	in	in	IN
10_1101-2020_09_23_308239	23	16	time	time	NN
10_1101-2020_09_23_308239	23	17	required	require	VBN
10_1101-2020_09_23_308239	23	18	for	for	IN
10_1101-2020_09_23_308239	23	19	development	development	NN
10_1101-2020_09_23_308239	23	20	as	as	IN
10_1101-2020_09_23_308239	23	21	important	important	JJ
10_1101-2020_09_23_308239	23	22	steps	step	NNS
10_1101-2020_09_23_308239	23	23	in	in	IN
10_1101-2020_09_23_308239	23	24	the	the	DT
10_1101-2020_09_23_308239	23	25	drug	drug	NN
10_1101-2020_09_23_308239	23	26	discovery	discovery	NN
10_1101-2020_09_23_308239	23	27	workflow	workflow	NNP
10_1101-2020_09_23_308239	23	28	have	have	VBP
10_1101-2020_09_23_308239	23	29	already	already	RB
10_1101-2020_09_23_308239	23	30	been	be	VBN
10_1101-2020_09_23_308239	23	31	successfully	successfully	RB
10_1101-2020_09_23_308239	23	32	passed	pass	VBN
10_1101-2020_09_23_308239	23	33	for	for	IN
10_1101-2020_09_23_308239	23	34	these	these	DT
10_1101-2020_09_23_308239	23	35	compounds21	compounds21	NN
10_1101-2020_09_23_308239	23	36	22	22	CD
10_1101-2020_09_23_308239	23	37	.	.	.
10_1101-2020_09_23_308239	24	1	Our	-PRON-	PRP$
10_1101-2020_09_23_308239	24	2	group	group	NN
10_1101-2020_09_23_308239	24	3	and	and	CC
10_1101-2020_09_23_308239	24	4	many	many	JJ
10_1101-2020_09_23_308239	24	5	others	other	NNS
10_1101-2020_09_23_308239	24	6	have	have	VBP
10_1101-2020_09_23_308239	24	7	already	already	RB
10_1101-2020_09_23_308239	24	8	begun	begin	VBN
10_1101-2020_09_23_308239	24	9	performing	perform	VBG
10_1101-2020_09_23_308239	24	10	assays	assays	RB
10_1101-2020_09_23_308239	24	11	to	to	IN
10_1101-2020_09_23_308239	24	12	screen	screen	NN
10_1101-2020_09_23_308239	24	13	for	for	IN
10_1101-2020_09_23_308239	24	14	experimental	experimental	JJ
10_1101-2020_09_23_308239	24	15	compounds	compound	NNS
10_1101-2020_09_23_308239	24	16	and	and	CC
10_1101-2020_09_23_308239	24	17	approved	approve	VBD
10_1101-2020_09_23_308239	24	18	drugs	drug	NNS
10_1101-2020_09_23_308239	24	19	to	to	TO
10_1101-2020_09_23_308239	24	20	serve	serve	VB
10_1101-2020_09_23_308239	24	21	as	as	IN
10_1101-2020_09_23_308239	24	22	new	new	JJ
10_1101-2020_09_23_308239	24	23	therapeutics	therapeutic	NNS
10_1101-2020_09_23_308239	24	24	for	for	IN
10_1101-2020_09_23_308239	24	25	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	24	26	.	.	.
10_1101-2020_09_23_308239	25	1	Dedicated	dedicated	JJ
10_1101-2020_09_23_308239	25	2	drug	drug	NN
10_1101-2020_09_23_308239	25	3	repurposing	repurposing	NN
10_1101-2020_09_23_308239	25	4	collections	collection	NNS
10_1101-2020_09_23_308239	25	5	,	,	,
10_1101-2020_09_23_308239	25	6	such	such	JJ
10_1101-2020_09_23_308239	25	7	as	as	IN
10_1101-2020_09_23_308239	25	8	the	the	DT
10_1101-2020_09_23_308239	25	9	Broad	Broad	NNP
10_1101-2020_09_23_308239	25	10	Institute	Institute	NNP
10_1101-2020_09_23_308239	25	11	library23	library23	NNP
10_1101-2020_09_23_308239	25	12	,	,	,
10_1101-2020_09_23_308239	25	13	and	and	CC
10_1101-2020_09_23_308239	25	14	the	the	DT
10_1101-2020_09_23_308239	25	15	even	even	RB
10_1101-2020_09_23_308239	25	16	more	more	RBR
10_1101-2020_09_23_308239	25	17	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	25	18	ReFRAME	ReFRAME	NNP
10_1101-2020_09_23_308239	25	19	library24	library24	NNP
10_1101-2020_09_23_308239	25	20	,	,	,
10_1101-2020_09_23_308239	25	21	were	be	VBD
10_1101-2020_09_23_308239	25	22	used	use	VBN
10_1101-2020_09_23_308239	25	23	to	to	TO
10_1101-2020_09_23_308239	25	24	experimentally	experimentally	RB
10_1101-2020_09_23_308239	25	25	screen	screen	VB
10_1101-2020_09_23_308239	25	26	for	for	IN
10_1101-2020_09_23_308239	25	27	either	either	DT
10_1101-2020_09_23_308239	25	28	viral	viral	JJ
10_1101-2020_09_23_308239	25	29	proteins	protein	NNS
10_1101-2020_09_23_308239	25	30	as	as	IN
10_1101-2020_09_23_308239	25	31	targets	target	NNS
10_1101-2020_09_23_308239	25	32	for	for	IN
10_1101-2020_09_23_308239	25	33	functional	functional	JJ
10_1101-2020_09_23_308239	25	34	inhibition25	inhibition25	NNS
10_1101-2020_09_23_308239	25	35	,	,	,
10_1101-2020_09_23_308239	25	36	or	or	CC
10_1101-2020_09_23_308239	25	37	for	for	IN
10_1101-2020_09_23_308239	25	38	virally	virally	RB
10_1101-2020_09_23_308239	25	39	infected	infect	VBN
10_1101-2020_09_23_308239	25	40	cells	cell	NNS
10_1101-2020_09_23_308239	25	41	in	in	IN
10_1101-2020_09_23_308239	25	42	phenotypic	phenotypic	NN
10_1101-2020_09_23_308239	25	43	assays26	assays26	NNS
10_1101-2020_09_23_308239	25	44	.	.	.
10_1101-2020_09_23_308239	26	1	In	in	IN
10_1101-2020_09_23_308239	26	2	our	-PRON-	PRP$
10_1101-2020_09_23_308239	26	3	own	own	JJ
10_1101-2020_09_23_308239	26	4	work	work	NN
10_1101-2020_09_23_308239	26	5	,	,	,
10_1101-2020_09_23_308239	26	6	compounds	compound	NNS
10_1101-2020_09_23_308239	26	7	were	be	VBD
10_1101-2020_09_23_308239	26	8	assessed	assess	VBN
10_1101-2020_09_23_308239	26	9	for	for	IN
10_1101-2020_09_23_308239	26	10	their	-PRON-	PRP$
10_1101-2020_09_23_308239	26	11	inhibition	inhibition	NN
10_1101-2020_09_23_308239	26	12	of	of	IN
10_1101-2020_09_23_308239	26	13	virus	virus	NN
10_1101-2020_09_23_308239	26	14	-	-	HYPH
10_1101-2020_09_23_308239	26	15	induced	induce	VBN
10_1101-2020_09_23_308239	26	16	cytotoxicity	cytotoxicity	NN
10_1101-2020_09_23_308239	26	17	using	use	VBG
10_1101-2020_09_23_308239	26	18	the	the	DT
10_1101-2020_09_23_308239	26	19	human	human	JJ
10_1101-2020_09_23_308239	26	20	cell	cell	NN
10_1101-2020_09_23_308239	26	21	line	line	NN
10_1101-2020_09_23_308239	26	22	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	26	23	and	and	CC
10_1101-2020_09_23_308239	26	24	a	a	DT
10_1101-2020_09_23_308239	26	25	SARS	SARS	NNP
10_1101-2020_09_23_308239	26	26	-	-	HYPH
10_1101-2020_09_23_308239	26	27	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	26	28	isolate27	isolate27	NNP
10_1101-2020_09_23_308239	26	29	.	.	.
10_1101-2020_09_23_308239	27	1	A	a	DT
10_1101-2020_09_23_308239	27	2	total	total	NN
10_1101-2020_09_23_308239	27	3	of	of	IN
10_1101-2020_09_23_308239	27	4	63	63	CD
10_1101-2020_09_23_308239	27	5	compounds	compound	NNS
10_1101-2020_09_23_308239	27	6	with	with	IN
10_1101-2020_09_23_308239	27	7	IC50	IC50	NNP
10_1101-2020_09_23_308239	27	8	<	<	NNP
10_1101-2020_09_23_308239	27	9	20	20	CD
10_1101-2020_09_23_308239	27	10	µM	µM	NNP
10_1101-2020_09_23_308239	27	11	were	be	VBD
10_1101-2020_09_23_308239	27	12	identified	identify	VBN
10_1101-2020_09_23_308239	27	13	,	,	,
10_1101-2020_09_23_308239	27	14	from	from	IN
10_1101-2020_09_23_308239	27	15	which	which	WDT
10_1101-2020_09_23_308239	27	16	90	90	CD
10_1101-2020_09_23_308239	27	17	%	%	NN
10_1101-2020_09_23_308239	27	18	have	have	VBP
10_1101-2020_09_23_308239	27	19	not	not	RB
10_1101-2020_09_23_308239	27	20	yet	yet	RB
10_1101-2020_09_23_308239	27	21	been	be	VBN
10_1101-2020_09_23_308239	27	22	previously	previously	RB
10_1101-2020_09_23_308239	27	23	reported	report	VBN
10_1101-2020_09_23_308239	27	24	as	as	IN
10_1101-2020_09_23_308239	27	25	being	be	VBG
10_1101-2020_09_23_308239	27	26	active	active	JJ
10_1101-2020_09_23_308239	27	27	against	against	IN
10_1101-2020_09_23_308239	27	28	SARS	SARS	NNP
10_1101-2020_09_23_308239	27	29	-	-	HYPH
10_1101-2020_09_23_308239	27	30	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	27	31	.	.	.
10_1101-2020_09_23_308239	28	1	Out	out	IN
10_1101-2020_09_23_308239	28	2	of	of	IN
10_1101-2020_09_23_308239	28	3	the	the	DT
10_1101-2020_09_23_308239	28	4	active	active	JJ
10_1101-2020_09_23_308239	28	5	compounds	compound	NNS
10_1101-2020_09_23_308239	28	6	,	,	,
10_1101-2020_09_23_308239	28	7	31	31	CD
10_1101-2020_09_23_308239	28	8	are	be	VBP
10_1101-2020_09_23_308239	28	9	approved	approve	VBN
10_1101-2020_09_23_308239	28	10	drugs	drug	NNS
10_1101-2020_09_23_308239	28	11	,	,	,
10_1101-2020_09_23_308239	28	12	23	23	CD
10_1101-2020_09_23_308239	28	13	are	be	VBP
10_1101-2020_09_23_308239	28	14	in	in	IN
10_1101-2020_09_23_308239	28	15	phases	phase	NNS
10_1101-2020_09_23_308239	28	16	1	1	CD
10_1101-2020_09_23_308239	28	17	-	-	SYM
10_1101-2020_09_23_308239	28	18	3	3	CD
10_1101-2020_09_23_308239	28	19	and	and	CC
10_1101-2020_09_23_308239	28	20	9	9	CD
10_1101-2020_09_23_308239	28	21	are	be	VBP
10_1101-2020_09_23_308239	28	22	preclinical	preclinical	JJ
10_1101-2020_09_23_308239	28	23	candidate	candidate	NN
10_1101-2020_09_23_308239	28	24	molecules	molecule	NNS
10_1101-2020_09_23_308239	28	25	.	.	.
10_1101-2020_09_23_308239	29	1	The	the	DT
10_1101-2020_09_23_308239	29	2	described	describe	VBN
10_1101-2020_09_23_308239	29	3	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	29	4	of	of	IN
10_1101-2020_09_23_308239	29	5	action	action	NN
10_1101-2020_09_23_308239	29	6	for	for	IN
10_1101-2020_09_23_308239	29	7	the	the	DT
10_1101-2020_09_23_308239	29	8	inhibitors	inhibitor	NNS
10_1101-2020_09_23_308239	29	9	included	include	VBD
10_1101-2020_09_23_308239	29	10	kinase	kinase	NNP
10_1101-2020_09_23_308239	29	11	signaling	signal	VBG
10_1101-2020_09_23_308239	29	12	,	,	,
10_1101-2020_09_23_308239	29	13	PDE	PDE	NNP
10_1101-2020_09_23_308239	29	14	activity	activity	NN
10_1101-2020_09_23_308239	29	15	modulation	modulation	NN
10_1101-2020_09_23_308239	29	16	,	,	,
10_1101-2020_09_23_308239	29	17	and	and	CC
10_1101-2020_09_23_308239	29	18	long	long	JJ
10_1101-2020_09_23_308239	29	19	chain	chain	NN
10_1101-2020_09_23_308239	29	20	acyl	acyl	NN
10_1101-2020_09_23_308239	29	21	transferase	transferase	NN
10_1101-2020_09_23_308239	29	22	inhibition	inhibition	NN
10_1101-2020_09_23_308239	29	23	(	(	-LRB-
10_1101-2020_09_23_308239	29	24	e.g.	e.g.	RB
10_1101-2020_09_23_308239	30	1	“	"	``
10_1101-2020_09_23_308239	30	2	azole	azole	NNP
10_1101-2020_09_23_308239	30	3	class	class	NNP
10_1101-2020_09_23_308239	30	4	antifungals	antifungals	NNPS
10_1101-2020_09_23_308239	30	5	”	"	''
10_1101-2020_09_23_308239	30	6	)	)	-RRB-
10_1101-2020_09_23_308239	30	7	.	.	.
10_1101-2020_09_23_308239	31	1	The	the	DT
10_1101-2020_09_23_308239	31	2	approach	approach	NN
10_1101-2020_09_23_308239	31	3	presented	present	VBN
10_1101-2020_09_23_308239	31	4	here	here	RB
10_1101-2020_09_23_308239	31	5	integrates	integrate	VBZ
10_1101-2020_09_23_308239	31	6	experimental	experimental	JJ
10_1101-2020_09_23_308239	31	7	results	result	NNS
10_1101-2020_09_23_308239	31	8	and	and	CC
10_1101-2020_09_23_308239	31	9	the	the	DT
10_1101-2020_09_23_308239	31	10	output	output	NN
10_1101-2020_09_23_308239	31	11	from	from	IN
10_1101-2020_09_23_308239	31	12	other	other	JJ
10_1101-2020_09_23_308239	31	13	informatic	informatic	JJ
10_1101-2020_09_23_308239	31	14	pipelines	pipeline	NNS
10_1101-2020_09_23_308239	31	15	,	,	,
10_1101-2020_09_23_308239	31	16	and	and	CC
10_1101-2020_09_23_308239	31	17	combines	combine	VBZ
10_1101-2020_09_23_308239	31	18	proprietary	proprietary	JJ
10_1101-2020_09_23_308239	31	19	and	and	CC
10_1101-2020_09_23_308239	31	20	public	public	JJ
10_1101-2020_09_23_308239	31	21	data	datum	NNS
10_1101-2020_09_23_308239	31	22	to	to	TO
10_1101-2020_09_23_308239	31	23	provide	provide	VB
10_1101-2020_09_23_308239	31	24	a	a	DT
10_1101-2020_09_23_308239	31	25	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	31	26	overview	overview	NN
10_1101-2020_09_23_308239	31	27	on	on	IN
10_1101-2020_09_23_308239	31	28	the	the	DT
10_1101-2020_09_23_308239	31	29	therapeutic	therapeutic	JJ
10_1101-2020_09_23_308239	31	30	efficacy	efficacy	NN
10_1101-2020_09_23_308239	31	31	of	of	IN
10_1101-2020_09_23_308239	31	32	candidate	candidate	NN
10_1101-2020_09_23_308239	31	33	compounds	compound	NNS
10_1101-2020_09_23_308239	31	34	,	,	,
10_1101-2020_09_23_308239	31	35	the	the	DT
10_1101-2020_09_23_308239	31	36	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	31	37	targeted	target	VBN
10_1101-2020_09_23_308239	31	38	by	by	IN
10_1101-2020_09_23_308239	31	39	.CC	.CC	:
10_1101-2020_09_23_308239	31	40	-	-	:
10_1101-2020_09_23_308239	31	41	BY	by	IN
10_1101-2020_09_23_308239	31	42	-	-	HYPH
10_1101-2020_09_23_308239	31	43	NC	NC	NNP
10_1101-2020_09_23_308239	31	44	-	-	HYPH
10_1101-2020_09_23_308239	31	45	ND	ND	NNP
10_1101-2020_09_23_308239	31	46	4.0	4.0	CD
10_1101-2020_09_23_308239	31	47	International	international	JJ
10_1101-2020_09_23_308239	31	48	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	31	49	.	.	.
10_1101-2020_09_23_308239	32	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	32	2	is	be	VBZ
10_1101-2020_09_23_308239	32	3	made	make	VBN
10_1101-2020_09_23_308239	32	4	available	available	JJ
10_1101-2020_09_23_308239	32	5	under	under	IN
10_1101-2020_09_23_308239	32	6	a	a	DT
10_1101-2020_09_23_308239	32	7	preprint	preprint	NN
10_1101-2020_09_23_308239	32	8	(	(	-LRB-
10_1101-2020_09_23_308239	32	9	which	which	WDT
10_1101-2020_09_23_308239	32	10	was	be	VBD
10_1101-2020_09_23_308239	32	11	not	not	RB
10_1101-2020_09_23_308239	32	12	certified	certify	VBN
10_1101-2020_09_23_308239	32	13	by	by	IN
10_1101-2020_09_23_308239	32	14	peer	peer	NN
10_1101-2020_09_23_308239	32	15	review	review	NN
10_1101-2020_09_23_308239	32	16	)	)	-RRB-
10_1101-2020_09_23_308239	32	17	is	be	VBZ
10_1101-2020_09_23_308239	32	18	the	the	DT
10_1101-2020_09_23_308239	32	19	author	author	NN
10_1101-2020_09_23_308239	32	20	/	/	SYM
10_1101-2020_09_23_308239	32	21	funder	funder	NN
10_1101-2020_09_23_308239	32	22	,	,	,
10_1101-2020_09_23_308239	32	23	who	who	WP
10_1101-2020_09_23_308239	32	24	has	have	VBZ
10_1101-2020_09_23_308239	32	25	granted	grant	VBN
10_1101-2020_09_23_308239	32	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	32	27	a	a	DT
10_1101-2020_09_23_308239	32	28	license	license	NN
10_1101-2020_09_23_308239	32	29	to	to	TO
10_1101-2020_09_23_308239	32	30	display	display	VB
10_1101-2020_09_23_308239	32	31	the	the	DT
10_1101-2020_09_23_308239	32	32	preprint	preprint	NN
10_1101-2020_09_23_308239	32	33	in	in	IN
10_1101-2020_09_23_308239	32	34	The	the	DT
10_1101-2020_09_23_308239	32	35	copyright	copyright	NN
10_1101-2020_09_23_308239	32	36	holder	holder	NN
10_1101-2020_09_23_308239	32	37	for	for	IN
10_1101-2020_09_23_308239	32	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	32	39	version	version	NN
10_1101-2020_09_23_308239	32	40	posted	post	VBD
10_1101-2020_09_23_308239	32	41	February	February	NNP
10_1101-2020_09_23_308239	32	42	12	12	CD
10_1101-2020_09_23_308239	32	43	,	,	,
10_1101-2020_09_23_308239	32	44	2021	2021	CD
10_1101-2020_09_23_308239	32	45	.	.	.
10_1101-2020_09_23_308239	32	46	;	;	:
10_1101-2020_09_23_308239	32	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	32	48	:	:	:
10_1101-2020_09_23_308239	32	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	32	50	preprint	preprint	NN
10_1101-2020_09_23_308239	32	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	32	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	32	53	5	5	CD
10_1101-2020_09_23_308239	32	54	these	these	DT
10_1101-2020_09_23_308239	32	55	candidate	candidate	NN
10_1101-2020_09_23_308239	32	56	compounds	compound	NNS
10_1101-2020_09_23_308239	32	57	,	,	,
10_1101-2020_09_23_308239	32	58	and	and	CC
10_1101-2020_09_23_308239	32	59	a	a	DT
10_1101-2020_09_23_308239	32	60	rational	rational	JJ
10_1101-2020_09_23_308239	32	61	approach	approach	NN
10_1101-2020_09_23_308239	32	62	to	to	TO
10_1101-2020_09_23_308239	32	63	test	test	VB
10_1101-2020_09_23_308239	32	64	the	the	DT
10_1101-2020_09_23_308239	32	65	drug	drug	NN
10_1101-2020_09_23_308239	32	66	-	-	HYPH
10_1101-2020_09_23_308239	32	67	mechanism	mechanism	NN
10_1101-2020_09_23_308239	32	68	associations	association	NNS
10_1101-2020_09_23_308239	32	69	for	for	IN
10_1101-2020_09_23_308239	32	70	their	-PRON-	PRP$
10_1101-2020_09_23_308239	32	71	potential	potential	NN
10_1101-2020_09_23_308239	32	72	in	in	IN
10_1101-2020_09_23_308239	32	73	combination	combination	NN
10_1101-2020_09_23_308239	32	74	therapy	therapy	NN
10_1101-2020_09_23_308239	32	75	.	.	.
10_1101-2020_09_23_308239	33	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	33	2	-	-	:
10_1101-2020_09_23_308239	33	3	BY	by	IN
10_1101-2020_09_23_308239	33	4	-	-	HYPH
10_1101-2020_09_23_308239	33	5	NC	NC	NNP
10_1101-2020_09_23_308239	33	6	-	-	HYPH
10_1101-2020_09_23_308239	33	7	ND	ND	NNP
10_1101-2020_09_23_308239	33	8	4.0	4.0	CD
10_1101-2020_09_23_308239	33	9	International	international	JJ
10_1101-2020_09_23_308239	33	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	33	11	.	.	.
10_1101-2020_09_23_308239	34	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	34	2	is	be	VBZ
10_1101-2020_09_23_308239	34	3	made	make	VBN
10_1101-2020_09_23_308239	34	4	available	available	JJ
10_1101-2020_09_23_308239	34	5	under	under	IN
10_1101-2020_09_23_308239	34	6	a	a	DT
10_1101-2020_09_23_308239	34	7	preprint	preprint	NN
10_1101-2020_09_23_308239	34	8	(	(	-LRB-
10_1101-2020_09_23_308239	34	9	which	which	WDT
10_1101-2020_09_23_308239	34	10	was	be	VBD
10_1101-2020_09_23_308239	34	11	not	not	RB
10_1101-2020_09_23_308239	34	12	certified	certify	VBN
10_1101-2020_09_23_308239	34	13	by	by	IN
10_1101-2020_09_23_308239	34	14	peer	peer	NN
10_1101-2020_09_23_308239	34	15	review	review	NN
10_1101-2020_09_23_308239	34	16	)	)	-RRB-
10_1101-2020_09_23_308239	34	17	is	be	VBZ
10_1101-2020_09_23_308239	34	18	the	the	DT
10_1101-2020_09_23_308239	34	19	author	author	NN
10_1101-2020_09_23_308239	34	20	/	/	SYM
10_1101-2020_09_23_308239	34	21	funder	funder	NN
10_1101-2020_09_23_308239	34	22	,	,	,
10_1101-2020_09_23_308239	34	23	who	who	WP
10_1101-2020_09_23_308239	34	24	has	have	VBZ
10_1101-2020_09_23_308239	34	25	granted	grant	VBN
10_1101-2020_09_23_308239	34	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	34	27	a	a	DT
10_1101-2020_09_23_308239	34	28	license	license	NN
10_1101-2020_09_23_308239	34	29	to	to	TO
10_1101-2020_09_23_308239	34	30	display	display	VB
10_1101-2020_09_23_308239	34	31	the	the	DT
10_1101-2020_09_23_308239	34	32	preprint	preprint	NN
10_1101-2020_09_23_308239	34	33	in	in	IN
10_1101-2020_09_23_308239	34	34	The	the	DT
10_1101-2020_09_23_308239	34	35	copyright	copyright	NN
10_1101-2020_09_23_308239	34	36	holder	holder	NN
10_1101-2020_09_23_308239	34	37	for	for	IN
10_1101-2020_09_23_308239	34	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	34	39	version	version	NN
10_1101-2020_09_23_308239	34	40	posted	post	VBD
10_1101-2020_09_23_308239	34	41	February	February	NNP
10_1101-2020_09_23_308239	34	42	12	12	CD
10_1101-2020_09_23_308239	34	43	,	,	,
10_1101-2020_09_23_308239	34	44	2021	2021	CD
10_1101-2020_09_23_308239	34	45	.	.	.
10_1101-2020_09_23_308239	34	46	;	;	:
10_1101-2020_09_23_308239	34	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	34	48	:	:	:
10_1101-2020_09_23_308239	34	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	34	50	preprint	preprint	NN
10_1101-2020_09_23_308239	34	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	34	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	34	53	6	6	CD
10_1101-2020_09_23_308239	34	54	Methodology	Methodology	NNP
10_1101-2020_09_23_308239	34	55	Generation	Generation	NNP
10_1101-2020_09_23_308239	34	56	of	of	IN
10_1101-2020_09_23_308239	34	57	the	the	DT
10_1101-2020_09_23_308239	34	58	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	34	59	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	34	60	Disparate	Disparate	NNP
10_1101-2020_09_23_308239	34	61	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	34	62	disease	disease	NN
10_1101-2020_09_23_308239	34	63	maps	map	NNS
10_1101-2020_09_23_308239	34	64	focus	focus	NN
10_1101-2020_09_23_308239	34	65	on	on	IN
10_1101-2020_09_23_308239	34	66	different	different	JJ
10_1101-2020_09_23_308239	34	67	aspects	aspect	NNS
10_1101-2020_09_23_308239	34	68	of	of	IN
10_1101-2020_09_23_308239	34	69	COVID-19	covid-19	NN
10_1101-2020_09_23_308239	34	70	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	34	71	.	.	.
10_1101-2020_09_23_308239	35	1	Based	base	VBN
10_1101-2020_09_23_308239	35	2	on	on	IN
10_1101-2020_09_23_308239	35	3	comparisons	comparison	NNS
10_1101-2020_09_23_308239	35	4	of	of	IN
10_1101-2020_09_23_308239	35	5	the	the	DT
10_1101-2020_09_23_308239	35	6	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	35	7	knowledge	knowledge	NN
10_1101-2020_09_23_308239	35	8	graphs	graphs	NNPS
10_1101-2020_09_23_308239	35	9	,	,	,
10_1101-2020_09_23_308239	35	10	we	-PRON-	PRP
10_1101-2020_09_23_308239	35	11	found	find	VBD
10_1101-2020_09_23_308239	35	12	that	that	IN
10_1101-2020_09_23_308239	35	13	not	not	RB
10_1101-2020_09_23_308239	35	14	a	a	DT
10_1101-2020_09_23_308239	35	15	single	single	JJ
10_1101-2020_09_23_308239	35	16	disease	disease	NN
10_1101-2020_09_23_308239	35	17	map	map	NN
10_1101-2020_09_23_308239	35	18	covers	cover	VBZ
10_1101-2020_09_23_308239	35	19	all	all	DT
10_1101-2020_09_23_308239	35	20	aspects	aspect	NNS
10_1101-2020_09_23_308239	35	21	relevant	relevant	JJ
10_1101-2020_09_23_308239	35	22	for	for	IN
10_1101-2020_09_23_308239	35	23	the	the	DT
10_1101-2020_09_23_308239	35	24	understanding	understanding	NN
10_1101-2020_09_23_308239	35	25	of	of	IN
10_1101-2020_09_23_308239	35	26	the	the	DT
10_1101-2020_09_23_308239	35	27	virus	virus	NN
10_1101-2020_09_23_308239	35	28	,	,	,
10_1101-2020_09_23_308239	35	29	host	host	NN
10_1101-2020_09_23_308239	35	30	interaction	interaction	NN
10_1101-2020_09_23_308239	35	31	and	and	CC
10_1101-2020_09_23_308239	35	32	the	the	DT
10_1101-2020_09_23_308239	35	33	resulting	result	VBG
10_1101-2020_09_23_308239	35	34	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	35	35	.	.	.
10_1101-2020_09_23_308239	36	1	Thus	thus	RB
10_1101-2020_09_23_308239	36	2	,	,	,
10_1101-2020_09_23_308239	36	3	we	-PRON-	PRP
10_1101-2020_09_23_308239	36	4	optimized	optimize	VBD
10_1101-2020_09_23_308239	36	5	the	the	DT
10_1101-2020_09_23_308239	36	6	representation	representation	NN
10_1101-2020_09_23_308239	36	7	of	of	IN
10_1101-2020_09_23_308239	36	8	essential	essential	JJ
10_1101-2020_09_23_308239	36	9	COVID-19	COVID-19	HYPH
10_1101-2020_09_23_308239	36	10	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	36	11	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	36	12	by	by	IN
10_1101-2020_09_23_308239	36	13	integrating	integrate	VBG
10_1101-2020_09_23_308239	36	14	several	several	JJ
10_1101-2020_09_23_308239	36	15	public	public	JJ
10_1101-2020_09_23_308239	36	16	and	and	CC
10_1101-2020_09_23_308239	36	17	proprietary	proprietary	JJ
10_1101-2020_09_23_308239	36	18	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	36	19	knowledge	knowledge	NN
10_1101-2020_09_23_308239	36	20	graphs	graphs	NNPS
10_1101-2020_09_23_308239	36	21	,	,	,
10_1101-2020_09_23_308239	36	22	disease	disease	NN
10_1101-2020_09_23_308239	36	23	maps	map	NNS
10_1101-2020_09_23_308239	36	24	,	,	,
10_1101-2020_09_23_308239	36	25	and	and	CC
10_1101-2020_09_23_308239	36	26	experimental	experimental	JJ
10_1101-2020_09_23_308239	36	27	data	datum	NNS
10_1101-2020_09_23_308239	36	28	(	(	-LRB-
10_1101-2020_09_23_308239	36	29	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	36	30	Table	Table	NNP
10_1101-2020_09_23_308239	36	31	1	1	CD
10_1101-2020_09_23_308239	36	32	)	)	-RRB-
10_1101-2020_09_23_308239	36	33	into	into	IN
10_1101-2020_09_23_308239	36	34	one	one	CD
10_1101-2020_09_23_308239	36	35	unified	unified	JJ
10_1101-2020_09_23_308239	36	36	knowledge	knowledge	NN
10_1101-2020_09_23_308239	36	37	graph	graph	NN
10_1101-2020_09_23_308239	36	38	,	,	,
10_1101-2020_09_23_308239	36	39	the	the	DT
10_1101-2020_09_23_308239	36	40	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	36	41	Supergraph	Supergraph	NNP
10_1101-2020_09_23_308239	36	42	.	.	.
10_1101-2020_09_23_308239	37	1	To	to	IN
10_1101-2020_09_23_308239	37	2	this	this	DT
10_1101-2020_09_23_308239	37	3	end	end	NN
10_1101-2020_09_23_308239	37	4	,	,	,
10_1101-2020_09_23_308239	37	5	we	-PRON-	PRP
10_1101-2020_09_23_308239	37	6	converted	convert	VBD
10_1101-2020_09_23_308239	37	7	all	all	DT
10_1101-2020_09_23_308239	37	8	knowledge	knowledge	NN
10_1101-2020_09_23_308239	37	9	graphs	graph	NNS
10_1101-2020_09_23_308239	37	10	and	and	CC
10_1101-2020_09_23_308239	37	11	interactomes	interactome	NNS
10_1101-2020_09_23_308239	37	12	into	into	IN
10_1101-2020_09_23_308239	37	13	OpenBEL28	OpenBEL28	NNP
10_1101-2020_09_23_308239	37	14	,	,	,
10_1101-2020_09_23_308239	37	15	a	a	DT
10_1101-2020_09_23_308239	37	16	language	language	NN
10_1101-2020_09_23_308239	37	17	that	that	WDT
10_1101-2020_09_23_308239	37	18	is	be	VBZ
10_1101-2020_09_23_308239	37	19	both	both	DT
10_1101-2020_09_23_308239	37	20	ideally	ideally	RB
10_1101-2020_09_23_308239	37	21	suited	suit	VBN
10_1101-2020_09_23_308239	37	22	to	to	TO
10_1101-2020_09_23_308239	37	23	capture	capture	VB
10_1101-2020_09_23_308239	37	24	and	and	CC
10_1101-2020_09_23_308239	37	25	to	to	TO
10_1101-2020_09_23_308239	37	26	represent	represent	VB
10_1101-2020_09_23_308239	37	27	“	"	``
10_1101-2020_09_23_308239	37	28	cause	cause	VB
10_1101-2020_09_23_308239	37	29	-	-	HYPH
10_1101-2020_09_23_308239	37	30	and	and	CC
10_1101-2020_09_23_308239	37	31	-	-	HYPH
10_1101-2020_09_23_308239	37	32	effect	effect	NN
10_1101-2020_09_23_308239	37	33	”	"	''
10_1101-2020_09_23_308239	37	34	relationships	relationship	NNS
10_1101-2020_09_23_308239	37	35	in	in	IN
10_1101-2020_09_23_308239	37	36	biomedicine	biomedicine	NN
10_1101-2020_09_23_308239	37	37	and	and	CC
10_1101-2020_09_23_308239	37	38	is	be	VBZ
10_1101-2020_09_23_308239	37	39	fully	fully	RB
10_1101-2020_09_23_308239	37	40	interoperable	interoperable	JJ
10_1101-2020_09_23_308239	37	41	with	with	IN
10_1101-2020_09_23_308239	37	42	major	major	JJ
10_1101-2020_09_23_308239	37	43	pathway	pathway	NN
10_1101-2020_09_23_308239	37	44	databases29	databases29	NNP
10_1101-2020_09_23_308239	37	45	30	30	CD
10_1101-2020_09_23_308239	37	46	.	.	.
10_1101-2020_09_23_308239	38	1	In	in	IN
10_1101-2020_09_23_308239	38	2	order	order	NN
10_1101-2020_09_23_308239	38	3	to	to	TO
10_1101-2020_09_23_308239	38	4	ensure	ensure	VB
10_1101-2020_09_23_308239	38	5	that	that	IN
10_1101-2020_09_23_308239	38	6	molecular	molecular	JJ
10_1101-2020_09_23_308239	38	7	interactions	interaction	NNS
10_1101-2020_09_23_308239	38	8	were	be	VBD
10_1101-2020_09_23_308239	38	9	correctly	correctly	RB
10_1101-2020_09_23_308239	38	10	normalized	normalize	VBN
10_1101-2020_09_23_308239	38	11	,	,	,
10_1101-2020_09_23_308239	38	12	individual	individual	JJ
10_1101-2020_09_23_308239	38	13	pipelines	pipeline	NNS
10_1101-2020_09_23_308239	38	14	were	be	VBD
10_1101-2020_09_23_308239	38	15	constructed	construct	VBN
10_1101-2020_09_23_308239	38	16	for	for	IN
10_1101-2020_09_23_308239	38	17	each	each	DT
10_1101-2020_09_23_308239	38	18	model	model	NN
10_1101-2020_09_23_308239	38	19	to	to	TO
10_1101-2020_09_23_308239	38	20	convert	convert	VB
10_1101-2020_09_23_308239	38	21	the	the	DT
10_1101-2020_09_23_308239	38	22	raw	raw	JJ
10_1101-2020_09_23_308239	38	23	data	datum	NNS
10_1101-2020_09_23_308239	38	24	to	to	IN
10_1101-2020_09_23_308239	38	25	the	the	DT
10_1101-2020_09_23_308239	38	26	OpenBEL	openbel	JJ
10_1101-2020_09_23_308239	38	27	format	format	NN
10_1101-2020_09_23_308239	38	28	.	.	.
10_1101-2020_09_23_308239	39	1	For	for	IN
10_1101-2020_09_23_308239	39	2	example	example	NN
10_1101-2020_09_23_308239	39	3	,	,	,
10_1101-2020_09_23_308239	39	4	the	the	DT
10_1101-2020_09_23_308239	39	5	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	39	6	Disease	Disease	NNP
10_1101-2020_09_23_308239	39	7	Map	Map	NNP
10_1101-2020_09_23_308239	39	8	contained	contain	VBD
10_1101-2020_09_23_308239	39	9	16	16	CD
10_1101-2020_09_23_308239	39	10	separate	separate	JJ
10_1101-2020_09_23_308239	39	11	files	file	NNS
10_1101-2020_09_23_308239	39	12	,	,	,
10_1101-2020_09_23_308239	39	13	each	each	DT
10_1101-2020_09_23_308239	39	14	of	of	IN
10_1101-2020_09_23_308239	39	15	which	which	WDT
10_1101-2020_09_23_308239	39	16	represented	represent	VBD
10_1101-2020_09_23_308239	39	17	a	a	DT
10_1101-2020_09_23_308239	39	18	specific	specific	JJ
10_1101-2020_09_23_308239	39	19	biological	biological	JJ
10_1101-2020_09_23_308239	39	20	focus	focus	NN
10_1101-2020_09_23_308239	39	21	of	of	IN
10_1101-2020_09_23_308239	39	22	the	the	DT
10_1101-2020_09_23_308239	39	23	virus	virus	NN
10_1101-2020_09_23_308239	39	24	.	.	.
10_1101-2020_09_23_308239	40	1	Each	each	DT
10_1101-2020_09_23_308239	40	2	file	file	NN
10_1101-2020_09_23_308239	40	3	was	be	VBD
10_1101-2020_09_23_308239	40	4	parsed	parse	VBN
10_1101-2020_09_23_308239	40	5	individually	individually	RB
10_1101-2020_09_23_308239	40	6	and	and	CC
10_1101-2020_09_23_308239	40	7	the	the	DT
10_1101-2020_09_23_308239	40	8	entities	entity	NNS
10_1101-2020_09_23_308239	40	9	and	and	CC
10_1101-2020_09_23_308239	40	10	relationships	relationship	NNS
10_1101-2020_09_23_308239	40	11	that	that	WDT
10_1101-2020_09_23_308239	40	12	did	do	VBD
10_1101-2020_09_23_308239	40	13	not	not	RB
10_1101-2020_09_23_308239	40	14	adhere	adhere	VB
10_1101-2020_09_23_308239	40	15	to	to	IN
10_1101-2020_09_23_308239	40	16	the	the	DT
10_1101-2020_09_23_308239	40	17	OpenBEL	openbel	ADD
10_1101-2020_09_23_308239	40	18	grammar	grammar	NN
10_1101-2020_09_23_308239	40	19	were	be	VBD
10_1101-2020_09_23_308239	40	20	mapped	map	VBN
10_1101-2020_09_23_308239	40	21	accordingly	accordingly	RB
10_1101-2020_09_23_308239	40	22	.	.	.
10_1101-2020_09_23_308239	41	1	Whilst	whilst	IN
10_1101-2020_09_23_308239	41	2	most	most	JJS
10_1101-2020_09_23_308239	41	3	of	of	IN
10_1101-2020_09_23_308239	41	4	the	the	DT
10_1101-2020_09_23_308239	41	5	entities	entity	NNS
10_1101-2020_09_23_308239	41	6	and	and	CC
10_1101-2020_09_23_308239	41	7	relationships	relationship	NNS
10_1101-2020_09_23_308239	41	8	in	in	IN
10_1101-2020_09_23_308239	41	9	the	the	DT
10_1101-2020_09_23_308239	41	10	source	source	NN
10_1101-2020_09_23_308239	41	11	disease	disease	NN
10_1101-2020_09_23_308239	41	12	maps	map	NNS
10_1101-2020_09_23_308239	41	13	could	could	MD
10_1101-2020_09_23_308239	41	14	be	be	VB
10_1101-2020_09_23_308239	41	15	readily	readily	RB
10_1101-2020_09_23_308239	41	16	translated	translate	VBN
10_1101-2020_09_23_308239	41	17	into	into	IN
10_1101-2020_09_23_308239	41	18	OpenBEL	openbel	NN
10_1101-2020_09_23_308239	41	19	,	,	,
10_1101-2020_09_23_308239	41	20	a	a	DT
10_1101-2020_09_23_308239	41	21	small	small	JJ
10_1101-2020_09_23_308239	41	22	number	number	NN
10_1101-2020_09_23_308239	41	23	of	of	IN
10_1101-2020_09_23_308239	41	24	triples	triple	NNS
10_1101-2020_09_23_308239	41	25	from	from	IN
10_1101-2020_09_23_308239	41	26	different	different	JJ
10_1101-2020_09_23_308239	41	27	source	source	NN
10_1101-2020_09_23_308239	41	28	disease	disease	NN
10_1101-2020_09_23_308239	41	29	maps	map	NNS
10_1101-2020_09_23_308239	41	30	required	require	VBD
10_1101-2020_09_23_308239	41	31	a	a	DT
10_1101-2020_09_23_308239	41	32	more	more	RBR
10_1101-2020_09_23_308239	41	33	in	in	IN
10_1101-2020_09_23_308239	41	34	-	-	HYPH
10_1101-2020_09_23_308239	41	35	depth	depth	NN
10_1101-2020_09_23_308239	41	36	transformation	transformation	NN
10_1101-2020_09_23_308239	41	37	.	.	.
10_1101-2020_09_23_308239	42	1	When	when	WRB
10_1101-2020_09_23_308239	42	2	classic	classic	JJ
10_1101-2020_09_23_308239	42	3	methods	method	NNS
10_1101-2020_09_23_308239	42	4	of	of	IN
10_1101-2020_09_23_308239	42	5	naming	naming	NN
10_1101-2020_09_23_308239	42	6	objects	object	NNS
10_1101-2020_09_23_308239	42	7	in	in	IN
10_1101-2020_09_23_308239	42	8	triples	triple	NNS
10_1101-2020_09_23_308239	42	9	failed	fail	VBD
10_1101-2020_09_23_308239	42	10	,	,	,
10_1101-2020_09_23_308239	42	11	the	the	DT
10_1101-2020_09_23_308239	42	12	recently	recently	RB
10_1101-2020_09_23_308239	42	13	generated	generate	VBN
10_1101-2020_09_23_308239	42	14	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	42	15	ontology31	ontology31	RB
10_1101-2020_09_23_308239	42	16	as	as	RB
10_1101-2020_09_23_308239	42	17	well	well	RB
10_1101-2020_09_23_308239	42	18	as	as	IN
10_1101-2020_09_23_308239	42	19	other	other	JJ
10_1101-2020_09_23_308239	42	20	available	available	JJ
10_1101-2020_09_23_308239	42	21	standard	standard	JJ
10_1101-2020_09_23_308239	42	22	ontologies	ontology	NNS
10_1101-2020_09_23_308239	42	23	and	and	CC
10_1101-2020_09_23_308239	42	24	vocabularies	vocabulary	NNS
10_1101-2020_09_23_308239	42	25	were	be	VBD
10_1101-2020_09_23_308239	42	26	used	use	VBN
10_1101-2020_09_23_308239	42	27	to	to	TO
10_1101-2020_09_23_308239	42	28	normalize	normalize	VB
10_1101-2020_09_23_308239	42	29	and	and	CC
10_1101-2020_09_23_308239	42	30	reference	reference	VB
10_1101-2020_09_23_308239	42	31	these	these	DT
10_1101-2020_09_23_308239	42	32	entities	entity	NNS
10_1101-2020_09_23_308239	42	33	.	.	.
10_1101-2020_09_23_308239	43	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	43	2	-	-	:
10_1101-2020_09_23_308239	43	3	BY	by	IN
10_1101-2020_09_23_308239	43	4	-	-	HYPH
10_1101-2020_09_23_308239	43	5	NC	NC	NNP
10_1101-2020_09_23_308239	43	6	-	-	HYPH
10_1101-2020_09_23_308239	43	7	ND	ND	NNP
10_1101-2020_09_23_308239	43	8	4.0	4.0	CD
10_1101-2020_09_23_308239	43	9	International	international	JJ
10_1101-2020_09_23_308239	43	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	43	11	.	.	.
10_1101-2020_09_23_308239	44	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	44	2	is	be	VBZ
10_1101-2020_09_23_308239	44	3	made	make	VBN
10_1101-2020_09_23_308239	44	4	available	available	JJ
10_1101-2020_09_23_308239	44	5	under	under	IN
10_1101-2020_09_23_308239	44	6	a	a	DT
10_1101-2020_09_23_308239	44	7	preprint	preprint	NN
10_1101-2020_09_23_308239	44	8	(	(	-LRB-
10_1101-2020_09_23_308239	44	9	which	which	WDT
10_1101-2020_09_23_308239	44	10	was	be	VBD
10_1101-2020_09_23_308239	44	11	not	not	RB
10_1101-2020_09_23_308239	44	12	certified	certify	VBN
10_1101-2020_09_23_308239	44	13	by	by	IN
10_1101-2020_09_23_308239	44	14	peer	peer	NN
10_1101-2020_09_23_308239	44	15	review	review	NN
10_1101-2020_09_23_308239	44	16	)	)	-RRB-
10_1101-2020_09_23_308239	44	17	is	be	VBZ
10_1101-2020_09_23_308239	44	18	the	the	DT
10_1101-2020_09_23_308239	44	19	author	author	NN
10_1101-2020_09_23_308239	44	20	/	/	SYM
10_1101-2020_09_23_308239	44	21	funder	funder	NN
10_1101-2020_09_23_308239	44	22	,	,	,
10_1101-2020_09_23_308239	44	23	who	who	WP
10_1101-2020_09_23_308239	44	24	has	have	VBZ
10_1101-2020_09_23_308239	44	25	granted	grant	VBN
10_1101-2020_09_23_308239	44	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	44	27	a	a	DT
10_1101-2020_09_23_308239	44	28	license	license	NN
10_1101-2020_09_23_308239	44	29	to	to	TO
10_1101-2020_09_23_308239	44	30	display	display	VB
10_1101-2020_09_23_308239	44	31	the	the	DT
10_1101-2020_09_23_308239	44	32	preprint	preprint	NN
10_1101-2020_09_23_308239	44	33	in	in	IN
10_1101-2020_09_23_308239	44	34	The	the	DT
10_1101-2020_09_23_308239	44	35	copyright	copyright	NN
10_1101-2020_09_23_308239	44	36	holder	holder	NN
10_1101-2020_09_23_308239	44	37	for	for	IN
10_1101-2020_09_23_308239	44	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	44	39	version	version	NN
10_1101-2020_09_23_308239	44	40	posted	post	VBD
10_1101-2020_09_23_308239	44	41	February	February	NNP
10_1101-2020_09_23_308239	44	42	12	12	CD
10_1101-2020_09_23_308239	44	43	,	,	,
10_1101-2020_09_23_308239	44	44	2021	2021	CD
10_1101-2020_09_23_308239	44	45	.	.	.
10_1101-2020_09_23_308239	44	46	;	;	:
10_1101-2020_09_23_308239	44	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	44	48	:	:	:
10_1101-2020_09_23_308239	44	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	44	50	preprint	preprint	NN
10_1101-2020_09_23_308239	44	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	44	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	44	53	7	7	CD
10_1101-2020_09_23_308239	44	54	In	in	IN
10_1101-2020_09_23_308239	44	55	addition	addition	NN
10_1101-2020_09_23_308239	44	56	to	to	IN
10_1101-2020_09_23_308239	44	57	combining	combine	VBG
10_1101-2020_09_23_308239	44	58	the	the	DT
10_1101-2020_09_23_308239	44	59	listed	list	VBN
10_1101-2020_09_23_308239	44	60	models	model	NNS
10_1101-2020_09_23_308239	44	61	,	,	,
10_1101-2020_09_23_308239	44	62	we	-PRON-	PRP
10_1101-2020_09_23_308239	44	63	also	also	RB
10_1101-2020_09_23_308239	44	64	performed	perform	VBD
10_1101-2020_09_23_308239	44	65	a	a	DT
10_1101-2020_09_23_308239	44	66	dedicated	dedicated	JJ
10_1101-2020_09_23_308239	44	67	curation	curation	NN
10_1101-2020_09_23_308239	44	68	of	of	IN
10_1101-2020_09_23_308239	44	69	the	the	DT
10_1101-2020_09_23_308239	44	70	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	44	71	supergraph	supergraph	NN
10_1101-2020_09_23_308239	44	72	in	in	IN
10_1101-2020_09_23_308239	44	73	order	order	NN
10_1101-2020_09_23_308239	44	74	to	to	TO
10_1101-2020_09_23_308239	44	75	annotate	annotate	VB
10_1101-2020_09_23_308239	44	76	the	the	DT
10_1101-2020_09_23_308239	44	77	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	44	78	pertaining	pertain	VBG
10_1101-2020_09_23_308239	44	79	to	to	IN
10_1101-2020_09_23_308239	44	80	selected	select	VBN
10_1101-2020_09_23_308239	44	81	targets	target	NNS
10_1101-2020_09_23_308239	44	82	and	and	CC
10_1101-2020_09_23_308239	44	83	the	the	DT
10_1101-2020_09_23_308239	44	84	biology	biology	NN
10_1101-2020_09_23_308239	44	85	around	around	IN
10_1101-2020_09_23_308239	44	86	prioritized	prioritize	VBD
10_1101-2020_09_23_308239	44	87	repurposing	repurposing	NN
10_1101-2020_09_23_308239	44	88	candidates	candidate	NNS
10_1101-2020_09_23_308239	44	89	.	.	.
10_1101-2020_09_23_308239	45	1	The	the	DT
10_1101-2020_09_23_308239	45	2	resulting	result	VBG
10_1101-2020_09_23_308239	45	3	BEL	BEL	NNP
10_1101-2020_09_23_308239	45	4	graphs	graph	NNS
10_1101-2020_09_23_308239	45	5	were	be	VBD
10_1101-2020_09_23_308239	45	6	quality	quality	NN
10_1101-2020_09_23_308239	45	7	controlled	control	VBN
10_1101-2020_09_23_308239	45	8	and	and	CC
10_1101-2020_09_23_308239	45	9	subsequently	subsequently	RB
10_1101-2020_09_23_308239	45	10	loaded	load	VBN
10_1101-2020_09_23_308239	45	11	into	into	IN
10_1101-2020_09_23_308239	45	12	a	a	DT
10_1101-2020_09_23_308239	45	13	dedicated	dedicated	JJ
10_1101-2020_09_23_308239	45	14	graph	graph	NN
10_1101-2020_09_23_308239	45	15	database	database	NN
10_1101-2020_09_23_308239	45	16	system	system	NN
10_1101-2020_09_23_308239	45	17	underlying	underlie	VBG
10_1101-2020_09_23_308239	45	18	the	the	DT
10_1101-2020_09_23_308239	45	19	Biomedical	Biomedical	NNP
10_1101-2020_09_23_308239	45	20	Knowledge	Knowledge	NNP
10_1101-2020_09_23_308239	45	21	Miner	Miner	NNP
10_1101-2020_09_23_308239	45	22	(	(	-LRB-
10_1101-2020_09_23_308239	45	23	BiKMi	BiKMi	NNP
10_1101-2020_09_23_308239	45	24	)	)	-RRB-
10_1101-2020_09_23_308239	45	25	,	,	,
10_1101-2020_09_23_308239	45	26	which	which	WDT
10_1101-2020_09_23_308239	45	27	allows	allow	VBZ
10_1101-2020_09_23_308239	45	28	for	for	IN
10_1101-2020_09_23_308239	45	29	comparison	comparison	NN
10_1101-2020_09_23_308239	45	30	and	and	CC
10_1101-2020_09_23_308239	45	31	extension	extension	NN
10_1101-2020_09_23_308239	45	32	of	of	IN
10_1101-2020_09_23_308239	45	33	biomedical	biomedical	JJ
10_1101-2020_09_23_308239	45	34	knowledge	knowledge	NN
10_1101-2020_09_23_308239	45	35	graphs	graphs	NN
10_1101-2020_09_23_308239	45	36	(	(	-LRB-
10_1101-2020_09_23_308239	45	37	see	see	VB
10_1101-2020_09_23_308239	45	38	http://bikmi.covid19-knowledgespace.de	http://bikmi.covid19-knowledgespace.de	NNP
10_1101-2020_09_23_308239	45	39	)	)	-RRB-
10_1101-2020_09_23_308239	45	40	.	.	.
10_1101-2020_09_23_308239	46	1	Once	once	IN
10_1101-2020_09_23_308239	46	2	the	the	DT
10_1101-2020_09_23_308239	46	3	models	model	NNS
10_1101-2020_09_23_308239	46	4	were	be	VBD
10_1101-2020_09_23_308239	46	5	converted	convert	VBN
10_1101-2020_09_23_308239	46	6	to	to	IN
10_1101-2020_09_23_308239	46	7	OpenBEL	OpenBEL	,
10_1101-2020_09_23_308239	46	8	and	and	CC
10_1101-2020_09_23_308239	46	9	imported	import	VBN
10_1101-2020_09_23_308239	46	10	into	into	IN
10_1101-2020_09_23_308239	46	11	the	the	DT
10_1101-2020_09_23_308239	46	12	database	database	NN
10_1101-2020_09_23_308239	46	13	,	,	,
10_1101-2020_09_23_308239	46	14	the	the	DT
10_1101-2020_09_23_308239	46	15	resulting	result	VBG
10_1101-2020_09_23_308239	46	16	nodes	node	NNS
10_1101-2020_09_23_308239	46	17	from	from	IN
10_1101-2020_09_23_308239	46	18	each	each	DT
10_1101-2020_09_23_308239	46	19	mechanism	mechanism	NN
10_1101-2020_09_23_308239	46	20	-	-	HYPH
10_1101-2020_09_23_308239	46	21	based	base	VBN
10_1101-2020_09_23_308239	46	22	model	model	NN
10_1101-2020_09_23_308239	46	23	were	be	VBD
10_1101-2020_09_23_308239	46	24	compared	compare	VBN
10_1101-2020_09_23_308239	46	25	(	(	-LRB-
10_1101-2020_09_23_308239	46	26	Figure	figure	NN
10_1101-2020_09_23_308239	46	27	1	1	CD
10_1101-2020_09_23_308239	46	28	)	)	-RRB-
10_1101-2020_09_23_308239	46	29	.	.	.
10_1101-2020_09_23_308239	47	1	Even	even	RB
10_1101-2020_09_23_308239	47	2	when	when	WRB
10_1101-2020_09_23_308239	47	3	separated	separate	VBN
10_1101-2020_09_23_308239	47	4	by	by	IN
10_1101-2020_09_23_308239	47	5	data	datum	NNS
10_1101-2020_09_23_308239	47	6	origin	origin	NN
10_1101-2020_09_23_308239	47	7	type	type	NN
10_1101-2020_09_23_308239	47	8	,	,	,
10_1101-2020_09_23_308239	47	9	the	the	DT
10_1101-2020_09_23_308239	47	10	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	47	11	knowledge	knowledge	NN
10_1101-2020_09_23_308239	47	12	graphs	graphs	NNPS
10_1101-2020_09_23_308239	47	13	had	have	VBD
10_1101-2020_09_23_308239	47	14	very	very	RB
10_1101-2020_09_23_308239	47	15	little	little	JJ
10_1101-2020_09_23_308239	47	16	overlap	overlap	NN
10_1101-2020_09_23_308239	47	17	(	(	-LRB-
10_1101-2020_09_23_308239	47	18	3	3	CD
10_1101-2020_09_23_308239	47	19	shared	share	VBN
10_1101-2020_09_23_308239	47	20	nodes	node	NNS
10_1101-2020_09_23_308239	47	21	between	between	IN
10_1101-2020_09_23_308239	47	22	all	all	DT
10_1101-2020_09_23_308239	47	23	manually	manually	RB
10_1101-2020_09_23_308239	47	24	curated	curate	VBN
10_1101-2020_09_23_308239	47	25	models	model	NNS
10_1101-2020_09_23_308239	47	26	and	and	CC
10_1101-2020_09_23_308239	47	27	no	no	DT
10_1101-2020_09_23_308239	47	28	shared	share	VBN
10_1101-2020_09_23_308239	47	29	nodes	node	NNS
10_1101-2020_09_23_308239	47	30	between	between	IN
10_1101-2020_09_23_308239	47	31	all	all	DT
10_1101-2020_09_23_308239	47	32	models	model	NNS
10_1101-2020_09_23_308239	47	33	derived	derive	VBN
10_1101-2020_09_23_308239	47	34	from	from	IN
10_1101-2020_09_23_308239	47	35	interaction	interaction	NN
10_1101-2020_09_23_308239	47	36	databases	database	NNS
10_1101-2020_09_23_308239	47	37	)	)	-RRB-
10_1101-2020_09_23_308239	47	38	,	,	,
10_1101-2020_09_23_308239	47	39	but	but	CC
10_1101-2020_09_23_308239	47	40	by	by	IN
10_1101-2020_09_23_308239	47	41	unifying	unify	VBG
10_1101-2020_09_23_308239	47	42	the	the	DT
10_1101-2020_09_23_308239	47	43	models	model	NNS
10_1101-2020_09_23_308239	47	44	,	,	,
10_1101-2020_09_23_308239	47	45	our	-PRON-	PRP$
10_1101-2020_09_23_308239	47	46	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	47	47	supergraph	supergraph	NN
10_1101-2020_09_23_308239	47	48	improves	improve	VBZ
10_1101-2020_09_23_308239	47	49	the	the	DT
10_1101-2020_09_23_308239	47	50	coverage	coverage	NN
10_1101-2020_09_23_308239	47	51	of	of	IN
10_1101-2020_09_23_308239	47	52	essential	essential	JJ
10_1101-2020_09_23_308239	47	53	virus-	virus-	NN
10_1101-2020_09_23_308239	47	54	and	and	CC
10_1101-2020_09_23_308239	47	55	host	host	NN
10_1101-2020_09_23_308239	47	56	-	-	HYPH
10_1101-2020_09_23_308239	47	57	physiology	physiology	NN
10_1101-2020_09_23_308239	47	58	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	47	59	substantially	substantially	RB
10_1101-2020_09_23_308239	47	60	.	.	.
10_1101-2020_09_23_308239	48	1	Figure	figure	NN
10_1101-2020_09_23_308239	48	2	1	1	CD
10_1101-2020_09_23_308239	48	3	:	:	:
10_1101-2020_09_23_308239	48	4	Venn	Venn	NNP
10_1101-2020_09_23_308239	48	5	diagrams	diagram	NNS
10_1101-2020_09_23_308239	48	6	comparing	compare	VBG
10_1101-2020_09_23_308239	48	7	major	major	JJ
10_1101-2020_09_23_308239	48	8	mechanistic	mechanistic	JJ
10_1101-2020_09_23_308239	48	9	models	model	NNS
10_1101-2020_09_23_308239	48	10	in	in	IN
10_1101-2020_09_23_308239	48	11	the	the	DT
10_1101-2020_09_23_308239	48	12	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	48	13	supergraph	supergraph	NN
10_1101-2020_09_23_308239	48	14	.	.	.
10_1101-2020_09_23_308239	49	1	Mechanism	Mechanism	NNP
10_1101-2020_09_23_308239	49	2	-	-	HYPH
10_1101-2020_09_23_308239	49	3	based	base	VBN
10_1101-2020_09_23_308239	49	4	models	model	NNS
10_1101-2020_09_23_308239	49	5	were	be	VBD
10_1101-2020_09_23_308239	49	6	divided	divide	VBN
10_1101-2020_09_23_308239	49	7	,	,	,
10_1101-2020_09_23_308239	49	8	and	and	CC
10_1101-2020_09_23_308239	49	9	their	-PRON-	PRP$
10_1101-2020_09_23_308239	49	10	entities	entity	NNS
10_1101-2020_09_23_308239	49	11	compared	compare	VBN
10_1101-2020_09_23_308239	49	12	within	within	IN
10_1101-2020_09_23_308239	49	13	their	-PRON-	PRP$
10_1101-2020_09_23_308239	49	14	resulting	result	VBG
10_1101-2020_09_23_308239	49	15	subgroups	subgroup	NNS
10_1101-2020_09_23_308239	49	16	.	.	.
10_1101-2020_09_23_308239	50	1	Model	model	NN
10_1101-2020_09_23_308239	50	2	abbreviations	abbreviation	NNS
10_1101-2020_09_23_308239	50	3	are	be	VBP
10_1101-2020_09_23_308239	50	4	defined	define	VBN
10_1101-2020_09_23_308239	50	5	in	in	IN
10_1101-2020_09_23_308239	50	6	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	50	7	Table	Table	NNP
10_1101-2020_09_23_308239	50	8	1	1	CD
10_1101-2020_09_23_308239	50	9	.	.	.
10_1101-2020_09_23_308239	50	10	a	a	LS
10_1101-2020_09_23_308239	50	11	)	)	-RRB-
10_1101-2020_09_23_308239	50	12	Manual	Manual	NNP
10_1101-2020_09_23_308239	50	13	node	node	NN
10_1101-2020_09_23_308239	50	14	comparison	comparison	NN
10_1101-2020_09_23_308239	50	15	shows	show	VBZ
10_1101-2020_09_23_308239	50	16	the	the	DT
10_1101-2020_09_23_308239	50	17	overlap	overlap	NN
10_1101-2020_09_23_308239	50	18	of	of	IN
10_1101-2020_09_23_308239	50	19	entities	entity	NNS
10_1101-2020_09_23_308239	50	20	in	in	IN
10_1101-2020_09_23_308239	50	21	the	the	DT
10_1101-2020_09_23_308239	50	22	models	model	NNS
10_1101-2020_09_23_308239	50	23	that	that	WDT
10_1101-2020_09_23_308239	50	24	are	be	VBP
10_1101-2020_09_23_308239	50	25	knowledge	knowledge	NN
10_1101-2020_09_23_308239	50	26	-	-	HYPH
10_1101-2020_09_23_308239	50	27	based	base	VBN
10_1101-2020_09_23_308239	50	28	,	,	,
10_1101-2020_09_23_308239	50	29	manually	manually	RB
10_1101-2020_09_23_308239	50	30	curated	curate	VBD
10_1101-2020_09_23_308239	50	31	relationships	relationship	NNS
10_1101-2020_09_23_308239	50	32	that	that	WDT
10_1101-2020_09_23_308239	50	33	have	have	VBP
10_1101-2020_09_23_308239	50	34	been	be	VBN
10_1101-2020_09_23_308239	50	35	directly	directly	RB
10_1101-2020_09_23_308239	50	36	encoded	encode	VBN
10_1101-2020_09_23_308239	50	37	in	in	IN
10_1101-2020_09_23_308239	50	38	OpenBEL	openbel	ADD
10_1101-2020_09_23_308239	50	39	.	.	.
10_1101-2020_09_23_308239	51	1	b	b	LS
10_1101-2020_09_23_308239	51	2	)	)	-RRB-
10_1101-2020_09_23_308239	51	3	Automated	Automated	NNP
10_1101-2020_09_23_308239	51	4	node	node	NN
10_1101-2020_09_23_308239	51	5	comparison	comparison	NN
10_1101-2020_09_23_308239	51	6	shows	show	VBZ
10_1101-2020_09_23_308239	51	7	the	the	DT
10_1101-2020_09_23_308239	51	8	overlap	overlap	NN
10_1101-2020_09_23_308239	51	9	of	of	IN
10_1101-2020_09_23_308239	51	10	entities	entity	NNS
10_1101-2020_09_23_308239	51	11	in	in	IN
10_1101-2020_09_23_308239	51	12	models	model	NNS
10_1101-2020_09_23_308239	51	13	re	re	VBP
10_1101-2020_09_23_308239	51	14	-	-	VBD
10_1101-2020_09_23_308239	51	15	encoded	encode	VBD
10_1101-2020_09_23_308239	51	16	into	into	IN
10_1101-2020_09_23_308239	51	17	OpenBEL	OpenBEL	NNP
10_1101-2020_09_23_308239	51	18	from	from	IN
10_1101-2020_09_23_308239	51	19	other	other	JJ
10_1101-2020_09_23_308239	51	20	formats	format	NNS
10_1101-2020_09_23_308239	51	21	(	(	-LRB-
10_1101-2020_09_23_308239	51	22	e.g.	e.g.	RB
10_1101-2020_09_23_308239	52	1	SBML	SBML	NNP
10_1101-2020_09_23_308239	52	2	models	model	NNS
10_1101-2020_09_23_308239	52	3	)	)	-RRB-
10_1101-2020_09_23_308239	52	4	.	.	.
10_1101-2020_09_23_308239	53	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	53	2	-	-	:
10_1101-2020_09_23_308239	53	3	BY	by	IN
10_1101-2020_09_23_308239	53	4	-	-	HYPH
10_1101-2020_09_23_308239	53	5	NC	NC	NNP
10_1101-2020_09_23_308239	53	6	-	-	HYPH
10_1101-2020_09_23_308239	53	7	ND	ND	NNP
10_1101-2020_09_23_308239	53	8	4.0	4.0	CD
10_1101-2020_09_23_308239	53	9	International	international	JJ
10_1101-2020_09_23_308239	53	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	53	11	.	.	.
10_1101-2020_09_23_308239	54	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	54	2	is	be	VBZ
10_1101-2020_09_23_308239	54	3	made	make	VBN
10_1101-2020_09_23_308239	54	4	available	available	JJ
10_1101-2020_09_23_308239	54	5	under	under	IN
10_1101-2020_09_23_308239	54	6	a	a	DT
10_1101-2020_09_23_308239	54	7	preprint	preprint	NN
10_1101-2020_09_23_308239	54	8	(	(	-LRB-
10_1101-2020_09_23_308239	54	9	which	which	WDT
10_1101-2020_09_23_308239	54	10	was	be	VBD
10_1101-2020_09_23_308239	54	11	not	not	RB
10_1101-2020_09_23_308239	54	12	certified	certify	VBN
10_1101-2020_09_23_308239	54	13	by	by	IN
10_1101-2020_09_23_308239	54	14	peer	peer	NN
10_1101-2020_09_23_308239	54	15	review	review	NN
10_1101-2020_09_23_308239	54	16	)	)	-RRB-
10_1101-2020_09_23_308239	54	17	is	be	VBZ
10_1101-2020_09_23_308239	54	18	the	the	DT
10_1101-2020_09_23_308239	54	19	author	author	NN
10_1101-2020_09_23_308239	54	20	/	/	SYM
10_1101-2020_09_23_308239	54	21	funder	funder	NN
10_1101-2020_09_23_308239	54	22	,	,	,
10_1101-2020_09_23_308239	54	23	who	who	WP
10_1101-2020_09_23_308239	54	24	has	have	VBZ
10_1101-2020_09_23_308239	54	25	granted	grant	VBN
10_1101-2020_09_23_308239	54	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	54	27	a	a	DT
10_1101-2020_09_23_308239	54	28	license	license	NN
10_1101-2020_09_23_308239	54	29	to	to	TO
10_1101-2020_09_23_308239	54	30	display	display	VB
10_1101-2020_09_23_308239	54	31	the	the	DT
10_1101-2020_09_23_308239	54	32	preprint	preprint	NN
10_1101-2020_09_23_308239	54	33	in	in	IN
10_1101-2020_09_23_308239	54	34	The	the	DT
10_1101-2020_09_23_308239	54	35	copyright	copyright	NN
10_1101-2020_09_23_308239	54	36	holder	holder	NN
10_1101-2020_09_23_308239	54	37	for	for	IN
10_1101-2020_09_23_308239	54	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	54	39	version	version	NN
10_1101-2020_09_23_308239	54	40	posted	post	VBD
10_1101-2020_09_23_308239	54	41	February	February	NNP
10_1101-2020_09_23_308239	54	42	12	12	CD
10_1101-2020_09_23_308239	54	43	,	,	,
10_1101-2020_09_23_308239	54	44	2021	2021	CD
10_1101-2020_09_23_308239	54	45	.	.	.
10_1101-2020_09_23_308239	54	46	;	;	:
10_1101-2020_09_23_308239	54	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	54	48	:	:	:
10_1101-2020_09_23_308239	54	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	54	50	preprint	preprint	NN
10_1101-2020_09_23_308239	54	51	http://bikmi.covid19-knowledgespace.de/	http://bikmi.covid19-knowledgespace.de/	NNP
10_1101-2020_09_23_308239	54	52	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	NNP
10_1101-2020_09_23_308239	54	53	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NNP
10_1101-2020_09_23_308239	54	54	8	8	CD
10_1101-2020_09_23_308239	54	55	Additionally	additionally	RB
10_1101-2020_09_23_308239	54	56	,	,	,
10_1101-2020_09_23_308239	54	57	by	by	IN
10_1101-2020_09_23_308239	54	58	enriching	enrich	VBG
10_1101-2020_09_23_308239	54	59	the	the	DT
10_1101-2020_09_23_308239	54	60	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	54	61	supergraph	supergraph	NN
10_1101-2020_09_23_308239	54	62	with	with	IN
10_1101-2020_09_23_308239	54	63	drug	drug	NN
10_1101-2020_09_23_308239	54	64	-	-	HYPH
10_1101-2020_09_23_308239	54	65	target	target	NN
10_1101-2020_09_23_308239	54	66	information	information	NN
10_1101-2020_09_23_308239	54	67	linked	link	VBN
10_1101-2020_09_23_308239	54	68	from	from	IN
10_1101-2020_09_23_308239	54	69	highly	highly	RB
10_1101-2020_09_23_308239	54	70	curated	curate	VBN
10_1101-2020_09_23_308239	54	71	drug	drug	NN
10_1101-2020_09_23_308239	54	72	-	-	HYPH
10_1101-2020_09_23_308239	54	73	target	target	NN
10_1101-2020_09_23_308239	54	74	databases	database	NNS
10_1101-2020_09_23_308239	54	75	(	(	-LRB-
10_1101-2020_09_23_308239	54	76	DrugBank	DrugBank	NNP
10_1101-2020_09_23_308239	54	77	,	,	,
10_1101-2020_09_23_308239	54	78	ChEMBL	ChEMBL	NNP
10_1101-2020_09_23_308239	54	79	,	,	,
10_1101-2020_09_23_308239	54	80	PubChem	PubChem	NNP
10_1101-2020_09_23_308239	54	81	)	)	-RRB-
10_1101-2020_09_23_308239	54	82	,	,	,
10_1101-2020_09_23_308239	54	83	we	-PRON-	PRP
10_1101-2020_09_23_308239	54	84	created	create	VBD
10_1101-2020_09_23_308239	54	85	an	an	DT
10_1101-2020_09_23_308239	54	86	initial	initial	JJ
10_1101-2020_09_23_308239	54	87	version	version	NN
10_1101-2020_09_23_308239	54	88	of	of	IN
10_1101-2020_09_23_308239	54	89	the	the	DT
10_1101-2020_09_23_308239	54	90	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	54	91	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	54	92	,	,	,
10_1101-2020_09_23_308239	54	93	a	a	DT
10_1101-2020_09_23_308239	54	94	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	54	95	drug	drug	NN
10_1101-2020_09_23_308239	54	96	-	-	HYPH
10_1101-2020_09_23_308239	54	97	target	target	NN
10_1101-2020_09_23_308239	54	98	-	-	HYPH
10_1101-2020_09_23_308239	54	99	mechanism	mechanism	NN
10_1101-2020_09_23_308239	54	100	graph	graph	NN
10_1101-2020_09_23_308239	54	101	representing	representing	NN
10_1101-2020_09_23_308239	54	102	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	54	103	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	54	104	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	54	105	that	that	WDT
10_1101-2020_09_23_308239	54	106	includes	include	VBZ
10_1101-2020_09_23_308239	54	107	both	both	DT
10_1101-2020_09_23_308239	54	108	drug	drug	NN
10_1101-2020_09_23_308239	54	109	targets	target	NNS
10_1101-2020_09_23_308239	54	110	and	and	CC
10_1101-2020_09_23_308239	54	111	their	-PRON-	PRP$
10_1101-2020_09_23_308239	54	112	ligands	ligand	NNS
10_1101-2020_09_23_308239	54	113	(	(	-LRB-
10_1101-2020_09_23_308239	54	114	Figure	figure	NN
10_1101-2020_09_23_308239	54	115	2	2	CD
10_1101-2020_09_23_308239	54	116	)	)	-RRB-
10_1101-2020_09_23_308239	54	117	.	.	.
10_1101-2020_09_23_308239	55	1	In	in	IN
10_1101-2020_09_23_308239	55	2	order	order	NN
10_1101-2020_09_23_308239	55	3	to	to	TO
10_1101-2020_09_23_308239	55	4	maximize	maximize	VB
10_1101-2020_09_23_308239	55	5	its	-PRON-	PRP$
10_1101-2020_09_23_308239	55	6	utility	utility	NN
10_1101-2020_09_23_308239	55	7	,	,	,
10_1101-2020_09_23_308239	55	8	this	this	DT
10_1101-2020_09_23_308239	55	9	network	network	NN
10_1101-2020_09_23_308239	55	10	includes	include	VBZ
10_1101-2020_09_23_308239	55	11	both	both	DT
10_1101-2020_09_23_308239	55	12	experimentally	experimentally	RB
10_1101-2020_09_23_308239	55	13	validated	validate	VBN
10_1101-2020_09_23_308239	55	14	drug	drug	NN
10_1101-2020_09_23_308239	55	15	-	-	HYPH
10_1101-2020_09_23_308239	55	16	target	target	NN
10_1101-2020_09_23_308239	55	17	relationships	relationship	NNS
10_1101-2020_09_23_308239	55	18	as	as	RB
10_1101-2020_09_23_308239	55	19	well	well	RB
10_1101-2020_09_23_308239	55	20	as	as	IN
10_1101-2020_09_23_308239	55	21	a	a	DT
10_1101-2020_09_23_308239	55	22	wide	wide	JJ
10_1101-2020_09_23_308239	55	23	distribution	distribution	NN
10_1101-2020_09_23_308239	55	24	of	of	IN
10_1101-2020_09_23_308239	55	25	biological	biological	JJ
10_1101-2020_09_23_308239	55	26	entities	entity	NNS
10_1101-2020_09_23_308239	55	27	and	and	CC
10_1101-2020_09_23_308239	55	28	concepts	concept	NNS
10_1101-2020_09_23_308239	55	29	(	(	-LRB-
10_1101-2020_09_23_308239	55	30	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	55	31	Figure	Figure	NNP
10_1101-2020_09_23_308239	55	32	1	1	CD
10_1101-2020_09_23_308239	55	33	)	)	-RRB-
10_1101-2020_09_23_308239	55	34	.	.	.
10_1101-2020_09_23_308239	56	1	The	the	DT
10_1101-2020_09_23_308239	56	2	entire	entire	JJ
10_1101-2020_09_23_308239	56	3	COVID-19	COVID-19	:
10_1101-2020_09_23_308239	56	4	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	56	5	was	be	VBD
10_1101-2020_09_23_308239	56	6	manually	manually	RB
10_1101-2020_09_23_308239	56	7	inspected	inspect	VBN
10_1101-2020_09_23_308239	56	8	and	and	CC
10_1101-2020_09_23_308239	56	9	re	re	RB
10_1101-2020_09_23_308239	56	10	-	-	VBN
10_1101-2020_09_23_308239	56	11	curated	curated	JJ
10_1101-2020_09_23_308239	56	12	;	;	:
10_1101-2020_09_23_308239	56	13	this	this	DT
10_1101-2020_09_23_308239	56	14	graph	graph	NN
10_1101-2020_09_23_308239	56	15	database	database	NN
10_1101-2020_09_23_308239	56	16	is	be	VBZ
10_1101-2020_09_23_308239	56	17	openly	openly	RB
10_1101-2020_09_23_308239	56	18	accessible	accessible	JJ
10_1101-2020_09_23_308239	56	19	to	to	IN
10_1101-2020_09_23_308239	56	20	the	the	DT
10_1101-2020_09_23_308239	56	21	scientific	scientific	JJ
10_1101-2020_09_23_308239	56	22	community	community	NN
10_1101-2020_09_23_308239	56	23	at	at	IN
10_1101-2020_09_23_308239	56	24	http://graphstore.scai.fraunhofer.de	http://graphstore.scai.fraunhofer.de	NNP
10_1101-2020_09_23_308239	56	25	.	.	.
10_1101-2020_09_23_308239	57	1	Figure	figure	NN
10_1101-2020_09_23_308239	57	2	2	2	CD
10_1101-2020_09_23_308239	57	3	:	:	:
10_1101-2020_09_23_308239	57	4	The	the	DT
10_1101-2020_09_23_308239	57	5	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	57	6	supergraph	supergraph	NN
10_1101-2020_09_23_308239	57	7	integrates	integrate	VBZ
10_1101-2020_09_23_308239	57	8	drug	drug	NN
10_1101-2020_09_23_308239	57	9	-	-	HYPH
10_1101-2020_09_23_308239	57	10	target	target	NN
10_1101-2020_09_23_308239	57	11	information	information	NN
10_1101-2020_09_23_308239	57	12	to	to	TO
10_1101-2020_09_23_308239	57	13	form	form	VB
10_1101-2020_09_23_308239	57	14	the	the	DT
10_1101-2020_09_23_308239	57	15	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	57	16	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	57	17	.	.	.
10_1101-2020_09_23_308239	58	1	a	a	LS
10_1101-2020_09_23_308239	58	2	)	)	-RRB-
10_1101-2020_09_23_308239	58	3	An	an	DT
10_1101-2020_09_23_308239	58	4	aggregate	aggregate	NN
10_1101-2020_09_23_308239	58	5	of	of	IN
10_1101-2020_09_23_308239	58	6	10	10	CD
10_1101-2020_09_23_308239	58	7	constituent	constituent	NN
10_1101-2020_09_23_308239	58	8	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	58	9	computable	computable	JJ
10_1101-2020_09_23_308239	58	10	models	model	NNS
10_1101-2020_09_23_308239	58	11	covering	cover	VBG
10_1101-2020_09_23_308239	58	12	a	a	DT
10_1101-2020_09_23_308239	58	13	wide	wide	JJ
10_1101-2020_09_23_308239	58	14	spectrum	spectrum	NN
10_1101-2020_09_23_308239	58	15	of	of	IN
10_1101-2020_09_23_308239	58	16	pathophysiological	pathophysiological	JJ
10_1101-2020_09_23_308239	58	17	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	58	18	associated	associate	VBN
10_1101-2020_09_23_308239	58	19	with	with	IN
10_1101-2020_09_23_308239	58	20	SARS	SARS	NNP
10_1101-2020_09_23_308239	58	21	-	-	HYPH
10_1101-2020_09_23_308239	58	22	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	58	23	infection	infection	NN
10_1101-2020_09_23_308239	58	24	or	or	CC
10_1101-2020_09_23_308239	58	25	harmonized	harmonize	VBD
10_1101-2020_09_23_308239	58	26	to	to	TO
10_1101-2020_09_23_308239	58	27	generate	generate	VB
10_1101-2020_09_23_308239	58	28	the	the	DT
10_1101-2020_09_23_308239	58	29	mechanism	mechanism	NN
10_1101-2020_09_23_308239	58	30	-	-	HYPH
10_1101-2020_09_23_308239	58	31	based	base	VBN
10_1101-2020_09_23_308239	58	32	COVID-19	covid-19	NN
10_1101-2020_09_23_308239	58	33	supergraph	supergraph	NN
10_1101-2020_09_23_308239	58	34	.	.	.
10_1101-2020_09_23_308239	59	1	b	b	LS
10_1101-2020_09_23_308239	59	2	)	)	-RRB-
10_1101-2020_09_23_308239	59	3	The	the	DT
10_1101-2020_09_23_308239	59	4	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	59	5	supergraph	supergraph	NN
10_1101-2020_09_23_308239	59	6	is	be	VBZ
10_1101-2020_09_23_308239	59	7	annotated	annotate	VBN
10_1101-2020_09_23_308239	59	8	with	with	IN
10_1101-2020_09_23_308239	59	9	drug	drug	NN
10_1101-2020_09_23_308239	59	10	-	-	HYPH
10_1101-2020_09_23_308239	59	11	target	target	NN
10_1101-2020_09_23_308239	59	12	information	information	NN
10_1101-2020_09_23_308239	59	13	from	from	IN
10_1101-2020_09_23_308239	59	14	a	a	DT
10_1101-2020_09_23_308239	59	15	variety	variety	NN
10_1101-2020_09_23_308239	59	16	of	of	IN
10_1101-2020_09_23_308239	59	17	curated	curate	VBN
10_1101-2020_09_23_308239	59	18	sources	source	NNS
10_1101-2020_09_23_308239	59	19	to	to	TO
10_1101-2020_09_23_308239	59	20	generate	generate	VB
10_1101-2020_09_23_308239	59	21	the	the	DT
10_1101-2020_09_23_308239	59	22	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	59	23	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	59	24	composed	compose	VBN
10_1101-2020_09_23_308239	59	25	of	of	IN
10_1101-2020_09_23_308239	59	26	150662	150662	CD
10_1101-2020_09_23_308239	59	27	nodes	node	NNS
10_1101-2020_09_23_308239	59	28	(	(	-LRB-
10_1101-2020_09_23_308239	59	29	representing	represent	VBG
10_1101-2020_09_23_308239	59	30	proteins	protein	NNS
10_1101-2020_09_23_308239	59	31	,	,	,
10_1101-2020_09_23_308239	59	32	.CC	.CC	:
10_1101-2020_09_23_308239	59	33	-	-	:
10_1101-2020_09_23_308239	59	34	BY	by	IN
10_1101-2020_09_23_308239	59	35	-	-	HYPH
10_1101-2020_09_23_308239	59	36	NC	NC	NNP
10_1101-2020_09_23_308239	59	37	-	-	HYPH
10_1101-2020_09_23_308239	59	38	ND	ND	NNP
10_1101-2020_09_23_308239	59	39	4.0	4.0	CD
10_1101-2020_09_23_308239	59	40	International	international	JJ
10_1101-2020_09_23_308239	59	41	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	59	42	.	.	.
10_1101-2020_09_23_308239	60	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	60	2	is	be	VBZ
10_1101-2020_09_23_308239	60	3	made	make	VBN
10_1101-2020_09_23_308239	60	4	available	available	JJ
10_1101-2020_09_23_308239	60	5	under	under	IN
10_1101-2020_09_23_308239	60	6	a	a	DT
10_1101-2020_09_23_308239	60	7	preprint	preprint	NN
10_1101-2020_09_23_308239	60	8	(	(	-LRB-
10_1101-2020_09_23_308239	60	9	which	which	WDT
10_1101-2020_09_23_308239	60	10	was	be	VBD
10_1101-2020_09_23_308239	60	11	not	not	RB
10_1101-2020_09_23_308239	60	12	certified	certify	VBN
10_1101-2020_09_23_308239	60	13	by	by	IN
10_1101-2020_09_23_308239	60	14	peer	peer	NN
10_1101-2020_09_23_308239	60	15	review	review	NN
10_1101-2020_09_23_308239	60	16	)	)	-RRB-
10_1101-2020_09_23_308239	60	17	is	be	VBZ
10_1101-2020_09_23_308239	60	18	the	the	DT
10_1101-2020_09_23_308239	60	19	author	author	NN
10_1101-2020_09_23_308239	60	20	/	/	SYM
10_1101-2020_09_23_308239	60	21	funder	funder	NN
10_1101-2020_09_23_308239	60	22	,	,	,
10_1101-2020_09_23_308239	60	23	who	who	WP
10_1101-2020_09_23_308239	60	24	has	have	VBZ
10_1101-2020_09_23_308239	60	25	granted	grant	VBN
10_1101-2020_09_23_308239	60	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	60	27	a	a	DT
10_1101-2020_09_23_308239	60	28	license	license	NN
10_1101-2020_09_23_308239	60	29	to	to	TO
10_1101-2020_09_23_308239	60	30	display	display	VB
10_1101-2020_09_23_308239	60	31	the	the	DT
10_1101-2020_09_23_308239	60	32	preprint	preprint	NN
10_1101-2020_09_23_308239	60	33	in	in	IN
10_1101-2020_09_23_308239	60	34	The	the	DT
10_1101-2020_09_23_308239	60	35	copyright	copyright	NN
10_1101-2020_09_23_308239	60	36	holder	holder	NN
10_1101-2020_09_23_308239	60	37	for	for	IN
10_1101-2020_09_23_308239	60	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	60	39	version	version	NN
10_1101-2020_09_23_308239	60	40	posted	post	VBD
10_1101-2020_09_23_308239	60	41	February	February	NNP
10_1101-2020_09_23_308239	60	42	12	12	CD
10_1101-2020_09_23_308239	60	43	,	,	,
10_1101-2020_09_23_308239	60	44	2021	2021	CD
10_1101-2020_09_23_308239	60	45	.	.	.
10_1101-2020_09_23_308239	60	46	;	;	:
10_1101-2020_09_23_308239	60	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	60	48	:	:	:
10_1101-2020_09_23_308239	60	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	60	50	preprint	preprint	NN
10_1101-2020_09_23_308239	60	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	60	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	60	53	9	9	CD
10_1101-2020_09_23_308239	60	54	pathologies	pathology	NNS
10_1101-2020_09_23_308239	60	55	,	,	,
10_1101-2020_09_23_308239	60	56	and	and	CC
10_1101-2020_09_23_308239	60	57	other	other	JJ
10_1101-2020_09_23_308239	60	58	biological	biological	JJ
10_1101-2020_09_23_308239	60	59	entities	entity	NNS
10_1101-2020_09_23_308239	60	60	/	/	SYM
10_1101-2020_09_23_308239	60	61	concepts	concept	NNS
10_1101-2020_09_23_308239	60	62	)	)	-RRB-
10_1101-2020_09_23_308239	60	63	and	and	CC
10_1101-2020_09_23_308239	60	64	573929	573929	CD
10_1101-2020_09_23_308239	60	65	edges	edge	NNS
10_1101-2020_09_23_308239	60	66	(	(	-LRB-
10_1101-2020_09_23_308239	60	67	indicating	indicate	VBG
10_1101-2020_09_23_308239	60	68	relationships	relationship	NNS
10_1101-2020_09_23_308239	60	69	or	or	CC
10_1101-2020_09_23_308239	60	70	interactions	interaction	NNS
10_1101-2020_09_23_308239	60	71	between	between	IN
10_1101-2020_09_23_308239	60	72	the	the	DT
10_1101-2020_09_23_308239	60	73	pair	pair	NN
10_1101-2020_09_23_308239	60	74	of	of	IN
10_1101-2020_09_23_308239	60	75	nodes	node	NNS
10_1101-2020_09_23_308239	60	76	they	-PRON-	PRP
10_1101-2020_09_23_308239	60	77	connect	connect	VBP
10_1101-2020_09_23_308239	60	78	)	)	-RRB-
10_1101-2020_09_23_308239	60	79	.	.	.
10_1101-2020_09_23_308239	61	1	Systematic	systematic	JJ
10_1101-2020_09_23_308239	61	2	review	review	NN
10_1101-2020_09_23_308239	61	3	and	and	CC
10_1101-2020_09_23_308239	61	4	integration	integration	NN
10_1101-2020_09_23_308239	61	5	of	of	IN
10_1101-2020_09_23_308239	61	6	information	information	NN
10_1101-2020_09_23_308239	61	7	from	from	IN
10_1101-2020_09_23_308239	61	8	phenotypic	phenotypic	NN
10_1101-2020_09_23_308239	61	9	screening	screening	NN
10_1101-2020_09_23_308239	61	10	At	at	IN
10_1101-2020_09_23_308239	61	11	the	the	DT
10_1101-2020_09_23_308239	61	12	time	time	NN
10_1101-2020_09_23_308239	61	13	of	of	IN
10_1101-2020_09_23_308239	61	14	the	the	DT
10_1101-2020_09_23_308239	61	15	writing	writing	NN
10_1101-2020_09_23_308239	61	16	of	of	IN
10_1101-2020_09_23_308239	61	17	this	this	DT
10_1101-2020_09_23_308239	61	18	paper	paper	NN
10_1101-2020_09_23_308239	61	19	,	,	,
10_1101-2020_09_23_308239	61	20	six	six	CD
10_1101-2020_09_23_308239	61	21	phenotypic	phenotypic	JJ
10_1101-2020_09_23_308239	61	22	cellular	cellular	JJ
10_1101-2020_09_23_308239	61	23	screening	screening	NN
10_1101-2020_09_23_308239	61	24	experiments	experiment	NNS
10_1101-2020_09_23_308239	61	25	have	have	VBP
10_1101-2020_09_23_308239	61	26	been	be	VBN
10_1101-2020_09_23_308239	61	27	shared	share	VBN
10_1101-2020_09_23_308239	61	28	via	via	IN
10_1101-2020_09_23_308239	61	29	archive	archive	JJ
10_1101-2020_09_23_308239	61	30	servers	server	NNS
10_1101-2020_09_23_308239	61	31	and	and	CC
10_1101-2020_09_23_308239	61	32	journal	journal	NN
10_1101-2020_09_23_308239	61	33	publications	publication	NNS
10_1101-2020_09_23_308239	61	34	(	(	-LRB-
10_1101-2020_09_23_308239	61	35	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	61	36	Table	Table	NNP
10_1101-2020_09_23_308239	61	37	2	2	CD
10_1101-2020_09_23_308239	61	38	)	)	-RRB-
10_1101-2020_09_23_308239	61	39	.	.	.
10_1101-2020_09_23_308239	62	1	Although	although	IN
10_1101-2020_09_23_308239	62	2	only	only	RB
10_1101-2020_09_23_308239	62	3	a	a	DT
10_1101-2020_09_23_308239	62	4	limited	limited	JJ
10_1101-2020_09_23_308239	62	5	number	number	NN
10_1101-2020_09_23_308239	62	6	of	of	IN
10_1101-2020_09_23_308239	62	7	these	these	DT
10_1101-2020_09_23_308239	62	8	manuscripts	manuscript	NNS
10_1101-2020_09_23_308239	62	9	have	have	VBP
10_1101-2020_09_23_308239	62	10	been	be	VBN
10_1101-2020_09_23_308239	62	11	officially	officially	RB
10_1101-2020_09_23_308239	62	12	accepted	accept	VBN
10_1101-2020_09_23_308239	62	13	and	and	CC
10_1101-2020_09_23_308239	62	14	published	publish	VBN
10_1101-2020_09_23_308239	62	15	,	,	,
10_1101-2020_09_23_308239	62	16	we	-PRON-	PRP
10_1101-2020_09_23_308239	62	17	were	be	VBD
10_1101-2020_09_23_308239	62	18	able	able	JJ
10_1101-2020_09_23_308239	62	19	to	to	TO
10_1101-2020_09_23_308239	62	20	extract	extract	VB
10_1101-2020_09_23_308239	62	21	their	-PRON-	PRP$
10_1101-2020_09_23_308239	62	22	primary	primary	JJ
10_1101-2020_09_23_308239	62	23	findings	finding	NNS
10_1101-2020_09_23_308239	62	24	from	from	IN
10_1101-2020_09_23_308239	62	25	the	the	DT
10_1101-2020_09_23_308239	62	26	pre	pre	JJ
10_1101-2020_09_23_308239	62	27	-	-	NN
10_1101-2020_09_23_308239	62	28	publication	publication	JJ
10_1101-2020_09_23_308239	62	29	archive	archive	JJ
10_1101-2020_09_23_308239	62	30	servers	server	NNS
10_1101-2020_09_23_308239	62	31	.	.	.
10_1101-2020_09_23_308239	63	1	A	a	DT
10_1101-2020_09_23_308239	63	2	significant	significant	JJ
10_1101-2020_09_23_308239	63	3	number	number	NN
10_1101-2020_09_23_308239	63	4	of	of	IN
10_1101-2020_09_23_308239	63	5	reports	report	NNS
10_1101-2020_09_23_308239	63	6	on	on	IN
10_1101-2020_09_23_308239	63	7	drug	drug	NN
10_1101-2020_09_23_308239	63	8	repurposing	repurposing	NN
10_1101-2020_09_23_308239	63	9	screenings	screening	NNS
10_1101-2020_09_23_308239	63	10	in	in	IN
10_1101-2020_09_23_308239	63	11	the	the	DT
10_1101-2020_09_23_308239	63	12	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	63	13	context	context	NN
10_1101-2020_09_23_308239	63	14	demonstrate	demonstrate	NN
10_1101-2020_09_23_308239	63	15	how	how	WRB
10_1101-2020_09_23_308239	63	16	appealing	appeal	VBG
10_1101-2020_09_23_308239	63	17	the	the	DT
10_1101-2020_09_23_308239	63	18	concept	concept	NN
10_1101-2020_09_23_308239	63	19	of	of	IN
10_1101-2020_09_23_308239	63	20	drug	drug	NN
10_1101-2020_09_23_308239	63	21	repurposing	repurposing	NN
10_1101-2020_09_23_308239	63	22	is	be	VBZ
10_1101-2020_09_23_308239	63	23	as	as	IN
10_1101-2020_09_23_308239	63	24	a	a	DT
10_1101-2020_09_23_308239	63	25	quick	quick	JJ
10_1101-2020_09_23_308239	63	26	answer	answer	NN
10_1101-2020_09_23_308239	63	27	to	to	IN
10_1101-2020_09_23_308239	63	28	the	the	DT
10_1101-2020_09_23_308239	63	29	challenge	challenge	NN
10_1101-2020_09_23_308239	63	30	of	of	IN
10_1101-2020_09_23_308239	63	31	a	a	DT
10_1101-2020_09_23_308239	63	32	global	global	JJ
10_1101-2020_09_23_308239	63	33	pandemic	pandemic	NN
10_1101-2020_09_23_308239	63	34	.	.	.
10_1101-2020_09_23_308239	64	1	Drug	drug	NN
10_1101-2020_09_23_308239	64	2	repurposing	repurposing	NN
10_1101-2020_09_23_308239	64	3	screenings	screening	NNS
10_1101-2020_09_23_308239	64	4	were	be	VBD
10_1101-2020_09_23_308239	64	5	all	all	DT
10_1101-2020_09_23_308239	64	6	performed	perform	VBN
10_1101-2020_09_23_308239	64	7	with	with	IN
10_1101-2020_09_23_308239	64	8	compounds	compound	NNS
10_1101-2020_09_23_308239	64	9	for	for	IN
10_1101-2020_09_23_308239	64	10	which	which	WDT
10_1101-2020_09_23_308239	64	11	a	a	DT
10_1101-2020_09_23_308239	64	12	significant	significant	JJ
10_1101-2020_09_23_308239	64	13	amount	amount	NN
10_1101-2020_09_23_308239	64	14	of	of	IN
10_1101-2020_09_23_308239	64	15	information	information	NN
10_1101-2020_09_23_308239	64	16	on	on	IN
10_1101-2020_09_23_308239	64	17	safety	safety	NN
10_1101-2020_09_23_308239	64	18	in	in	IN
10_1101-2020_09_23_308239	64	19	humans	human	NNS
10_1101-2020_09_23_308239	64	20	and	and	CC
10_1101-2020_09_23_308239	64	21	primary	primary	JJ
10_1101-2020_09_23_308239	64	22	mechanism	mechanism	NN
10_1101-2020_09_23_308239	64	23	of	of	IN
10_1101-2020_09_23_308239	64	24	action	action	NN
10_1101-2020_09_23_308239	64	25	is	be	VBZ
10_1101-2020_09_23_308239	64	26	available	available	JJ
10_1101-2020_09_23_308239	64	27	.	.	.
10_1101-2020_09_23_308239	65	1	We	-PRON-	PRP
10_1101-2020_09_23_308239	65	2	generated	generate	VBD
10_1101-2020_09_23_308239	65	3	a	a	DT
10_1101-2020_09_23_308239	65	4	list	list	NN
10_1101-2020_09_23_308239	65	5	of	of	IN
10_1101-2020_09_23_308239	65	6	“	"	``
10_1101-2020_09_23_308239	65	7	hits	hit	NNS
10_1101-2020_09_23_308239	65	8	”	"	''
10_1101-2020_09_23_308239	65	9	from	from	IN
10_1101-2020_09_23_308239	65	10	cellular	cellular	JJ
10_1101-2020_09_23_308239	65	11	screening	screening	NN
10_1101-2020_09_23_308239	65	12	experiments	experiment	NNS
10_1101-2020_09_23_308239	65	13	while	while	IN
10_1101-2020_09_23_308239	65	14	results	result	NNS
10_1101-2020_09_23_308239	65	15	derived	derive	VBN
10_1101-2020_09_23_308239	65	16	from	from	IN
10_1101-2020_09_23_308239	65	17	publications	publication	NNS
10_1101-2020_09_23_308239	65	18	that	that	WDT
10_1101-2020_09_23_308239	65	19	reported	report	VBD
10_1101-2020_09_23_308239	65	20	on	on	IN
10_1101-2020_09_23_308239	65	21	in	in	IN
10_1101-2020_09_23_308239	65	22	-	-	HYPH
10_1101-2020_09_23_308239	65	23	silico	silico	NN
10_1101-2020_09_23_308239	65	24	screening	screening	NN
10_1101-2020_09_23_308239	65	25	were	be	VBD
10_1101-2020_09_23_308239	65	26	ignored	ignore	VBN
10_1101-2020_09_23_308239	65	27	.	.	.
10_1101-2020_09_23_308239	66	1	Therefore	therefore	RB
10_1101-2020_09_23_308239	66	2	,	,	,
10_1101-2020_09_23_308239	66	3	we	-PRON-	PRP
10_1101-2020_09_23_308239	66	4	keep	keep	VBP
10_1101-2020_09_23_308239	66	5	a	a	DT
10_1101-2020_09_23_308239	66	6	strict	strict	JJ
10_1101-2020_09_23_308239	66	7	focus	focus	NN
10_1101-2020_09_23_308239	66	8	on	on	IN
10_1101-2020_09_23_308239	66	9	well	well	RB
10_1101-2020_09_23_308239	66	10	-	-	HYPH
10_1101-2020_09_23_308239	66	11	characterized	characterize	VBN
10_1101-2020_09_23_308239	66	12	,	,	,
10_1101-2020_09_23_308239	66	13	well	well	RB
10_1101-2020_09_23_308239	66	14	-	-	HYPH
10_1101-2020_09_23_308239	66	15	understood	understand	VBN
10_1101-2020_09_23_308239	66	16	candidate	candidate	NN
10_1101-2020_09_23_308239	66	17	molecules	molecule	NNS
10_1101-2020_09_23_308239	66	18	in	in	IN
10_1101-2020_09_23_308239	66	19	order	order	NN
10_1101-2020_09_23_308239	66	20	to	to	TO
10_1101-2020_09_23_308239	66	21	ensure	ensure	VB
10_1101-2020_09_23_308239	66	22	that	that	IN
10_1101-2020_09_23_308239	66	23	one	one	CD
10_1101-2020_09_23_308239	66	24	of	of	IN
10_1101-2020_09_23_308239	66	25	the	the	DT
10_1101-2020_09_23_308239	66	26	pivotal	pivotal	JJ
10_1101-2020_09_23_308239	66	27	advantages	advantage	NNS
10_1101-2020_09_23_308239	66	28	of	of	IN
10_1101-2020_09_23_308239	66	29	this	this	DT
10_1101-2020_09_23_308239	66	30	knowledge	knowledge	NN
10_1101-2020_09_23_308239	66	31	base	base	NN
10_1101-2020_09_23_308239	66	32	is	be	VBZ
10_1101-2020_09_23_308239	66	33	its	-PRON-	PRP$
10_1101-2020_09_23_308239	66	34	use	use	NN
10_1101-2020_09_23_308239	66	35	for	for	IN
10_1101-2020_09_23_308239	66	36	drug	drug	NN
10_1101-2020_09_23_308239	66	37	repurposing	repurposing	NN
10_1101-2020_09_23_308239	66	38	.	.	.
10_1101-2020_09_23_308239	67	1	Subgraph	Subgraph	NNP
10_1101-2020_09_23_308239	67	2	annotation	annotation	NN
10_1101-2020_09_23_308239	67	3	The	the	DT
10_1101-2020_09_23_308239	67	4	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	67	5	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	67	6	contains	contain	VBZ
10_1101-2020_09_23_308239	67	7	several	several	JJ
10_1101-2020_09_23_308239	67	8	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	67	9	,	,	,
10_1101-2020_09_23_308239	67	10	three	three	CD
10_1101-2020_09_23_308239	67	11	of	of	IN
10_1101-2020_09_23_308239	67	12	which	which	WDT
10_1101-2020_09_23_308239	67	13	correspond	correspond	VBP
10_1101-2020_09_23_308239	67	14	to	to	IN
10_1101-2020_09_23_308239	67	15	major	major	JJ
10_1101-2020_09_23_308239	67	16	views	view	NNS
10_1101-2020_09_23_308239	67	17	on	on	IN
10_1101-2020_09_23_308239	67	18	the	the	DT
10_1101-2020_09_23_308239	67	19	biology	biology	NN
10_1101-2020_09_23_308239	67	20	of	of	IN
10_1101-2020_09_23_308239	67	21	SARS	SARS	NNP
10_1101-2020_09_23_308239	67	22	-	-	HYPH
10_1101-2020_09_23_308239	67	23	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	67	24	as	as	RB
10_1101-2020_09_23_308239	67	25	well	well	RB
10_1101-2020_09_23_308239	67	26	as	as	IN
10_1101-2020_09_23_308239	67	27	the	the	DT
10_1101-2020_09_23_308239	67	28	clinical	clinical	JJ
10_1101-2020_09_23_308239	67	29	impact	impact	NN
10_1101-2020_09_23_308239	67	30	of	of	IN
10_1101-2020_09_23_308239	67	31	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	67	32	:	:	:
10_1101-2020_09_23_308239	67	33	-	-	:
10_1101-2020_09_23_308239	67	34	the	the	DT
10_1101-2020_09_23_308239	67	35	viral	viral	JJ
10_1101-2020_09_23_308239	67	36	life	life	NN
10_1101-2020_09_23_308239	67	37	cycle	cycle	NN
10_1101-2020_09_23_308239	67	38	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	67	39	focuses	focus	VBZ
10_1101-2020_09_23_308239	67	40	on	on	IN
10_1101-2020_09_23_308239	67	41	the	the	DT
10_1101-2020_09_23_308239	67	42	stages	stage	NNS
10_1101-2020_09_23_308239	67	43	of	of	IN
10_1101-2020_09_23_308239	67	44	viral	viral	JJ
10_1101-2020_09_23_308239	67	45	infection	infection	NN
10_1101-2020_09_23_308239	67	46	,	,	,
10_1101-2020_09_23_308239	67	47	replication	replication	NN
10_1101-2020_09_23_308239	67	48	,	,	,
10_1101-2020_09_23_308239	67	49	and	and	CC
10_1101-2020_09_23_308239	67	50	spreading	spread	VBG
10_1101-2020_09_23_308239	67	51	.	.	.
10_1101-2020_09_23_308239	68	1	-	-	:
10_1101-2020_09_23_308239	68	2	the	the	DT
10_1101-2020_09_23_308239	68	3	host	host	NN
10_1101-2020_09_23_308239	68	4	response	response	NN
10_1101-2020_09_23_308239	68	5	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	68	6	represents	represent	VBZ
10_1101-2020_09_23_308239	68	7	essential	essential	JJ
10_1101-2020_09_23_308239	68	8	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	68	9	active	active	JJ
10_1101-2020_09_23_308239	68	10	in	in	IN
10_1101-2020_09_23_308239	68	11	host	host	NN
10_1101-2020_09_23_308239	68	12	cells	cell	NNS
10_1101-2020_09_23_308239	68	13	infected	infect	VBN
10_1101-2020_09_23_308239	68	14	by	by	IN
10_1101-2020_09_23_308239	68	15	the	the	DT
10_1101-2020_09_23_308239	68	16	virus	virus	NN
10_1101-2020_09_23_308239	68	17	.	.	.
10_1101-2020_09_23_308239	69	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	69	2	-	-	:
10_1101-2020_09_23_308239	69	3	BY	by	IN
10_1101-2020_09_23_308239	69	4	-	-	HYPH
10_1101-2020_09_23_308239	69	5	NC	NC	NNP
10_1101-2020_09_23_308239	69	6	-	-	HYPH
10_1101-2020_09_23_308239	69	7	ND	ND	NNP
10_1101-2020_09_23_308239	69	8	4.0	4.0	CD
10_1101-2020_09_23_308239	69	9	International	international	JJ
10_1101-2020_09_23_308239	69	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	69	11	.	.	.
10_1101-2020_09_23_308239	70	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	70	2	is	be	VBZ
10_1101-2020_09_23_308239	70	3	made	make	VBN
10_1101-2020_09_23_308239	70	4	available	available	JJ
10_1101-2020_09_23_308239	70	5	under	under	IN
10_1101-2020_09_23_308239	70	6	a	a	DT
10_1101-2020_09_23_308239	70	7	preprint	preprint	NN
10_1101-2020_09_23_308239	70	8	(	(	-LRB-
10_1101-2020_09_23_308239	70	9	which	which	WDT
10_1101-2020_09_23_308239	70	10	was	be	VBD
10_1101-2020_09_23_308239	70	11	not	not	RB
10_1101-2020_09_23_308239	70	12	certified	certify	VBN
10_1101-2020_09_23_308239	70	13	by	by	IN
10_1101-2020_09_23_308239	70	14	peer	peer	NN
10_1101-2020_09_23_308239	70	15	review	review	NN
10_1101-2020_09_23_308239	70	16	)	)	-RRB-
10_1101-2020_09_23_308239	70	17	is	be	VBZ
10_1101-2020_09_23_308239	70	18	the	the	DT
10_1101-2020_09_23_308239	70	19	author	author	NN
10_1101-2020_09_23_308239	70	20	/	/	SYM
10_1101-2020_09_23_308239	70	21	funder	funder	NN
10_1101-2020_09_23_308239	70	22	,	,	,
10_1101-2020_09_23_308239	70	23	who	who	WP
10_1101-2020_09_23_308239	70	24	has	have	VBZ
10_1101-2020_09_23_308239	70	25	granted	grant	VBN
10_1101-2020_09_23_308239	70	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	70	27	a	a	DT
10_1101-2020_09_23_308239	70	28	license	license	NN
10_1101-2020_09_23_308239	70	29	to	to	TO
10_1101-2020_09_23_308239	70	30	display	display	VB
10_1101-2020_09_23_308239	70	31	the	the	DT
10_1101-2020_09_23_308239	70	32	preprint	preprint	NN
10_1101-2020_09_23_308239	70	33	in	in	IN
10_1101-2020_09_23_308239	70	34	The	the	DT
10_1101-2020_09_23_308239	70	35	copyright	copyright	NN
10_1101-2020_09_23_308239	70	36	holder	holder	NN
10_1101-2020_09_23_308239	70	37	for	for	IN
10_1101-2020_09_23_308239	70	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	70	39	version	version	NN
10_1101-2020_09_23_308239	70	40	posted	post	VBD
10_1101-2020_09_23_308239	70	41	February	February	NNP
10_1101-2020_09_23_308239	70	42	12	12	CD
10_1101-2020_09_23_308239	70	43	,	,	,
10_1101-2020_09_23_308239	70	44	2021	2021	CD
10_1101-2020_09_23_308239	70	45	.	.	.
10_1101-2020_09_23_308239	70	46	;	;	:
10_1101-2020_09_23_308239	70	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	70	48	:	:	:
10_1101-2020_09_23_308239	70	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	70	50	preprint	preprint	NN
10_1101-2020_09_23_308239	70	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	70	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	70	53	10	10	CD
10_1101-2020_09_23_308239	70	54	-	-	:
10_1101-2020_09_23_308239	70	55	the	the	DT
10_1101-2020_09_23_308239	70	56	clinical	clinical	JJ
10_1101-2020_09_23_308239	70	57	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	70	58	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	70	59	illustrates	illustrate	VBZ
10_1101-2020_09_23_308239	70	60	major	major	JJ
10_1101-2020_09_23_308239	70	61	pathophysiological	pathophysiological	JJ
10_1101-2020_09_23_308239	70	62	processes	process	NNS
10_1101-2020_09_23_308239	70	63	of	of	IN
10_1101-2020_09_23_308239	70	64	clinical	clinical	JJ
10_1101-2020_09_23_308239	70	65	relevance	relevance	NN
10_1101-2020_09_23_308239	70	66	.	.	.
10_1101-2020_09_23_308239	71	1	These	these	DT
10_1101-2020_09_23_308239	71	2	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	71	3	were	be	VBD
10_1101-2020_09_23_308239	71	4	annotated	annotate	VBN
10_1101-2020_09_23_308239	71	5	by	by	IN
10_1101-2020_09_23_308239	71	6	identifying	identify	VBG
10_1101-2020_09_23_308239	71	7	nodes	node	NNS
10_1101-2020_09_23_308239	71	8	within	within	IN
10_1101-2020_09_23_308239	71	9	the	the	DT
10_1101-2020_09_23_308239	71	10	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	71	11	PHARMACOME	pharmacome	NN
10_1101-2020_09_23_308239	71	12	that	that	WDT
10_1101-2020_09_23_308239	71	13	represent	represent	VBP
10_1101-2020_09_23_308239	71	14	specific	specific	JJ
10_1101-2020_09_23_308239	71	15	biological	biological	JJ
10_1101-2020_09_23_308239	71	16	processes	process	NNS
10_1101-2020_09_23_308239	71	17	or	or	CC
10_1101-2020_09_23_308239	71	18	pathologies	pathology	NNS
10_1101-2020_09_23_308239	71	19	associated	associate	VBN
10_1101-2020_09_23_308239	71	20	with	with	IN
10_1101-2020_09_23_308239	71	21	each	each	DT
10_1101-2020_09_23_308239	71	22	subgraph	subgraph	JJ
10_1101-2020_09_23_308239	71	23	category	category	NN
10_1101-2020_09_23_308239	71	24	and	and	CC
10_1101-2020_09_23_308239	71	25	traversing	traverse	VBG
10_1101-2020_09_23_308239	71	26	out	out	RP
10_1101-2020_09_23_308239	71	27	to	to	IN
10_1101-2020_09_23_308239	71	28	their	-PRON-	PRP$
10_1101-2020_09_23_308239	71	29	first	first	JJ
10_1101-2020_09_23_308239	71	30	-	-	HYPH
10_1101-2020_09_23_308239	71	31	degree	degree	NN
10_1101-2020_09_23_308239	71	32	neighbors	neighbor	NNS
10_1101-2020_09_23_308239	71	33	.	.	.
10_1101-2020_09_23_308239	72	1	For	for	IN
10_1101-2020_09_23_308239	72	2	example	example	NN
10_1101-2020_09_23_308239	72	3	,	,	,
10_1101-2020_09_23_308239	72	4	a	a	DT
10_1101-2020_09_23_308239	72	5	biological	biological	JJ
10_1101-2020_09_23_308239	72	6	process	process	NN
10_1101-2020_09_23_308239	72	7	node	node	RB
10_1101-2020_09_23_308239	72	8	representing	represent	VBG
10_1101-2020_09_23_308239	72	9	“	"	``
10_1101-2020_09_23_308239	72	10	viral	viral	JJ
10_1101-2020_09_23_308239	72	11	translation	translation	NN
10_1101-2020_09_23_308239	72	12	”	"	''
10_1101-2020_09_23_308239	72	13	would	would	MD
10_1101-2020_09_23_308239	72	14	be	be	VB
10_1101-2020_09_23_308239	72	15	classified	classify	VBN
10_1101-2020_09_23_308239	72	16	as	as	IN
10_1101-2020_09_23_308239	72	17	a	a	DT
10_1101-2020_09_23_308239	72	18	starting	starting	NN
10_1101-2020_09_23_308239	72	19	node	node	NN
10_1101-2020_09_23_308239	72	20	for	for	IN
10_1101-2020_09_23_308239	72	21	the	the	DT
10_1101-2020_09_23_308239	72	22	viral	viral	JJ
10_1101-2020_09_23_308239	72	23	life	life	NN
10_1101-2020_09_23_308239	72	24	cycle	cycle	NN
10_1101-2020_09_23_308239	72	25	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	72	26	while	while	IN
10_1101-2020_09_23_308239	72	27	a	a	DT
10_1101-2020_09_23_308239	72	28	node	node	RB
10_1101-2020_09_23_308239	72	29	defined	define	VBN
10_1101-2020_09_23_308239	72	30	as	as	IN
10_1101-2020_09_23_308239	72	31	“	"	``
10_1101-2020_09_23_308239	72	32	defense	defense	NN
10_1101-2020_09_23_308239	72	33	response	response	NN
10_1101-2020_09_23_308239	72	34	to	to	IN
10_1101-2020_09_23_308239	72	35	virus	virus	NN
10_1101-2020_09_23_308239	72	36	"	"	''
10_1101-2020_09_23_308239	72	37	would	would	MD
10_1101-2020_09_23_308239	72	38	be	be	VB
10_1101-2020_09_23_308239	72	39	categorized	categorize	VBN
10_1101-2020_09_23_308239	72	40	as	as	IN
10_1101-2020_09_23_308239	72	41	belonging	belong	VBG
10_1101-2020_09_23_308239	72	42	to	to	IN
10_1101-2020_09_23_308239	72	43	the	the	DT
10_1101-2020_09_23_308239	72	44	host	host	NN
10_1101-2020_09_23_308239	72	45	response	response	NN
10_1101-2020_09_23_308239	72	46	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	72	47	.	.	.
10_1101-2020_09_23_308239	73	1	Though	though	IN
10_1101-2020_09_23_308239	73	2	the	the	DT
10_1101-2020_09_23_308239	73	3	viral	viral	JJ
10_1101-2020_09_23_308239	73	4	life	life	NN
10_1101-2020_09_23_308239	73	5	cycle	cycle	NN
10_1101-2020_09_23_308239	73	6	and	and	CC
10_1101-2020_09_23_308239	73	7	host	host	NN
10_1101-2020_09_23_308239	73	8	response	response	NN
10_1101-2020_09_23_308239	73	9	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	73	10	contain	contain	VBP
10_1101-2020_09_23_308239	73	11	a	a	DT
10_1101-2020_09_23_308239	73	12	wide	wide	JJ
10_1101-2020_09_23_308239	73	13	variety	variety	NN
10_1101-2020_09_23_308239	73	14	of	of	IN
10_1101-2020_09_23_308239	73	15	node	node	NN
10_1101-2020_09_23_308239	73	16	types	type	NNS
10_1101-2020_09_23_308239	73	17	,	,	,
10_1101-2020_09_23_308239	73	18	the	the	DT
10_1101-2020_09_23_308239	73	19	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	73	20	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	73	21	is	be	VBZ
10_1101-2020_09_23_308239	73	22	restricted	restrict	VBN
10_1101-2020_09_23_308239	73	23	to	to	IN
10_1101-2020_09_23_308239	73	24	pathology	pathology	NN
10_1101-2020_09_23_308239	73	25	nodes	node	NNS
10_1101-2020_09_23_308239	73	26	associated	associate	VBN
10_1101-2020_09_23_308239	73	27	with	with	IN
10_1101-2020_09_23_308239	73	28	either	either	CC
10_1101-2020_09_23_308239	73	29	the	the	DT
10_1101-2020_09_23_308239	73	30	SARS	SARS	NNP
10_1101-2020_09_23_308239	73	31	-	-	HYPH
10_1101-2020_09_23_308239	73	32	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	73	33	virus	virus	NN
10_1101-2020_09_23_308239	73	34	or	or	CC
10_1101-2020_09_23_308239	73	35	the	the	DT
10_1101-2020_09_23_308239	73	36	COVID-19	covid-19	NN
10_1101-2020_09_23_308239	73	37	pathology	pathology	NN
10_1101-2020_09_23_308239	73	38	.	.	.
10_1101-2020_09_23_308239	74	1	Mapping	map	VBG
10_1101-2020_09_23_308239	74	2	of	of	IN
10_1101-2020_09_23_308239	74	3	gene	gene	NN
10_1101-2020_09_23_308239	74	4	expression	expression	NN
10_1101-2020_09_23_308239	74	5	data	datum	NNS
10_1101-2020_09_23_308239	74	6	onto	onto	IN
10_1101-2020_09_23_308239	74	7	the	the	DT
10_1101-2020_09_23_308239	74	8	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	74	9	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	74	10	Two	two	CD
10_1101-2020_09_23_308239	74	11	single	single	JJ
10_1101-2020_09_23_308239	74	12	cell	cell	NN
10_1101-2020_09_23_308239	74	13	sequencing	sequencing	NN
10_1101-2020_09_23_308239	74	14	data	data	NN
10_1101-2020_09_23_308239	74	15	sets	set	NNS
10_1101-2020_09_23_308239	74	16	representing	represent	VBG
10_1101-2020_09_23_308239	74	17	infected	infected	JJ
10_1101-2020_09_23_308239	74	18	and	and	CC
10_1101-2020_09_23_308239	74	19	non	non	JJ
10_1101-2020_09_23_308239	74	20	-	-	JJ
10_1101-2020_09_23_308239	74	21	infected	infected	JJ
10_1101-2020_09_23_308239	74	22	cells	cell	NNS
10_1101-2020_09_23_308239	74	23	directly	directly	RB
10_1101-2020_09_23_308239	74	24	derived	derive	VBN
10_1101-2020_09_23_308239	74	25	from	from	IN
10_1101-2020_09_23_308239	74	26	human	human	JJ
10_1101-2020_09_23_308239	74	27	samples32	samples32	NNS
10_1101-2020_09_23_308239	74	28	and	and	CC
10_1101-2020_09_23_308239	74	29	cultured	culture	VBD
10_1101-2020_09_23_308239	74	30	human	human	JJ
10_1101-2020_09_23_308239	74	31	bronchial	bronchial	JJ
10_1101-2020_09_23_308239	74	32	epithelial	epithelial	NN
10_1101-2020_09_23_308239	74	33	cells33	cells33	NN
10_1101-2020_09_23_308239	74	34	(	(	-LRB-
10_1101-2020_09_23_308239	74	35	HBECs	HBECs	NNP
10_1101-2020_09_23_308239	74	36	)	)	-RRB-
10_1101-2020_09_23_308239	74	37	were	be	VBD
10_1101-2020_09_23_308239	74	38	used	use	VBN
10_1101-2020_09_23_308239	74	39	to	to	TO
10_1101-2020_09_23_308239	74	40	identify	identify	VB
10_1101-2020_09_23_308239	74	41	the	the	DT
10_1101-2020_09_23_308239	74	42	areas	area	NNS
10_1101-2020_09_23_308239	74	43	of	of	IN
10_1101-2020_09_23_308239	74	44	the	the	DT
10_1101-2020_09_23_308239	74	45	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	74	46	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	74	47	responding	respond	VBG
10_1101-2020_09_23_308239	74	48	at	at	IN
10_1101-2020_09_23_308239	74	49	gene	gene	NN
10_1101-2020_09_23_308239	74	50	expression	expression	NN
10_1101-2020_09_23_308239	74	51	level	level	NN
10_1101-2020_09_23_308239	74	52	to	to	IN
10_1101-2020_09_23_308239	74	53	SARS	SARS	NNP
10_1101-2020_09_23_308239	74	54	-	-	HYPH
10_1101-2020_09_23_308239	74	55	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	74	56	infection	infection	NN
10_1101-2020_09_23_308239	74	57	.	.	.
10_1101-2020_09_23_308239	75	1	Details	detail	NNS
10_1101-2020_09_23_308239	75	2	of	of	IN
10_1101-2020_09_23_308239	75	3	the	the	DT
10_1101-2020_09_23_308239	75	4	gene	gene	NN
10_1101-2020_09_23_308239	75	5	expression	expression	NN
10_1101-2020_09_23_308239	75	6	data	datum	NNS
10_1101-2020_09_23_308239	75	7	processing	processing	NN
10_1101-2020_09_23_308239	75	8	and	and	CC
10_1101-2020_09_23_308239	75	9	mapping	mapping	NN
10_1101-2020_09_23_308239	75	10	are	be	VBP
10_1101-2020_09_23_308239	75	11	available	available	JJ
10_1101-2020_09_23_308239	75	12	in	in	IN
10_1101-2020_09_23_308239	75	13	the	the	DT
10_1101-2020_09_23_308239	75	14	supplementary	supplementary	JJ
10_1101-2020_09_23_308239	75	15	material	material	NN
10_1101-2020_09_23_308239	75	16	(	(	-LRB-
10_1101-2020_09_23_308239	75	17	section	section	NN
10_1101-2020_09_23_308239	75	18	gene	gene	NN
10_1101-2020_09_23_308239	75	19	expression	expression	NNP
10_1101-2020_09_23_308239	75	20	data	data	NNP
10_1101-2020_09_23_308239	75	21	analysis	analysis	NN
10_1101-2020_09_23_308239	75	22	)	)	-RRB-
10_1101-2020_09_23_308239	75	23	.	.	.
10_1101-2020_09_23_308239	76	1	Pathway	pathway	JJ
10_1101-2020_09_23_308239	76	2	enrichment	enrichment	NN
10_1101-2020_09_23_308239	76	3	Associated	associated	JJ
10_1101-2020_09_23_308239	76	4	pathways	pathway	NNS
10_1101-2020_09_23_308239	76	5	for	for	IN
10_1101-2020_09_23_308239	76	6	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	76	7	and	and	CC
10_1101-2020_09_23_308239	76	8	significant	significant	JJ
10_1101-2020_09_23_308239	76	9	targets	target	NNS
10_1101-2020_09_23_308239	76	10	were	be	VBD
10_1101-2020_09_23_308239	76	11	identified	identify	VBN
10_1101-2020_09_23_308239	76	12	using	use	VBG
10_1101-2020_09_23_308239	76	13	the	the	DT
10_1101-2020_09_23_308239	76	14	Enrichr34	Enrichr34	NNP
10_1101-2020_09_23_308239	76	15	feature	feature	NN
10_1101-2020_09_23_308239	76	16	of	of	IN
10_1101-2020_09_23_308239	76	17	the	the	DT
10_1101-2020_09_23_308239	76	18	gseapy	gseapy	NN
10_1101-2020_09_23_308239	76	19	Python	Python	NNP
10_1101-2020_09_23_308239	76	20	package35	package35	NNP
10_1101-2020_09_23_308239	76	21	.	.	.
10_1101-2020_09_23_308239	77	1	Briefly	briefly	RB
10_1101-2020_09_23_308239	77	2	,	,	,
10_1101-2020_09_23_308239	77	3	gene	gene	NN
10_1101-2020_09_23_308239	77	4	symbol	symbol	NN
10_1101-2020_09_23_308239	77	5	lists	list	NNS
10_1101-2020_09_23_308239	77	6	were	be	VBD
10_1101-2020_09_23_308239	77	7	assembled	assemble	VBN
10_1101-2020_09_23_308239	77	8	from	from	IN
10_1101-2020_09_23_308239	77	9	their	-PRON-	PRP$
10_1101-2020_09_23_308239	77	10	respective	respective	JJ
10_1101-2020_09_23_308239	77	11	subgraph	subgraph	NN
10_1101-2020_09_23_308239	77	12	or	or	CC
10_1101-2020_09_23_308239	77	13	dataset	dataset	NN
10_1101-2020_09_23_308239	77	14	and	and	CC
10_1101-2020_09_23_308239	77	15	compared	compare	VBN
10_1101-2020_09_23_308239	77	16	against	against	IN
10_1101-2020_09_23_308239	77	17	multiple	multiple	JJ
10_1101-2020_09_23_308239	77	18	pathway	pathway	JJ
10_1101-2020_09_23_308239	77	19	gene	gene	NN
10_1101-2020_09_23_308239	77	20	set	set	NN
10_1101-2020_09_23_308239	77	21	libraries	library	NNS
10_1101-2020_09_23_308239	77	22	including	include	VBG
10_1101-2020_09_23_308239	77	23	Reactome	Reactome	NNP
10_1101-2020_09_23_308239	77	24	,	,	,
10_1101-2020_09_23_308239	77	25	KEGG	KEGG	NNP
10_1101-2020_09_23_308239	77	26	,	,	,
10_1101-2020_09_23_308239	77	27	and	and	CC
10_1101-2020_09_23_308239	77	28	WikiPathways	WikiPathways	NNP
10_1101-2020_09_23_308239	77	29	.	.	.
10_1101-2020_09_23_308239	78	1	To	to	TO
10_1101-2020_09_23_308239	78	2	account	account	VB
10_1101-2020_09_23_308239	78	3	for	for	IN
10_1101-2020_09_23_308239	78	4	multiple	multiple	JJ
10_1101-2020_09_23_308239	78	5	comparisons	comparison	NNS
10_1101-2020_09_23_308239	78	6	,	,	,
10_1101-2020_09_23_308239	78	7	p	p	NN
10_1101-2020_09_23_308239	78	8	-	-	HYPH
10_1101-2020_09_23_308239	78	9	values	value	NNS
10_1101-2020_09_23_308239	78	10	.CC	.CC	NFP
10_1101-2020_09_23_308239	78	11	-	-	:
10_1101-2020_09_23_308239	78	12	BY	by	IN
10_1101-2020_09_23_308239	78	13	-	-	HYPH
10_1101-2020_09_23_308239	78	14	NC	NC	NNP
10_1101-2020_09_23_308239	78	15	-	-	HYPH
10_1101-2020_09_23_308239	78	16	ND	ND	NNP
10_1101-2020_09_23_308239	78	17	4.0	4.0	CD
10_1101-2020_09_23_308239	78	18	International	international	JJ
10_1101-2020_09_23_308239	78	19	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	78	20	.	.	.
10_1101-2020_09_23_308239	79	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	79	2	is	be	VBZ
10_1101-2020_09_23_308239	79	3	made	make	VBN
10_1101-2020_09_23_308239	79	4	available	available	JJ
10_1101-2020_09_23_308239	79	5	under	under	IN
10_1101-2020_09_23_308239	79	6	a	a	DT
10_1101-2020_09_23_308239	79	7	preprint	preprint	NN
10_1101-2020_09_23_308239	79	8	(	(	-LRB-
10_1101-2020_09_23_308239	79	9	which	which	WDT
10_1101-2020_09_23_308239	79	10	was	be	VBD
10_1101-2020_09_23_308239	79	11	not	not	RB
10_1101-2020_09_23_308239	79	12	certified	certify	VBN
10_1101-2020_09_23_308239	79	13	by	by	IN
10_1101-2020_09_23_308239	79	14	peer	peer	NN
10_1101-2020_09_23_308239	79	15	review	review	NN
10_1101-2020_09_23_308239	79	16	)	)	-RRB-
10_1101-2020_09_23_308239	79	17	is	be	VBZ
10_1101-2020_09_23_308239	79	18	the	the	DT
10_1101-2020_09_23_308239	79	19	author	author	NN
10_1101-2020_09_23_308239	79	20	/	/	SYM
10_1101-2020_09_23_308239	79	21	funder	funder	NN
10_1101-2020_09_23_308239	79	22	,	,	,
10_1101-2020_09_23_308239	79	23	who	who	WP
10_1101-2020_09_23_308239	79	24	has	have	VBZ
10_1101-2020_09_23_308239	79	25	granted	grant	VBN
10_1101-2020_09_23_308239	79	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	79	27	a	a	DT
10_1101-2020_09_23_308239	79	28	license	license	NN
10_1101-2020_09_23_308239	79	29	to	to	TO
10_1101-2020_09_23_308239	79	30	display	display	VB
10_1101-2020_09_23_308239	79	31	the	the	DT
10_1101-2020_09_23_308239	79	32	preprint	preprint	NN
10_1101-2020_09_23_308239	79	33	in	in	IN
10_1101-2020_09_23_308239	79	34	The	the	DT
10_1101-2020_09_23_308239	79	35	copyright	copyright	NN
10_1101-2020_09_23_308239	79	36	holder	holder	NN
10_1101-2020_09_23_308239	79	37	for	for	IN
10_1101-2020_09_23_308239	79	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	79	39	version	version	NN
10_1101-2020_09_23_308239	79	40	posted	post	VBD
10_1101-2020_09_23_308239	79	41	February	February	NNP
10_1101-2020_09_23_308239	79	42	12	12	CD
10_1101-2020_09_23_308239	79	43	,	,	,
10_1101-2020_09_23_308239	79	44	2021	2021	CD
10_1101-2020_09_23_308239	79	45	.	.	.
10_1101-2020_09_23_308239	79	46	;	;	:
10_1101-2020_09_23_308239	79	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	79	48	:	:	:
10_1101-2020_09_23_308239	79	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	79	50	preprint	preprint	NN
10_1101-2020_09_23_308239	79	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	79	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	79	53	11	11	CD
10_1101-2020_09_23_308239	79	54	were	be	VBD
10_1101-2020_09_23_308239	79	55	corrected	correct	VBN
10_1101-2020_09_23_308239	79	56	using	use	VBG
10_1101-2020_09_23_308239	79	57	the	the	DT
10_1101-2020_09_23_308239	79	58	Benjamini	Benjamini	NNP
10_1101-2020_09_23_308239	79	59	-	-	HYPH
10_1101-2020_09_23_308239	79	60	Hochberg36	Hochberg36	NNP
10_1101-2020_09_23_308239	79	61	method	method	NN
10_1101-2020_09_23_308239	79	62	and	and	CC
10_1101-2020_09_23_308239	79	63	results	result	VBZ
10_1101-2020_09_23_308239	79	64	with	with	IN
10_1101-2020_09_23_308239	79	65	p	p	NN
10_1101-2020_09_23_308239	79	66	-	-	HYPH
10_1101-2020_09_23_308239	79	67	values	value	NNS
10_1101-2020_09_23_308239	79	68	<	<	XX
10_1101-2020_09_23_308239	79	69	0.01	0.01	CD
10_1101-2020_09_23_308239	79	70	were	be	VBD
10_1101-2020_09_23_308239	79	71	considered	consider	VBN
10_1101-2020_09_23_308239	79	72	significantly	significantly	RB
10_1101-2020_09_23_308239	79	73	enriched	enrich	VBN
10_1101-2020_09_23_308239	79	74	.	.	.
10_1101-2020_09_23_308239	80	1	Drug	drug	NN
10_1101-2020_09_23_308239	80	2	repurposing	repurposing	NN
10_1101-2020_09_23_308239	80	3	screening	screening	NN
10_1101-2020_09_23_308239	80	4	We	-PRON-	PRP
10_1101-2020_09_23_308239	80	5	performed	perform	VBD
10_1101-2020_09_23_308239	80	6	phenotypic	phenotypic	NN
10_1101-2020_09_23_308239	80	7	assays	assay	NNS
10_1101-2020_09_23_308239	80	8	to	to	TO
10_1101-2020_09_23_308239	80	9	screen	screen	NN
10_1101-2020_09_23_308239	80	10	for	for	IN
10_1101-2020_09_23_308239	80	11	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	80	12	drugs	drug	NNS
10_1101-2020_09_23_308239	80	13	that	that	WDT
10_1101-2020_09_23_308239	80	14	inhibit	inhibit	VBP
10_1101-2020_09_23_308239	80	15	the	the	DT
10_1101-2020_09_23_308239	80	16	replication	replication	NN
10_1101-2020_09_23_308239	80	17	and	and	CC
10_1101-2020_09_23_308239	80	18	the	the	DT
10_1101-2020_09_23_308239	80	19	cytopathic	cytopathic	JJ
10_1101-2020_09_23_308239	80	20	effects	effect	NNS
10_1101-2020_09_23_308239	80	21	of	of	IN
10_1101-2020_09_23_308239	80	22	virus	virus	NN
10_1101-2020_09_23_308239	80	23	infection	infection	NN
10_1101-2020_09_23_308239	80	24	.	.	.
10_1101-2020_09_23_308239	81	1	A	a	DT
10_1101-2020_09_23_308239	81	2	derivative	derivative	NN
10_1101-2020_09_23_308239	81	3	of	of	IN
10_1101-2020_09_23_308239	81	4	the	the	DT
10_1101-2020_09_23_308239	81	5	Broad	Broad	NNP
10_1101-2020_09_23_308239	81	6	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	81	7	library	library	NN
10_1101-2020_09_23_308239	81	8	was	be	VBD
10_1101-2020_09_23_308239	81	9	used	use	VBN
10_1101-2020_09_23_308239	81	10	to	to	TO
10_1101-2020_09_23_308239	81	11	incubate	incubate	VB
10_1101-2020_09_23_308239	81	12	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	81	13	cells	cell	NNS
10_1101-2020_09_23_308239	81	14	before	before	IN
10_1101-2020_09_23_308239	81	15	infecting	infect	VBG
10_1101-2020_09_23_308239	81	16	them	-PRON-	PRP
10_1101-2020_09_23_308239	81	17	with	with	IN
10_1101-2020_09_23_308239	81	18	an	an	DT
10_1101-2020_09_23_308239	81	19	isolate	isolate	NN
10_1101-2020_09_23_308239	81	20	of	of	IN
10_1101-2020_09_23_308239	81	21	SARS	SARS	NNP
10_1101-2020_09_23_308239	81	22	-	-	HYPH
10_1101-2020_09_23_308239	81	23	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	81	24	(	(	-LRB-
10_1101-2020_09_23_308239	81	25	FFM-1	FFM-1	NNP
10_1101-2020_09_23_308239	81	26	isolate	isolate	NN
10_1101-2020_09_23_308239	81	27	,	,	,
10_1101-2020_09_23_308239	81	28	see	see	VB
10_1101-2020_09_23_308239	81	29	37	37	CD
10_1101-2020_09_23_308239	81	30	)	)	-RRB-
10_1101-2020_09_23_308239	81	31	.	.	.
10_1101-2020_09_23_308239	82	1	Survival	survival	NN
10_1101-2020_09_23_308239	82	2	of	of	IN
10_1101-2020_09_23_308239	82	3	cells	cell	NNS
10_1101-2020_09_23_308239	82	4	was	be	VBD
10_1101-2020_09_23_308239	82	5	assessed	assess	VBN
10_1101-2020_09_23_308239	82	6	using	use	VBG
10_1101-2020_09_23_308239	82	7	a	a	DT
10_1101-2020_09_23_308239	82	8	cell	cell	NN
10_1101-2020_09_23_308239	82	9	viability	viability	NN
10_1101-2020_09_23_308239	82	10	assay	assay	NN
10_1101-2020_09_23_308239	82	11	and	and	CC
10_1101-2020_09_23_308239	82	12	measured	measure	VBN
10_1101-2020_09_23_308239	82	13	by	by	IN
10_1101-2020_09_23_308239	82	14	high-	high-	JJ
10_1101-2020_09_23_308239	82	15	content	content	NN
10_1101-2020_09_23_308239	82	16	imaging	imaging	NN
10_1101-2020_09_23_308239	82	17	using	use	VBG
10_1101-2020_09_23_308239	82	18	the	the	DT
10_1101-2020_09_23_308239	82	19	Operetta	Operetta	NNP
10_1101-2020_09_23_308239	82	20	CLS	CLS	NNP
10_1101-2020_09_23_308239	82	21	platform	platform	NN
10_1101-2020_09_23_308239	82	22	(	(	-LRB-
10_1101-2020_09_23_308239	82	23	PerkinElmer	PerkinElmer	NNP
10_1101-2020_09_23_308239	82	24	)	)	-RRB-
10_1101-2020_09_23_308239	82	25	.	.	.
10_1101-2020_09_23_308239	83	1	Details	detail	NNS
10_1101-2020_09_23_308239	83	2	of	of	IN
10_1101-2020_09_23_308239	83	3	the	the	DT
10_1101-2020_09_23_308239	83	4	drug	drug	NN
10_1101-2020_09_23_308239	83	5	repurposing	repurposing	NN
10_1101-2020_09_23_308239	83	6	screening	screening	NN
10_1101-2020_09_23_308239	83	7	are	be	VBP
10_1101-2020_09_23_308239	83	8	described	describe	VBN
10_1101-2020_09_23_308239	83	9	in	in	IN
10_1101-2020_09_23_308239	83	10	the	the	DT
10_1101-2020_09_23_308239	83	11	supplemental	supplemental	JJ
10_1101-2020_09_23_308239	83	12	material	material	NN
10_1101-2020_09_23_308239	83	13	.	.	.
10_1101-2020_09_23_308239	84	1	Drug	drug	NN
10_1101-2020_09_23_308239	84	2	combinations	combination	NNS
10_1101-2020_09_23_308239	84	3	assessment	assessment	NN
10_1101-2020_09_23_308239	84	4	with	with	IN
10_1101-2020_09_23_308239	84	5	anti	anti	JJ
10_1101-2020_09_23_308239	84	6	-	-	JJ
10_1101-2020_09_23_308239	84	7	cytopathic	cytopathic	JJ
10_1101-2020_09_23_308239	84	8	effect	effect	NN
10_1101-2020_09_23_308239	84	9	measured	measure	VBN
10_1101-2020_09_23_308239	84	10	in	in	IN
10_1101-2020_09_23_308239	84	11	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	84	12	cells	cell	NNS
10_1101-2020_09_23_308239	84	13	As	as	IN
10_1101-2020_09_23_308239	84	14	described	describe	VBN
10_1101-2020_09_23_308239	84	15	in	in	IN
10_1101-2020_09_23_308239	84	16	Ellinger	Ellinger	NNP
10_1101-2020_09_23_308239	84	17	et	et	NNP
10_1101-2020_09_23_308239	84	18	al	al	NNP
10_1101-2020_09_23_308239	84	19	.	.	.
10_1101-2020_09_23_308239	84	20	,38	,38	,
10_1101-2020_09_23_308239	84	21	we	-PRON-	PRP
10_1101-2020_09_23_308239	84	22	challenged	challenge	VBD
10_1101-2020_09_23_308239	84	23	four	four	CD
10_1101-2020_09_23_308239	84	24	combinations	combination	NNS
10_1101-2020_09_23_308239	84	25	of	of	IN
10_1101-2020_09_23_308239	84	26	five	five	CD
10_1101-2020_09_23_308239	84	27	different	different	JJ
10_1101-2020_09_23_308239	84	28	compounds	compound	NNS
10_1101-2020_09_23_308239	84	29	with	with	IN
10_1101-2020_09_23_308239	84	30	the	the	DT
10_1101-2020_09_23_308239	84	31	SARS	SARS	NNP
10_1101-2020_09_23_308239	84	32	-	-	HYPH
10_1101-2020_09_23_308239	84	33	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	84	34	virus	virus	NN
10_1101-2020_09_23_308239	84	35	in	in	IN
10_1101-2020_09_23_308239	84	36	four	four	CD
10_1101-2020_09_23_308239	84	37	96-well	96-well	CD
10_1101-2020_09_23_308239	84	38	plates	plate	NNS
10_1101-2020_09_23_308239	84	39	containing	contain	VBG
10_1101-2020_09_23_308239	84	40	two	two	CD
10_1101-2020_09_23_308239	84	41	drugs	drug	NNS
10_1101-2020_09_23_308239	84	42	each	each	DT
10_1101-2020_09_23_308239	84	43	.	.	.
10_1101-2020_09_23_308239	85	1	Eight	eight	CD
10_1101-2020_09_23_308239	85	2	drug	drug	NN
10_1101-2020_09_23_308239	85	3	concentrations	concentration	NNS
10_1101-2020_09_23_308239	85	4	were	be	VBD
10_1101-2020_09_23_308239	85	5	chosen	choose	VBN
10_1101-2020_09_23_308239	85	6	ranging	range	VBG
10_1101-2020_09_23_308239	85	7	from	from	IN
10_1101-2020_09_23_308239	85	8	20	20	CD
10_1101-2020_09_23_308239	85	9	µM	µM	NNP
10_1101-2020_09_23_308239	85	10	to	to	IN
10_1101-2020_09_23_308239	85	11	0.01	0.01	CD
10_1101-2020_09_23_308239	85	12	µM	µM	NNP
10_1101-2020_09_23_308239	85	13	,	,	,
10_1101-2020_09_23_308239	85	14	diluted	dilute	VBN
10_1101-2020_09_23_308239	85	15	by	by	IN
10_1101-2020_09_23_308239	85	16	a	a	DT
10_1101-2020_09_23_308239	85	17	factor	factor	NN
10_1101-2020_09_23_308239	85	18	of	of	IN
10_1101-2020_09_23_308239	85	19	3	3	CD
10_1101-2020_09_23_308239	85	20	and	and	CC
10_1101-2020_09_23_308239	85	21	positioned	position	VBD
10_1101-2020_09_23_308239	85	22	orthogonally	orthogonally	RB
10_1101-2020_09_23_308239	85	23	to	to	IN
10_1101-2020_09_23_308239	85	24	each	each	DT
10_1101-2020_09_23_308239	85	25	other	other	JJ
10_1101-2020_09_23_308239	85	26	in	in	IN
10_1101-2020_09_23_308239	85	27	rows	row	NNS
10_1101-2020_09_23_308239	85	28	and	and	CC
10_1101-2020_09_23_308239	85	29	columns	column	NNS
10_1101-2020_09_23_308239	85	30	.	.	.
10_1101-2020_09_23_308239	86	1	No	no	DT
10_1101-2020_09_23_308239	86	2	pharmacological	pharmacological	JJ
10_1101-2020_09_23_308239	86	3	control	control	NN
10_1101-2020_09_23_308239	86	4	was	be	VBD
10_1101-2020_09_23_308239	86	5	used	use	VBN
10_1101-2020_09_23_308239	86	6	,	,	,
10_1101-2020_09_23_308239	86	7	only	only	RB
10_1101-2020_09_23_308239	86	8	cells	cell	NNS
10_1101-2020_09_23_308239	86	9	with	with	IN
10_1101-2020_09_23_308239	86	10	and	and	CC
10_1101-2020_09_23_308239	86	11	without	without	IN
10_1101-2020_09_23_308239	86	12	exposure	exposure	NN
10_1101-2020_09_23_308239	86	13	to	to	IN
10_1101-2020_09_23_308239	86	14	SARS	SARS	NNP
10_1101-2020_09_23_308239	86	15	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	86	16	virus	virus	NN
10_1101-2020_09_23_308239	86	17	at	at	IN
10_1101-2020_09_23_308239	86	18	0.01	0.01	CD
10_1101-2020_09_23_308239	86	19	MOI	MOI	NNP
10_1101-2020_09_23_308239	86	20	.	.	.
10_1101-2020_09_23_308239	87	1	In	in	IN
10_1101-2020_09_23_308239	87	2	addition	addition	NN
10_1101-2020_09_23_308239	87	3	,	,	,
10_1101-2020_09_23_308239	87	4	recently	recently	RB
10_1101-2020_09_23_308239	87	5	published	publish	VBN
10_1101-2020_09_23_308239	87	6	data	datum	NNS
10_1101-2020_09_23_308239	87	7	from	from	IN
10_1101-2020_09_23_308239	87	8	the	the	DT
10_1101-2020_09_23_308239	87	9	work	work	NN
10_1101-2020_09_23_308239	87	10	of	of	IN
10_1101-2020_09_23_308239	87	11	Bobrowski	Bobrowski	NNP
10_1101-2020_09_23_308239	87	12	et	et	NNP
10_1101-2020_09_23_308239	87	13	al.39	al.39	NNP
10_1101-2020_09_23_308239	87	14	,	,	,
10_1101-2020_09_23_308239	87	15	were	be	VBD
10_1101-2020_09_23_308239	87	16	mapped	map	VBN
10_1101-2020_09_23_308239	87	17	to	to	IN
10_1101-2020_09_23_308239	87	18	the	the	DT
10_1101-2020_09_23_308239	87	19	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	87	20	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	87	21	and	and	CC
10_1101-2020_09_23_308239	87	22	compared	compare	VBN
10_1101-2020_09_23_308239	87	23	to	to	IN
10_1101-2020_09_23_308239	87	24	the	the	DT
10_1101-2020_09_23_308239	87	25	results	result	NNS
10_1101-2020_09_23_308239	87	26	of	of	IN
10_1101-2020_09_23_308239	87	27	the	the	DT
10_1101-2020_09_23_308239	87	28	combinatorial	combinatorial	JJ
10_1101-2020_09_23_308239	87	29	treatment	treatment	NN
10_1101-2020_09_23_308239	87	30	experiments	experiment	NNS
10_1101-2020_09_23_308239	87	31	performed	perform	VBN
10_1101-2020_09_23_308239	87	32	here	here	RB
10_1101-2020_09_23_308239	87	33	.	.	.
10_1101-2020_09_23_308239	88	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	88	2	-	-	:
10_1101-2020_09_23_308239	88	3	BY	by	IN
10_1101-2020_09_23_308239	88	4	-	-	HYPH
10_1101-2020_09_23_308239	88	5	NC	NC	NNP
10_1101-2020_09_23_308239	88	6	-	-	HYPH
10_1101-2020_09_23_308239	88	7	ND	ND	NNP
10_1101-2020_09_23_308239	88	8	4.0	4.0	CD
10_1101-2020_09_23_308239	88	9	International	international	JJ
10_1101-2020_09_23_308239	88	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	88	11	.	.	.
10_1101-2020_09_23_308239	89	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	89	2	is	be	VBZ
10_1101-2020_09_23_308239	89	3	made	make	VBN
10_1101-2020_09_23_308239	89	4	available	available	JJ
10_1101-2020_09_23_308239	89	5	under	under	IN
10_1101-2020_09_23_308239	89	6	a	a	DT
10_1101-2020_09_23_308239	89	7	preprint	preprint	NN
10_1101-2020_09_23_308239	89	8	(	(	-LRB-
10_1101-2020_09_23_308239	89	9	which	which	WDT
10_1101-2020_09_23_308239	89	10	was	be	VBD
10_1101-2020_09_23_308239	89	11	not	not	RB
10_1101-2020_09_23_308239	89	12	certified	certify	VBN
10_1101-2020_09_23_308239	89	13	by	by	IN
10_1101-2020_09_23_308239	89	14	peer	peer	NN
10_1101-2020_09_23_308239	89	15	review	review	NN
10_1101-2020_09_23_308239	89	16	)	)	-RRB-
10_1101-2020_09_23_308239	89	17	is	be	VBZ
10_1101-2020_09_23_308239	89	18	the	the	DT
10_1101-2020_09_23_308239	89	19	author	author	NN
10_1101-2020_09_23_308239	89	20	/	/	SYM
10_1101-2020_09_23_308239	89	21	funder	funder	NN
10_1101-2020_09_23_308239	89	22	,	,	,
10_1101-2020_09_23_308239	89	23	who	who	WP
10_1101-2020_09_23_308239	89	24	has	have	VBZ
10_1101-2020_09_23_308239	89	25	granted	grant	VBN
10_1101-2020_09_23_308239	89	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	89	27	a	a	DT
10_1101-2020_09_23_308239	89	28	license	license	NN
10_1101-2020_09_23_308239	89	29	to	to	TO
10_1101-2020_09_23_308239	89	30	display	display	VB
10_1101-2020_09_23_308239	89	31	the	the	DT
10_1101-2020_09_23_308239	89	32	preprint	preprint	NN
10_1101-2020_09_23_308239	89	33	in	in	IN
10_1101-2020_09_23_308239	89	34	The	the	DT
10_1101-2020_09_23_308239	89	35	copyright	copyright	NN
10_1101-2020_09_23_308239	89	36	holder	holder	NN
10_1101-2020_09_23_308239	89	37	for	for	IN
10_1101-2020_09_23_308239	89	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	89	39	version	version	NN
10_1101-2020_09_23_308239	89	40	posted	post	VBD
10_1101-2020_09_23_308239	89	41	February	February	NNP
10_1101-2020_09_23_308239	89	42	12	12	CD
10_1101-2020_09_23_308239	89	43	,	,	,
10_1101-2020_09_23_308239	89	44	2021	2021	CD
10_1101-2020_09_23_308239	89	45	.	.	.
10_1101-2020_09_23_308239	89	46	;	;	:
10_1101-2020_09_23_308239	89	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	89	48	:	:	:
10_1101-2020_09_23_308239	89	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	89	50	preprint	preprint	NN
10_1101-2020_09_23_308239	89	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	89	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	89	53	12	12	CD
10_1101-2020_09_23_308239	89	54	Results	result	NNS
10_1101-2020_09_23_308239	89	55	Comparative	comparative	JJ
10_1101-2020_09_23_308239	89	56	analysis	analysis	NN
10_1101-2020_09_23_308239	89	57	of	of	IN
10_1101-2020_09_23_308239	89	58	the	the	DT
10_1101-2020_09_23_308239	89	59	hits	hit	NNS
10_1101-2020_09_23_308239	89	60	from	from	IN
10_1101-2020_09_23_308239	89	61	different	different	JJ
10_1101-2020_09_23_308239	89	62	repurposing	repurposing	NN
10_1101-2020_09_23_308239	89	63	screenings	screening	NNS
10_1101-2020_09_23_308239	89	64	Data	Data	NNPS
10_1101-2020_09_23_308239	89	65	from	from	IN
10_1101-2020_09_23_308239	89	66	six	six	CD
10_1101-2020_09_23_308239	89	67	published	publish	VBN
10_1101-2020_09_23_308239	89	68	drug	drug	NN
10_1101-2020_09_23_308239	89	69	repurposing	repurposing	NN
10_1101-2020_09_23_308239	89	70	screenings	screening	NNS
10_1101-2020_09_23_308239	89	71	were	be	VBD
10_1101-2020_09_23_308239	89	72	downloaded	download	VBN
10_1101-2020_09_23_308239	89	73	,	,	,
10_1101-2020_09_23_308239	89	74	and	and	CC
10_1101-2020_09_23_308239	89	75	extensive	extensive	JJ
10_1101-2020_09_23_308239	89	76	mapping	mapping	NN
10_1101-2020_09_23_308239	89	77	and	and	CC
10_1101-2020_09_23_308239	89	78	curation	curation	NN
10_1101-2020_09_23_308239	89	79	was	be	VBD
10_1101-2020_09_23_308239	89	80	performed	perform	VBN
10_1101-2020_09_23_308239	89	81	in	in	IN
10_1101-2020_09_23_308239	89	82	order	order	NN
10_1101-2020_09_23_308239	89	83	to	to	TO
10_1101-2020_09_23_308239	89	84	harmonize	harmonize	VB
10_1101-2020_09_23_308239	89	85	chemical	chemical	JJ
10_1101-2020_09_23_308239	89	86	identifiers	identifier	NNS
10_1101-2020_09_23_308239	89	87	.	.	.
10_1101-2020_09_23_308239	90	1	The	the	DT
10_1101-2020_09_23_308239	90	2	curated	curated	JJ
10_1101-2020_09_23_308239	90	3	list	list	NN
10_1101-2020_09_23_308239	90	4	of	of	IN
10_1101-2020_09_23_308239	90	5	drug	drug	NN
10_1101-2020_09_23_308239	90	6	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	90	7	“	"	``
10_1101-2020_09_23_308239	90	8	hits	hit	NNS
10_1101-2020_09_23_308239	90	9	”	"	''
10_1101-2020_09_23_308239	90	10	together	together	RB
10_1101-2020_09_23_308239	90	11	with	with	IN
10_1101-2020_09_23_308239	90	12	an	an	DT
10_1101-2020_09_23_308239	90	13	annotation	annotation	NN
10_1101-2020_09_23_308239	90	14	of	of	IN
10_1101-2020_09_23_308239	90	15	the	the	DT
10_1101-2020_09_23_308239	90	16	assay	assay	NN
10_1101-2020_09_23_308239	90	17	conditions	condition	NNS
10_1101-2020_09_23_308239	90	18	is	be	VBZ
10_1101-2020_09_23_308239	90	19	available	available	JJ
10_1101-2020_09_23_308239	90	20	under	under	IN
10_1101-2020_09_23_308239	90	21	http://chembl.blogspot.com/2020/05/chembl27-sars-cov-2-release.html	http://chembl.blogspot.com/2020/05/chembl27-sars-cov-2-release.html	NNP
10_1101-2020_09_23_308239	90	22	Initially	initially	RB
10_1101-2020_09_23_308239	90	23	,	,	,
10_1101-2020_09_23_308239	90	24	we	-PRON-	PRP
10_1101-2020_09_23_308239	90	25	analyzed	analyze	VBD
10_1101-2020_09_23_308239	90	26	the	the	DT
10_1101-2020_09_23_308239	90	27	overlap	overlap	NN
10_1101-2020_09_23_308239	90	28	between	between	IN
10_1101-2020_09_23_308239	90	29	compounds	compound	NNS
10_1101-2020_09_23_308239	90	30	identified	identify	VBN
10_1101-2020_09_23_308239	90	31	in	in	IN
10_1101-2020_09_23_308239	90	32	the	the	DT
10_1101-2020_09_23_308239	90	33	reported	report	VBN
10_1101-2020_09_23_308239	90	34	drug	drug	NN
10_1101-2020_09_23_308239	90	35	repurposing	repurposing	NN
10_1101-2020_09_23_308239	90	36	screening	screening	NN
10_1101-2020_09_23_308239	90	37	experiments	experiment	NNS
10_1101-2020_09_23_308239	90	38	.	.	.
10_1101-2020_09_23_308239	91	1	Figure	figure	NN
10_1101-2020_09_23_308239	91	2	3A	3A	NNP
10_1101-2020_09_23_308239	91	3	shows	show	VBZ
10_1101-2020_09_23_308239	91	4	no	no	DT
10_1101-2020_09_23_308239	91	5	overlap	overlap	NN
10_1101-2020_09_23_308239	91	6	between	between	IN
10_1101-2020_09_23_308239	91	7	experiments	experiment	NNS
10_1101-2020_09_23_308239	91	8	,	,	,
10_1101-2020_09_23_308239	91	9	which	which	WDT
10_1101-2020_09_23_308239	91	10	is	be	VBZ
10_1101-2020_09_23_308239	91	11	not	not	RB
10_1101-2020_09_23_308239	91	12	surprising	surprising	JJ
10_1101-2020_09_23_308239	91	13	,	,	,
10_1101-2020_09_23_308239	91	14	as	as	IN
10_1101-2020_09_23_308239	91	15	we	-PRON-	PRP
10_1101-2020_09_23_308239	91	16	are	be	VBP
10_1101-2020_09_23_308239	91	17	comparing	compare	VBG
10_1101-2020_09_23_308239	91	18	highly	highly	RB
10_1101-2020_09_23_308239	91	19	specific	specific	JJ
10_1101-2020_09_23_308239	91	20	candidate	candidate	NN
10_1101-2020_09_23_308239	91	21	drug	drug	NN
10_1101-2020_09_23_308239	91	22	experiments	experiment	NNS
10_1101-2020_09_23_308239	91	23	with	with	IN
10_1101-2020_09_23_308239	91	24	screenings	screening	NNS
10_1101-2020_09_23_308239	91	25	based	base	VBN
10_1101-2020_09_23_308239	91	26	on	on	IN
10_1101-2020_09_23_308239	91	27	large	large	JJ
10_1101-2020_09_23_308239	91	28	drug	drug	NN
10_1101-2020_09_23_308239	91	29	repositioning	repositioning	NN
10_1101-2020_09_23_308239	91	30	libraries	library	NNS
10_1101-2020_09_23_308239	91	31	.	.	.
10_1101-2020_09_23_308239	92	1	However	however	RB
10_1101-2020_09_23_308239	92	2	,	,	,
10_1101-2020_09_23_308239	92	3	the	the	DT
10_1101-2020_09_23_308239	92	4	overlap	overlap	NN
10_1101-2020_09_23_308239	92	5	is	be	VBZ
10_1101-2020_09_23_308239	92	6	still	still	RB
10_1101-2020_09_23_308239	92	7	quite	quite	RB
10_1101-2020_09_23_308239	92	8	marginal	marginal	JJ
10_1101-2020_09_23_308239	92	9	for	for	IN
10_1101-2020_09_23_308239	92	10	those	those	DT
10_1101-2020_09_23_308239	92	11	screenings	screening	NNS
10_1101-2020_09_23_308239	92	12	where	where	WRB
10_1101-2020_09_23_308239	92	13	large	large	JJ
10_1101-2020_09_23_308239	92	14	compound	compound	NN
10_1101-2020_09_23_308239	92	15	collections	collection	NNS
10_1101-2020_09_23_308239	92	16	(	(	-LRB-
10_1101-2020_09_23_308239	92	17	Broad	broad	JJ
10_1101-2020_09_23_308239	92	18	library	library	NN
10_1101-2020_09_23_308239	92	19	,	,	,
10_1101-2020_09_23_308239	92	20	ReFRAME	reframe	JJ
10_1101-2020_09_23_308239	92	21	library	library	NN
10_1101-2020_09_23_308239	92	22	)	)	-RRB-
10_1101-2020_09_23_308239	92	23	have	have	VBP
10_1101-2020_09_23_308239	92	24	been	be	VBN
10_1101-2020_09_23_308239	92	25	used	use	VBN
10_1101-2020_09_23_308239	92	26	.	.	.
10_1101-2020_09_23_308239	93	1	Figure	figure	NN
10_1101-2020_09_23_308239	93	2	3	3	CD
10_1101-2020_09_23_308239	93	3	:	:	:
10_1101-2020_09_23_308239	93	4	Overlap	overlap	NN
10_1101-2020_09_23_308239	93	5	of	of	IN
10_1101-2020_09_23_308239	93	6	compound	compound	NN
10_1101-2020_09_23_308239	93	7	hits	hit	NNS
10_1101-2020_09_23_308239	93	8	between	between	IN
10_1101-2020_09_23_308239	93	9	different	different	JJ
10_1101-2020_09_23_308239	93	10	drug	drug	NN
10_1101-2020_09_23_308239	93	11	repurposing	repurposing	NN
10_1101-2020_09_23_308239	93	12	screening	screening	NN
10_1101-2020_09_23_308239	93	13	experiments	experiment	NNS
10_1101-2020_09_23_308239	93	14	.	.	.
10_1101-2020_09_23_308239	94	1	a	a	LS
10_1101-2020_09_23_308239	94	2	)	)	-RRB-
10_1101-2020_09_23_308239	94	3	Direct	direct	JJ
10_1101-2020_09_23_308239	94	4	comparison	comparison	NN
10_1101-2020_09_23_308239	94	5	of	of	IN
10_1101-2020_09_23_308239	94	6	overlapping	overlap	VBG
10_1101-2020_09_23_308239	94	7	hits	hit	NNS
10_1101-2020_09_23_308239	94	8	in	in	IN
10_1101-2020_09_23_308239	94	9	drug	drug	NN
10_1101-2020_09_23_308239	94	10	repurposing	repurposing	NN
10_1101-2020_09_23_308239	94	11	screenings	screening	NNS
10_1101-2020_09_23_308239	94	12	revealed	reveal	VBD
10_1101-2020_09_23_308239	94	13	no	no	DT
10_1101-2020_09_23_308239	94	14	overlap	overlap	NN
10_1101-2020_09_23_308239	94	15	between	between	IN
10_1101-2020_09_23_308239	94	16	the	the	DT
10_1101-2020_09_23_308239	94	17	experiments	experiment	NNS
10_1101-2020_09_23_308239	94	18	.	.	.
10_1101-2020_09_23_308239	95	1	These	these	DT
10_1101-2020_09_23_308239	95	2	experiments	experiment	NNS
10_1101-2020_09_23_308239	95	3	were	be	VBD
10_1101-2020_09_23_308239	95	4	performed	perform	VBN
10_1101-2020_09_23_308239	95	5	using	use	VBG
10_1101-2020_09_23_308239	95	6	different	different	JJ
10_1101-2020_09_23_308239	95	7	cell	cell	NN
10_1101-2020_09_23_308239	95	8	types	type	NNS
10_1101-2020_09_23_308239	95	9	(	(	-LRB-
10_1101-2020_09_23_308239	95	10	Vero	Vero	NNP
10_1101-2020_09_23_308239	95	11	E6	e6	NN
10_1101-2020_09_23_308239	95	12	cells	cell	NNS
10_1101-2020_09_23_308239	95	13	and	and	CC
10_1101-2020_09_23_308239	95	14	Caco2	caco2	JJ
10_1101-2020_09_23_308239	95	15	cells	cell	NNS
10_1101-2020_09_23_308239	95	16	)	)	-RRB-
10_1101-2020_09_23_308239	95	17	.	.	.
10_1101-2020_09_23_308239	96	1	b	b	LS
10_1101-2020_09_23_308239	96	2	)	)	-RRB-
10_1101-2020_09_23_308239	96	3	Protein	protein	NN
10_1101-2020_09_23_308239	96	4	target	target	NN
10_1101-2020_09_23_308239	96	5	space	space	NN
10_1101-2020_09_23_308239	96	6	overlap	overlap	NN
10_1101-2020_09_23_308239	96	7	between	between	IN
10_1101-2020_09_23_308239	96	8	different	different	JJ
10_1101-2020_09_23_308239	96	9	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	96	10	drug	drug	NN
10_1101-2020_09_23_308239	96	11	repurposing	repurposing	NN
10_1101-2020_09_23_308239	96	12	screenings	screening	NNS
10_1101-2020_09_23_308239	96	13	.	.	.
10_1101-2020_09_23_308239	97	1	Drug	drug	NN
10_1101-2020_09_23_308239	97	2	targets	target	NNS
10_1101-2020_09_23_308239	97	3	were	be	VBD
10_1101-2020_09_23_308239	97	4	identified	identify	VBN
10_1101-2020_09_23_308239	97	5	by	by	IN
10_1101-2020_09_23_308239	97	6	confidence	confidence	NN
10_1101-2020_09_23_308239	97	7	level	level	NN
10_1101-2020_09_23_308239	97	8	>	>	NN
10_1101-2020_09_23_308239	97	9	=	=	SYM
10_1101-2020_09_23_308239	97	10	8	8	CD
10_1101-2020_09_23_308239	97	11	and	and	CC
10_1101-2020_09_23_308239	97	12	single	single	JJ
10_1101-2020_09_23_308239	97	13	protein	protein	NN
10_1101-2020_09_23_308239	97	14	targets	target	NNS
10_1101-2020_09_23_308239	97	15	according	accord	VBG
10_1101-2020_09_23_308239	97	16	to	to	IN
10_1101-2020_09_23_308239	97	17	the	the	DT
10_1101-2020_09_23_308239	97	18	ChEMBL	ChEMBL	NNP
10_1101-2020_09_23_308239	97	19	database	database	NN
10_1101-2020_09_23_308239	97	20	.	.	.
10_1101-2020_09_23_308239	98	1	Comparison	comparison	NN
10_1101-2020_09_23_308239	98	2	of	of	IN
10_1101-2020_09_23_308239	98	3	experiments	experiment	NNS
10_1101-2020_09_23_308239	98	4	indicates	indicate	VBZ
10_1101-2020_09_23_308239	98	5	over	over	IN
10_1101-2020_09_23_308239	98	6	one	one	CD
10_1101-2020_09_23_308239	98	7	hundred	hundred	CD
10_1101-2020_09_23_308239	98	8	common	common	JJ
10_1101-2020_09_23_308239	98	9	protein	protein	NN
10_1101-2020_09_23_308239	98	10	targets	target	NNS
10_1101-2020_09_23_308239	98	11	.	.	.
10_1101-2020_09_23_308239	99	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	99	2	-	-	:
10_1101-2020_09_23_308239	99	3	BY	by	IN
10_1101-2020_09_23_308239	99	4	-	-	HYPH
10_1101-2020_09_23_308239	99	5	NC	NC	NNP
10_1101-2020_09_23_308239	99	6	-	-	HYPH
10_1101-2020_09_23_308239	99	7	ND	ND	NNP
10_1101-2020_09_23_308239	99	8	4.0	4.0	CD
10_1101-2020_09_23_308239	99	9	International	international	JJ
10_1101-2020_09_23_308239	99	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	99	11	.	.	.
10_1101-2020_09_23_308239	100	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	100	2	is	be	VBZ
10_1101-2020_09_23_308239	100	3	made	make	VBN
10_1101-2020_09_23_308239	100	4	available	available	JJ
10_1101-2020_09_23_308239	100	5	under	under	IN
10_1101-2020_09_23_308239	100	6	a	a	DT
10_1101-2020_09_23_308239	100	7	preprint	preprint	NN
10_1101-2020_09_23_308239	100	8	(	(	-LRB-
10_1101-2020_09_23_308239	100	9	which	which	WDT
10_1101-2020_09_23_308239	100	10	was	be	VBD
10_1101-2020_09_23_308239	100	11	not	not	RB
10_1101-2020_09_23_308239	100	12	certified	certify	VBN
10_1101-2020_09_23_308239	100	13	by	by	IN
10_1101-2020_09_23_308239	100	14	peer	peer	NN
10_1101-2020_09_23_308239	100	15	review	review	NN
10_1101-2020_09_23_308239	100	16	)	)	-RRB-
10_1101-2020_09_23_308239	100	17	is	be	VBZ
10_1101-2020_09_23_308239	100	18	the	the	DT
10_1101-2020_09_23_308239	100	19	author	author	NN
10_1101-2020_09_23_308239	100	20	/	/	SYM
10_1101-2020_09_23_308239	100	21	funder	funder	NN
10_1101-2020_09_23_308239	100	22	,	,	,
10_1101-2020_09_23_308239	100	23	who	who	WP
10_1101-2020_09_23_308239	100	24	has	have	VBZ
10_1101-2020_09_23_308239	100	25	granted	grant	VBN
10_1101-2020_09_23_308239	100	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	100	27	a	a	DT
10_1101-2020_09_23_308239	100	28	license	license	NN
10_1101-2020_09_23_308239	100	29	to	to	TO
10_1101-2020_09_23_308239	100	30	display	display	VB
10_1101-2020_09_23_308239	100	31	the	the	DT
10_1101-2020_09_23_308239	100	32	preprint	preprint	NN
10_1101-2020_09_23_308239	100	33	in	in	IN
10_1101-2020_09_23_308239	100	34	The	the	DT
10_1101-2020_09_23_308239	100	35	copyright	copyright	NN
10_1101-2020_09_23_308239	100	36	holder	holder	NN
10_1101-2020_09_23_308239	100	37	for	for	IN
10_1101-2020_09_23_308239	100	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	100	39	version	version	NN
10_1101-2020_09_23_308239	100	40	posted	post	VBD
10_1101-2020_09_23_308239	100	41	February	February	NNP
10_1101-2020_09_23_308239	100	42	12	12	CD
10_1101-2020_09_23_308239	100	43	,	,	,
10_1101-2020_09_23_308239	100	44	2021	2021	CD
10_1101-2020_09_23_308239	100	45	.	.	.
10_1101-2020_09_23_308239	100	46	;	;	:
10_1101-2020_09_23_308239	100	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	100	48	:	:	:
10_1101-2020_09_23_308239	100	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	100	50	preprint	preprint	NN
10_1101-2020_09_23_308239	100	51	http://chembl.blogspot.com/2020/05/chembl27-sars-cov-2-release.html	http://chembl.blogspot.com/2020/05/chembl27-sars-cov-2-release.html	VB
10_1101-2020_09_23_308239	100	52	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	-LRB-
10_1101-2020_09_23_308239	100	53	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	100	54	13	13	CD
10_1101-2020_09_23_308239	100	55	Mapping	mapping	NN
10_1101-2020_09_23_308239	100	56	of	of	IN
10_1101-2020_09_23_308239	100	57	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	100	58	hits	hit	NNS
10_1101-2020_09_23_308239	100	59	to	to	TO
10_1101-2020_09_23_308239	100	60	target	target	VB
10_1101-2020_09_23_308239	100	61	proteins	protein	NNS
10_1101-2020_09_23_308239	100	62	In	in	IN
10_1101-2020_09_23_308239	100	63	order	order	NN
10_1101-2020_09_23_308239	100	64	to	to	TO
10_1101-2020_09_23_308239	100	65	identify	identify	VB
10_1101-2020_09_23_308239	100	66	which	which	WDT
10_1101-2020_09_23_308239	100	67	proteins	protein	NNS
10_1101-2020_09_23_308239	100	68	are	be	VBP
10_1101-2020_09_23_308239	100	69	targeted	target	VBN
10_1101-2020_09_23_308239	100	70	by	by	IN
10_1101-2020_09_23_308239	100	71	the	the	DT
10_1101-2020_09_23_308239	100	72	repurposing	repurposing	NN
10_1101-2020_09_23_308239	100	73	hits	hit	NNS
10_1101-2020_09_23_308239	100	74	,	,	,
10_1101-2020_09_23_308239	100	75	and	and	CC
10_1101-2020_09_23_308239	100	76	to	to	TO
10_1101-2020_09_23_308239	100	77	investigate	investigate	VB
10_1101-2020_09_23_308239	100	78	the	the	DT
10_1101-2020_09_23_308239	100	79	extent	extent	NN
10_1101-2020_09_23_308239	100	80	to	to	TO
10_1101-2020_09_23_308239	100	81	which	which	WDT
10_1101-2020_09_23_308239	100	82	there	there	EX
10_1101-2020_09_23_308239	100	83	are	be	VBP
10_1101-2020_09_23_308239	100	84	overlaps	overlap	NNS
10_1101-2020_09_23_308239	100	85	between	between	IN
10_1101-2020_09_23_308239	100	86	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	100	87	experiments	experiment	NNS
10_1101-2020_09_23_308239	100	88	at	at	IN
10_1101-2020_09_23_308239	100	89	the	the	DT
10_1101-2020_09_23_308239	100	90	target	target	NN
10_1101-2020_09_23_308239	100	91	/	/	SYM
10_1101-2020_09_23_308239	100	92	protein	protein	NN
10_1101-2020_09_23_308239	100	93	level	level	NN
10_1101-2020_09_23_308239	100	94	,	,	,
10_1101-2020_09_23_308239	100	95	we	-PRON-	PRP
10_1101-2020_09_23_308239	100	96	mapped	map	VBD
10_1101-2020_09_23_308239	100	97	all	all	PDT
10_1101-2020_09_23_308239	100	98	the	the	DT
10_1101-2020_09_23_308239	100	99	identified	identify	VBN
10_1101-2020_09_23_308239	100	100	compounds	compound	NNS
10_1101-2020_09_23_308239	100	101	from	from	IN
10_1101-2020_09_23_308239	100	102	the	the	DT
10_1101-2020_09_23_308239	100	103	drug	drug	NN
10_1101-2020_09_23_308239	100	104	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	100	105	experiments	experiment	NNS
10_1101-2020_09_23_308239	100	106	to	to	IN
10_1101-2020_09_23_308239	100	107	their	-PRON-	PRP$
10_1101-2020_09_23_308239	100	108	respective	respective	JJ
10_1101-2020_09_23_308239	100	109	targets	target	NNS
10_1101-2020_09_23_308239	100	110	.	.	.
10_1101-2020_09_23_308239	101	1	As	as	IN
10_1101-2020_09_23_308239	101	2	most	most	JJS
10_1101-2020_09_23_308239	101	3	drugs	drug	NNS
10_1101-2020_09_23_308239	101	4	bind	bind	VBP
10_1101-2020_09_23_308239	101	5	to	to	IN
10_1101-2020_09_23_308239	101	6	more	more	JJR
10_1101-2020_09_23_308239	101	7	than	than	IN
10_1101-2020_09_23_308239	101	8	one	one	CD
10_1101-2020_09_23_308239	101	9	target	target	NN
10_1101-2020_09_23_308239	101	10	,	,	,
10_1101-2020_09_23_308239	101	11	we	-PRON-	PRP
10_1101-2020_09_23_308239	101	12	increase	increase	VBP
10_1101-2020_09_23_308239	101	13	the	the	DT
10_1101-2020_09_23_308239	101	14	likelihood	likelihood	NN
10_1101-2020_09_23_308239	101	15	of	of	IN
10_1101-2020_09_23_308239	101	16	overlaps	overlap	NNS
10_1101-2020_09_23_308239	101	17	between	between	IN
10_1101-2020_09_23_308239	101	18	the	the	DT
10_1101-2020_09_23_308239	101	19	drug	drug	NN
10_1101-2020_09_23_308239	101	20	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	101	21	experiments	experiment	NNS
10_1101-2020_09_23_308239	101	22	when	when	WRB
10_1101-2020_09_23_308239	101	23	we	-PRON-	PRP
10_1101-2020_09_23_308239	101	24	compare	compare	VBP
10_1101-2020_09_23_308239	101	25	them	-PRON-	PRP
10_1101-2020_09_23_308239	101	26	at	at	IN
10_1101-2020_09_23_308239	101	27	the	the	DT
10_1101-2020_09_23_308239	101	28	protein	protein	NN
10_1101-2020_09_23_308239	101	29	/	/	SYM
10_1101-2020_09_23_308239	101	30	target	target	NN
10_1101-2020_09_23_308239	101	31	space	space	NN
10_1101-2020_09_23_308239	101	32	.	.	.
10_1101-2020_09_23_308239	102	1	Indeed	indeed	RB
10_1101-2020_09_23_308239	102	2	,	,	,
10_1101-2020_09_23_308239	102	3	Figure	figure	NN
10_1101-2020_09_23_308239	102	4	3B	3b	NN
10_1101-2020_09_23_308239	102	5	shows	show	VBZ
10_1101-2020_09_23_308239	102	6	an	an	DT
10_1101-2020_09_23_308239	102	7	overlap	overlap	NN
10_1101-2020_09_23_308239	102	8	of	of	IN
10_1101-2020_09_23_308239	102	9	112	112	CD
10_1101-2020_09_23_308239	102	10	targets	target	NNS
10_1101-2020_09_23_308239	102	11	between	between	IN
10_1101-2020_09_23_308239	102	12	all	all	PDT
10_1101-2020_09_23_308239	102	13	the	the	DT
10_1101-2020_09_23_308239	102	14	drug	drug	NN
10_1101-2020_09_23_308239	102	15	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	102	16	experiments	experiment	NNS
10_1101-2020_09_23_308239	102	17	,	,	,
10_1101-2020_09_23_308239	102	18	thereby	thereby	RB
10_1101-2020_09_23_308239	102	19	creating	create	VBG
10_1101-2020_09_23_308239	102	20	a	a	DT
10_1101-2020_09_23_308239	102	21	list	list	NN
10_1101-2020_09_23_308239	102	22	of	of	IN
10_1101-2020_09_23_308239	102	23	potential	potential	JJ
10_1101-2020_09_23_308239	102	24	proteins	protein	NNS
10_1101-2020_09_23_308239	102	25	for	for	IN
10_1101-2020_09_23_308239	102	26	therapeutic	therapeutic	JJ
10_1101-2020_09_23_308239	102	27	intervention	intervention	NN
10_1101-2020_09_23_308239	102	28	when	when	WRB
10_1101-2020_09_23_308239	102	29	the	the	DT
10_1101-2020_09_23_308239	102	30	compound	compound	NN
10_1101-2020_09_23_308239	102	31	targets	target	NNS
10_1101-2020_09_23_308239	102	32	are	be	VBP
10_1101-2020_09_23_308239	102	33	considered	consider	VBN
10_1101-2020_09_23_308239	102	34	rather	rather	RB
10_1101-2020_09_23_308239	102	35	than	than	IN
10_1101-2020_09_23_308239	102	36	the	the	DT
10_1101-2020_09_23_308239	102	37	compounds	compound	NNS
10_1101-2020_09_23_308239	102	38	themselves	-PRON-	PRP
10_1101-2020_09_23_308239	102	39	.	.	.
10_1101-2020_09_23_308239	103	1	The	the	DT
10_1101-2020_09_23_308239	103	2	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	103	3	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	103	4	associates	associate	VBZ
10_1101-2020_09_23_308239	103	5	pathways	pathway	NNS
10_1101-2020_09_23_308239	103	6	derived	derive	VBN
10_1101-2020_09_23_308239	103	7	from	from	IN
10_1101-2020_09_23_308239	103	8	drug	drug	NN
10_1101-2020_09_23_308239	103	9	repurposing	repurposing	NN
10_1101-2020_09_23_308239	103	10	targets	target	NNS
10_1101-2020_09_23_308239	103	11	with	with	IN
10_1101-2020_09_23_308239	103	12	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	103	13	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	103	14	A	a	DT
10_1101-2020_09_23_308239	103	15	non	non	JJ
10_1101-2020_09_23_308239	103	16	-	-	JJ
10_1101-2020_09_23_308239	103	17	redundant	redundant	JJ
10_1101-2020_09_23_308239	103	18	list	list	NN
10_1101-2020_09_23_308239	103	19	of	of	IN
10_1101-2020_09_23_308239	103	20	drug	drug	NN
10_1101-2020_09_23_308239	103	21	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	103	22	candidate	candidate	NN
10_1101-2020_09_23_308239	103	23	molecules	molecule	NNS
10_1101-2020_09_23_308239	103	24	that	that	WDT
10_1101-2020_09_23_308239	103	25	display	display	VBP
10_1101-2020_09_23_308239	103	26	activity	activity	NN
10_1101-2020_09_23_308239	103	27	in	in	IN
10_1101-2020_09_23_308239	103	28	phenotypic	phenotypic	JJ
10_1101-2020_09_23_308239	103	29	(	(	-LRB-
10_1101-2020_09_23_308239	103	30	cellular	cellular	JJ
10_1101-2020_09_23_308239	103	31	)	)	-RRB-
10_1101-2020_09_23_308239	103	32	assays	assay	NNS
10_1101-2020_09_23_308239	103	33	was	be	VBD
10_1101-2020_09_23_308239	103	34	generated	generate	VBN
10_1101-2020_09_23_308239	103	35	and	and	CC
10_1101-2020_09_23_308239	103	36	mapped	map	VBN
10_1101-2020_09_23_308239	103	37	to	to	IN
10_1101-2020_09_23_308239	103	38	the	the	DT
10_1101-2020_09_23_308239	103	39	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	103	40	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	103	41	.	.	.
10_1101-2020_09_23_308239	104	1	Figure	figure	NN
10_1101-2020_09_23_308239	104	2	4	4	CD
10_1101-2020_09_23_308239	104	3	shows	show	VBZ
10_1101-2020_09_23_308239	104	4	the	the	DT
10_1101-2020_09_23_308239	104	5	distribution	distribution	NN
10_1101-2020_09_23_308239	104	6	of	of	IN
10_1101-2020_09_23_308239	104	7	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	104	8	drugs	drug	NNS
10_1101-2020_09_23_308239	104	9	in	in	IN
10_1101-2020_09_23_308239	104	10	the	the	DT
10_1101-2020_09_23_308239	104	11	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	104	12	cause	cause	NN
10_1101-2020_09_23_308239	104	13	-	-	HYPH
10_1101-2020_09_23_308239	104	14	and	and	CC
10_1101-2020_09_23_308239	104	15	-	-	HYPH
10_1101-2020_09_23_308239	104	16	effect	effect	NN
10_1101-2020_09_23_308239	104	17	graph	graph	NN
10_1101-2020_09_23_308239	104	18	,	,	,
10_1101-2020_09_23_308239	104	19	the	the	DT
10_1101-2020_09_23_308239	104	20	“	"	``
10_1101-2020_09_23_308239	104	21	responsive	responsive	JJ
10_1101-2020_09_23_308239	104	22	part	part	NN
10_1101-2020_09_23_308239	104	23	”	"	''
10_1101-2020_09_23_308239	104	24	of	of	IN
10_1101-2020_09_23_308239	104	25	the	the	DT
10_1101-2020_09_23_308239	104	26	graph	graph	NN
10_1101-2020_09_23_308239	104	27	that	that	WDT
10_1101-2020_09_23_308239	104	28	is	be	VBZ
10_1101-2020_09_23_308239	104	29	characterized	characterize	VBN
10_1101-2020_09_23_308239	104	30	by	by	IN
10_1101-2020_09_23_308239	104	31	changes	change	NNS
10_1101-2020_09_23_308239	104	32	in	in	IN
10_1101-2020_09_23_308239	104	33	gene	gene	NN
10_1101-2020_09_23_308239	104	34	expression	expression	NN
10_1101-2020_09_23_308239	104	35	associated	associate	VBN
10_1101-2020_09_23_308239	104	36	with	with	IN
10_1101-2020_09_23_308239	104	37	SARS	SARS	NNP
10_1101-2020_09_23_308239	104	38	-	-	HYPH
10_1101-2020_09_23_308239	104	39	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	104	40	infection	infection	NN
10_1101-2020_09_23_308239	104	41	and	and	CC
10_1101-2020_09_23_308239	104	42	the	the	DT
10_1101-2020_09_23_308239	104	43	overlap	overlap	NN
10_1101-2020_09_23_308239	104	44	between	between	IN
10_1101-2020_09_23_308239	104	45	the	the	DT
10_1101-2020_09_23_308239	104	46	two	two	CD
10_1101-2020_09_23_308239	104	47	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	104	48	.	.	.
10_1101-2020_09_23_308239	105	1	This	this	DT
10_1101-2020_09_23_308239	105	2	overlap	overlap	NN
10_1101-2020_09_23_308239	105	3	analysis	analysis	NN
10_1101-2020_09_23_308239	105	4	allows	allow	VBZ
10_1101-2020_09_23_308239	105	5	for	for	IN
10_1101-2020_09_23_308239	105	6	the	the	DT
10_1101-2020_09_23_308239	105	7	identification	identification	NN
10_1101-2020_09_23_308239	105	8	of	of	IN
10_1101-2020_09_23_308239	105	9	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	105	10	drugs	drug	NNS
10_1101-2020_09_23_308239	105	11	targeting	target	VBG
10_1101-2020_09_23_308239	105	12	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	105	13	that	that	WDT
10_1101-2020_09_23_308239	105	14	are	be	VBP
10_1101-2020_09_23_308239	105	15	modulated	modulate	VBN
10_1101-2020_09_23_308239	105	16	by	by	IN
10_1101-2020_09_23_308239	105	17	viral	viral	JJ
10_1101-2020_09_23_308239	105	18	infection	infection	NN
10_1101-2020_09_23_308239	105	19	.	.	.
10_1101-2020_09_23_308239	106	1	A	a	DT
10_1101-2020_09_23_308239	106	2	total	total	JJ
10_1101-2020_09_23_308239	106	3	number	number	NN
10_1101-2020_09_23_308239	106	4	of	of	IN
10_1101-2020_09_23_308239	106	5	870	870	CD
10_1101-2020_09_23_308239	106	6	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	106	7	were	be	VBD
10_1101-2020_09_23_308239	106	8	identified	identify	VBN
10_1101-2020_09_23_308239	106	9	as	as	IN
10_1101-2020_09_23_308239	106	10	being	be	VBG
10_1101-2020_09_23_308239	106	11	targeted	target	VBN
10_1101-2020_09_23_308239	106	12	by	by	IN
10_1101-2020_09_23_308239	106	13	most	most	JJS
10_1101-2020_09_23_308239	106	14	of	of	IN
10_1101-2020_09_23_308239	106	15	the	the	DT
10_1101-2020_09_23_308239	106	16	drug	drug	NN
10_1101-2020_09_23_308239	106	17	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	106	18	candidates	candidate	NNS
10_1101-2020_09_23_308239	106	19	(	(	-LRB-
10_1101-2020_09_23_308239	106	20	see	see	VB
10_1101-2020_09_23_308239	106	21	section	section	NN
10_1101-2020_09_23_308239	106	22	“	"	``
10_1101-2020_09_23_308239	106	23	Associated	Associated	NNP
10_1101-2020_09_23_308239	106	24	pathway	pathway	JJ
10_1101-2020_09_23_308239	106	25	identification	identification	NN
10_1101-2020_09_23_308239	106	26	”	"	''
10_1101-2020_09_23_308239	106	27	in	in	IN
10_1101-2020_09_23_308239	106	28	supplementary	supplementary	JJ
10_1101-2020_09_23_308239	106	29	materials	material	NNS
10_1101-2020_09_23_308239	106	30	)	)	-RRB-
10_1101-2020_09_23_308239	106	31	.	.	.
10_1101-2020_09_23_308239	107	1	When	when	WRB
10_1101-2020_09_23_308239	107	2	compared	compare	VBN
10_1101-2020_09_23_308239	107	3	to	to	IN
10_1101-2020_09_23_308239	107	4	the	the	DT
10_1101-2020_09_23_308239	107	5	annotated	annotated	JJ
10_1101-2020_09_23_308239	107	6	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	107	7	in	in	IN
10_1101-2020_09_23_308239	107	8	the	the	DT
10_1101-2020_09_23_308239	107	9	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	107	10	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	107	11	,	,	,
10_1101-2020_09_23_308239	107	12	201	201	CD
10_1101-2020_09_23_308239	107	13	of	of	IN
10_1101-2020_09_23_308239	107	14	the	the	DT
10_1101-2020_09_23_308239	107	15	227	227	CD
10_1101-2020_09_23_308239	107	16	determined	determine	VBD
10_1101-2020_09_23_308239	107	17	associated	associate	VBN
10_1101-2020_09_23_308239	107	18	pathways	pathway	NNS
10_1101-2020_09_23_308239	107	19	found	find	VBN
10_1101-2020_09_23_308239	107	20	for	for	IN
10_1101-2020_09_23_308239	107	21	the	the	DT
10_1101-2020_09_23_308239	107	22	viral	viral	JJ
10_1101-2020_09_23_308239	107	23	life	life	NN
10_1101-2020_09_23_308239	107	24	cycle	cycle	NN
10_1101-2020_09_23_308239	107	25	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	107	26	overlapped	overlap	VBD
10_1101-2020_09_23_308239	107	27	.CC	.CC	:
10_1101-2020_09_23_308239	107	28	-	-	:
10_1101-2020_09_23_308239	107	29	BY	by	IN
10_1101-2020_09_23_308239	107	30	-	-	HYPH
10_1101-2020_09_23_308239	107	31	NC	NC	NNP
10_1101-2020_09_23_308239	107	32	-	-	HYPH
10_1101-2020_09_23_308239	107	33	ND	ND	NNP
10_1101-2020_09_23_308239	107	34	4.0	4.0	CD
10_1101-2020_09_23_308239	107	35	International	international	JJ
10_1101-2020_09_23_308239	107	36	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	107	37	.	.	.
10_1101-2020_09_23_308239	108	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	108	2	is	be	VBZ
10_1101-2020_09_23_308239	108	3	made	make	VBN
10_1101-2020_09_23_308239	108	4	available	available	JJ
10_1101-2020_09_23_308239	108	5	under	under	IN
10_1101-2020_09_23_308239	108	6	a	a	DT
10_1101-2020_09_23_308239	108	7	preprint	preprint	NN
10_1101-2020_09_23_308239	108	8	(	(	-LRB-
10_1101-2020_09_23_308239	108	9	which	which	WDT
10_1101-2020_09_23_308239	108	10	was	be	VBD
10_1101-2020_09_23_308239	108	11	not	not	RB
10_1101-2020_09_23_308239	108	12	certified	certify	VBN
10_1101-2020_09_23_308239	108	13	by	by	IN
10_1101-2020_09_23_308239	108	14	peer	peer	NN
10_1101-2020_09_23_308239	108	15	review	review	NN
10_1101-2020_09_23_308239	108	16	)	)	-RRB-
10_1101-2020_09_23_308239	108	17	is	be	VBZ
10_1101-2020_09_23_308239	108	18	the	the	DT
10_1101-2020_09_23_308239	108	19	author	author	NN
10_1101-2020_09_23_308239	108	20	/	/	SYM
10_1101-2020_09_23_308239	108	21	funder	funder	NN
10_1101-2020_09_23_308239	108	22	,	,	,
10_1101-2020_09_23_308239	108	23	who	who	WP
10_1101-2020_09_23_308239	108	24	has	have	VBZ
10_1101-2020_09_23_308239	108	25	granted	grant	VBN
10_1101-2020_09_23_308239	108	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	108	27	a	a	DT
10_1101-2020_09_23_308239	108	28	license	license	NN
10_1101-2020_09_23_308239	108	29	to	to	TO
10_1101-2020_09_23_308239	108	30	display	display	VB
10_1101-2020_09_23_308239	108	31	the	the	DT
10_1101-2020_09_23_308239	108	32	preprint	preprint	NN
10_1101-2020_09_23_308239	108	33	in	in	IN
10_1101-2020_09_23_308239	108	34	The	the	DT
10_1101-2020_09_23_308239	108	35	copyright	copyright	NN
10_1101-2020_09_23_308239	108	36	holder	holder	NN
10_1101-2020_09_23_308239	108	37	for	for	IN
10_1101-2020_09_23_308239	108	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	108	39	version	version	NN
10_1101-2020_09_23_308239	108	40	posted	post	VBD
10_1101-2020_09_23_308239	108	41	February	February	NNP
10_1101-2020_09_23_308239	108	42	12	12	CD
10_1101-2020_09_23_308239	108	43	,	,	,
10_1101-2020_09_23_308239	108	44	2021	2021	CD
10_1101-2020_09_23_308239	108	45	.	.	.
10_1101-2020_09_23_308239	108	46	;	;	:
10_1101-2020_09_23_308239	108	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	108	48	:	:	:
10_1101-2020_09_23_308239	108	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	108	50	preprint	preprint	NN
10_1101-2020_09_23_308239	108	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	108	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	108	53	14	14	CD
10_1101-2020_09_23_308239	108	54	with	with	IN
10_1101-2020_09_23_308239	108	55	those	those	DT
10_1101-2020_09_23_308239	108	56	for	for	IN
10_1101-2020_09_23_308239	108	57	the	the	DT
10_1101-2020_09_23_308239	108	58	drug	drug	NN
10_1101-2020_09_23_308239	108	59	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	108	60	targets	target	NNS
10_1101-2020_09_23_308239	108	61	while	while	IN
10_1101-2020_09_23_308239	108	62	the	the	DT
10_1101-2020_09_23_308239	108	63	host	host	NN
10_1101-2020_09_23_308239	108	64	response	response	NN
10_1101-2020_09_23_308239	108	65	subgraph	subgraph	NNP
10_1101-2020_09_23_308239	108	66	shared	share	VBD
10_1101-2020_09_23_308239	108	67	90	90	CD
10_1101-2020_09_23_308239	108	68	of	of	IN
10_1101-2020_09_23_308239	108	69	its	-PRON-	PRP$
10_1101-2020_09_23_308239	108	70	105	105	CD
10_1101-2020_09_23_308239	108	71	pathways	pathway	NNS
10_1101-2020_09_23_308239	108	72	.	.	.
10_1101-2020_09_23_308239	109	1	Mapping	map	VBG
10_1101-2020_09_23_308239	109	2	of	of	IN
10_1101-2020_09_23_308239	109	3	drug	drug	NN
10_1101-2020_09_23_308239	109	4	repurposing	repurposing	NN
10_1101-2020_09_23_308239	109	5	signals	signal	NNS
10_1101-2020_09_23_308239	109	6	to	to	IN
10_1101-2020_09_23_308239	109	7	hypervariable	hypervariable	JJ
10_1101-2020_09_23_308239	109	8	regions	region	NNS
10_1101-2020_09_23_308239	109	9	of	of	IN
10_1101-2020_09_23_308239	109	10	the	the	DT
10_1101-2020_09_23_308239	109	11	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	109	12	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	109	13	One	one	CD
10_1101-2020_09_23_308239	109	14	of	of	IN
10_1101-2020_09_23_308239	109	15	the	the	DT
10_1101-2020_09_23_308239	109	16	key	key	JJ
10_1101-2020_09_23_308239	109	17	questions	question	NNS
10_1101-2020_09_23_308239	109	18	arising	arise	VBG
10_1101-2020_09_23_308239	109	19	from	from	IN
10_1101-2020_09_23_308239	109	20	the	the	DT
10_1101-2020_09_23_308239	109	21	network	network	NN
10_1101-2020_09_23_308239	109	22	analysis	analysis	NN
10_1101-2020_09_23_308239	109	23	is	be	VBZ
10_1101-2020_09_23_308239	109	24	whether	whether	IN
10_1101-2020_09_23_308239	109	25	the	the	DT
10_1101-2020_09_23_308239	109	26	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	109	27	drugs	drug	NNS
10_1101-2020_09_23_308239	109	28	target	target	VB
10_1101-2020_09_23_308239	109	29	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	109	30	are	be	VBP
10_1101-2020_09_23_308239	109	31	specifically	specifically	RB
10_1101-2020_09_23_308239	109	32	activated	activate	VBN
10_1101-2020_09_23_308239	109	33	during	during	IN
10_1101-2020_09_23_308239	109	34	viral	viral	JJ
10_1101-2020_09_23_308239	109	35	infection	infection	NN
10_1101-2020_09_23_308239	109	36	.	.	.
10_1101-2020_09_23_308239	110	1	In	in	IN
10_1101-2020_09_23_308239	110	2	order	order	NN
10_1101-2020_09_23_308239	110	3	to	to	TO
10_1101-2020_09_23_308239	110	4	establish	establish	VB
10_1101-2020_09_23_308239	110	5	this	this	DT
10_1101-2020_09_23_308239	110	6	link	link	NN
10_1101-2020_09_23_308239	110	7	,	,	,
10_1101-2020_09_23_308239	110	8	we	-PRON-	PRP
10_1101-2020_09_23_308239	110	9	mapped	map	VBD
10_1101-2020_09_23_308239	110	10	differential	differential	NN
10_1101-2020_09_23_308239	110	11	gene	gene	NN
10_1101-2020_09_23_308239	110	12	expression	expression	NN
10_1101-2020_09_23_308239	110	13	analyses	analyse	VBZ
10_1101-2020_09_23_308239	110	14	from	from	IN
10_1101-2020_09_23_308239	110	15	two	two	CD
10_1101-2020_09_23_308239	110	16	single	single	JJ
10_1101-2020_09_23_308239	110	17	-	-	HYPH
10_1101-2020_09_23_308239	110	18	cell	cell	NN
10_1101-2020_09_23_308239	110	19	sequencing	sequencing	NN
10_1101-2020_09_23_308239	110	20	studies	study	NNS
10_1101-2020_09_23_308239	110	21	to	to	IN
10_1101-2020_09_23_308239	110	22	our	-PRON-	PRP$
10_1101-2020_09_23_308239	110	23	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	110	24	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	110	25	(	(	-LRB-
10_1101-2020_09_23_308239	110	26	see	see	VB
10_1101-2020_09_23_308239	110	27	section	section	NN
10_1101-2020_09_23_308239	110	28	“	"	``
10_1101-2020_09_23_308239	110	29	Differential	Differential	NNP
10_1101-2020_09_23_308239	110	30	Gene	Gene	NNP
10_1101-2020_09_23_308239	110	31	Expression	Expression	NNP
10_1101-2020_09_23_308239	110	32	”	"	''
10_1101-2020_09_23_308239	110	33	in	in	IN
10_1101-2020_09_23_308239	110	34	supplementary	supplementary	JJ
10_1101-2020_09_23_308239	110	35	material	material	NN
10_1101-2020_09_23_308239	110	36	)	)	-RRB-
10_1101-2020_09_23_308239	110	37	.	.	.
10_1101-2020_09_23_308239	111	1	An	an	DT
10_1101-2020_09_23_308239	111	2	overlay	overlay	NN
10_1101-2020_09_23_308239	111	3	of	of	IN
10_1101-2020_09_23_308239	111	4	differential	differential	JJ
10_1101-2020_09_23_308239	111	5	gene	gene	NN
10_1101-2020_09_23_308239	111	6	expression	expression	NNP
10_1101-2020_09_23_308239	111	7	data	data	NNP
10_1101-2020_09_23_308239	111	8	(	(	-LRB-
10_1101-2020_09_23_308239	111	9	adjusted	adjust	VBN
10_1101-2020_09_23_308239	111	10	p	p	NN
10_1101-2020_09_23_308239	111	11	-	-	HYPH
10_1101-2020_09_23_308239	111	12	value	value	NN
10_1101-2020_09_23_308239	111	13	≤	≤	NNP
10_1101-2020_09_23_308239	111	14	0.1	0.1	CD
10_1101-2020_09_23_308239	111	15	and	and	CC
10_1101-2020_09_23_308239	111	16	abs(log	abs(log	JJ
10_1101-2020_09_23_308239	111	17	fold	fold	JJ
10_1101-2020_09_23_308239	111	18	-	-	HYPH
10_1101-2020_09_23_308239	111	19	change	change	NN
10_1101-2020_09_23_308239	111	20	)	)	-RRB-
10_1101-2020_09_23_308239	111	21	>	>	XX
10_1101-2020_09_23_308239	111	22	0.25	0.25	LS
10_1101-2020_09_23_308239	111	23	)	)	-RRB-
10_1101-2020_09_23_308239	111	24	on	on	IN
10_1101-2020_09_23_308239	111	25	the	the	DT
10_1101-2020_09_23_308239	111	26	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	111	27	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	111	28	reveals	reveal	VBZ
10_1101-2020_09_23_308239	111	29	a	a	DT
10_1101-2020_09_23_308239	111	30	distinct	distinct	JJ
10_1101-2020_09_23_308239	111	31	pattern	pattern	NN
10_1101-2020_09_23_308239	111	32	characterized	characterize	VBN
10_1101-2020_09_23_308239	111	33	by	by	IN
10_1101-2020_09_23_308239	111	34	the	the	DT
10_1101-2020_09_23_308239	111	35	high	high	JJ
10_1101-2020_09_23_308239	111	36	responsiveness	responsiveness	NN
10_1101-2020_09_23_308239	111	37	(	(	-LRB-
10_1101-2020_09_23_308239	111	38	expressed	express	VBN
10_1101-2020_09_23_308239	111	39	by	by	IN
10_1101-2020_09_23_308239	111	40	variation	variation	NN
10_1101-2020_09_23_308239	111	41	of	of	IN
10_1101-2020_09_23_308239	111	42	regulation	regulation	NN
10_1101-2020_09_23_308239	111	43	of	of	IN
10_1101-2020_09_23_308239	111	44	gene	gene	NN
10_1101-2020_09_23_308239	111	45	expression	expression	NN
10_1101-2020_09_23_308239	111	46	)	)	-RRB-
10_1101-2020_09_23_308239	111	47	to	to	IN
10_1101-2020_09_23_308239	111	48	the	the	DT
10_1101-2020_09_23_308239	111	49	viral	viral	JJ
10_1101-2020_09_23_308239	111	50	infection	infection	NN
10_1101-2020_09_23_308239	111	51	(	(	-LRB-
10_1101-2020_09_23_308239	111	52	Figure	Figure	NNP
10_1101-2020_09_23_308239	111	53	4A	4A	NNP
10_1101-2020_09_23_308239	111	54	)	)	-RRB-
10_1101-2020_09_23_308239	111	55	.	.	.
10_1101-2020_09_23_308239	112	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	112	2	-	-	:
10_1101-2020_09_23_308239	112	3	BY	by	IN
10_1101-2020_09_23_308239	112	4	-	-	HYPH
10_1101-2020_09_23_308239	112	5	NC	NC	NNP
10_1101-2020_09_23_308239	112	6	-	-	HYPH
10_1101-2020_09_23_308239	112	7	ND	ND	NNP
10_1101-2020_09_23_308239	112	8	4.0	4.0	CD
10_1101-2020_09_23_308239	112	9	International	international	JJ
10_1101-2020_09_23_308239	112	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	112	11	.	.	.
10_1101-2020_09_23_308239	113	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	113	2	is	be	VBZ
10_1101-2020_09_23_308239	113	3	made	make	VBN
10_1101-2020_09_23_308239	113	4	available	available	JJ
10_1101-2020_09_23_308239	113	5	under	under	IN
10_1101-2020_09_23_308239	113	6	a	a	DT
10_1101-2020_09_23_308239	113	7	preprint	preprint	NN
10_1101-2020_09_23_308239	113	8	(	(	-LRB-
10_1101-2020_09_23_308239	113	9	which	which	WDT
10_1101-2020_09_23_308239	113	10	was	be	VBD
10_1101-2020_09_23_308239	113	11	not	not	RB
10_1101-2020_09_23_308239	113	12	certified	certify	VBN
10_1101-2020_09_23_308239	113	13	by	by	IN
10_1101-2020_09_23_308239	113	14	peer	peer	NN
10_1101-2020_09_23_308239	113	15	review	review	NN
10_1101-2020_09_23_308239	113	16	)	)	-RRB-
10_1101-2020_09_23_308239	113	17	is	be	VBZ
10_1101-2020_09_23_308239	113	18	the	the	DT
10_1101-2020_09_23_308239	113	19	author	author	NN
10_1101-2020_09_23_308239	113	20	/	/	SYM
10_1101-2020_09_23_308239	113	21	funder	funder	NN
10_1101-2020_09_23_308239	113	22	,	,	,
10_1101-2020_09_23_308239	113	23	who	who	WP
10_1101-2020_09_23_308239	113	24	has	have	VBZ
10_1101-2020_09_23_308239	113	25	granted	grant	VBN
10_1101-2020_09_23_308239	113	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	113	27	a	a	DT
10_1101-2020_09_23_308239	113	28	license	license	NN
10_1101-2020_09_23_308239	113	29	to	to	TO
10_1101-2020_09_23_308239	113	30	display	display	VB
10_1101-2020_09_23_308239	113	31	the	the	DT
10_1101-2020_09_23_308239	113	32	preprint	preprint	NN
10_1101-2020_09_23_308239	113	33	in	in	IN
10_1101-2020_09_23_308239	113	34	The	the	DT
10_1101-2020_09_23_308239	113	35	copyright	copyright	NN
10_1101-2020_09_23_308239	113	36	holder	holder	NN
10_1101-2020_09_23_308239	113	37	for	for	IN
10_1101-2020_09_23_308239	113	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	113	39	version	version	NN
10_1101-2020_09_23_308239	113	40	posted	post	VBD
10_1101-2020_09_23_308239	113	41	February	February	NNP
10_1101-2020_09_23_308239	113	42	12	12	CD
10_1101-2020_09_23_308239	113	43	,	,	,
10_1101-2020_09_23_308239	113	44	2021	2021	CD
10_1101-2020_09_23_308239	113	45	.	.	.
10_1101-2020_09_23_308239	113	46	;	;	:
10_1101-2020_09_23_308239	113	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	113	48	:	:	:
10_1101-2020_09_23_308239	113	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	113	50	preprint	preprint	NN
10_1101-2020_09_23_308239	113	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	113	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	113	53	15	15	CD
10_1101-2020_09_23_308239	113	54	Figure	figure	NN
10_1101-2020_09_23_308239	113	55	4	4	CD
10_1101-2020_09_23_308239	113	56	:	:	:
10_1101-2020_09_23_308239	113	57	Identification	identification	NN
10_1101-2020_09_23_308239	113	58	of	of	IN
10_1101-2020_09_23_308239	113	59	suitable	suitable	JJ
10_1101-2020_09_23_308239	113	60	targets	target	NNS
10_1101-2020_09_23_308239	113	61	for	for	IN
10_1101-2020_09_23_308239	113	62	combination	combination	NN
10_1101-2020_09_23_308239	113	63	therapy	therapy	NN
10_1101-2020_09_23_308239	113	64	by	by	IN
10_1101-2020_09_23_308239	113	65	comparing	compare	VBG
10_1101-2020_09_23_308239	113	66	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	113	67	within	within	IN
10_1101-2020_09_23_308239	113	68	the	the	DT
10_1101-2020_09_23_308239	113	69	COVID-	COVID-	NNP
10_1101-2020_09_23_308239	113	70	19	19	CD
10_1101-2020_09_23_308239	113	71	PHARMACOME	pharmacome	NN
10_1101-2020_09_23_308239	113	72	.	.	.
10_1101-2020_09_23_308239	114	1	Incorporation	incorporation	NN
10_1101-2020_09_23_308239	114	2	of	of	IN
10_1101-2020_09_23_308239	114	3	gene	gene	NN
10_1101-2020_09_23_308239	114	4	expression	expression	NN
10_1101-2020_09_23_308239	114	5	data	datum	NNS
10_1101-2020_09_23_308239	114	6	into	into	IN
10_1101-2020_09_23_308239	114	7	the	the	DT
10_1101-2020_09_23_308239	114	8	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	114	9	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	114	10	resulted	result	VBD
10_1101-2020_09_23_308239	114	11	in	in	IN
10_1101-2020_09_23_308239	114	12	a	a	DT
10_1101-2020_09_23_308239	114	13	subgraph	subgraph	NN
10_1101-2020_09_23_308239	114	14	characterized	characterize	VBN
10_1101-2020_09_23_308239	114	15	by	by	IN
10_1101-2020_09_23_308239	114	16	the	the	DT
10_1101-2020_09_23_308239	114	17	entities	entity	NNS
10_1101-2020_09_23_308239	114	18	(	(	-LRB-
10_1101-2020_09_23_308239	114	19	genes	gene	NNS
10_1101-2020_09_23_308239	114	20	/	/	SYM
10_1101-2020_09_23_308239	114	21	proteins	protein	NNS
10_1101-2020_09_23_308239	114	22	)	)	-RRB-
10_1101-2020_09_23_308239	114	23	that	that	WDT
10_1101-2020_09_23_308239	114	24	respond	respond	VBP
10_1101-2020_09_23_308239	114	25	to	to	IN
10_1101-2020_09_23_308239	114	26	viral	viral	JJ
10_1101-2020_09_23_308239	114	27	infection	infection	NN
10_1101-2020_09_23_308239	114	28	(	(	-LRB-
10_1101-2020_09_23_308239	114	29	a	a	DT
10_1101-2020_09_23_308239	114	30	)	)	-RRB-
10_1101-2020_09_23_308239	114	31	.	.	.
10_1101-2020_09_23_308239	115	1	Mapping	map	VBG
10_1101-2020_09_23_308239	115	2	of	of	IN
10_1101-2020_09_23_308239	115	3	the	the	DT
10_1101-2020_09_23_308239	115	4	filtered	filter	VBN
10_1101-2020_09_23_308239	115	5	results	result	NNS
10_1101-2020_09_23_308239	115	6	obtained	obtain	VBN
10_1101-2020_09_23_308239	115	7	from	from	IN
10_1101-2020_09_23_308239	115	8	drug	drug	NN
10_1101-2020_09_23_308239	115	9	repurposing	repurposing	NN
10_1101-2020_09_23_308239	115	10	screenings	screening	NNS
10_1101-2020_09_23_308239	115	11	(	(	-LRB-
10_1101-2020_09_23_308239	115	12	IC50	IC50	NNP
10_1101-2020_09_23_308239	115	13	<	<	NNP
10_1101-2020_09_23_308239	115	14	10	10	CD
10_1101-2020_09_23_308239	115	15	µM	µM	NNP
10_1101-2020_09_23_308239	115	16	)	)	-RRB-
10_1101-2020_09_23_308239	115	17	to	to	IN
10_1101-2020_09_23_308239	115	18	the	the	DT
10_1101-2020_09_23_308239	115	19	PHARMACOME	pharmacome	NN
10_1101-2020_09_23_308239	115	20	resulted	result	VBD
10_1101-2020_09_23_308239	115	21	in	in	IN
10_1101-2020_09_23_308239	115	22	a	a	DT
10_1101-2020_09_23_308239	115	23	subgraph	subgraph	NN
10_1101-2020_09_23_308239	115	24	enriched	enrich	VBN
10_1101-2020_09_23_308239	115	25	for	for	IN
10_1101-2020_09_23_308239	115	26	drug	drug	NN
10_1101-2020_09_23_308239	115	27	repurposing	repurposing	NN
10_1101-2020_09_23_308239	115	28	targets	target	NNS
10_1101-2020_09_23_308239	115	29	(	(	-LRB-
10_1101-2020_09_23_308239	115	30	b	b	NN
10_1101-2020_09_23_308239	115	31	)	)	-RRB-
10_1101-2020_09_23_308239	115	32	.	.	.
10_1101-2020_09_23_308239	116	1	The	the	DT
10_1101-2020_09_23_308239	116	2	intersection	intersection	NN
10_1101-2020_09_23_308239	116	3	between	between	IN
10_1101-2020_09_23_308239	116	4	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	116	5	presented	present	VBN
10_1101-2020_09_23_308239	116	6	in	in	IN
10_1101-2020_09_23_308239	116	7	(	(	-LRB-
10_1101-2020_09_23_308239	116	8	a	a	DT
10_1101-2020_09_23_308239	116	9	)	)	-RRB-
10_1101-2020_09_23_308239	116	10	and	and	CC
10_1101-2020_09_23_308239	116	11	(	(	-LRB-
10_1101-2020_09_23_308239	116	12	b	b	NN
10_1101-2020_09_23_308239	116	13	)	)	-RRB-
10_1101-2020_09_23_308239	116	14	is	be	VBZ
10_1101-2020_09_23_308239	116	15	highly	highly	RB
10_1101-2020_09_23_308239	116	16	enriched	enrich	VBN
10_1101-2020_09_23_308239	116	17	for	for	IN
10_1101-2020_09_23_308239	116	18	drug	drug	NN
10_1101-2020_09_23_308239	116	19	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	116	20	targets	target	NNS
10_1101-2020_09_23_308239	116	21	directly	directly	RB
10_1101-2020_09_23_308239	116	22	linked	link	VBN
10_1101-2020_09_23_308239	116	23	to	to	IN
10_1101-2020_09_23_308239	116	24	the	the	DT
10_1101-2020_09_23_308239	116	25	viral	viral	JJ
10_1101-2020_09_23_308239	116	26	infection	infection	NN
10_1101-2020_09_23_308239	116	27	response	response	NN
10_1101-2020_09_23_308239	116	28	(	(	-LRB-
10_1101-2020_09_23_308239	116	29	c	c	NN
10_1101-2020_09_23_308239	116	30	)	)	-RRB-
10_1101-2020_09_23_308239	116	31	.	.	.
10_1101-2020_09_23_308239	117	1	Virus	virus	NN
10_1101-2020_09_23_308239	117	2	-	-	HYPH
10_1101-2020_09_23_308239	117	3	response	response	NN
10_1101-2020_09_23_308239	117	4	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	117	5	are	be	VBP
10_1101-2020_09_23_308239	117	6	targets	target	NNS
10_1101-2020_09_23_308239	117	7	for	for	IN
10_1101-2020_09_23_308239	117	8	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	117	9	drugs	drug	NNS
10_1101-2020_09_23_308239	117	10	In	in	IN
10_1101-2020_09_23_308239	117	11	the	the	DT
10_1101-2020_09_23_308239	117	12	next	next	JJ
10_1101-2020_09_23_308239	117	13	step	step	NN
10_1101-2020_09_23_308239	117	14	,	,	,
10_1101-2020_09_23_308239	117	15	we	-PRON-	PRP
10_1101-2020_09_23_308239	117	16	analyzed	analyze	VBD
10_1101-2020_09_23_308239	117	17	which	which	WDT
10_1101-2020_09_23_308239	117	18	areas	area	NNS
10_1101-2020_09_23_308239	117	19	of	of	IN
10_1101-2020_09_23_308239	117	20	the	the	DT
10_1101-2020_09_23_308239	117	21	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	117	22	graph	graph	NN
10_1101-2020_09_23_308239	117	23	respond	respond	NN
10_1101-2020_09_23_308239	117	24	to	to	IN
10_1101-2020_09_23_308239	117	25	SARS	SARS	NNP
10_1101-2020_09_23_308239	117	26	-	-	HYPH
10_1101-2020_09_23_308239	117	27	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	117	28	infection	infection	NN
10_1101-2020_09_23_308239	117	29	(	(	-LRB-
10_1101-2020_09_23_308239	117	30	indicated	indicate	VBN
10_1101-2020_09_23_308239	117	31	by	by	IN
10_1101-2020_09_23_308239	117	32	significant	significant	JJ
10_1101-2020_09_23_308239	117	33	variance	variance	NN
10_1101-2020_09_23_308239	117	34	in	in	IN
10_1101-2020_09_23_308239	117	35	gene	gene	NN
10_1101-2020_09_23_308239	117	36	expression	expression	NN
10_1101-2020_09_23_308239	117	37	)	)	-RRB-
10_1101-2020_09_23_308239	117	38	and	and	CC
10_1101-2020_09_23_308239	117	39	are	be	VBP
10_1101-2020_09_23_308239	117	40	targets	target	NNS
10_1101-2020_09_23_308239	117	41	for	for	IN
10_1101-2020_09_23_308239	117	42	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	117	43	drugs	drug	NNS
10_1101-2020_09_23_308239	117	44	.	.	.
10_1101-2020_09_23_308239	118	1	To	to	IN
10_1101-2020_09_23_308239	118	2	this	this	DT
10_1101-2020_09_23_308239	118	3	end	end	NN
10_1101-2020_09_23_308239	118	4	,	,	,
10_1101-2020_09_23_308239	118	5	we	-PRON-	PRP
10_1101-2020_09_23_308239	118	6	mapped	map	VBD
10_1101-2020_09_23_308239	118	7	signals	signal	NNS
10_1101-2020_09_23_308239	118	8	from	from	IN
10_1101-2020_09_23_308239	118	9	the	the	DT
10_1101-2020_09_23_308239	118	10	drug	drug	NN
10_1101-2020_09_23_308239	118	11	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	118	12	screenings	screening	NNS
10_1101-2020_09_23_308239	118	13	to	to	IN
10_1101-2020_09_23_308239	118	14	the	the	DT
10_1101-2020_09_23_308239	118	15	subgraph	subgraph	NN
10_1101-2020_09_23_308239	118	16	that	that	WDT
10_1101-2020_09_23_308239	118	17	showed	show	VBD
10_1101-2020_09_23_308239	118	18	responsiveness	responsiveness	NN
10_1101-2020_09_23_308239	118	19	to	to	IN
10_1101-2020_09_23_308239	118	20	SARS	SARS	NNP
10_1101-2020_09_23_308239	118	21	-	-	HYPH
10_1101-2020_09_23_308239	118	22	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	118	23	infection	infection	NN
10_1101-2020_09_23_308239	118	24	(	(	-LRB-
10_1101-2020_09_23_308239	118	25	Figure	figure	NN
10_1101-2020_09_23_308239	118	26	4B	4b	NN
10_1101-2020_09_23_308239	118	27	)	)	-RRB-
10_1101-2020_09_23_308239	118	28	.	.	.
10_1101-2020_09_23_308239	119	1	Figure	figure	NN
10_1101-2020_09_23_308239	119	2	4C	4c	NN
10_1101-2020_09_23_308239	119	3	depicts	depict	VBZ
10_1101-2020_09_23_308239	119	4	the	the	DT
10_1101-2020_09_23_308239	119	5	resulting	result	VBG
10_1101-2020_09_23_308239	119	6	subgraph	subgraph	NN
10_1101-2020_09_23_308239	119	7	that	that	WDT
10_1101-2020_09_23_308239	119	8	is	be	VBZ
10_1101-2020_09_23_308239	119	9	characterized	characterize	VBN
10_1101-2020_09_23_308239	119	10	by	by	IN
10_1101-2020_09_23_308239	119	11	the	the	DT
10_1101-2020_09_23_308239	119	12	transcriptional	transcriptional	JJ
10_1101-2020_09_23_308239	119	13	response	response	NN
10_1101-2020_09_23_308239	119	14	to	to	IN
10_1101-2020_09_23_308239	119	15	SARS	SARS	NNP
10_1101-2020_09_23_308239	119	16	-	-	HYPH
10_1101-2020_09_23_308239	119	17	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	119	18	infection	infection	NN
10_1101-2020_09_23_308239	119	19	and	and	CC
10_1101-2020_09_23_308239	119	20	the	the	DT
10_1101-2020_09_23_308239	119	21	presence	presence	NN
10_1101-2020_09_23_308239	119	22	of	of	IN
10_1101-2020_09_23_308239	119	23	target	target	NN
10_1101-2020_09_23_308239	119	24	proteins	protein	NNS
10_1101-2020_09_23_308239	119	25	of	of	IN
10_1101-2020_09_23_308239	119	26	compounds	compound	NNS
10_1101-2020_09_23_308239	119	27	that	that	WDT
10_1101-2020_09_23_308239	119	28	have	have	VBP
10_1101-2020_09_23_308239	119	29	been	be	VBN
10_1101-2020_09_23_308239	119	30	identified	identify	VBN
10_1101-2020_09_23_308239	119	31	in	in	IN
10_1101-2020_09_23_308239	119	32	drug	drug	NN
10_1101-2020_09_23_308239	119	33	repurposing	repurposing	NN
10_1101-2020_09_23_308239	119	34	screening	screening	NN
10_1101-2020_09_23_308239	119	35	experiments	experiment	NNS
10_1101-2020_09_23_308239	119	36	.	.	.
10_1101-2020_09_23_308239	120	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	120	2	-	-	:
10_1101-2020_09_23_308239	120	3	BY	by	IN
10_1101-2020_09_23_308239	120	4	-	-	HYPH
10_1101-2020_09_23_308239	120	5	NC	NC	NNP
10_1101-2020_09_23_308239	120	6	-	-	HYPH
10_1101-2020_09_23_308239	120	7	ND	ND	NNP
10_1101-2020_09_23_308239	120	8	4.0	4.0	CD
10_1101-2020_09_23_308239	120	9	International	international	JJ
10_1101-2020_09_23_308239	120	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	120	11	.	.	.
10_1101-2020_09_23_308239	121	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	121	2	is	be	VBZ
10_1101-2020_09_23_308239	121	3	made	make	VBN
10_1101-2020_09_23_308239	121	4	available	available	JJ
10_1101-2020_09_23_308239	121	5	under	under	IN
10_1101-2020_09_23_308239	121	6	a	a	DT
10_1101-2020_09_23_308239	121	7	preprint	preprint	NN
10_1101-2020_09_23_308239	121	8	(	(	-LRB-
10_1101-2020_09_23_308239	121	9	which	which	WDT
10_1101-2020_09_23_308239	121	10	was	be	VBD
10_1101-2020_09_23_308239	121	11	not	not	RB
10_1101-2020_09_23_308239	121	12	certified	certify	VBN
10_1101-2020_09_23_308239	121	13	by	by	IN
10_1101-2020_09_23_308239	121	14	peer	peer	NN
10_1101-2020_09_23_308239	121	15	review	review	NN
10_1101-2020_09_23_308239	121	16	)	)	-RRB-
10_1101-2020_09_23_308239	121	17	is	be	VBZ
10_1101-2020_09_23_308239	121	18	the	the	DT
10_1101-2020_09_23_308239	121	19	author	author	NN
10_1101-2020_09_23_308239	121	20	/	/	SYM
10_1101-2020_09_23_308239	121	21	funder	funder	NN
10_1101-2020_09_23_308239	121	22	,	,	,
10_1101-2020_09_23_308239	121	23	who	who	WP
10_1101-2020_09_23_308239	121	24	has	have	VBZ
10_1101-2020_09_23_308239	121	25	granted	grant	VBN
10_1101-2020_09_23_308239	121	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	121	27	a	a	DT
10_1101-2020_09_23_308239	121	28	license	license	NN
10_1101-2020_09_23_308239	121	29	to	to	TO
10_1101-2020_09_23_308239	121	30	display	display	VB
10_1101-2020_09_23_308239	121	31	the	the	DT
10_1101-2020_09_23_308239	121	32	preprint	preprint	NN
10_1101-2020_09_23_308239	121	33	in	in	IN
10_1101-2020_09_23_308239	121	34	The	the	DT
10_1101-2020_09_23_308239	121	35	copyright	copyright	NN
10_1101-2020_09_23_308239	121	36	holder	holder	NN
10_1101-2020_09_23_308239	121	37	for	for	IN
10_1101-2020_09_23_308239	121	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	121	39	version	version	NN
10_1101-2020_09_23_308239	121	40	posted	post	VBD
10_1101-2020_09_23_308239	121	41	February	February	NNP
10_1101-2020_09_23_308239	121	42	12	12	CD
10_1101-2020_09_23_308239	121	43	,	,	,
10_1101-2020_09_23_308239	121	44	2021	2021	CD
10_1101-2020_09_23_308239	121	45	.	.	.
10_1101-2020_09_23_308239	121	46	;	;	:
10_1101-2020_09_23_308239	121	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	121	48	:	:	:
10_1101-2020_09_23_308239	121	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	121	50	preprint	preprint	NN
10_1101-2020_09_23_308239	121	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	121	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	121	53	16	16	CD
10_1101-2020_09_23_308239	121	54	The	the	DT
10_1101-2020_09_23_308239	121	55	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	121	56	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	121	57	supports	support	VBZ
10_1101-2020_09_23_308239	121	58	rational	rational	JJ
10_1101-2020_09_23_308239	121	59	targeting	targeting	NN
10_1101-2020_09_23_308239	121	60	strategies	strategy	NNS
10_1101-2020_09_23_308239	121	61	for	for	IN
10_1101-2020_09_23_308239	121	62	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	121	63	combination	combination	NN
10_1101-2020_09_23_308239	121	64	therapy	therapy	NN
10_1101-2020_09_23_308239	121	65	We	-PRON-	PRP
10_1101-2020_09_23_308239	121	66	mapped	map	VBD
10_1101-2020_09_23_308239	121	67	existing	exist	VBG
10_1101-2020_09_23_308239	121	68	combinatorial	combinatorial	NN
10_1101-2020_09_23_308239	121	69	therapy	therapy	NN
10_1101-2020_09_23_308239	121	70	data	datum	NNS
10_1101-2020_09_23_308239	121	71	to	to	IN
10_1101-2020_09_23_308239	121	72	the	the	DT
10_1101-2020_09_23_308239	121	73	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	121	74	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	121	75	in	in	IN
10_1101-2020_09_23_308239	121	76	order	order	NN
10_1101-2020_09_23_308239	121	77	to	to	TO
10_1101-2020_09_23_308239	121	78	evaluate	evaluate	VB
10_1101-2020_09_23_308239	121	79	its	-PRON-	PRP$
10_1101-2020_09_23_308239	121	80	potential	potential	NN
10_1101-2020_09_23_308239	121	81	in	in	IN
10_1101-2020_09_23_308239	121	82	guiding	guide	VBG
10_1101-2020_09_23_308239	121	83	rational	rational	JJ
10_1101-2020_09_23_308239	121	84	approaches	approach	NNS
10_1101-2020_09_23_308239	121	85	towards	towards	IN
10_1101-2020_09_23_308239	121	86	combination	combination	NN
10_1101-2020_09_23_308239	121	87	therapy	therapy	NN
10_1101-2020_09_23_308239	121	88	using	use	VBG
10_1101-2020_09_23_308239	121	89	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	121	90	drug	drug	NN
10_1101-2020_09_23_308239	121	91	candidates	candidate	NNS
10_1101-2020_09_23_308239	121	92	.	.	.
10_1101-2020_09_23_308239	122	1	Combinatorial	combinatorial	JJ
10_1101-2020_09_23_308239	122	2	treatment	treatment	NN
10_1101-2020_09_23_308239	122	3	data	datum	NNS
10_1101-2020_09_23_308239	122	4	obtained	obtain	VBN
10_1101-2020_09_23_308239	122	5	from	from	IN
10_1101-2020_09_23_308239	122	6	the	the	DT
10_1101-2020_09_23_308239	122	7	results	result	NNS
10_1101-2020_09_23_308239	122	8	published	publish	VBN
10_1101-2020_09_23_308239	122	9	by	by	IN
10_1101-2020_09_23_308239	122	10	Bobrowski	Bobrowski	NNP
10_1101-2020_09_23_308239	122	11	et	et	FW
10_1101-2020_09_23_308239	122	12	al.40	al.40	NNP
10_1101-2020_09_23_308239	122	13	and	and	CC
10_1101-2020_09_23_308239	122	14	Ellinger	Ellinger	NNP
10_1101-2020_09_23_308239	122	15	et	et	NNP
10_1101-2020_09_23_308239	122	16	al.41	al.41	''
10_1101-2020_09_23_308239	122	17	were	be	VBD
10_1101-2020_09_23_308239	122	18	mapped	map	VBN
10_1101-2020_09_23_308239	122	19	to	to	IN
10_1101-2020_09_23_308239	122	20	the	the	DT
10_1101-2020_09_23_308239	122	21	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	122	22	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	122	23	.	.	.
10_1101-2020_09_23_308239	123	1	Figure	figure	NN
10_1101-2020_09_23_308239	123	2	5	5	CD
10_1101-2020_09_23_308239	123	3	provides	provide	VBZ
10_1101-2020_09_23_308239	123	4	an	an	DT
10_1101-2020_09_23_308239	123	5	overview	overview	NN
10_1101-2020_09_23_308239	123	6	of	of	IN
10_1101-2020_09_23_308239	123	7	the	the	DT
10_1101-2020_09_23_308239	123	8	mapped	map	VBN
10_1101-2020_09_23_308239	123	9	compounds	compound	NNS
10_1101-2020_09_23_308239	123	10	,	,	,
10_1101-2020_09_23_308239	123	11	thier	thi	JJR
10_1101-2020_09_23_308239	123	12	protein	protein	NN
10_1101-2020_09_23_308239	123	13	targets	target	NNS
10_1101-2020_09_23_308239	123	14	,	,	,
10_1101-2020_09_23_308239	123	15	and	and	CC
10_1101-2020_09_23_308239	123	16	the	the	DT
10_1101-2020_09_23_308239	123	17	interaction	interaction	NN
10_1101-2020_09_23_308239	123	18	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	123	19	.	.	.
10_1101-2020_09_23_308239	124	1	Analysis	analysis	NN
10_1101-2020_09_23_308239	124	2	of	of	IN
10_1101-2020_09_23_308239	124	3	the	the	DT
10_1101-2020_09_23_308239	124	4	overlaps	overlap	NNS
10_1101-2020_09_23_308239	124	5	between	between	IN
10_1101-2020_09_23_308239	124	6	the	the	DT
10_1101-2020_09_23_308239	124	7	drug	drug	NN
10_1101-2020_09_23_308239	124	8	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	124	9	screening	screening	NN
10_1101-2020_09_23_308239	124	10	data	datum	NNS
10_1101-2020_09_23_308239	124	11	showed	show	VBD
10_1101-2020_09_23_308239	124	12	that	that	IN
10_1101-2020_09_23_308239	124	13	four	four	CD
10_1101-2020_09_23_308239	124	14	of	of	IN
10_1101-2020_09_23_308239	124	15	the	the	DT
10_1101-2020_09_23_308239	124	16	ten	ten	CD
10_1101-2020_09_23_308239	124	17	compounds	compound	NNS
10_1101-2020_09_23_308239	124	18	reported	report	VBN
10_1101-2020_09_23_308239	124	19	in	in	IN
10_1101-2020_09_23_308239	124	20	the	the	DT
10_1101-2020_09_23_308239	124	21	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	124	22	treatment	treatment	NN
10_1101-2020_09_23_308239	124	23	approach	approach	NN
10_1101-2020_09_23_308239	124	24	by	by	IN
10_1101-2020_09_23_308239	124	25	drug	drug	NN
10_1101-2020_09_23_308239	124	26	repurposing	repurposing	NN
10_1101-2020_09_23_308239	124	27	data	datum	NNS
10_1101-2020_09_23_308239	124	28	were	be	VBD
10_1101-2020_09_23_308239	124	29	represented	represent	VBN
10_1101-2020_09_23_308239	124	30	in	in	IN
10_1101-2020_09_23_308239	124	31	our	-PRON-	PRP$
10_1101-2020_09_23_308239	124	32	initial	initial	JJ
10_1101-2020_09_23_308239	124	33	non-	non-	NN
10_1101-2020_09_23_308239	124	34	redundant	redundant	JJ
10_1101-2020_09_23_308239	124	35	set	set	NN
10_1101-2020_09_23_308239	124	36	of	of	IN
10_1101-2020_09_23_308239	124	37	candidate	candidate	NN
10_1101-2020_09_23_308239	124	38	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	124	39	drugs	drug	NNS
10_1101-2020_09_23_308239	124	40	.	.	.
10_1101-2020_09_23_308239	125	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	125	2	-	-	:
10_1101-2020_09_23_308239	125	3	BY	by	IN
10_1101-2020_09_23_308239	125	4	-	-	HYPH
10_1101-2020_09_23_308239	125	5	NC	NC	NNP
10_1101-2020_09_23_308239	125	6	-	-	HYPH
10_1101-2020_09_23_308239	125	7	ND	ND	NNP
10_1101-2020_09_23_308239	125	8	4.0	4.0	CD
10_1101-2020_09_23_308239	125	9	International	international	JJ
10_1101-2020_09_23_308239	125	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	125	11	.	.	.
10_1101-2020_09_23_308239	126	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	126	2	is	be	VBZ
10_1101-2020_09_23_308239	126	3	made	make	VBN
10_1101-2020_09_23_308239	126	4	available	available	JJ
10_1101-2020_09_23_308239	126	5	under	under	IN
10_1101-2020_09_23_308239	126	6	a	a	DT
10_1101-2020_09_23_308239	126	7	preprint	preprint	NN
10_1101-2020_09_23_308239	126	8	(	(	-LRB-
10_1101-2020_09_23_308239	126	9	which	which	WDT
10_1101-2020_09_23_308239	126	10	was	be	VBD
10_1101-2020_09_23_308239	126	11	not	not	RB
10_1101-2020_09_23_308239	126	12	certified	certify	VBN
10_1101-2020_09_23_308239	126	13	by	by	IN
10_1101-2020_09_23_308239	126	14	peer	peer	NN
10_1101-2020_09_23_308239	126	15	review	review	NN
10_1101-2020_09_23_308239	126	16	)	)	-RRB-
10_1101-2020_09_23_308239	126	17	is	be	VBZ
10_1101-2020_09_23_308239	126	18	the	the	DT
10_1101-2020_09_23_308239	126	19	author	author	NN
10_1101-2020_09_23_308239	126	20	/	/	SYM
10_1101-2020_09_23_308239	126	21	funder	funder	NN
10_1101-2020_09_23_308239	126	22	,	,	,
10_1101-2020_09_23_308239	126	23	who	who	WP
10_1101-2020_09_23_308239	126	24	has	have	VBZ
10_1101-2020_09_23_308239	126	25	granted	grant	VBN
10_1101-2020_09_23_308239	126	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	126	27	a	a	DT
10_1101-2020_09_23_308239	126	28	license	license	NN
10_1101-2020_09_23_308239	126	29	to	to	TO
10_1101-2020_09_23_308239	126	30	display	display	VB
10_1101-2020_09_23_308239	126	31	the	the	DT
10_1101-2020_09_23_308239	126	32	preprint	preprint	NN
10_1101-2020_09_23_308239	126	33	in	in	IN
10_1101-2020_09_23_308239	126	34	The	the	DT
10_1101-2020_09_23_308239	126	35	copyright	copyright	NN
10_1101-2020_09_23_308239	126	36	holder	holder	NN
10_1101-2020_09_23_308239	126	37	for	for	IN
10_1101-2020_09_23_308239	126	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	126	39	version	version	NN
10_1101-2020_09_23_308239	126	40	posted	post	VBD
10_1101-2020_09_23_308239	126	41	February	February	NNP
10_1101-2020_09_23_308239	126	42	12	12	CD
10_1101-2020_09_23_308239	126	43	,	,	,
10_1101-2020_09_23_308239	126	44	2021	2021	CD
10_1101-2020_09_23_308239	126	45	.	.	.
10_1101-2020_09_23_308239	126	46	;	;	:
10_1101-2020_09_23_308239	126	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	126	48	:	:	:
10_1101-2020_09_23_308239	126	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	126	50	preprint	preprint	NN
10_1101-2020_09_23_308239	126	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	126	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	126	53	17	17	CD
10_1101-2020_09_23_308239	126	54	Figure	figure	NN
10_1101-2020_09_23_308239	126	55	5	5	CD
10_1101-2020_09_23_308239	126	56	:	:	:
10_1101-2020_09_23_308239	126	57	Visualization	visualization	NN
10_1101-2020_09_23_308239	126	58	of	of	IN
10_1101-2020_09_23_308239	126	59	drug	drug	NN
10_1101-2020_09_23_308239	126	60	repurposing	repurposing	NN
10_1101-2020_09_23_308239	126	61	candidates	candidate	NNS
10_1101-2020_09_23_308239	126	62	(	(	-LRB-
10_1101-2020_09_23_308239	126	63	and	and	CC
10_1101-2020_09_23_308239	126	64	their	-PRON-	PRP$
10_1101-2020_09_23_308239	126	65	targets	target	NNS
10_1101-2020_09_23_308239	126	66	)	)	-RRB-
10_1101-2020_09_23_308239	126	67	used	use	VBN
10_1101-2020_09_23_308239	126	68	in	in	IN
10_1101-2020_09_23_308239	126	69	combination	combination	NN
10_1101-2020_09_23_308239	126	70	treatment	treatment	NN
10_1101-2020_09_23_308239	126	71	experiments	experiment	NNS
10_1101-2020_09_23_308239	126	72	.	.	.
10_1101-2020_09_23_308239	127	1	The	the	DT
10_1101-2020_09_23_308239	127	2	subgraph	subgraph	NN
10_1101-2020_09_23_308239	127	3	depicts	depict	VBZ
10_1101-2020_09_23_308239	127	4	the	the	DT
10_1101-2020_09_23_308239	127	5	drug	drug	NN
10_1101-2020_09_23_308239	127	6	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	127	7	candidate	candidate	NN
10_1101-2020_09_23_308239	127	8	molecules	molecule	NNS
10_1101-2020_09_23_308239	127	9	in	in	IN
10_1101-2020_09_23_308239	127	10	relation	relation	NN
10_1101-2020_09_23_308239	127	11	to	to	IN
10_1101-2020_09_23_308239	127	12	each	each	DT
10_1101-2020_09_23_308239	127	13	other	other	JJ
10_1101-2020_09_23_308239	127	14	and	and	CC
10_1101-2020_09_23_308239	127	15	their	-PRON-	PRP$
10_1101-2020_09_23_308239	127	16	targets	target	NNS
10_1101-2020_09_23_308239	127	17	.	.	.
10_1101-2020_09_23_308239	128	1	Shortest	short	JJS
10_1101-2020_09_23_308239	128	2	path	path	NN
10_1101-2020_09_23_308239	128	3	lengths	length	NNS
10_1101-2020_09_23_308239	128	4	between	between	IN
10_1101-2020_09_23_308239	128	5	drug	drug	NN
10_1101-2020_09_23_308239	128	6	combinations	combination	NNS
10_1101-2020_09_23_308239	128	7	were	be	VBD
10_1101-2020_09_23_308239	128	8	calculated	calculate	VBN
10_1101-2020_09_23_308239	128	9	from	from	IN
10_1101-2020_09_23_308239	128	10	this	this	DT
10_1101-2020_09_23_308239	128	11	subgraph	subgraph	NN
10_1101-2020_09_23_308239	128	12	and	and	CC
10_1101-2020_09_23_308239	128	13	are	be	VBP
10_1101-2020_09_23_308239	128	14	available	available	JJ
10_1101-2020_09_23_308239	128	15	in	in	IN
10_1101-2020_09_23_308239	128	16	the	the	DT
10_1101-2020_09_23_308239	128	17	supplementary	supplementary	JJ
10_1101-2020_09_23_308239	128	18	material	material	NN
10_1101-2020_09_23_308239	128	19	(	(	-LRB-
10_1101-2020_09_23_308239	128	20	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	128	21	Table	Table	NNP
10_1101-2020_09_23_308239	128	22	5	5	CD
10_1101-2020_09_23_308239	128	23	)	)	-RRB-
10_1101-2020_09_23_308239	128	24	.	.	.
10_1101-2020_09_23_308239	129	1	Based	base	VBN
10_1101-2020_09_23_308239	129	2	on	on	IN
10_1101-2020_09_23_308239	129	3	the	the	DT
10_1101-2020_09_23_308239	129	4	association	association	NN
10_1101-2020_09_23_308239	129	5	between	between	IN
10_1101-2020_09_23_308239	129	6	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	129	7	drug	drug	NN
10_1101-2020_09_23_308239	129	8	candidates	candidate	NNS
10_1101-2020_09_23_308239	129	9	and	and	CC
10_1101-2020_09_23_308239	129	10	the	the	DT
10_1101-2020_09_23_308239	129	11	areas	area	NNS
10_1101-2020_09_23_308239	129	12	of	of	IN
10_1101-2020_09_23_308239	129	13	the	the	DT
10_1101-2020_09_23_308239	129	14	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	129	15	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	129	16	that	that	WDT
10_1101-2020_09_23_308239	129	17	respond	respond	VBP
10_1101-2020_09_23_308239	129	18	to	to	IN
10_1101-2020_09_23_308239	129	19	SARS	SARS	NNP
10_1101-2020_09_23_308239	129	20	-	-	HYPH
10_1101-2020_09_23_308239	129	21	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	129	22	infection	infection	NN
10_1101-2020_09_23_308239	129	23	(	(	-LRB-
10_1101-2020_09_23_308239	129	24	Figure	figure	NN
10_1101-2020_09_23_308239	129	25	4	4	CD
10_1101-2020_09_23_308239	129	26	)	)	-RRB-
10_1101-2020_09_23_308239	129	27	,	,	,
10_1101-2020_09_23_308239	129	28	we	-PRON-	PRP
10_1101-2020_09_23_308239	129	29	hypothesized	hypothesize	VBD
10_1101-2020_09_23_308239	129	30	that	that	IN
10_1101-2020_09_23_308239	129	31	the	the	DT
10_1101-2020_09_23_308239	129	32	number	number	NN
10_1101-2020_09_23_308239	129	33	of	of	IN
10_1101-2020_09_23_308239	129	34	edges	edge	NNS
10_1101-2020_09_23_308239	129	35	between	between	IN
10_1101-2020_09_23_308239	129	36	a	a	DT
10_1101-2020_09_23_308239	129	37	pair	pair	NN
10_1101-2020_09_23_308239	129	38	of	of	IN
10_1101-2020_09_23_308239	129	39	drug	drug	NN
10_1101-2020_09_23_308239	129	40	nodes	node	NNS
10_1101-2020_09_23_308239	129	41	may	may	MD
10_1101-2020_09_23_308239	129	42	be	be	VB
10_1101-2020_09_23_308239	129	43	linked	link	VBN
10_1101-2020_09_23_308239	129	44	to	to	IN
10_1101-2020_09_23_308239	129	45	the	the	DT
10_1101-2020_09_23_308239	129	46	effectiveness	effectiveness	NN
10_1101-2020_09_23_308239	129	47	of	of	IN
10_1101-2020_09_23_308239	129	48	the	the	DT
10_1101-2020_09_23_308239	129	49	drug	drug	NN
10_1101-2020_09_23_308239	129	50	combination	combination	NN
10_1101-2020_09_23_308239	129	51	(	(	-LRB-
10_1101-2020_09_23_308239	129	52	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	129	53	Figure	Figure	NNP
10_1101-2020_09_23_308239	129	54	2	2	CD
10_1101-2020_09_23_308239	129	55	)	)	-RRB-
10_1101-2020_09_23_308239	129	56	.	.	.
10_1101-2020_09_23_308239	130	1	In	in	IN
10_1101-2020_09_23_308239	130	2	order	order	NN
10_1101-2020_09_23_308239	130	3	to	to	TO
10_1101-2020_09_23_308239	130	4	evaluate	evaluate	VB
10_1101-2020_09_23_308239	130	5	whether	whether	IN
10_1101-2020_09_23_308239	130	6	the	the	DT
10_1101-2020_09_23_308239	130	7	determined	determine	VBN
10_1101-2020_09_23_308239	130	8	outcome	outcome	NN
10_1101-2020_09_23_308239	130	9	of	of	IN
10_1101-2020_09_23_308239	130	10	a	a	DT
10_1101-2020_09_23_308239	130	11	combination	combination	NN
10_1101-2020_09_23_308239	130	12	of	of	IN
10_1101-2020_09_23_308239	130	13	drugs	drug	NNS
10_1101-2020_09_23_308239	130	14	correlated	correlate	VBN
10_1101-2020_09_23_308239	130	15	with	with	IN
10_1101-2020_09_23_308239	130	16	the	the	DT
10_1101-2020_09_23_308239	130	17	distance	distance	NN
10_1101-2020_09_23_308239	130	18	between	between	IN
10_1101-2020_09_23_308239	130	19	said	say	VBD
10_1101-2020_09_23_308239	130	20	drug	drug	NN
10_1101-2020_09_23_308239	130	21	nodes	node	NNS
10_1101-2020_09_23_308239	130	22	,	,	,
10_1101-2020_09_23_308239	130	23	we	-PRON-	PRP
10_1101-2020_09_23_308239	130	24	compared	compare	VBD
10_1101-2020_09_23_308239	130	25	distances	distance	NNS
10_1101-2020_09_23_308239	130	26	for	for	IN
10_1101-2020_09_23_308239	130	27	combinations	combination	NNS
10_1101-2020_09_23_308239	130	28	of	of	IN
10_1101-2020_09_23_308239	130	29	drugs	drug	NNS
10_1101-2020_09_23_308239	130	30	within	within	IN
10_1101-2020_09_23_308239	130	31	the	the	DT
10_1101-2020_09_23_308239	130	32	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	130	33	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	130	34	for	for	IN
10_1101-2020_09_23_308239	130	35	which	which	WDT
10_1101-2020_09_23_308239	130	36	.CC	.cc	NN
10_1101-2020_09_23_308239	130	37	-	-	HYPH
10_1101-2020_09_23_308239	130	38	BY	by	IN
10_1101-2020_09_23_308239	130	39	-	-	HYPH
10_1101-2020_09_23_308239	130	40	NC	NC	NNP
10_1101-2020_09_23_308239	130	41	-	-	HYPH
10_1101-2020_09_23_308239	130	42	ND	ND	NNP
10_1101-2020_09_23_308239	130	43	4.0	4.0	CD
10_1101-2020_09_23_308239	130	44	International	international	JJ
10_1101-2020_09_23_308239	130	45	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	130	46	.	.	.
10_1101-2020_09_23_308239	131	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	131	2	is	be	VBZ
10_1101-2020_09_23_308239	131	3	made	make	VBN
10_1101-2020_09_23_308239	131	4	available	available	JJ
10_1101-2020_09_23_308239	131	5	under	under	IN
10_1101-2020_09_23_308239	131	6	a	a	DT
10_1101-2020_09_23_308239	131	7	preprint	preprint	NN
10_1101-2020_09_23_308239	131	8	(	(	-LRB-
10_1101-2020_09_23_308239	131	9	which	which	WDT
10_1101-2020_09_23_308239	131	10	was	be	VBD
10_1101-2020_09_23_308239	131	11	not	not	RB
10_1101-2020_09_23_308239	131	12	certified	certify	VBN
10_1101-2020_09_23_308239	131	13	by	by	IN
10_1101-2020_09_23_308239	131	14	peer	peer	NN
10_1101-2020_09_23_308239	131	15	review	review	NN
10_1101-2020_09_23_308239	131	16	)	)	-RRB-
10_1101-2020_09_23_308239	131	17	is	be	VBZ
10_1101-2020_09_23_308239	131	18	the	the	DT
10_1101-2020_09_23_308239	131	19	author	author	NN
10_1101-2020_09_23_308239	131	20	/	/	SYM
10_1101-2020_09_23_308239	131	21	funder	funder	NN
10_1101-2020_09_23_308239	131	22	,	,	,
10_1101-2020_09_23_308239	131	23	who	who	WP
10_1101-2020_09_23_308239	131	24	has	have	VBZ
10_1101-2020_09_23_308239	131	25	granted	grant	VBN
10_1101-2020_09_23_308239	131	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	131	27	a	a	DT
10_1101-2020_09_23_308239	131	28	license	license	NN
10_1101-2020_09_23_308239	131	29	to	to	TO
10_1101-2020_09_23_308239	131	30	display	display	VB
10_1101-2020_09_23_308239	131	31	the	the	DT
10_1101-2020_09_23_308239	131	32	preprint	preprint	NN
10_1101-2020_09_23_308239	131	33	in	in	IN
10_1101-2020_09_23_308239	131	34	The	the	DT
10_1101-2020_09_23_308239	131	35	copyright	copyright	NN
10_1101-2020_09_23_308239	131	36	holder	holder	NN
10_1101-2020_09_23_308239	131	37	for	for	IN
10_1101-2020_09_23_308239	131	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	131	39	version	version	NN
10_1101-2020_09_23_308239	131	40	posted	post	VBD
10_1101-2020_09_23_308239	131	41	February	February	NNP
10_1101-2020_09_23_308239	131	42	12	12	CD
10_1101-2020_09_23_308239	131	43	,	,	,
10_1101-2020_09_23_308239	131	44	2021	2021	CD
10_1101-2020_09_23_308239	131	45	.	.	.
10_1101-2020_09_23_308239	131	46	;	;	:
10_1101-2020_09_23_308239	131	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	131	48	:	:	:
10_1101-2020_09_23_308239	131	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	131	50	preprint	preprint	NN
10_1101-2020_09_23_308239	131	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	131	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	131	53	18	18	CD
10_1101-2020_09_23_308239	131	54	their	-PRON-	PRP$
10_1101-2020_09_23_308239	131	55	effect	effect	NN
10_1101-2020_09_23_308239	131	56	was	be	VBD
10_1101-2020_09_23_308239	131	57	known	know	VBN
10_1101-2020_09_23_308239	131	58	(	(	-LRB-
10_1101-2020_09_23_308239	131	59	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	131	60	Tables	Tables	NNP
10_1101-2020_09_23_308239	131	61	3	3	CD
10_1101-2020_09_23_308239	131	62	&	&	CC
10_1101-2020_09_23_308239	131	63	5	5	CD
10_1101-2020_09_23_308239	131	64	)	)	-RRB-
10_1101-2020_09_23_308239	131	65	.	.	.
10_1101-2020_09_23_308239	132	1	Of	of	IN
10_1101-2020_09_23_308239	132	2	the	the	DT
10_1101-2020_09_23_308239	132	3	47	47	CD
10_1101-2020_09_23_308239	132	4	drug	drug	NN
10_1101-2020_09_23_308239	132	5	combinations	combination	NNS
10_1101-2020_09_23_308239	132	6	we	-PRON-	PRP
10_1101-2020_09_23_308239	132	7	were	be	VBD
10_1101-2020_09_23_308239	132	8	able	able	JJ
10_1101-2020_09_23_308239	132	9	to	to	TO
10_1101-2020_09_23_308239	132	10	check	check	VB
10_1101-2020_09_23_308239	132	11	within	within	IN
10_1101-2020_09_23_308239	132	12	the	the	DT
10_1101-2020_09_23_308239	132	13	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	132	14	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	132	15	,	,	,
10_1101-2020_09_23_308239	132	16	we	-PRON-	PRP
10_1101-2020_09_23_308239	132	17	found	find	VBD
10_1101-2020_09_23_308239	132	18	that	that	IN
10_1101-2020_09_23_308239	132	19	the	the	DT
10_1101-2020_09_23_308239	132	20	pairs	pair	NNS
10_1101-2020_09_23_308239	132	21	of	of	IN
10_1101-2020_09_23_308239	132	22	drugs	drug	NNS
10_1101-2020_09_23_308239	132	23	known	know	VBN
10_1101-2020_09_23_308239	132	24	to	to	TO
10_1101-2020_09_23_308239	132	25	have	have	VB
10_1101-2020_09_23_308239	132	26	a	a	DT
10_1101-2020_09_23_308239	132	27	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	132	28	effect	effect	NN
10_1101-2020_09_23_308239	132	29	in	in	IN
10_1101-2020_09_23_308239	132	30	the	the	DT
10_1101-2020_09_23_308239	132	31	treatment	treatment	NN
10_1101-2020_09_23_308239	132	32	of	of	IN
10_1101-2020_09_23_308239	132	33	SARS	SARS	NNP
10_1101-2020_09_23_308239	132	34	-	-	HYPH
10_1101-2020_09_23_308239	132	35	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	132	36	had	have	VBD
10_1101-2020_09_23_308239	132	37	an	an	DT
10_1101-2020_09_23_308239	132	38	average	average	JJ
10_1101-2020_09_23_308239	132	39	shortest	short	JJS
10_1101-2020_09_23_308239	132	40	path	path	NN
10_1101-2020_09_23_308239	132	41	length	length	NN
10_1101-2020_09_23_308239	132	42	of	of	IN
10_1101-2020_09_23_308239	132	43	2.43	2.43	CD
10_1101-2020_09_23_308239	132	44	,	,	,
10_1101-2020_09_23_308239	132	45	while	while	IN
10_1101-2020_09_23_308239	132	46	antagonistic	antagonistic	JJ
10_1101-2020_09_23_308239	132	47	combinations	combination	NNS
10_1101-2020_09_23_308239	132	48	were	be	VBD
10_1101-2020_09_23_308239	132	49	found	find	VBN
10_1101-2020_09_23_308239	132	50	to	to	TO
10_1101-2020_09_23_308239	132	51	be	be	VB
10_1101-2020_09_23_308239	132	52	farther	far	RBR
10_1101-2020_09_23_308239	132	53	apart	apart	RB
10_1101-2020_09_23_308239	132	54	with	with	IN
10_1101-2020_09_23_308239	132	55	an	an	DT
10_1101-2020_09_23_308239	132	56	average	average	JJ
10_1101-2020_09_23_308239	132	57	shortest	short	JJS
10_1101-2020_09_23_308239	132	58	path	path	NN
10_1101-2020_09_23_308239	132	59	length	length	NN
10_1101-2020_09_23_308239	132	60	of	of	IN
10_1101-2020_09_23_308239	132	61	4.0	4.0	CD
10_1101-2020_09_23_308239	132	62	(	(	-LRB-
10_1101-2020_09_23_308239	132	63	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	132	64	Table	Table	NNP
10_1101-2020_09_23_308239	132	65	7	7	CD
10_1101-2020_09_23_308239	132	66	)	)	-RRB-
10_1101-2020_09_23_308239	132	67	.	.	.
10_1101-2020_09_23_308239	133	1	Based	base	VBN
10_1101-2020_09_23_308239	133	2	on	on	IN
10_1101-2020_09_23_308239	133	3	our	-PRON-	PRP$
10_1101-2020_09_23_308239	133	4	calculations	calculation	NNS
10_1101-2020_09_23_308239	133	5	,	,	,
10_1101-2020_09_23_308239	133	6	we	-PRON-	PRP
10_1101-2020_09_23_308239	133	7	formulated	formulate	VBD
10_1101-2020_09_23_308239	133	8	three	three	CD
10_1101-2020_09_23_308239	133	9	categories	category	NNS
10_1101-2020_09_23_308239	133	10	for	for	IN
10_1101-2020_09_23_308239	133	11	predicting	predict	VBG
10_1101-2020_09_23_308239	133	12	the	the	DT
10_1101-2020_09_23_308239	133	13	outcome	outcome	NN
10_1101-2020_09_23_308239	133	14	of	of	IN
10_1101-2020_09_23_308239	133	15	new	new	JJ
10_1101-2020_09_23_308239	133	16	drug	drug	NN
10_1101-2020_09_23_308239	133	17	combinations	combination	NNS
10_1101-2020_09_23_308239	133	18	on	on	IN
10_1101-2020_09_23_308239	133	19	infection	infection	NN
10_1101-2020_09_23_308239	133	20	using	use	VBG
10_1101-2020_09_23_308239	133	21	the	the	DT
10_1101-2020_09_23_308239	133	22	shortest	short	JJS
10_1101-2020_09_23_308239	133	23	path	path	NN
10_1101-2020_09_23_308239	133	24	lengths	length	NNS
10_1101-2020_09_23_308239	133	25	between	between	IN
10_1101-2020_09_23_308239	133	26	them	-PRON-	PRP
10_1101-2020_09_23_308239	133	27	within	within	IN
10_1101-2020_09_23_308239	133	28	the	the	DT
10_1101-2020_09_23_308239	133	29	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	133	30	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	133	31	.	.	.
10_1101-2020_09_23_308239	134	1	Drug	drug	NN
10_1101-2020_09_23_308239	134	2	combinations	combination	NNS
10_1101-2020_09_23_308239	134	3	with	with	IN
10_1101-2020_09_23_308239	134	4	shortest	short	JJS
10_1101-2020_09_23_308239	134	5	path	path	NN
10_1101-2020_09_23_308239	134	6	lengths	length	NNS
10_1101-2020_09_23_308239	134	7	of	of	IN
10_1101-2020_09_23_308239	134	8	2	2	CD
10_1101-2020_09_23_308239	134	9	indicate	indicate	VBP
10_1101-2020_09_23_308239	134	10	a	a	DT
10_1101-2020_09_23_308239	134	11	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	134	12	relationship	relationship	NN
10_1101-2020_09_23_308239	134	13	between	between	IN
10_1101-2020_09_23_308239	134	14	the	the	DT
10_1101-2020_09_23_308239	134	15	compounds	compound	NNS
10_1101-2020_09_23_308239	134	16	,	,	,
10_1101-2020_09_23_308239	134	17	3	3	CD
10_1101-2020_09_23_308239	134	18	was	be	VBD
10_1101-2020_09_23_308239	134	19	determined	determined	JJ
10_1101-2020_09_23_308239	134	20	to	to	TO
10_1101-2020_09_23_308239	134	21	be	be	VB
10_1101-2020_09_23_308239	134	22	inconclusive	inconclusive	JJ
10_1101-2020_09_23_308239	134	23	as	as	IN
10_1101-2020_09_23_308239	134	24	our	-PRON-	PRP$
10_1101-2020_09_23_308239	134	25	calculations	calculation	NNS
10_1101-2020_09_23_308239	134	26	did	do	VBD
10_1101-2020_09_23_308239	134	27	not	not	RB
10_1101-2020_09_23_308239	134	28	justify	justify	VB
10_1101-2020_09_23_308239	134	29	a	a	DT
10_1101-2020_09_23_308239	134	30	specific	specific	JJ
10_1101-2020_09_23_308239	134	31	outcome	outcome	NN
10_1101-2020_09_23_308239	134	32	,	,	,
10_1101-2020_09_23_308239	134	33	and	and	CC
10_1101-2020_09_23_308239	134	34	those	those	DT
10_1101-2020_09_23_308239	134	35	with	with	IN
10_1101-2020_09_23_308239	134	36	a	a	DT
10_1101-2020_09_23_308239	134	37	shortest	short	JJS
10_1101-2020_09_23_308239	134	38	path	path	NN
10_1101-2020_09_23_308239	134	39	length	length	NN
10_1101-2020_09_23_308239	134	40	of	of	IN
10_1101-2020_09_23_308239	134	41	4	4	CD
10_1101-2020_09_23_308239	134	42	or	or	CC
10_1101-2020_09_23_308239	134	43	more	more	JJR
10_1101-2020_09_23_308239	134	44	were	be	VBD
10_1101-2020_09_23_308239	134	45	predicted	predict	VBN
10_1101-2020_09_23_308239	134	46	to	to	TO
10_1101-2020_09_23_308239	134	47	have	have	VB
10_1101-2020_09_23_308239	134	48	an	an	DT
10_1101-2020_09_23_308239	134	49	antagonistic	antagonistic	JJ
10_1101-2020_09_23_308239	134	50	relationship	relationship	NN
10_1101-2020_09_23_308239	134	51	.	.	.
10_1101-2020_09_23_308239	135	1	In	in	IN
10_1101-2020_09_23_308239	135	2	order	order	NN
10_1101-2020_09_23_308239	135	3	to	to	TO
10_1101-2020_09_23_308239	135	4	test	test	VB
10_1101-2020_09_23_308239	135	5	our	-PRON-	PRP$
10_1101-2020_09_23_308239	135	6	ability	ability	NN
10_1101-2020_09_23_308239	135	7	to	to	TO
10_1101-2020_09_23_308239	135	8	predict	predict	VB
10_1101-2020_09_23_308239	135	9	the	the	DT
10_1101-2020_09_23_308239	135	10	outcome	outcome	NN
10_1101-2020_09_23_308239	135	11	of	of	IN
10_1101-2020_09_23_308239	135	12	novel	novel	JJ
10_1101-2020_09_23_308239	135	13	drug	drug	NN
10_1101-2020_09_23_308239	135	14	combinations	combination	NNS
10_1101-2020_09_23_308239	135	15	,	,	,
10_1101-2020_09_23_308239	135	16	we	-PRON-	PRP
10_1101-2020_09_23_308239	135	17	selected	select	VBD
10_1101-2020_09_23_308239	135	18	five	five	CD
10_1101-2020_09_23_308239	135	19	compounds	compound	NNS
10_1101-2020_09_23_308239	135	20	:	:	:
10_1101-2020_09_23_308239	135	21	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	135	22	(	(	-LRB-
10_1101-2020_09_23_308239	135	23	a	a	DT
10_1101-2020_09_23_308239	135	24	virus	virus	NN
10_1101-2020_09_23_308239	135	25	replicase	replicase	NN
10_1101-2020_09_23_308239	135	26	inhibitor	inhibitor	NN
10_1101-2020_09_23_308239	135	27	)	)	-RRB-
10_1101-2020_09_23_308239	135	28	,	,	,
10_1101-2020_09_23_308239	135	29	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	135	30	(	(	-LRB-
10_1101-2020_09_23_308239	135	31	a	a	DT
10_1101-2020_09_23_308239	135	32	virus	virus	NN
10_1101-2020_09_23_308239	135	33	protease	protease	NN
10_1101-2020_09_23_308239	135	34	inhibitor	inhibitor	NN
10_1101-2020_09_23_308239	135	35	)	)	-RRB-
10_1101-2020_09_23_308239	135	36	,	,	,
10_1101-2020_09_23_308239	135	37	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	135	38	(	(	-LRB-
10_1101-2020_09_23_308239	135	39	a	a	DT
10_1101-2020_09_23_308239	135	40	selective	selective	JJ
10_1101-2020_09_23_308239	135	41	estrogen	estrogen	NNP
10_1101-2020_09_23_308239	135	42	receptor	receptor	NN
10_1101-2020_09_23_308239	135	43	modulator	modulator	NNP
10_1101-2020_09_23_308239	135	44	)	)	-RRB-
10_1101-2020_09_23_308239	135	45	,	,	,
10_1101-2020_09_23_308239	135	46	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	135	47	(	(	-LRB-
10_1101-2020_09_23_308239	135	48	a	a	DT
10_1101-2020_09_23_308239	135	49	chemotherapy	chemotherapy	NN
10_1101-2020_09_23_308239	135	50	compound	compound	NN
10_1101-2020_09_23_308239	135	51	interfering	interfere	VBG
10_1101-2020_09_23_308239	135	52	with	with	IN
10_1101-2020_09_23_308239	135	53	cell	cell	NN
10_1101-2020_09_23_308239	135	54	growth	growth	NN
10_1101-2020_09_23_308239	135	55	)	)	-RRB-
10_1101-2020_09_23_308239	135	56	,	,	,
10_1101-2020_09_23_308239	135	57	and	and	CC
10_1101-2020_09_23_308239	135	58	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	135	59	(	(	-LRB-
10_1101-2020_09_23_308239	135	60	a	a	DT
10_1101-2020_09_23_308239	135	61	pleiotropic	pleiotropic	JJ
10_1101-2020_09_23_308239	135	62	compound	compound	NN
10_1101-2020_09_23_308239	135	63	with	with	IN
10_1101-2020_09_23_308239	135	64	several	several	JJ
10_1101-2020_09_23_308239	135	65	pharmacological	pharmacological	JJ
10_1101-2020_09_23_308239	135	66	activities	activity	NNS
10_1101-2020_09_23_308239	135	67	,	,	,
10_1101-2020_09_23_308239	135	68	including	include	VBG
10_1101-2020_09_23_308239	135	69	inhibition	inhibition	NN
10_1101-2020_09_23_308239	135	70	of	of	IN
10_1101-2020_09_23_308239	135	71	protein	protein	NN
10_1101-2020_09_23_308239	135	72	synthesis	synthesis	NN
10_1101-2020_09_23_308239	135	73	and	and	CC
10_1101-2020_09_23_308239	135	74	nucleotide	nucleotide	JJ
10_1101-2020_09_23_308239	135	75	synthesis	synthesis	NN
10_1101-2020_09_23_308239	135	76	)	)	-RRB-
10_1101-2020_09_23_308239	135	77	.	.	.
10_1101-2020_09_23_308239	136	1	These	these	DT
10_1101-2020_09_23_308239	136	2	compounds	compound	NNS
10_1101-2020_09_23_308239	136	3	were	be	VBD
10_1101-2020_09_23_308239	136	4	used	use	VBN
10_1101-2020_09_23_308239	136	5	in	in	IN
10_1101-2020_09_23_308239	136	6	four	four	CD
10_1101-2020_09_23_308239	136	7	different	different	JJ
10_1101-2020_09_23_308239	136	8	combinations	combination	NNS
10_1101-2020_09_23_308239	136	9	(	(	-LRB-
10_1101-2020_09_23_308239	136	10	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	136	11	/	/	SYM
10_1101-2020_09_23_308239	136	12	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	136	13	,	,	,
10_1101-2020_09_23_308239	136	14	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	136	15	/	/	SYM
10_1101-2020_09_23_308239	136	16	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	136	17	,	,	,
10_1101-2020_09_23_308239	136	18	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	136	19	/	/	SYM
10_1101-2020_09_23_308239	136	20	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	136	21	and	and	CC
10_1101-2020_09_23_308239	136	22	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	136	23	/	/	SYM
10_1101-2020_09_23_308239	136	24	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	136	25	)	)	-RRB-
10_1101-2020_09_23_308239	136	26	to	to	TO
10_1101-2020_09_23_308239	136	27	test	test	VB
10_1101-2020_09_23_308239	136	28	the	the	DT
10_1101-2020_09_23_308239	136	29	potency	potency	NN
10_1101-2020_09_23_308239	136	30	of	of	IN
10_1101-2020_09_23_308239	136	31	these	these	DT
10_1101-2020_09_23_308239	136	32	drug	drug	NN
10_1101-2020_09_23_308239	136	33	pairings	pairing	NNS
10_1101-2020_09_23_308239	136	34	in	in	IN
10_1101-2020_09_23_308239	136	35	phenotypic	phenotypic	JJ
10_1101-2020_09_23_308239	136	36	,	,	,
10_1101-2020_09_23_308239	136	37	cellular	cellular	JJ
10_1101-2020_09_23_308239	136	38	assays	assay	NNS
10_1101-2020_09_23_308239	136	39	.	.	.
10_1101-2020_09_23_308239	137	1	Figure	figure	NN
10_1101-2020_09_23_308239	137	2	6	6	CD
10_1101-2020_09_23_308239	137	3	shows	show	VBZ
10_1101-2020_09_23_308239	137	4	the	the	DT
10_1101-2020_09_23_308239	137	5	results	result	NNS
10_1101-2020_09_23_308239	137	6	of	of	IN
10_1101-2020_09_23_308239	137	7	these	these	DT
10_1101-2020_09_23_308239	137	8	combinatorial	combinatorial	JJ
10_1101-2020_09_23_308239	137	9	treatments	treatment	NNS
10_1101-2020_09_23_308239	137	10	on	on	IN
10_1101-2020_09_23_308239	137	11	the	the	DT
10_1101-2020_09_23_308239	137	12	virus	virus	NN
10_1101-2020_09_23_308239	137	13	-	-	HYPH
10_1101-2020_09_23_308239	137	14	induced	induce	VBN
10_1101-2020_09_23_308239	137	15	cytopathic	cytopathic	JJ
10_1101-2020_09_23_308239	137	16	effect	effect	NN
10_1101-2020_09_23_308239	137	17	in	in	IN
10_1101-2020_09_23_308239	137	18	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	137	19	cells	cell	NNS
10_1101-2020_09_23_308239	137	20	.	.	.
10_1101-2020_09_23_308239	138	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	138	2	-	-	:
10_1101-2020_09_23_308239	138	3	BY	by	IN
10_1101-2020_09_23_308239	138	4	-	-	HYPH
10_1101-2020_09_23_308239	138	5	NC	NC	NNP
10_1101-2020_09_23_308239	138	6	-	-	HYPH
10_1101-2020_09_23_308239	138	7	ND	ND	NNP
10_1101-2020_09_23_308239	138	8	4.0	4.0	CD
10_1101-2020_09_23_308239	138	9	International	international	JJ
10_1101-2020_09_23_308239	138	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	138	11	.	.	.
10_1101-2020_09_23_308239	139	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	139	2	is	be	VBZ
10_1101-2020_09_23_308239	139	3	made	make	VBN
10_1101-2020_09_23_308239	139	4	available	available	JJ
10_1101-2020_09_23_308239	139	5	under	under	IN
10_1101-2020_09_23_308239	139	6	a	a	DT
10_1101-2020_09_23_308239	139	7	preprint	preprint	NN
10_1101-2020_09_23_308239	139	8	(	(	-LRB-
10_1101-2020_09_23_308239	139	9	which	which	WDT
10_1101-2020_09_23_308239	139	10	was	be	VBD
10_1101-2020_09_23_308239	139	11	not	not	RB
10_1101-2020_09_23_308239	139	12	certified	certify	VBN
10_1101-2020_09_23_308239	139	13	by	by	IN
10_1101-2020_09_23_308239	139	14	peer	peer	NN
10_1101-2020_09_23_308239	139	15	review	review	NN
10_1101-2020_09_23_308239	139	16	)	)	-RRB-
10_1101-2020_09_23_308239	139	17	is	be	VBZ
10_1101-2020_09_23_308239	139	18	the	the	DT
10_1101-2020_09_23_308239	139	19	author	author	NN
10_1101-2020_09_23_308239	139	20	/	/	SYM
10_1101-2020_09_23_308239	139	21	funder	funder	NN
10_1101-2020_09_23_308239	139	22	,	,	,
10_1101-2020_09_23_308239	139	23	who	who	WP
10_1101-2020_09_23_308239	139	24	has	have	VBZ
10_1101-2020_09_23_308239	139	25	granted	grant	VBN
10_1101-2020_09_23_308239	139	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	139	27	a	a	DT
10_1101-2020_09_23_308239	139	28	license	license	NN
10_1101-2020_09_23_308239	139	29	to	to	TO
10_1101-2020_09_23_308239	139	30	display	display	VB
10_1101-2020_09_23_308239	139	31	the	the	DT
10_1101-2020_09_23_308239	139	32	preprint	preprint	NN
10_1101-2020_09_23_308239	139	33	in	in	IN
10_1101-2020_09_23_308239	139	34	The	the	DT
10_1101-2020_09_23_308239	139	35	copyright	copyright	NN
10_1101-2020_09_23_308239	139	36	holder	holder	NN
10_1101-2020_09_23_308239	139	37	for	for	IN
10_1101-2020_09_23_308239	139	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	139	39	version	version	NN
10_1101-2020_09_23_308239	139	40	posted	post	VBD
10_1101-2020_09_23_308239	139	41	February	February	NNP
10_1101-2020_09_23_308239	139	42	12	12	CD
10_1101-2020_09_23_308239	139	43	,	,	,
10_1101-2020_09_23_308239	139	44	2021	2021	CD
10_1101-2020_09_23_308239	139	45	.	.	.
10_1101-2020_09_23_308239	139	46	;	;	:
10_1101-2020_09_23_308239	139	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	139	48	:	:	:
10_1101-2020_09_23_308239	139	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	139	50	preprint	preprint	NN
10_1101-2020_09_23_308239	139	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	139	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	139	53	19	19	CD
10_1101-2020_09_23_308239	139	54	Figure	figure	NN
10_1101-2020_09_23_308239	139	55	6	6	CD
10_1101-2020_09_23_308239	139	56	:	:	:
10_1101-2020_09_23_308239	139	57	Dose	dose	NN
10_1101-2020_09_23_308239	139	58	-	-	HYPH
10_1101-2020_09_23_308239	139	59	response	response	NN
10_1101-2020_09_23_308239	139	60	curves	curve	NNS
10_1101-2020_09_23_308239	139	61	(	(	-LRB-
10_1101-2020_09_23_308239	139	62	DRC	DRC	NNP
10_1101-2020_09_23_308239	139	63	)	)	-RRB-
10_1101-2020_09_23_308239	139	64	depicting	depict	VBG
10_1101-2020_09_23_308239	139	65	viral	viral	JJ
10_1101-2020_09_23_308239	139	66	inhibition	inhibition	NN
10_1101-2020_09_23_308239	139	67	of	of	IN
10_1101-2020_09_23_308239	139	68	SARS	SARS	NNP
10_1101-2020_09_23_308239	139	69	-	-	HYPH
10_1101-2020_09_23_308239	139	70	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	139	71	by	by	IN
10_1101-2020_09_23_308239	139	72	select	select	JJ
10_1101-2020_09_23_308239	139	73	drug	drug	NN
10_1101-2020_09_23_308239	139	74	combinations	combination	NNS
10_1101-2020_09_23_308239	139	75	.	.	.
10_1101-2020_09_23_308239	140	1	a	a	LS
10_1101-2020_09_23_308239	140	2	)	)	-RRB-
10_1101-2020_09_23_308239	140	3	A	a	DT
10_1101-2020_09_23_308239	140	4	threshold	threshold	NN
10_1101-2020_09_23_308239	140	5	effect	effect	NN
10_1101-2020_09_23_308239	140	6	can	can	MD
10_1101-2020_09_23_308239	140	7	be	be	VB
10_1101-2020_09_23_308239	140	8	seen	see	VBN
10_1101-2020_09_23_308239	140	9	with	with	IN
10_1101-2020_09_23_308239	140	10	the	the	DT
10_1101-2020_09_23_308239	140	11	Remdesivir	Remdesivir	NNPS
10_1101-2020_09_23_308239	140	12	/	/	SYM
10_1101-2020_09_23_308239	140	13	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	140	14	combination	combination	NN
10_1101-2020_09_23_308239	140	15	when	when	WRB
10_1101-2020_09_23_308239	140	16	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	140	17	reaches	reach	VBZ
10_1101-2020_09_23_308239	140	18	20	20	CD
10_1101-2020_09_23_308239	140	19	µM	µM	NNP
10_1101-2020_09_23_308239	140	20	,	,	,
10_1101-2020_09_23_308239	140	21	well	well	RB
10_1101-2020_09_23_308239	140	22	beyond	beyond	IN
10_1101-2020_09_23_308239	140	23	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	140	24	’s	’s	NNP
10_1101-2020_09_23_308239	140	25	IC50	IC50	NNP
10_1101-2020_09_23_308239	140	26	alone	alone	RB
10_1101-2020_09_23_308239	140	27	.	.	.
10_1101-2020_09_23_308239	141	1	Remdesivir	remdesivir	JJ
10_1101-2020_09_23_308239	141	2	activity	activity	NN
10_1101-2020_09_23_308239	141	3	does	do	VBZ
10_1101-2020_09_23_308239	141	4	not	not	RB
10_1101-2020_09_23_308239	141	5	appear	appear	VB
10_1101-2020_09_23_308239	141	6	to	to	TO
10_1101-2020_09_23_308239	141	7	be	be	VB
10_1101-2020_09_23_308239	141	8	affected	affect	VBN
10_1101-2020_09_23_308239	141	9	by	by	IN
10_1101-2020_09_23_308239	141	10	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	141	11	,	,	,
10_1101-2020_09_23_308239	141	12	while	while	IN
10_1101-2020_09_23_308239	141	13	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	141	14	seems	seem	VBZ
10_1101-2020_09_23_308239	141	15	to	to	TO
10_1101-2020_09_23_308239	141	16	be	be	VB
10_1101-2020_09_23_308239	141	17	equally	equally	RB
10_1101-2020_09_23_308239	141	18	affected	affect	VBN
10_1101-2020_09_23_308239	141	19	(	(	-LRB-
10_1101-2020_09_23_308239	141	20	de	de	FW
10_1101-2020_09_23_308239	141	21	-	-	VBN
10_1101-2020_09_23_308239	141	22	potentiated	potentiate	VBN
10_1101-2020_09_23_308239	141	23	)	)	-RRB-
10_1101-2020_09_23_308239	141	24	by	by	IN
10_1101-2020_09_23_308239	141	25	low	low	JJ
10_1101-2020_09_23_308239	141	26	to	to	IN
10_1101-2020_09_23_308239	141	27	high	high	JJ
10_1101-2020_09_23_308239	141	28	concentrations	concentration	NNS
10_1101-2020_09_23_308239	141	29	of	of	IN
10_1101-2020_09_23_308239	141	30	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	141	31	.	.	.
10_1101-2020_09_23_308239	142	1	b	b	LS
10_1101-2020_09_23_308239	142	2	)	)	-RRB-
10_1101-2020_09_23_308239	142	3	Viral	viral	JJ
10_1101-2020_09_23_308239	142	4	inhibition	inhibition	NN
10_1101-2020_09_23_308239	142	5	for	for	IN
10_1101-2020_09_23_308239	142	6	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	142	7	/	/	SYM
10_1101-2020_09_23_308239	142	8	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	142	9	can	can	MD
10_1101-2020_09_23_308239	142	10	be	be	VB
10_1101-2020_09_23_308239	142	11	seen	see	VBN
10_1101-2020_09_23_308239	142	12	only	only	RB
10_1101-2020_09_23_308239	142	13	at	at	IN
10_1101-2020_09_23_308239	142	14	lower	low	JJR
10_1101-2020_09_23_308239	142	15	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	142	16	concentrations	concentration	NNS
10_1101-2020_09_23_308239	142	17	,	,	,
10_1101-2020_09_23_308239	142	18	at	at	IN
10_1101-2020_09_23_308239	142	19	higher	high	JJR
10_1101-2020_09_23_308239	142	20	concentrations	concentration	NNS
10_1101-2020_09_23_308239	142	21	the	the	DT
10_1101-2020_09_23_308239	142	22	clear	clear	JJ
10_1101-2020_09_23_308239	142	23	curve	curve	NN
10_1101-2020_09_23_308239	142	24	shift	shift	NN
10_1101-2020_09_23_308239	142	25	of	of	IN
10_1101-2020_09_23_308239	142	26	Remdesivir	Remdesivir	NNPS
10_1101-2020_09_23_308239	142	27	at	at	IN
10_1101-2020_09_23_308239	142	28	lower	low	JJR
10_1101-2020_09_23_308239	142	29	concentration	concentration	NN
10_1101-2020_09_23_308239	142	30	(	(	-LRB-
10_1101-2020_09_23_308239	142	31	effect	effect	NN
10_1101-2020_09_23_308239	142	32	beyond	beyond	IN
10_1101-2020_09_23_308239	142	33	Loewe	Loewe	NNP
10_1101-2020_09_23_308239	142	34	’s	’s	POS
10_1101-2020_09_23_308239	142	35	additivity	additivity	NN
10_1101-2020_09_23_308239	142	36	formula	formula	NN
10_1101-2020_09_23_308239	142	37	)	)	-RRB-
10_1101-2020_09_23_308239	142	38	could	could	MD
10_1101-2020_09_23_308239	142	39	not	not	RB
10_1101-2020_09_23_308239	142	40	be	be	VB
10_1101-2020_09_23_308239	142	41	appreciated	appreciate	VBN
10_1101-2020_09_23_308239	142	42	.	.	.
10_1101-2020_09_23_308239	143	1	c	c	LS
10_1101-2020_09_23_308239	143	2	)	)	-RRB-
10_1101-2020_09_23_308239	143	3	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	143	4	had	have	VBD
10_1101-2020_09_23_308239	143	5	an	an	DT
10_1101-2020_09_23_308239	143	6	antagonistic	antagonistic	JJ
10_1101-2020_09_23_308239	143	7	effect	effect	NN
10_1101-2020_09_23_308239	143	8	on	on	IN
10_1101-2020_09_23_308239	143	9	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	143	10	’s	’s	POS
10_1101-2020_09_23_308239	143	11	viral	viral	JJ
10_1101-2020_09_23_308239	143	12	replication	replication	NN
10_1101-2020_09_23_308239	143	13	inhibition	inhibition	NN
10_1101-2020_09_23_308239	143	14	activity	activity	NN
10_1101-2020_09_23_308239	143	15	.	.	.
10_1101-2020_09_23_308239	144	1	d	d	LS
10_1101-2020_09_23_308239	144	2	)	)	-RRB-
10_1101-2020_09_23_308239	144	3	A	a	DT
10_1101-2020_09_23_308239	144	4	clear	clear	JJ
10_1101-2020_09_23_308239	144	5	shift	shift	NN
10_1101-2020_09_23_308239	144	6	in	in	IN
10_1101-2020_09_23_308239	144	7	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	144	8	’s	’s	POS
10_1101-2020_09_23_308239	144	9	DRC	drc	NN
10_1101-2020_09_23_308239	144	10	can	can	MD
10_1101-2020_09_23_308239	144	11	be	be	VB
10_1101-2020_09_23_308239	144	12	observed	observe	VBN
10_1101-2020_09_23_308239	144	13	when	when	WRB
10_1101-2020_09_23_308239	144	14	combined	combine	VBN
10_1101-2020_09_23_308239	144	15	with	with	IN
10_1101-2020_09_23_308239	144	16	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	144	17	,	,	,
10_1101-2020_09_23_308239	144	18	but	but	CC
10_1101-2020_09_23_308239	144	19	also	also	RB
10_1101-2020_09_23_308239	144	20	suggests	suggest	VBZ
10_1101-2020_09_23_308239	144	21	a	a	DT
10_1101-2020_09_23_308239	144	22	threshold	threshold	NN
10_1101-2020_09_23_308239	144	23	effect	effect	NN
10_1101-2020_09_23_308239	144	24	when	when	WRB
10_1101-2020_09_23_308239	144	25	Raloxifene	raloxifene	JJ
10_1101-2020_09_23_308239	144	26	concentrations	concentration	NNS
10_1101-2020_09_23_308239	144	27	are	be	VBP
10_1101-2020_09_23_308239	144	28	higher	high	JJR
10_1101-2020_09_23_308239	144	29	than	than	IN
10_1101-2020_09_23_308239	144	30	2.2	2.2	CD
10_1101-2020_09_23_308239	144	31	µM.	µM.	NNS
10_1101-2020_09_23_308239	145	1	Our	-PRON-	PRP$
10_1101-2020_09_23_308239	145	2	results	result	NNS
10_1101-2020_09_23_308239	145	3	indicate	indicate	VBP
10_1101-2020_09_23_308239	145	4	that	that	IN
10_1101-2020_09_23_308239	145	5	compound	compound	NN
10_1101-2020_09_23_308239	145	6	combinations	combination	NNS
10_1101-2020_09_23_308239	145	7	acting	act	VBG
10_1101-2020_09_23_308239	145	8	on	on	IN
10_1101-2020_09_23_308239	145	9	different	different	JJ
10_1101-2020_09_23_308239	145	10	viral	viral	JJ
10_1101-2020_09_23_308239	145	11	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	145	12	,	,	,
10_1101-2020_09_23_308239	145	13	such	such	JJ
10_1101-2020_09_23_308239	145	14	as	as	IN
10_1101-2020_09_23_308239	145	15	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	145	16	and	and	CC
10_1101-2020_09_23_308239	145	17	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	145	18	(	(	-LRB-
10_1101-2020_09_23_308239	145	19	Figure	Figure	NNP
10_1101-2020_09_23_308239	145	20	6b	6b	NNP
10_1101-2020_09_23_308239	145	21	)	)	-RRB-
10_1101-2020_09_23_308239	145	22	or	or	CC
10_1101-2020_09_23_308239	145	23	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	145	24	and	and	CC
10_1101-2020_09_23_308239	145	25	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	145	26	(	(	-LRB-
10_1101-2020_09_23_308239	145	27	Figure	Figure	NNP
10_1101-2020_09_23_308239	145	28	6d	6d	NNP
10_1101-2020_09_23_308239	145	29	)	)	-RRB-
10_1101-2020_09_23_308239	145	30	,	,	,
10_1101-2020_09_23_308239	145	31	showed	show	VBD
10_1101-2020_09_23_308239	145	32	synergy	synergy	NN
10_1101-2020_09_23_308239	145	33	,	,	,
10_1101-2020_09_23_308239	145	34	while	while	IN
10_1101-2020_09_23_308239	145	35	compounds	compound	NNS
10_1101-2020_09_23_308239	145	36	acting	act	VBG
10_1101-2020_09_23_308239	145	37	on	on	IN
10_1101-2020_09_23_308239	145	38	host	host	NN
10_1101-2020_09_23_308239	145	39	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	145	40	,	,	,
10_1101-2020_09_23_308239	145	41	for	for	IN
10_1101-2020_09_23_308239	145	42	instance	instance	NN
10_1101-2020_09_23_308239	145	43	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	145	44	or	or	CC
10_1101-2020_09_23_308239	145	45	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	145	46	,	,	,
10_1101-2020_09_23_308239	145	47	when	when	WRB
10_1101-2020_09_23_308239	145	48	combined	combine	VBN
10_1101-2020_09_23_308239	145	49	with	with	IN
10_1101-2020_09_23_308239	145	50	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	145	51	(	(	-LRB-
10_1101-2020_09_23_308239	145	52	Figure	Figure	NNP
10_1101-2020_09_23_308239	145	53	6a	6a	NNP
10_1101-2020_09_23_308239	145	54	and	and	CC
10_1101-2020_09_23_308239	145	55	Figure	Figure	NNP
10_1101-2020_09_23_308239	145	56	6c	6c	NNP
10_1101-2020_09_23_308239	145	57	,	,	,
10_1101-2020_09_23_308239	145	58	respectively	respectively	RB
10_1101-2020_09_23_308239	145	59	)	)	-RRB-
10_1101-2020_09_23_308239	145	60	,	,	,
10_1101-2020_09_23_308239	145	61	resulted	result	VBD
10_1101-2020_09_23_308239	145	62	in	in	IN
10_1101-2020_09_23_308239	145	63	neither	neither	CC
10_1101-2020_09_23_308239	145	64	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	145	65	nor	nor	CC
10_1101-2020_09_23_308239	145	66	additive	additive	JJ
10_1101-2020_09_23_308239	145	67	effects	effect	NNS
10_1101-2020_09_23_308239	145	68	.	.	.
10_1101-2020_09_23_308239	146	1	Interestingly	interestingly	RB
10_1101-2020_09_23_308239	146	2	,	,	,
10_1101-2020_09_23_308239	146	3	our	-PRON-	PRP$
10_1101-2020_09_23_308239	146	4	experiments	experiment	NNS
10_1101-2020_09_23_308239	146	5	revealed	reveal	VBD
10_1101-2020_09_23_308239	146	6	that	that	IN
10_1101-2020_09_23_308239	146	7	the	the	DT
10_1101-2020_09_23_308239	146	8	HIV	HIV	NNP
10_1101-2020_09_23_308239	146	9	-	-	HYPH
10_1101-2020_09_23_308239	146	10	Protease	Protease	NNP
10_1101-2020_09_23_308239	146	11	inhibitor	inhibitor	NN
10_1101-2020_09_23_308239	146	12	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	146	13	,	,	,
10_1101-2020_09_23_308239	146	14	which	which	WDT
10_1101-2020_09_23_308239	146	15	already	already	RB
10_1101-2020_09_23_308239	146	16	appeared	appear	VBD
10_1101-2020_09_23_308239	146	17	to	to	TO
10_1101-2020_09_23_308239	146	18	be	be	VB
10_1101-2020_09_23_308239	146	19	active	active	JJ
10_1101-2020_09_23_308239	146	20	against	against	IN
10_1101-2020_09_23_308239	146	21	viral	viral	JJ
10_1101-2020_09_23_308239	146	22	post	post	NN
10_1101-2020_09_23_308239	146	23	-	-	JJ
10_1101-2020_09_23_308239	146	24	entry	entry	JJ
10_1101-2020_09_23_308239	146	25	fusion	fusion	NN
10_1101-2020_09_23_308239	146	26	steps	step	NNS
10_1101-2020_09_23_308239	146	27	of	of	IN
10_1101-2020_09_23_308239	146	28	both	both	DT
10_1101-2020_09_23_308239	146	29	SARS	SARS	NNP
10_1101-2020_09_23_308239	146	30	-	-	HYPH
10_1101-2020_09_23_308239	146	31	CoV42	CoV42	NNP
10_1101-2020_09_23_308239	146	32	and	and	CC
10_1101-2020_09_23_308239	146	33	SARS	SARS	NNP
10_1101-2020_09_23_308239	146	34	-	-	HYPH
10_1101-2020_09_23_308239	146	35	CoV-243	CoV-243	NNP
10_1101-2020_09_23_308239	146	36	,	,	,
10_1101-2020_09_23_308239	146	37	displayed	display	VBD
10_1101-2020_09_23_308239	146	38	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	146	39	effects	effect	NNS
10_1101-2020_09_23_308239	146	40	when	when	WRB
10_1101-2020_09_23_308239	146	41	combined	combine	VBN
10_1101-2020_09_23_308239	146	42	with	with	IN
10_1101-2020_09_23_308239	146	43	high	high	JJ
10_1101-2020_09_23_308239	146	44	concentrations	concentration	NNS
10_1101-2020_09_23_308239	146	45	of	of	IN
10_1101-2020_09_23_308239	146	46	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	146	47	.	.	.
10_1101-2020_09_23_308239	147	1	This	this	DT
10_1101-2020_09_23_308239	147	2	result	result	NN
10_1101-2020_09_23_308239	147	3	agrees	agree	VBZ
10_1101-2020_09_23_308239	147	4	with	with	IN
10_1101-2020_09_23_308239	147	5	our	-PRON-	PRP$
10_1101-2020_09_23_308239	147	6	predictions	prediction	NNS
10_1101-2020_09_23_308239	147	7	generated	generate	VBN
10_1101-2020_09_23_308239	147	8	using	use	VBG
10_1101-2020_09_23_308239	147	9	the	the	DT
10_1101-2020_09_23_308239	147	10	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	147	11	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	147	12	in	in	IN
10_1101-2020_09_23_308239	147	13	which	which	WDT
10_1101-2020_09_23_308239	147	14	the	the	DT
10_1101-2020_09_23_308239	147	15	drug	drug	NN
10_1101-2020_09_23_308239	147	16	.CC	.CC	:
10_1101-2020_09_23_308239	147	17	-	-	:
10_1101-2020_09_23_308239	147	18	BY	by	IN
10_1101-2020_09_23_308239	147	19	-	-	HYPH
10_1101-2020_09_23_308239	147	20	NC	NC	NNP
10_1101-2020_09_23_308239	147	21	-	-	HYPH
10_1101-2020_09_23_308239	147	22	ND	ND	NNP
10_1101-2020_09_23_308239	147	23	4.0	4.0	CD
10_1101-2020_09_23_308239	147	24	International	international	JJ
10_1101-2020_09_23_308239	147	25	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	147	26	.	.	.
10_1101-2020_09_23_308239	148	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	148	2	is	be	VBZ
10_1101-2020_09_23_308239	148	3	made	make	VBN
10_1101-2020_09_23_308239	148	4	available	available	JJ
10_1101-2020_09_23_308239	148	5	under	under	IN
10_1101-2020_09_23_308239	148	6	a	a	DT
10_1101-2020_09_23_308239	148	7	preprint	preprint	NN
10_1101-2020_09_23_308239	148	8	(	(	-LRB-
10_1101-2020_09_23_308239	148	9	which	which	WDT
10_1101-2020_09_23_308239	148	10	was	be	VBD
10_1101-2020_09_23_308239	148	11	not	not	RB
10_1101-2020_09_23_308239	148	12	certified	certify	VBN
10_1101-2020_09_23_308239	148	13	by	by	IN
10_1101-2020_09_23_308239	148	14	peer	peer	NN
10_1101-2020_09_23_308239	148	15	review	review	NN
10_1101-2020_09_23_308239	148	16	)	)	-RRB-
10_1101-2020_09_23_308239	148	17	is	be	VBZ
10_1101-2020_09_23_308239	148	18	the	the	DT
10_1101-2020_09_23_308239	148	19	author	author	NN
10_1101-2020_09_23_308239	148	20	/	/	SYM
10_1101-2020_09_23_308239	148	21	funder	funder	NN
10_1101-2020_09_23_308239	148	22	,	,	,
10_1101-2020_09_23_308239	148	23	who	who	WP
10_1101-2020_09_23_308239	148	24	has	have	VBZ
10_1101-2020_09_23_308239	148	25	granted	grant	VBN
10_1101-2020_09_23_308239	148	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	148	27	a	a	DT
10_1101-2020_09_23_308239	148	28	license	license	NN
10_1101-2020_09_23_308239	148	29	to	to	TO
10_1101-2020_09_23_308239	148	30	display	display	VB
10_1101-2020_09_23_308239	148	31	the	the	DT
10_1101-2020_09_23_308239	148	32	preprint	preprint	NN
10_1101-2020_09_23_308239	148	33	in	in	IN
10_1101-2020_09_23_308239	148	34	The	the	DT
10_1101-2020_09_23_308239	148	35	copyright	copyright	NN
10_1101-2020_09_23_308239	148	36	holder	holder	NN
10_1101-2020_09_23_308239	148	37	for	for	IN
10_1101-2020_09_23_308239	148	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	148	39	version	version	NN
10_1101-2020_09_23_308239	148	40	posted	post	VBD
10_1101-2020_09_23_308239	148	41	February	February	NNP
10_1101-2020_09_23_308239	148	42	12	12	CD
10_1101-2020_09_23_308239	148	43	,	,	,
10_1101-2020_09_23_308239	148	44	2021	2021	CD
10_1101-2020_09_23_308239	148	45	.	.	.
10_1101-2020_09_23_308239	148	46	;	;	:
10_1101-2020_09_23_308239	148	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	148	48	:	:	:
10_1101-2020_09_23_308239	148	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	148	50	preprint	preprint	NN
10_1101-2020_09_23_308239	148	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	148	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	148	53	20	20	CD
10_1101-2020_09_23_308239	148	54	combination	combination	NN
10_1101-2020_09_23_308239	148	55	with	with	IN
10_1101-2020_09_23_308239	148	56	the	the	DT
10_1101-2020_09_23_308239	148	57	shortest	short	JJS
10_1101-2020_09_23_308239	148	58	distance	distance	NN
10_1101-2020_09_23_308239	148	59	,	,	,
10_1101-2020_09_23_308239	148	60	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	148	61	and	and	CC
10_1101-2020_09_23_308239	148	62	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	148	63	(	(	-LRB-
10_1101-2020_09_23_308239	148	64	Supplementary	Supplementary	NNP
10_1101-2020_09_23_308239	148	65	Table	Table	NNP
10_1101-2020_09_23_308239	148	66	5	5	CD
10_1101-2020_09_23_308239	148	67	)	)	-RRB-
10_1101-2020_09_23_308239	148	68	,	,	,
10_1101-2020_09_23_308239	148	69	would	would	MD
10_1101-2020_09_23_308239	148	70	have	have	VB
10_1101-2020_09_23_308239	148	71	a	a	DT
10_1101-2020_09_23_308239	148	72	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	148	73	effect	effect	NN
10_1101-2020_09_23_308239	148	74	on	on	IN
10_1101-2020_09_23_308239	148	75	SARS	SARS	NNP
10_1101-2020_09_23_308239	148	76	-	-	HYPH
10_1101-2020_09_23_308239	148	77	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	148	78	pathology	pathology	NN
10_1101-2020_09_23_308239	148	79	.	.	.
10_1101-2020_09_23_308239	149	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	149	2	-	-	:
10_1101-2020_09_23_308239	149	3	BY	by	IN
10_1101-2020_09_23_308239	149	4	-	-	HYPH
10_1101-2020_09_23_308239	149	5	NC	NC	NNP
10_1101-2020_09_23_308239	149	6	-	-	HYPH
10_1101-2020_09_23_308239	149	7	ND	ND	NNP
10_1101-2020_09_23_308239	149	8	4.0	4.0	CD
10_1101-2020_09_23_308239	149	9	International	international	JJ
10_1101-2020_09_23_308239	149	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	149	11	.	.	.
10_1101-2020_09_23_308239	150	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	150	2	is	be	VBZ
10_1101-2020_09_23_308239	150	3	made	make	VBN
10_1101-2020_09_23_308239	150	4	available	available	JJ
10_1101-2020_09_23_308239	150	5	under	under	IN
10_1101-2020_09_23_308239	150	6	a	a	DT
10_1101-2020_09_23_308239	150	7	preprint	preprint	NN
10_1101-2020_09_23_308239	150	8	(	(	-LRB-
10_1101-2020_09_23_308239	150	9	which	which	WDT
10_1101-2020_09_23_308239	150	10	was	be	VBD
10_1101-2020_09_23_308239	150	11	not	not	RB
10_1101-2020_09_23_308239	150	12	certified	certify	VBN
10_1101-2020_09_23_308239	150	13	by	by	IN
10_1101-2020_09_23_308239	150	14	peer	peer	NN
10_1101-2020_09_23_308239	150	15	review	review	NN
10_1101-2020_09_23_308239	150	16	)	)	-RRB-
10_1101-2020_09_23_308239	150	17	is	be	VBZ
10_1101-2020_09_23_308239	150	18	the	the	DT
10_1101-2020_09_23_308239	150	19	author	author	NN
10_1101-2020_09_23_308239	150	20	/	/	SYM
10_1101-2020_09_23_308239	150	21	funder	funder	NN
10_1101-2020_09_23_308239	150	22	,	,	,
10_1101-2020_09_23_308239	150	23	who	who	WP
10_1101-2020_09_23_308239	150	24	has	have	VBZ
10_1101-2020_09_23_308239	150	25	granted	grant	VBN
10_1101-2020_09_23_308239	150	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	150	27	a	a	DT
10_1101-2020_09_23_308239	150	28	license	license	NN
10_1101-2020_09_23_308239	150	29	to	to	TO
10_1101-2020_09_23_308239	150	30	display	display	VB
10_1101-2020_09_23_308239	150	31	the	the	DT
10_1101-2020_09_23_308239	150	32	preprint	preprint	NN
10_1101-2020_09_23_308239	150	33	in	in	IN
10_1101-2020_09_23_308239	150	34	The	the	DT
10_1101-2020_09_23_308239	150	35	copyright	copyright	NN
10_1101-2020_09_23_308239	150	36	holder	holder	NN
10_1101-2020_09_23_308239	150	37	for	for	IN
10_1101-2020_09_23_308239	150	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	150	39	version	version	NN
10_1101-2020_09_23_308239	150	40	posted	post	VBD
10_1101-2020_09_23_308239	150	41	February	February	NNP
10_1101-2020_09_23_308239	150	42	12	12	CD
10_1101-2020_09_23_308239	150	43	,	,	,
10_1101-2020_09_23_308239	150	44	2021	2021	CD
10_1101-2020_09_23_308239	150	45	.	.	.
10_1101-2020_09_23_308239	150	46	;	;	:
10_1101-2020_09_23_308239	150	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	150	48	:	:	:
10_1101-2020_09_23_308239	150	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	150	50	preprint	preprint	NN
10_1101-2020_09_23_308239	150	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	150	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	150	53	21	21	CD
10_1101-2020_09_23_308239	150	54	Discussion	Discussion	NNP
10_1101-2020_09_23_308239	150	55	By	by	IN
10_1101-2020_09_23_308239	150	56	combining	combine	VBG
10_1101-2020_09_23_308239	150	57	a	a	DT
10_1101-2020_09_23_308239	150	58	significant	significant	JJ
10_1101-2020_09_23_308239	150	59	number	number	NN
10_1101-2020_09_23_308239	150	60	of	of	IN
10_1101-2020_09_23_308239	150	61	knowledge	knowledge	NN
10_1101-2020_09_23_308239	150	62	graphs	graph	NNS
10_1101-2020_09_23_308239	150	63	which	which	WDT
10_1101-2020_09_23_308239	150	64	represent	represent	VBP
10_1101-2020_09_23_308239	150	65	various	various	JJ
10_1101-2020_09_23_308239	150	66	aspects	aspect	NNS
10_1101-2020_09_23_308239	150	67	of	of	IN
10_1101-2020_09_23_308239	150	68	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	150	69	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	150	70	and	and	CC
10_1101-2020_09_23_308239	150	71	drug	drug	NN
10_1101-2020_09_23_308239	150	72	-	-	HYPH
10_1101-2020_09_23_308239	150	73	target	target	NN
10_1101-2020_09_23_308239	150	74	information	information	NN
10_1101-2020_09_23_308239	150	75	we	-PRON-	PRP
10_1101-2020_09_23_308239	150	76	were	be	VBD
10_1101-2020_09_23_308239	150	77	able	able	JJ
10_1101-2020_09_23_308239	150	78	to	to	TO
10_1101-2020_09_23_308239	150	79	generate	generate	VB
10_1101-2020_09_23_308239	150	80	the	the	DT
10_1101-2020_09_23_308239	150	81	COVID-	COVID-	NNP
10_1101-2020_09_23_308239	150	82	19	19	CD
10_1101-2020_09_23_308239	150	83	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	150	84	,	,	,
10_1101-2020_09_23_308239	150	85	a	a	DT
10_1101-2020_09_23_308239	150	86	unique	unique	JJ
10_1101-2020_09_23_308239	150	87	resource	resource	NN
10_1101-2020_09_23_308239	150	88	that	that	WDT
10_1101-2020_09_23_308239	150	89	covers	cover	VBZ
10_1101-2020_09_23_308239	150	90	a	a	DT
10_1101-2020_09_23_308239	150	91	wide	wide	JJ
10_1101-2020_09_23_308239	150	92	spectrum	spectrum	NN
10_1101-2020_09_23_308239	150	93	of	of	IN
10_1101-2020_09_23_308239	150	94	cause	cause	NN
10_1101-2020_09_23_308239	150	95	-	-	HYPH
10_1101-2020_09_23_308239	150	96	and	and	CC
10_1101-2020_09_23_308239	150	97	-	-	HYPH
10_1101-2020_09_23_308239	150	98	effect	effect	NN
10_1101-2020_09_23_308239	150	99	knowledge	knowledge	NN
10_1101-2020_09_23_308239	150	100	about	about	IN
10_1101-2020_09_23_308239	150	101	SARS	SARS	NNP
10_1101-2020_09_23_308239	150	102	-	-	HYPH
10_1101-2020_09_23_308239	150	103	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	150	104	and	and	CC
10_1101-2020_09_23_308239	150	105	its	-PRON-	PRP$
10_1101-2020_09_23_308239	150	106	interactions	interaction	NNS
10_1101-2020_09_23_308239	150	107	with	with	IN
10_1101-2020_09_23_308239	150	108	the	the	DT
10_1101-2020_09_23_308239	150	109	human	human	JJ
10_1101-2020_09_23_308239	150	110	host	host	NN
10_1101-2020_09_23_308239	150	111	.	.	.
10_1101-2020_09_23_308239	151	1	Based	base	VBN
10_1101-2020_09_23_308239	151	2	on	on	IN
10_1101-2020_09_23_308239	151	3	a	a	DT
10_1101-2020_09_23_308239	151	4	systematic	systematic	JJ
10_1101-2020_09_23_308239	151	5	review	review	NN
10_1101-2020_09_23_308239	151	6	of	of	IN
10_1101-2020_09_23_308239	151	7	the	the	DT
10_1101-2020_09_23_308239	151	8	results	result	NNS
10_1101-2020_09_23_308239	151	9	derived	derive	VBN
10_1101-2020_09_23_308239	151	10	from	from	IN
10_1101-2020_09_23_308239	151	11	published	publish	VBN
10_1101-2020_09_23_308239	151	12	drug	drug	NN
10_1101-2020_09_23_308239	151	13	repurposing	repurposing	NN
10_1101-2020_09_23_308239	151	14	screening	screening	NN
10_1101-2020_09_23_308239	151	15	experiments	experiment	NNS
10_1101-2020_09_23_308239	151	16	,	,	,
10_1101-2020_09_23_308239	151	17	as	as	RB
10_1101-2020_09_23_308239	151	18	well	well	RB
10_1101-2020_09_23_308239	151	19	as	as	IN
10_1101-2020_09_23_308239	151	20	our	-PRON-	PRP$
10_1101-2020_09_23_308239	151	21	own	own	JJ
10_1101-2020_09_23_308239	151	22	drug	drug	NN
10_1101-2020_09_23_308239	151	23	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	151	24	screening	screening	NN
10_1101-2020_09_23_308239	151	25	results	result	NNS
10_1101-2020_09_23_308239	151	26	,	,	,
10_1101-2020_09_23_308239	151	27	we	-PRON-	PRP
10_1101-2020_09_23_308239	151	28	were	be	VBD
10_1101-2020_09_23_308239	151	29	able	able	JJ
10_1101-2020_09_23_308239	151	30	to	to	TO
10_1101-2020_09_23_308239	151	31	identify	identify	VB
10_1101-2020_09_23_308239	151	32	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	151	33	targeted	target	VBN
10_1101-2020_09_23_308239	151	34	by	by	IN
10_1101-2020_09_23_308239	151	35	a	a	DT
10_1101-2020_09_23_308239	151	36	variety	variety	NN
10_1101-2020_09_23_308239	151	37	of	of	IN
10_1101-2020_09_23_308239	151	38	compounds	compound	NNS
10_1101-2020_09_23_308239	151	39	showing	show	VBG
10_1101-2020_09_23_308239	151	40	virus	virus	NN
10_1101-2020_09_23_308239	151	41	inhibition	inhibition	NN
10_1101-2020_09_23_308239	151	42	in	in	IN
10_1101-2020_09_23_308239	151	43	phenotypic	phenotypic	JJ
10_1101-2020_09_23_308239	151	44	,	,	,
10_1101-2020_09_23_308239	151	45	cellular	cellular	JJ
10_1101-2020_09_23_308239	151	46	assays	assay	NNS
10_1101-2020_09_23_308239	151	47	.	.	.
10_1101-2020_09_23_308239	152	1	With	with	IN
10_1101-2020_09_23_308239	152	2	the	the	DT
10_1101-2020_09_23_308239	152	3	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	152	4	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	152	5	,	,	,
10_1101-2020_09_23_308239	152	6	we	-PRON-	PRP
10_1101-2020_09_23_308239	152	7	are	be	VBP
10_1101-2020_09_23_308239	152	8	now	now	RB
10_1101-2020_09_23_308239	152	9	able	able	JJ
10_1101-2020_09_23_308239	152	10	to	to	TO
10_1101-2020_09_23_308239	152	11	link	link	VB
10_1101-2020_09_23_308239	152	12	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	152	13	drugs	drug	NNS
10_1101-2020_09_23_308239	152	14	,	,	,
10_1101-2020_09_23_308239	152	15	their	-PRON-	PRP$
10_1101-2020_09_23_308239	152	16	targets	target	NNS
10_1101-2020_09_23_308239	152	17	and	and	CC
10_1101-2020_09_23_308239	152	18	the	the	DT
10_1101-2020_09_23_308239	152	19	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	152	20	modulated	modulate	VBN
10_1101-2020_09_23_308239	152	21	by	by	IN
10_1101-2020_09_23_308239	152	22	said	say	VBD
10_1101-2020_09_23_308239	152	23	drugs	drug	NNS
10_1101-2020_09_23_308239	152	24	within	within	IN
10_1101-2020_09_23_308239	152	25	one	one	CD
10_1101-2020_09_23_308239	152	26	computable	computable	JJ
10_1101-2020_09_23_308239	152	27	data	data	NN
10_1101-2020_09_23_308239	152	28	structure	structure	NN
10_1101-2020_09_23_308239	152	29	,	,	,
10_1101-2020_09_23_308239	152	30	thereby	thereby	RB
10_1101-2020_09_23_308239	152	31	enabling	enable	VBG
10_1101-2020_09_23_308239	152	32	us	-PRON-	PRP
10_1101-2020_09_23_308239	152	33	to	to	TO
10_1101-2020_09_23_308239	152	34	target	target	VB
10_1101-2020_09_23_308239	152	35	-	-	:
10_1101-2020_09_23_308239	152	36	in	in	IN
10_1101-2020_09_23_308239	152	37	a	a	DT
10_1101-2020_09_23_308239	152	38	combinatorial	combinatorial	JJ
10_1101-2020_09_23_308239	152	39	treatment	treatment	NN
10_1101-2020_09_23_308239	152	40	approach	approach	NN
10_1101-2020_09_23_308239	152	41	-	-	HYPH
10_1101-2020_09_23_308239	152	42	different	different	JJ
10_1101-2020_09_23_308239	152	43	,	,	,
10_1101-2020_09_23_308239	152	44	independent	independent	JJ
10_1101-2020_09_23_308239	152	45	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	152	46	.	.	.
10_1101-2020_09_23_308239	153	1	By	by	IN
10_1101-2020_09_23_308239	153	2	challenging	challenge	VBG
10_1101-2020_09_23_308239	153	3	the	the	DT
10_1101-2020_09_23_308239	153	4	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	153	5	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	153	6	with	with	IN
10_1101-2020_09_23_308239	153	7	gene	gene	NN
10_1101-2020_09_23_308239	153	8	expression	expression	NN
10_1101-2020_09_23_308239	153	9	data	datum	NNS
10_1101-2020_09_23_308239	153	10	,	,	,
10_1101-2020_09_23_308239	153	11	we	-PRON-	PRP
10_1101-2020_09_23_308239	153	12	have	have	VBP
10_1101-2020_09_23_308239	153	13	identified	identify	VBN
10_1101-2020_09_23_308239	153	14	subgraphs	subgraph	NNS
10_1101-2020_09_23_308239	153	15	that	that	WDT
10_1101-2020_09_23_308239	153	16	are	be	VBP
10_1101-2020_09_23_308239	153	17	responsive	responsive	JJ
10_1101-2020_09_23_308239	153	18	(	(	-LRB-
10_1101-2020_09_23_308239	153	19	at	at	IN
10_1101-2020_09_23_308239	153	20	gene	gene	NN
10_1101-2020_09_23_308239	153	21	expression	expression	NN
10_1101-2020_09_23_308239	153	22	level	level	NN
10_1101-2020_09_23_308239	153	23	)	)	-RRB-
10_1101-2020_09_23_308239	153	24	to	to	IN
10_1101-2020_09_23_308239	153	25	virus	virus	NN
10_1101-2020_09_23_308239	153	26	infection	infection	NN
10_1101-2020_09_23_308239	153	27	.	.	.
10_1101-2020_09_23_308239	154	1	Network	network	NN
10_1101-2020_09_23_308239	154	2	analysis	analysis	NN
10_1101-2020_09_23_308239	154	3	along	along	IN
10_1101-2020_09_23_308239	154	4	with	with	IN
10_1101-2020_09_23_308239	154	5	the	the	DT
10_1101-2020_09_23_308239	154	6	overview	overview	NN
10_1101-2020_09_23_308239	154	7	on	on	IN
10_1101-2020_09_23_308239	154	8	previous	previous	JJ
10_1101-2020_09_23_308239	154	9	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	154	10	experiments	experiment	NNS
10_1101-2020_09_23_308239	154	11	provided	provide	VBD
10_1101-2020_09_23_308239	154	12	us	-PRON-	PRP
10_1101-2020_09_23_308239	154	13	with	with	IN
10_1101-2020_09_23_308239	154	14	the	the	DT
10_1101-2020_09_23_308239	154	15	insights	insight	NNS
10_1101-2020_09_23_308239	154	16	needed	need	VBN
10_1101-2020_09_23_308239	154	17	to	to	TO
10_1101-2020_09_23_308239	154	18	select	select	VB
10_1101-2020_09_23_308239	154	19	the	the	DT
10_1101-2020_09_23_308239	154	20	optimal	optimal	NN
10_1101-2020_09_23_308239	154	21	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	154	22	drug	drug	NN
10_1101-2020_09_23_308239	154	23	candidates	candidate	NNS
10_1101-2020_09_23_308239	154	24	for	for	IN
10_1101-2020_09_23_308239	154	25	combination	combination	NN
10_1101-2020_09_23_308239	154	26	therapy	therapy	NN
10_1101-2020_09_23_308239	154	27	.	.	.
10_1101-2020_09_23_308239	155	1	Experimental	experimental	JJ
10_1101-2020_09_23_308239	155	2	verification	verification	NN
10_1101-2020_09_23_308239	155	3	showed	show	VBD
10_1101-2020_09_23_308239	155	4	that	that	IN
10_1101-2020_09_23_308239	155	5	this	this	DT
10_1101-2020_09_23_308239	155	6	systematic	systematic	JJ
10_1101-2020_09_23_308239	155	7	approach	approach	NN
10_1101-2020_09_23_308239	155	8	is	be	VBZ
10_1101-2020_09_23_308239	155	9	valid	valid	JJ
10_1101-2020_09_23_308239	155	10	;	;	:
10_1101-2020_09_23_308239	155	11	we	-PRON-	PRP
10_1101-2020_09_23_308239	155	12	were	be	VBD
10_1101-2020_09_23_308239	155	13	able	able	JJ
10_1101-2020_09_23_308239	155	14	to	to	TO
10_1101-2020_09_23_308239	155	15	identify	identify	VB
10_1101-2020_09_23_308239	155	16	two	two	CD
10_1101-2020_09_23_308239	155	17	drug	drug	NN
10_1101-2020_09_23_308239	155	18	-	-	HYPH
10_1101-2020_09_23_308239	155	19	target	target	NN
10_1101-2020_09_23_308239	155	20	-	-	HYPH
10_1101-2020_09_23_308239	155	21	mechanism	mechanism	NN
10_1101-2020_09_23_308239	155	22	combinations	combination	NNS
10_1101-2020_09_23_308239	155	23	that	that	WDT
10_1101-2020_09_23_308239	155	24	demonstrated	demonstrate	VBD
10_1101-2020_09_23_308239	155	25	synergistic	synergistic	JJ
10_1101-2020_09_23_308239	155	26	action	action	NN
10_1101-2020_09_23_308239	155	27	of	of	IN
10_1101-2020_09_23_308239	155	28	the	the	DT
10_1101-2020_09_23_308239	155	29	repurposed	repurposed	JJ
10_1101-2020_09_23_308239	155	30	drugs	drug	NNS
10_1101-2020_09_23_308239	155	31	targeting	target	VBG
10_1101-2020_09_23_308239	155	32	different	different	JJ
10_1101-2020_09_23_308239	155	33	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	155	34	in	in	IN
10_1101-2020_09_23_308239	155	35	combinatorial	combinatorial	JJ
10_1101-2020_09_23_308239	155	36	treatments	treatment	NNS
10_1101-2020_09_23_308239	155	37	.	.	.
10_1101-2020_09_23_308239	156	1	We	-PRON-	PRP
10_1101-2020_09_23_308239	156	2	are	be	VBP
10_1101-2020_09_23_308239	156	3	fully	fully	RB
10_1101-2020_09_23_308239	156	4	aware	aware	JJ
10_1101-2020_09_23_308239	156	5	of	of	IN
10_1101-2020_09_23_308239	156	6	the	the	DT
10_1101-2020_09_23_308239	156	7	fact	fact	NN
10_1101-2020_09_23_308239	156	8	that	that	IN
10_1101-2020_09_23_308239	156	9	the	the	DT
10_1101-2020_09_23_308239	156	10	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	156	11	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	156	12	combines	combine	VBZ
10_1101-2020_09_23_308239	156	13	experimental	experimental	JJ
10_1101-2020_09_23_308239	156	14	results	result	NNS
10_1101-2020_09_23_308239	156	15	generated	generate	VBN
10_1101-2020_09_23_308239	156	16	in	in	IN
10_1101-2020_09_23_308239	156	17	different	different	JJ
10_1101-2020_09_23_308239	156	18	assay	assay	NN
10_1101-2020_09_23_308239	156	19	conditions	condition	NNS
10_1101-2020_09_23_308239	156	20	.	.	.
10_1101-2020_09_23_308239	157	1	In	in	IN
10_1101-2020_09_23_308239	157	2	the	the	DT
10_1101-2020_09_23_308239	157	3	course	course	NN
10_1101-2020_09_23_308239	157	4	of	of	IN
10_1101-2020_09_23_308239	157	5	our	-PRON-	PRP$
10_1101-2020_09_23_308239	157	6	work	work	NN
10_1101-2020_09_23_308239	157	7	,	,	,
10_1101-2020_09_23_308239	157	8	we	-PRON-	PRP
10_1101-2020_09_23_308239	157	9	accumulated	accumulate	VBD
10_1101-2020_09_23_308239	157	10	evidence	evidence	NN
10_1101-2020_09_23_308239	157	11	that	that	IN
10_1101-2020_09_23_308239	157	12	assay	assay	VBP
10_1101-2020_09_23_308239	157	13	responses	response	NNS
10_1101-2020_09_23_308239	157	14	recorded	record	VBD
10_1101-2020_09_23_308239	157	15	using	use	VBG
10_1101-2020_09_23_308239	157	16	Vero	Vero	NNP
10_1101-2020_09_23_308239	157	17	E6	E6	NNP
10_1101-2020_09_23_308239	157	18	cells	cell	NNS
10_1101-2020_09_23_308239	157	19	in	in	IN
10_1101-2020_09_23_308239	157	20	comparison	comparison	NN
10_1101-2020_09_23_308239	157	21	to	to	IN
10_1101-2020_09_23_308239	157	22	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	157	23	cells	cell	NNS
10_1101-2020_09_23_308239	157	24	may	may	MD
10_1101-2020_09_23_308239	157	25	only	only	RB
10_1101-2020_09_23_308239	157	26	partially	partially	RB
10_1101-2020_09_23_308239	157	27	overlap	overlap	VB
10_1101-2020_09_23_308239	157	28	.	.	.
10_1101-2020_09_23_308239	158	1	Comparative	comparative	JJ
10_1101-2020_09_23_308239	158	2	analysis	analysis	NN
10_1101-2020_09_23_308239	158	3	of	of	IN
10_1101-2020_09_23_308239	158	4	the	the	DT
10_1101-2020_09_23_308239	158	5	results	result	NNS
10_1101-2020_09_23_308239	158	6	of	of	IN
10_1101-2020_09_23_308239	158	7	both	both	DT
10_1101-2020_09_23_308239	158	8	assay	assay	NN
10_1101-2020_09_23_308239	158	9	systems	system	NNS
10_1101-2020_09_23_308239	158	10	to	to	TO
10_1101-2020_09_23_308239	158	11	virus	virus	NN
10_1101-2020_09_23_308239	158	12	infection	infection	NN
10_1101-2020_09_23_308239	158	13	by	by	IN
10_1101-2020_09_23_308239	158	14	means	mean	NNS
10_1101-2020_09_23_308239	158	15	of	of	IN
10_1101-2020_09_23_308239	158	16	transcriptome	transcriptome	RBS
10_1101-2020_09_23_308239	158	17	-	-	HYPH
10_1101-2020_09_23_308239	158	18	wide	wide	JJ
10_1101-2020_09_23_308239	158	19	gene	gene	NN
10_1101-2020_09_23_308239	158	20	expression	expression	NN
10_1101-2020_09_23_308239	158	21	analysis	analysis	NN
10_1101-2020_09_23_308239	158	22	is	be	VBZ
10_1101-2020_09_23_308239	158	23	one	one	CD
10_1101-2020_09_23_308239	158	24	of	of	IN
10_1101-2020_09_23_308239	158	25	the	the	DT
10_1101-2020_09_23_308239	158	26	experiments	experiment	NNS
10_1101-2020_09_23_308239	158	27	.CC	.CC	NFP
10_1101-2020_09_23_308239	158	28	-	-	:
10_1101-2020_09_23_308239	158	29	BY	by	IN
10_1101-2020_09_23_308239	158	30	-	-	HYPH
10_1101-2020_09_23_308239	158	31	NC	NC	NNP
10_1101-2020_09_23_308239	158	32	-	-	HYPH
10_1101-2020_09_23_308239	158	33	ND	ND	NNP
10_1101-2020_09_23_308239	158	34	4.0	4.0	CD
10_1101-2020_09_23_308239	158	35	International	international	JJ
10_1101-2020_09_23_308239	158	36	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	158	37	.	.	.
10_1101-2020_09_23_308239	159	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	159	2	is	be	VBZ
10_1101-2020_09_23_308239	159	3	made	make	VBN
10_1101-2020_09_23_308239	159	4	available	available	JJ
10_1101-2020_09_23_308239	159	5	under	under	IN
10_1101-2020_09_23_308239	159	6	a	a	DT
10_1101-2020_09_23_308239	159	7	preprint	preprint	NN
10_1101-2020_09_23_308239	159	8	(	(	-LRB-
10_1101-2020_09_23_308239	159	9	which	which	WDT
10_1101-2020_09_23_308239	159	10	was	be	VBD
10_1101-2020_09_23_308239	159	11	not	not	RB
10_1101-2020_09_23_308239	159	12	certified	certify	VBN
10_1101-2020_09_23_308239	159	13	by	by	IN
10_1101-2020_09_23_308239	159	14	peer	peer	NN
10_1101-2020_09_23_308239	159	15	review	review	NN
10_1101-2020_09_23_308239	159	16	)	)	-RRB-
10_1101-2020_09_23_308239	159	17	is	be	VBZ
10_1101-2020_09_23_308239	159	18	the	the	DT
10_1101-2020_09_23_308239	159	19	author	author	NN
10_1101-2020_09_23_308239	159	20	/	/	SYM
10_1101-2020_09_23_308239	159	21	funder	funder	NN
10_1101-2020_09_23_308239	159	22	,	,	,
10_1101-2020_09_23_308239	159	23	who	who	WP
10_1101-2020_09_23_308239	159	24	has	have	VBZ
10_1101-2020_09_23_308239	159	25	granted	grant	VBN
10_1101-2020_09_23_308239	159	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	159	27	a	a	DT
10_1101-2020_09_23_308239	159	28	license	license	NN
10_1101-2020_09_23_308239	159	29	to	to	TO
10_1101-2020_09_23_308239	159	30	display	display	VB
10_1101-2020_09_23_308239	159	31	the	the	DT
10_1101-2020_09_23_308239	159	32	preprint	preprint	NN
10_1101-2020_09_23_308239	159	33	in	in	IN
10_1101-2020_09_23_308239	159	34	The	the	DT
10_1101-2020_09_23_308239	159	35	copyright	copyright	NN
10_1101-2020_09_23_308239	159	36	holder	holder	NN
10_1101-2020_09_23_308239	159	37	for	for	IN
10_1101-2020_09_23_308239	159	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	159	39	version	version	NN
10_1101-2020_09_23_308239	159	40	posted	post	VBD
10_1101-2020_09_23_308239	159	41	February	February	NNP
10_1101-2020_09_23_308239	159	42	12	12	CD
10_1101-2020_09_23_308239	159	43	,	,	,
10_1101-2020_09_23_308239	159	44	2021	2021	CD
10_1101-2020_09_23_308239	159	45	.	.	.
10_1101-2020_09_23_308239	159	46	;	;	:
10_1101-2020_09_23_308239	159	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	159	48	:	:	:
10_1101-2020_09_23_308239	159	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	159	50	preprint	preprint	NN
10_1101-2020_09_23_308239	159	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	159	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	159	53	22	22	CD
10_1101-2020_09_23_308239	159	54	we	-PRON-	PRP
10_1101-2020_09_23_308239	159	55	plan	plan	VBP
10_1101-2020_09_23_308239	159	56	to	to	TO
10_1101-2020_09_23_308239	159	57	perform	perform	VB
10_1101-2020_09_23_308239	159	58	next	next	RB
10_1101-2020_09_23_308239	159	59	.	.	.
10_1101-2020_09_23_308239	160	1	However	however	RB
10_1101-2020_09_23_308239	160	2	,	,	,
10_1101-2020_09_23_308239	160	3	for	for	IN
10_1101-2020_09_23_308239	160	4	the	the	DT
10_1101-2020_09_23_308239	160	5	identification	identification	NN
10_1101-2020_09_23_308239	160	6	of	of	IN
10_1101-2020_09_23_308239	160	7	meaningful	meaningful	JJ
10_1101-2020_09_23_308239	160	8	combinations	combination	NNS
10_1101-2020_09_23_308239	160	9	of	of	IN
10_1101-2020_09_23_308239	160	10	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	160	11	drugs	drug	NNS
10_1101-2020_09_23_308239	160	12	,	,	,
10_1101-2020_09_23_308239	160	13	the	the	DT
10_1101-2020_09_23_308239	160	14	current	current	JJ
10_1101-2020_09_23_308239	160	15	model	model	NN
10_1101-2020_09_23_308239	160	16	-	-	HYPH
10_1101-2020_09_23_308239	160	17	driven	drive	VBN
10_1101-2020_09_23_308239	160	18	information	information	NN
10_1101-2020_09_23_308239	160	19	fusion	fusion	NN
10_1101-2020_09_23_308239	160	20	approach	approach	NN
10_1101-2020_09_23_308239	160	21	was	be	VBD
10_1101-2020_09_23_308239	160	22	shown	show	VBN
10_1101-2020_09_23_308239	160	23	to	to	IN
10_1101-2020_09_23_308239	160	24	work	work	VB
10_1101-2020_09_23_308239	160	25	well	well	RB
10_1101-2020_09_23_308239	160	26	despite	despite	IN
10_1101-2020_09_23_308239	160	27	the	the	DT
10_1101-2020_09_23_308239	160	28	putative	putative	JJ
10_1101-2020_09_23_308239	160	29	differences	difference	NNS
10_1101-2020_09_23_308239	160	30	between	between	IN
10_1101-2020_09_23_308239	160	31	drug	drug	NN
10_1101-2020_09_23_308239	160	32	repurposing	repurposing	NN
10_1101-2020_09_23_308239	160	33	screening	screening	NN
10_1101-2020_09_23_308239	160	34	assays	assays	RB
10_1101-2020_09_23_308239	160	35	.	.	.
10_1101-2020_09_23_308239	161	1	Given	give	VBN
10_1101-2020_09_23_308239	161	2	the	the	DT
10_1101-2020_09_23_308239	161	3	urgent	urgent	JJ
10_1101-2020_09_23_308239	161	4	need	need	NN
10_1101-2020_09_23_308239	161	5	for	for	IN
10_1101-2020_09_23_308239	161	6	treatments	treatment	NNS
10_1101-2020_09_23_308239	161	7	that	that	WDT
10_1101-2020_09_23_308239	161	8	work	work	VBP
10_1101-2020_09_23_308239	161	9	in	in	IN
10_1101-2020_09_23_308239	161	10	an	an	DT
10_1101-2020_09_23_308239	161	11	acute	acute	JJ
10_1101-2020_09_23_308239	161	12	infection	infection	NN
10_1101-2020_09_23_308239	161	13	situation	situation	NN
10_1101-2020_09_23_308239	161	14	,	,	,
10_1101-2020_09_23_308239	161	15	our	-PRON-	PRP$
10_1101-2020_09_23_308239	161	16	approach	approach	NN
10_1101-2020_09_23_308239	161	17	described	describe	VBN
10_1101-2020_09_23_308239	161	18	here	here	RB
10_1101-2020_09_23_308239	161	19	paves	pave	VBZ
10_1101-2020_09_23_308239	161	20	the	the	DT
10_1101-2020_09_23_308239	161	21	way	way	NN
10_1101-2020_09_23_308239	161	22	for	for	IN
10_1101-2020_09_23_308239	161	23	systematic	systematic	JJ
10_1101-2020_09_23_308239	161	24	and	and	CC
10_1101-2020_09_23_308239	161	25	rational	rational	JJ
10_1101-2020_09_23_308239	161	26	approaches	approach	NNS
10_1101-2020_09_23_308239	161	27	towards	towards	IN
10_1101-2020_09_23_308239	161	28	combination	combination	NN
10_1101-2020_09_23_308239	161	29	therapy	therapy	NN
10_1101-2020_09_23_308239	161	30	of	of	IN
10_1101-2020_09_23_308239	161	31	SARS	SARS	NNP
10_1101-2020_09_23_308239	161	32	-	-	HYPH
10_1101-2020_09_23_308239	161	33	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	161	34	infections	infection	NNS
10_1101-2020_09_23_308239	161	35	.	.	.
10_1101-2020_09_23_308239	162	1	We	-PRON-	PRP
10_1101-2020_09_23_308239	162	2	want	want	VBP
10_1101-2020_09_23_308239	162	3	to	to	TO
10_1101-2020_09_23_308239	162	4	encourage	encourage	VB
10_1101-2020_09_23_308239	162	5	all	all	PDT
10_1101-2020_09_23_308239	162	6	our	-PRON-	PRP$
10_1101-2020_09_23_308239	162	7	colleagues	colleague	NNS
10_1101-2020_09_23_308239	162	8	to	to	TO
10_1101-2020_09_23_308239	162	9	make	make	VB
10_1101-2020_09_23_308239	162	10	use	use	NN
10_1101-2020_09_23_308239	162	11	of	of	IN
10_1101-2020_09_23_308239	162	12	the	the	DT
10_1101-2020_09_23_308239	162	13	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	162	14	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	162	15	,	,	,
10_1101-2020_09_23_308239	162	16	improve	improve	VB
10_1101-2020_09_23_308239	162	17	it	-PRON-	PRP
10_1101-2020_09_23_308239	162	18	,	,	,
10_1101-2020_09_23_308239	162	19	and	and	CC
10_1101-2020_09_23_308239	162	20	add	add	VB
10_1101-2020_09_23_308239	162	21	useful	useful	JJ
10_1101-2020_09_23_308239	162	22	information	information	NN
10_1101-2020_09_23_308239	162	23	about	about	IN
10_1101-2020_09_23_308239	162	24	pharmacological	pharmacological	JJ
10_1101-2020_09_23_308239	162	25	findings	finding	NNS
10_1101-2020_09_23_308239	162	26	(	(	-LRB-
10_1101-2020_09_23_308239	162	27	e.g.	e.g.	RB
10_1101-2020_09_23_308239	163	1	from	from	IN
10_1101-2020_09_23_308239	163	2	candidate	candidate	NN
10_1101-2020_09_23_308239	163	3	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	163	4	drug	drug	NN
10_1101-2020_09_23_308239	163	5	combination	combination	NN
10_1101-2020_09_23_308239	163	6	screenings	screening	NNS
10_1101-2020_09_23_308239	163	7	)	)	-RRB-
10_1101-2020_09_23_308239	163	8	.	.	.
10_1101-2020_09_23_308239	164	1	In	in	IN
10_1101-2020_09_23_308239	164	2	addition	addition	NN
10_1101-2020_09_23_308239	164	3	to	to	IN
10_1101-2020_09_23_308239	164	4	vaccination	vaccination	NN
10_1101-2020_09_23_308239	164	5	and	and	CC
10_1101-2020_09_23_308239	164	6	antibody	antibody	NN
10_1101-2020_09_23_308239	164	7	therapy	therapy	NN
10_1101-2020_09_23_308239	164	8	,	,	,
10_1101-2020_09_23_308239	164	9	(	(	-LRB-
10_1101-2020_09_23_308239	164	10	combination	combination	NN
10_1101-2020_09_23_308239	164	11	)	)	-RRB-
10_1101-2020_09_23_308239	164	12	treatment	treatment	NN
10_1101-2020_09_23_308239	164	13	with	with	IN
10_1101-2020_09_23_308239	164	14	small	small	JJ
10_1101-2020_09_23_308239	164	15	molecules	molecule	NNS
10_1101-2020_09_23_308239	164	16	remains	remain	VBZ
10_1101-2020_09_23_308239	164	17	one	one	CD
10_1101-2020_09_23_308239	164	18	of	of	IN
10_1101-2020_09_23_308239	164	19	the	the	DT
10_1101-2020_09_23_308239	164	20	key	key	JJ
10_1101-2020_09_23_308239	164	21	therapeutic	therapeutic	JJ
10_1101-2020_09_23_308239	164	22	options	option	NNS
10_1101-2020_09_23_308239	164	23	for	for	IN
10_1101-2020_09_23_308239	164	24	combatting	combat	VBG
10_1101-2020_09_23_308239	164	25	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	164	26	.	.	.
10_1101-2020_09_23_308239	165	1	The	the	DT
10_1101-2020_09_23_308239	165	2	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	165	3	PHARMACOME	PHARMACOME	NNP
10_1101-2020_09_23_308239	165	4	will	will	MD
10_1101-2020_09_23_308239	165	5	therefore	therefore	RB
10_1101-2020_09_23_308239	165	6	be	be	VB
10_1101-2020_09_23_308239	165	7	continuously	continuously	RB
10_1101-2020_09_23_308239	165	8	improved	improve	VBN
10_1101-2020_09_23_308239	165	9	and	and	CC
10_1101-2020_09_23_308239	165	10	expanded	expand	VBN
10_1101-2020_09_23_308239	165	11	to	to	TO
10_1101-2020_09_23_308239	165	12	serve	serve	VB
10_1101-2020_09_23_308239	165	13	integrative	integrative	JJ
10_1101-2020_09_23_308239	165	14	approaches	approach	NNS
10_1101-2020_09_23_308239	165	15	in	in	IN
10_1101-2020_09_23_308239	165	16	anti	anti	JJ
10_1101-2020_09_23_308239	165	17	-	-	NNP
10_1101-2020_09_23_308239	165	18	SARS	SARS	NNP
10_1101-2020_09_23_308239	165	19	-	-	HYPH
10_1101-2020_09_23_308239	165	20	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	165	21	drug	drug	NN
10_1101-2020_09_23_308239	165	22	discovery	discovery	NN
10_1101-2020_09_23_308239	165	23	and	and	CC
10_1101-2020_09_23_308239	165	24	development	development	NN
10_1101-2020_09_23_308239	165	25	.	.	.
10_1101-2020_09_23_308239	166	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	166	2	-	-	:
10_1101-2020_09_23_308239	166	3	BY	by	IN
10_1101-2020_09_23_308239	166	4	-	-	HYPH
10_1101-2020_09_23_308239	166	5	NC	NC	NNP
10_1101-2020_09_23_308239	166	6	-	-	HYPH
10_1101-2020_09_23_308239	166	7	ND	ND	NNP
10_1101-2020_09_23_308239	166	8	4.0	4.0	CD
10_1101-2020_09_23_308239	166	9	International	international	JJ
10_1101-2020_09_23_308239	166	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	166	11	.	.	.
10_1101-2020_09_23_308239	167	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	167	2	is	be	VBZ
10_1101-2020_09_23_308239	167	3	made	make	VBN
10_1101-2020_09_23_308239	167	4	available	available	JJ
10_1101-2020_09_23_308239	167	5	under	under	IN
10_1101-2020_09_23_308239	167	6	a	a	DT
10_1101-2020_09_23_308239	167	7	preprint	preprint	NN
10_1101-2020_09_23_308239	167	8	(	(	-LRB-
10_1101-2020_09_23_308239	167	9	which	which	WDT
10_1101-2020_09_23_308239	167	10	was	be	VBD
10_1101-2020_09_23_308239	167	11	not	not	RB
10_1101-2020_09_23_308239	167	12	certified	certify	VBN
10_1101-2020_09_23_308239	167	13	by	by	IN
10_1101-2020_09_23_308239	167	14	peer	peer	NN
10_1101-2020_09_23_308239	167	15	review	review	NN
10_1101-2020_09_23_308239	167	16	)	)	-RRB-
10_1101-2020_09_23_308239	167	17	is	be	VBZ
10_1101-2020_09_23_308239	167	18	the	the	DT
10_1101-2020_09_23_308239	167	19	author	author	NN
10_1101-2020_09_23_308239	167	20	/	/	SYM
10_1101-2020_09_23_308239	167	21	funder	funder	NN
10_1101-2020_09_23_308239	167	22	,	,	,
10_1101-2020_09_23_308239	167	23	who	who	WP
10_1101-2020_09_23_308239	167	24	has	have	VBZ
10_1101-2020_09_23_308239	167	25	granted	grant	VBN
10_1101-2020_09_23_308239	167	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	167	27	a	a	DT
10_1101-2020_09_23_308239	167	28	license	license	NN
10_1101-2020_09_23_308239	167	29	to	to	TO
10_1101-2020_09_23_308239	167	30	display	display	VB
10_1101-2020_09_23_308239	167	31	the	the	DT
10_1101-2020_09_23_308239	167	32	preprint	preprint	NN
10_1101-2020_09_23_308239	167	33	in	in	IN
10_1101-2020_09_23_308239	167	34	The	the	DT
10_1101-2020_09_23_308239	167	35	copyright	copyright	NN
10_1101-2020_09_23_308239	167	36	holder	holder	NN
10_1101-2020_09_23_308239	167	37	for	for	IN
10_1101-2020_09_23_308239	167	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	167	39	version	version	NN
10_1101-2020_09_23_308239	167	40	posted	post	VBD
10_1101-2020_09_23_308239	167	41	February	February	NNP
10_1101-2020_09_23_308239	167	42	12	12	CD
10_1101-2020_09_23_308239	167	43	,	,	,
10_1101-2020_09_23_308239	167	44	2021	2021	CD
10_1101-2020_09_23_308239	167	45	.	.	.
10_1101-2020_09_23_308239	167	46	;	;	:
10_1101-2020_09_23_308239	167	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	167	48	:	:	:
10_1101-2020_09_23_308239	167	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	167	50	preprint	preprint	NN
10_1101-2020_09_23_308239	167	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	167	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	167	53	23	23	CD
10_1101-2020_09_23_308239	167	54	Acknowledgements	Acknowledgements	NNPS
10_1101-2020_09_23_308239	167	55	In	in	IN
10_1101-2020_09_23_308239	167	56	part	part	NN
10_1101-2020_09_23_308239	167	57	,	,	,
10_1101-2020_09_23_308239	167	58	this	this	DT
10_1101-2020_09_23_308239	167	59	project	project	NN
10_1101-2020_09_23_308239	167	60	is	be	VBZ
10_1101-2020_09_23_308239	167	61	supported	support	VBN
10_1101-2020_09_23_308239	167	62	by	by	IN
10_1101-2020_09_23_308239	167	63	the	the	DT
10_1101-2020_09_23_308239	167	64	European	European	NNP
10_1101-2020_09_23_308239	167	65	Union	Union	NNP
10_1101-2020_09_23_308239	167	66	’s	’s	POS
10_1101-2020_09_23_308239	167	67	Horizon	Horizon	NNP
10_1101-2020_09_23_308239	167	68	2020	2020	CD
10_1101-2020_09_23_308239	167	69	research	research	NN
10_1101-2020_09_23_308239	167	70	and	and	CC
10_1101-2020_09_23_308239	167	71	innovation	innovation	NN
10_1101-2020_09_23_308239	167	72	program	program	NN
10_1101-2020_09_23_308239	167	73	under	under	IN
10_1101-2020_09_23_308239	167	74	grant	grant	NN
10_1101-2020_09_23_308239	167	75	agreement	agreement	NN
10_1101-2020_09_23_308239	167	76	No	no	DT
10_1101-2020_09_23_308239	167	77	101003551	101003551	CD
10_1101-2020_09_23_308239	167	78	,	,	,
10_1101-2020_09_23_308239	167	79	project	project	NN
10_1101-2020_09_23_308239	167	80	Exscalate4CoV.	Exscalate4CoV.	NNP
10_1101-2020_09_23_308239	168	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	168	2	-	-	:
10_1101-2020_09_23_308239	168	3	BY	by	IN
10_1101-2020_09_23_308239	168	4	-	-	HYPH
10_1101-2020_09_23_308239	168	5	NC	NC	NNP
10_1101-2020_09_23_308239	168	6	-	-	HYPH
10_1101-2020_09_23_308239	168	7	ND	ND	NNP
10_1101-2020_09_23_308239	168	8	4.0	4.0	CD
10_1101-2020_09_23_308239	168	9	International	international	JJ
10_1101-2020_09_23_308239	168	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	168	11	.	.	.
10_1101-2020_09_23_308239	169	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	169	2	is	be	VBZ
10_1101-2020_09_23_308239	169	3	made	make	VBN
10_1101-2020_09_23_308239	169	4	available	available	JJ
10_1101-2020_09_23_308239	169	5	under	under	IN
10_1101-2020_09_23_308239	169	6	a	a	DT
10_1101-2020_09_23_308239	169	7	preprint	preprint	NN
10_1101-2020_09_23_308239	169	8	(	(	-LRB-
10_1101-2020_09_23_308239	169	9	which	which	WDT
10_1101-2020_09_23_308239	169	10	was	be	VBD
10_1101-2020_09_23_308239	169	11	not	not	RB
10_1101-2020_09_23_308239	169	12	certified	certify	VBN
10_1101-2020_09_23_308239	169	13	by	by	IN
10_1101-2020_09_23_308239	169	14	peer	peer	NN
10_1101-2020_09_23_308239	169	15	review	review	NN
10_1101-2020_09_23_308239	169	16	)	)	-RRB-
10_1101-2020_09_23_308239	169	17	is	be	VBZ
10_1101-2020_09_23_308239	169	18	the	the	DT
10_1101-2020_09_23_308239	169	19	author	author	NN
10_1101-2020_09_23_308239	169	20	/	/	SYM
10_1101-2020_09_23_308239	169	21	funder	funder	NN
10_1101-2020_09_23_308239	169	22	,	,	,
10_1101-2020_09_23_308239	169	23	who	who	WP
10_1101-2020_09_23_308239	169	24	has	have	VBZ
10_1101-2020_09_23_308239	169	25	granted	grant	VBN
10_1101-2020_09_23_308239	169	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	169	27	a	a	DT
10_1101-2020_09_23_308239	169	28	license	license	NN
10_1101-2020_09_23_308239	169	29	to	to	TO
10_1101-2020_09_23_308239	169	30	display	display	VB
10_1101-2020_09_23_308239	169	31	the	the	DT
10_1101-2020_09_23_308239	169	32	preprint	preprint	NN
10_1101-2020_09_23_308239	169	33	in	in	IN
10_1101-2020_09_23_308239	169	34	The	the	DT
10_1101-2020_09_23_308239	169	35	copyright	copyright	NN
10_1101-2020_09_23_308239	169	36	holder	holder	NN
10_1101-2020_09_23_308239	169	37	for	for	IN
10_1101-2020_09_23_308239	169	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	169	39	version	version	NN
10_1101-2020_09_23_308239	169	40	posted	post	VBD
10_1101-2020_09_23_308239	169	41	February	February	NNP
10_1101-2020_09_23_308239	169	42	12	12	CD
10_1101-2020_09_23_308239	169	43	,	,	,
10_1101-2020_09_23_308239	169	44	2021	2021	CD
10_1101-2020_09_23_308239	169	45	.	.	.
10_1101-2020_09_23_308239	169	46	;	;	:
10_1101-2020_09_23_308239	169	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	169	48	:	:	:
10_1101-2020_09_23_308239	169	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	169	50	preprint	preprint	NN
10_1101-2020_09_23_308239	169	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	169	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	169	53	24	24	CD
10_1101-2020_09_23_308239	169	54	References	reference	NNS
10_1101-2020_09_23_308239	169	55	1	1	CD
10_1101-2020_09_23_308239	169	56	Xu	Xu	NNP
10_1101-2020_09_23_308239	169	57	,	,	,
10_1101-2020_09_23_308239	169	58	B.	B.	NNP
10_1101-2020_09_23_308239	169	59	,	,	,
10_1101-2020_09_23_308239	169	60	Gutierrez	Gutierrez	NNP
10_1101-2020_09_23_308239	169	61	,	,	,
10_1101-2020_09_23_308239	169	62	B.	B.	NNP
10_1101-2020_09_23_308239	169	63	,	,	,
10_1101-2020_09_23_308239	169	64	Mekaru	Mekaru	NNP
10_1101-2020_09_23_308239	169	65	,	,	,
10_1101-2020_09_23_308239	169	66	S.	S.	NNP
10_1101-2020_09_23_308239	169	67	,	,	,
10_1101-2020_09_23_308239	169	68	Sewalk	Sewalk	NNP
10_1101-2020_09_23_308239	169	69	,	,	,
10_1101-2020_09_23_308239	169	70	K.	K.	NNP
10_1101-2020_09_23_308239	169	71	,	,	,
10_1101-2020_09_23_308239	169	72	Goodwin	Goodwin	NNP
10_1101-2020_09_23_308239	169	73	,	,	,
10_1101-2020_09_23_308239	169	74	L.	L.	NNP
10_1101-2020_09_23_308239	169	75	,	,	,
10_1101-2020_09_23_308239	169	76	Loskill	Loskill	NNP
10_1101-2020_09_23_308239	169	77	,	,	,
10_1101-2020_09_23_308239	169	78	A.	A.	NNP
10_1101-2020_09_23_308239	169	79	,	,	,
10_1101-2020_09_23_308239	169	80	...	...	.
10_1101-2020_09_23_308239	169	81	&	&	CC
10_1101-2020_09_23_308239	169	82	Zarebski	Zarebski	NNP
10_1101-2020_09_23_308239	169	83	,	,	,
10_1101-2020_09_23_308239	169	84	A.	A.	NNP
10_1101-2020_09_23_308239	169	85	E.	E.	NNP
10_1101-2020_09_23_308239	169	86	(	(	-LRB-
10_1101-2020_09_23_308239	169	87	2020	2020	CD
10_1101-2020_09_23_308239	169	88	)	)	-RRB-
10_1101-2020_09_23_308239	169	89	.	.	.
10_1101-2020_09_23_308239	170	1	Epidemiological	epidemiological	JJ
10_1101-2020_09_23_308239	170	2	data	datum	NNS
10_1101-2020_09_23_308239	170	3	from	from	IN
10_1101-2020_09_23_308239	170	4	the	the	DT
10_1101-2020_09_23_308239	170	5	COVID-19	covid-19	JJ
10_1101-2020_09_23_308239	170	6	outbreak	outbreak	NN
10_1101-2020_09_23_308239	170	7	,	,	,
10_1101-2020_09_23_308239	170	8	real	real	JJ
10_1101-2020_09_23_308239	170	9	-	-	HYPH
10_1101-2020_09_23_308239	170	10	time	time	NN
10_1101-2020_09_23_308239	170	11	case	case	NN
10_1101-2020_09_23_308239	170	12	information	information	NN
10_1101-2020_09_23_308239	170	13	.	.	.
10_1101-2020_09_23_308239	171	1	Scientific	scientific	JJ
10_1101-2020_09_23_308239	171	2	data	datum	NNS
10_1101-2020_09_23_308239	171	3	,	,	,
10_1101-2020_09_23_308239	171	4	7(1	7(1	NNP
10_1101-2020_09_23_308239	171	5	)	)	-RRB-
10_1101-2020_09_23_308239	171	6	,	,	,
10_1101-2020_09_23_308239	171	7	1	1	CD
10_1101-2020_09_23_308239	171	8	-	-	SYM
10_1101-2020_09_23_308239	171	9	6	6	CD
10_1101-2020_09_23_308239	171	10	.	.	.
10_1101-2020_09_23_308239	172	1	2	2	CD
10_1101-2020_09_23_308239	172	2	Lipsitch	Lipsitch	NNP
10_1101-2020_09_23_308239	172	3	,	,	,
10_1101-2020_09_23_308239	172	4	M.	M.	NNP
10_1101-2020_09_23_308239	172	5	,	,	,
10_1101-2020_09_23_308239	172	6	Swerdlow	Swerdlow	NNP
10_1101-2020_09_23_308239	172	7	,	,	,
10_1101-2020_09_23_308239	172	8	D.	D.	NNP
10_1101-2020_09_23_308239	172	9	L.	L.	NNP
10_1101-2020_09_23_308239	172	10	,	,	,
10_1101-2020_09_23_308239	172	11	&	&	CC
10_1101-2020_09_23_308239	172	12	Finelli	Finelli	NNP
10_1101-2020_09_23_308239	172	13	,	,	,
10_1101-2020_09_23_308239	172	14	L.	L.	NNP
10_1101-2020_09_23_308239	172	15	(	(	-LRB-
10_1101-2020_09_23_308239	172	16	2020	2020	CD
10_1101-2020_09_23_308239	172	17	)	)	-RRB-
10_1101-2020_09_23_308239	172	18	.	.	.
10_1101-2020_09_23_308239	173	1	Defining	define	VBG
10_1101-2020_09_23_308239	173	2	the	the	DT
10_1101-2020_09_23_308239	173	3	epidemiology	epidemiology	NN
10_1101-2020_09_23_308239	173	4	of	of	IN
10_1101-2020_09_23_308239	173	5	Covid-19—studies	Covid-19—studies	NNP
10_1101-2020_09_23_308239	173	6	needed	need	VBD
10_1101-2020_09_23_308239	173	7	.	.	.
10_1101-2020_09_23_308239	174	1	New	New	NNP
10_1101-2020_09_23_308239	174	2	England	England	NNP
10_1101-2020_09_23_308239	174	3	journal	journal	NN
10_1101-2020_09_23_308239	174	4	of	of	IN
10_1101-2020_09_23_308239	174	5	medicine	medicine	NNP
10_1101-2020_09_23_308239	174	6	,	,	,
10_1101-2020_09_23_308239	174	7	382(13	382(13	LS
10_1101-2020_09_23_308239	174	8	)	)	-RRB-
10_1101-2020_09_23_308239	174	9	,	,	,
10_1101-2020_09_23_308239	174	10	1194	1194	CD
10_1101-2020_09_23_308239	174	11	-	-	SYM
10_1101-2020_09_23_308239	174	12	1196	1196	CD
10_1101-2020_09_23_308239	174	13	.	.	.
10_1101-2020_09_23_308239	175	1	3	3	CD
10_1101-2020_09_23_308239	175	2	Holmdahl	Holmdahl	NNP
10_1101-2020_09_23_308239	175	3	,	,	,
10_1101-2020_09_23_308239	175	4	I.	I.	NNP
10_1101-2020_09_23_308239	175	5	,	,	,
10_1101-2020_09_23_308239	175	6	&	&	CC
10_1101-2020_09_23_308239	175	7	Buckee	Buckee	NNP
10_1101-2020_09_23_308239	175	8	,	,	,
10_1101-2020_09_23_308239	175	9	C.	C.	NNP
10_1101-2020_09_23_308239	175	10	(	(	-LRB-
10_1101-2020_09_23_308239	175	11	2020	2020	CD
10_1101-2020_09_23_308239	175	12	)	)	-RRB-
10_1101-2020_09_23_308239	175	13	.	.	.
10_1101-2020_09_23_308239	176	1	Wrong	wrong	JJ
10_1101-2020_09_23_308239	176	2	but	but	CC
10_1101-2020_09_23_308239	176	3	Useful	useful	JJ
10_1101-2020_09_23_308239	176	4	—	—	:
10_1101-2020_09_23_308239	176	5	What	what	WP
10_1101-2020_09_23_308239	176	6	Covid-19	Covid-19	NNP
10_1101-2020_09_23_308239	176	7	Epidemiologic	Epidemiologic	NNP
10_1101-2020_09_23_308239	176	8	Models	Models	NNPS
10_1101-2020_09_23_308239	176	9	Can	Can	MD
10_1101-2020_09_23_308239	176	10	and	and	CC
10_1101-2020_09_23_308239	176	11	Can	can	MD
10_1101-2020_09_23_308239	176	12	not	not	RB
10_1101-2020_09_23_308239	176	13	Tell	tell	VB
10_1101-2020_09_23_308239	176	14	Us	-PRON-	PRP
10_1101-2020_09_23_308239	176	15	.	.	.
10_1101-2020_09_23_308239	177	1	New	New	NNP
10_1101-2020_09_23_308239	177	2	England	England	NNP
10_1101-2020_09_23_308239	177	3	Journal	Journal	NNP
10_1101-2020_09_23_308239	177	4	of	of	IN
10_1101-2020_09_23_308239	177	5	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	177	6	.	.	.
10_1101-2020_09_23_308239	178	1	4	4	CD
10_1101-2020_09_23_308239	178	2	Cao	Cao	NNP
10_1101-2020_09_23_308239	178	3	,	,	,
10_1101-2020_09_23_308239	178	4	W.	W.	NNP
10_1101-2020_09_23_308239	178	5	,	,	,
10_1101-2020_09_23_308239	178	6	&	&	CC
10_1101-2020_09_23_308239	178	7	Li	Li	NNP
10_1101-2020_09_23_308239	178	8	,	,	,
10_1101-2020_09_23_308239	178	9	T.	T.	NNP
10_1101-2020_09_23_308239	178	10	(	(	-LRB-
10_1101-2020_09_23_308239	178	11	2020	2020	CD
10_1101-2020_09_23_308239	178	12	)	)	-RRB-
10_1101-2020_09_23_308239	178	13	.	.	.
10_1101-2020_09_23_308239	179	1	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	179	2	:	:	:
10_1101-2020_09_23_308239	179	3	towards	towards	IN
10_1101-2020_09_23_308239	179	4	understanding	understanding	NN
10_1101-2020_09_23_308239	179	5	of	of	IN
10_1101-2020_09_23_308239	179	6	pathogenesis	pathogenesis	NN
10_1101-2020_09_23_308239	179	7	.	.	.
10_1101-2020_09_23_308239	180	1	Cell	Cell	NNP
10_1101-2020_09_23_308239	180	2	Research	Research	NNP
10_1101-2020_09_23_308239	180	3	,	,	,
10_1101-2020_09_23_308239	180	4	1	1	CD
10_1101-2020_09_23_308239	180	5	-	-	SYM
10_1101-2020_09_23_308239	180	6	3	3	CD
10_1101-2020_09_23_308239	180	7	.	.	.
10_1101-2020_09_23_308239	181	1	5	5	CD
10_1101-2020_09_23_308239	181	2	Liao	Liao	NNP
10_1101-2020_09_23_308239	181	3	,	,	,
10_1101-2020_09_23_308239	181	4	M.	M.	NNP
10_1101-2020_09_23_308239	181	5	,	,	,
10_1101-2020_09_23_308239	181	6	Liu	Liu	NNP
10_1101-2020_09_23_308239	181	7	,	,	,
10_1101-2020_09_23_308239	181	8	Y.	Y.	NNP
10_1101-2020_09_23_308239	181	9	,	,	,
10_1101-2020_09_23_308239	181	10	Yuan	Yuan	NNP
10_1101-2020_09_23_308239	181	11	,	,	,
10_1101-2020_09_23_308239	181	12	J.	J.	NNP
10_1101-2020_09_23_308239	181	13	,	,	,
10_1101-2020_09_23_308239	181	14	Wen	Wen	NNP
10_1101-2020_09_23_308239	181	15	,	,	,
10_1101-2020_09_23_308239	181	16	Y.	Y.	NNP
10_1101-2020_09_23_308239	181	17	,	,	,
10_1101-2020_09_23_308239	181	18	Xu	Xu	NNP
10_1101-2020_09_23_308239	181	19	,	,	,
10_1101-2020_09_23_308239	181	20	G.	G.	NNP
10_1101-2020_09_23_308239	181	21	,	,	,
10_1101-2020_09_23_308239	181	22	Zhao	Zhao	NNP
10_1101-2020_09_23_308239	181	23	,	,	,
10_1101-2020_09_23_308239	181	24	J.	J.	NNP
10_1101-2020_09_23_308239	181	25	,	,	,
10_1101-2020_09_23_308239	181	26	...	...	NFP
10_1101-2020_09_23_308239	181	27	&	&	CC
10_1101-2020_09_23_308239	181	28	Liu	Liu	NNP
10_1101-2020_09_23_308239	181	29	,	,	,
10_1101-2020_09_23_308239	181	30	L.	L.	NNP
10_1101-2020_09_23_308239	181	31	(	(	-LRB-
10_1101-2020_09_23_308239	181	32	2020	2020	CD
10_1101-2020_09_23_308239	181	33	)	)	-RRB-
10_1101-2020_09_23_308239	181	34	.	.	.
10_1101-2020_09_23_308239	182	1	Single	single	JJ
10_1101-2020_09_23_308239	182	2	-	-	HYPH
10_1101-2020_09_23_308239	182	3	cell	cell	NN
10_1101-2020_09_23_308239	182	4	landscape	landscape	NN
10_1101-2020_09_23_308239	182	5	of	of	IN
10_1101-2020_09_23_308239	182	6	bronchoalveolar	bronchoalveolar	JJ
10_1101-2020_09_23_308239	182	7	immune	immune	JJ
10_1101-2020_09_23_308239	182	8	cells	cell	NNS
10_1101-2020_09_23_308239	182	9	in	in	IN
10_1101-2020_09_23_308239	182	10	patients	patient	NNS
10_1101-2020_09_23_308239	182	11	with	with	IN
10_1101-2020_09_23_308239	182	12	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	182	13	.	.	.
10_1101-2020_09_23_308239	183	1	Nature	Nature	NNP
10_1101-2020_09_23_308239	183	2	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	183	3	,	,	,
10_1101-2020_09_23_308239	183	4	1	1	CD
10_1101-2020_09_23_308239	183	5	-	-	SYM
10_1101-2020_09_23_308239	183	6	3	3	CD
10_1101-2020_09_23_308239	183	7	.	.	.
10_1101-2020_09_23_308239	184	1	6	6	CD
10_1101-2020_09_23_308239	184	2	Tay	Tay	NNP
10_1101-2020_09_23_308239	184	3	,	,	,
10_1101-2020_09_23_308239	184	4	M.	M.	NNP
10_1101-2020_09_23_308239	184	5	Z.	Z.	NNP
10_1101-2020_09_23_308239	184	6	,	,	,
10_1101-2020_09_23_308239	184	7	Poh	Poh	NNP
10_1101-2020_09_23_308239	184	8	,	,	,
10_1101-2020_09_23_308239	184	9	C.	C.	NNP
10_1101-2020_09_23_308239	184	10	M.	M.	NNP
10_1101-2020_09_23_308239	184	11	,	,	,
10_1101-2020_09_23_308239	184	12	Rénia	Rénia	NNP
10_1101-2020_09_23_308239	184	13	,	,	,
10_1101-2020_09_23_308239	184	14	L.	L.	NNP
10_1101-2020_09_23_308239	184	15	,	,	,
10_1101-2020_09_23_308239	184	16	MacAry	MacAry	NNP
10_1101-2020_09_23_308239	184	17	,	,	,
10_1101-2020_09_23_308239	184	18	P.	P.	NNP
10_1101-2020_09_23_308239	184	19	A.	A.	NNP
10_1101-2020_09_23_308239	184	20	,	,	,
10_1101-2020_09_23_308239	184	21	&	&	CC
10_1101-2020_09_23_308239	184	22	Ng	Ng	NNP
10_1101-2020_09_23_308239	184	23	,	,	,
10_1101-2020_09_23_308239	184	24	L.	L.	NNP
10_1101-2020_09_23_308239	184	25	F.	F.	NNP
10_1101-2020_09_23_308239	184	26	(	(	-LRB-
10_1101-2020_09_23_308239	184	27	2020	2020	CD
10_1101-2020_09_23_308239	184	28	)	)	-RRB-
10_1101-2020_09_23_308239	184	29	.	.	.
10_1101-2020_09_23_308239	185	1	The	the	DT
10_1101-2020_09_23_308239	185	2	trinity	trinity	NN
10_1101-2020_09_23_308239	185	3	of	of	IN
10_1101-2020_09_23_308239	185	4	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	185	5	:	:	:
10_1101-2020_09_23_308239	185	6	immunity	immunity	NN
10_1101-2020_09_23_308239	185	7	,	,	,
10_1101-2020_09_23_308239	185	8	inflammation	inflammation	NN
10_1101-2020_09_23_308239	185	9	and	and	CC
10_1101-2020_09_23_308239	185	10	intervention	intervention	NN
10_1101-2020_09_23_308239	185	11	.	.	.
10_1101-2020_09_23_308239	186	1	Nature	Nature	NNP
10_1101-2020_09_23_308239	186	2	Reviews	Reviews	NNPS
10_1101-2020_09_23_308239	186	3	Immunology	immunology	NN
10_1101-2020_09_23_308239	186	4	,	,	,
10_1101-2020_09_23_308239	186	5	1	1	CD
10_1101-2020_09_23_308239	186	6	-	-	SYM
10_1101-2020_09_23_308239	186	7	12	12	CD
10_1101-2020_09_23_308239	186	8	.	.	.
10_1101-2020_09_23_308239	187	1	7	7	CD
10_1101-2020_09_23_308239	187	2	Gervasoni	Gervasoni	NNP
10_1101-2020_09_23_308239	187	3	,	,	,
10_1101-2020_09_23_308239	187	4	S.	S.	NNP
10_1101-2020_09_23_308239	187	5	;	;	:
10_1101-2020_09_23_308239	187	6	Vistoli	Vistoli	NNP
10_1101-2020_09_23_308239	187	7	,	,	,
10_1101-2020_09_23_308239	187	8	G.	G.	NNP
10_1101-2020_09_23_308239	187	9	;	;	:
10_1101-2020_09_23_308239	187	10	Talarico	Talarico	NNP
10_1101-2020_09_23_308239	187	11	,	,	,
10_1101-2020_09_23_308239	187	12	C.	C.	NNP
10_1101-2020_09_23_308239	187	13	;	;	:
10_1101-2020_09_23_308239	187	14	Manelfi	Manelfi	NNP
10_1101-2020_09_23_308239	187	15	,	,	,
10_1101-2020_09_23_308239	187	16	C.	C.	NNP
10_1101-2020_09_23_308239	187	17	;	;	:
10_1101-2020_09_23_308239	187	18	Beccari	Beccari	NNP
10_1101-2020_09_23_308239	187	19	,	,	,
10_1101-2020_09_23_308239	187	20	A.R.	A.R.	NNP
10_1101-2020_09_23_308239	188	1	;	;	:
10_1101-2020_09_23_308239	188	2	Studer	Studer	NNP
10_1101-2020_09_23_308239	188	3	,	,	,
10_1101-2020_09_23_308239	188	4	G.	G.	NNP
10_1101-2020_09_23_308239	188	5	;	;	:
10_1101-2020_09_23_308239	188	6	Tauriello	Tauriello	NNP
10_1101-2020_09_23_308239	188	7	,	,	,
10_1101-2020_09_23_308239	188	8	G.	G.	NNP
10_1101-2020_09_23_308239	188	9	;	;	:
10_1101-2020_09_23_308239	188	10	Waterhouse	Waterhouse	NNP
10_1101-2020_09_23_308239	188	11	,	,	,
10_1101-2020_09_23_308239	188	12	A.M.	A.M.	NNP
10_1101-2020_09_23_308239	188	13	;	;	:
10_1101-2020_09_23_308239	188	14	Schwede	Schwede	NNP
10_1101-2020_09_23_308239	188	15	,	,	,
10_1101-2020_09_23_308239	188	16	T.	T.	NNP
10_1101-2020_09_23_308239	188	17	;	;	:
10_1101-2020_09_23_308239	188	18	Pedretti	Pedretti	NNP
10_1101-2020_09_23_308239	188	19	,	,	,
10_1101-2020_09_23_308239	188	20	A.	a.	NN
10_1101-2020_09_23_308239	189	1	A	a	DT
10_1101-2020_09_23_308239	189	2	Comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	189	3	Mapping	Mapping	NNP
10_1101-2020_09_23_308239	189	4	of	of	IN
10_1101-2020_09_23_308239	189	5	the	the	DT
10_1101-2020_09_23_308239	189	6	Druggable	Druggable	NNP
10_1101-2020_09_23_308239	189	7	Cavities	Cavities	NNPS
10_1101-2020_09_23_308239	189	8	within	within	IN
10_1101-2020_09_23_308239	189	9	the	the	DT
10_1101-2020_09_23_308239	189	10	SARS	SARS	NNP
10_1101-2020_09_23_308239	189	11	-	-	HYPH
10_1101-2020_09_23_308239	189	12	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	189	13	Therapeutically	therapeutically	RB
10_1101-2020_09_23_308239	189	14	Relevant	relevant	JJ
10_1101-2020_09_23_308239	189	15	Proteins	Proteins	NNP
10_1101-2020_09_23_308239	189	16	by	by	IN
10_1101-2020_09_23_308239	189	17	Combining	combine	VBG
10_1101-2020_09_23_308239	189	18	Pocket	Pocket	NNP
10_1101-2020_09_23_308239	189	19	and	and	CC
10_1101-2020_09_23_308239	189	20	Docking	Docking	NNP
10_1101-2020_09_23_308239	189	21	Searches	Searches	NNP
10_1101-2020_09_23_308239	189	22	as	as	IN
10_1101-2020_09_23_308239	189	23	Implemented	implement	VBN
10_1101-2020_09_23_308239	189	24	in	in	IN
10_1101-2020_09_23_308239	189	25	Pockets	Pockets	NNP
10_1101-2020_09_23_308239	189	26	2.0	2.0	CD
10_1101-2020_09_23_308239	189	27	.	.	.
10_1101-2020_09_23_308239	190	1	Int	Int	NNP
10_1101-2020_09_23_308239	190	2	.	.	.
10_1101-2020_09_23_308239	191	1	J.	J.	NNP
10_1101-2020_09_23_308239	191	2	Mol	Mol	NNP
10_1101-2020_09_23_308239	191	3	.	.	.
10_1101-2020_09_23_308239	192	1	Sci	Sci	NNP
10_1101-2020_09_23_308239	192	2	.	.	.
10_1101-2020_09_23_308239	193	1	2020	2020	CD
10_1101-2020_09_23_308239	193	2	,	,	,
10_1101-2020_09_23_308239	193	3	21	21	CD
10_1101-2020_09_23_308239	193	4	,	,	,
10_1101-2020_09_23_308239	193	5	5152	5152	CD
10_1101-2020_09_23_308239	193	6	.	.	.
10_1101-2020_09_23_308239	194	1	8	8	CD
10_1101-2020_09_23_308239	194	2	Ostaszewski	Ostaszewski	NNP
10_1101-2020_09_23_308239	194	3	,	,	,
10_1101-2020_09_23_308239	194	4	M.	M.	NNP
10_1101-2020_09_23_308239	194	5	,	,	,
10_1101-2020_09_23_308239	194	6	Mazein	Mazein	NNP
10_1101-2020_09_23_308239	194	7	,	,	,
10_1101-2020_09_23_308239	194	8	A.	A.	NNP
10_1101-2020_09_23_308239	194	9	,	,	,
10_1101-2020_09_23_308239	194	10	Gillespie	Gillespie	NNP
10_1101-2020_09_23_308239	194	11	,	,	,
10_1101-2020_09_23_308239	194	12	M.	M.	NNP
10_1101-2020_09_23_308239	194	13	E.	E.	NNP
10_1101-2020_09_23_308239	194	14	,	,	,
10_1101-2020_09_23_308239	194	15	Kuperstein	Kuperstein	NNP
10_1101-2020_09_23_308239	194	16	,	,	,
10_1101-2020_09_23_308239	194	17	I.	I.	NNP
10_1101-2020_09_23_308239	194	18	,	,	,
10_1101-2020_09_23_308239	194	19	Niarakis	Niarakis	NNP
10_1101-2020_09_23_308239	194	20	,	,	,
10_1101-2020_09_23_308239	194	21	A.	A.	NNP
10_1101-2020_09_23_308239	194	22	,	,	,
10_1101-2020_09_23_308239	194	23	Hermjakob	Hermjakob	NNP
10_1101-2020_09_23_308239	194	24	,	,	,
10_1101-2020_09_23_308239	194	25	H.	H.	NNP
10_1101-2020_09_23_308239	194	26	,	,	,
10_1101-2020_09_23_308239	194	27	...	...	NFP
10_1101-2020_09_23_308239	194	28	&	&	CC
10_1101-2020_09_23_308239	194	29	Schreiber	Schreiber	NNP
10_1101-2020_09_23_308239	194	30	,	,	,
10_1101-2020_09_23_308239	194	31	F.	F.	NNP
10_1101-2020_09_23_308239	194	32	(	(	-LRB-
10_1101-2020_09_23_308239	194	33	2020	2020	CD
10_1101-2020_09_23_308239	194	34	)	)	-RRB-
10_1101-2020_09_23_308239	194	35	.	.	.
10_1101-2020_09_23_308239	195	1	COVID-19	COVID-19	:
10_1101-2020_09_23_308239	195	2	Disease	Disease	NNP
10_1101-2020_09_23_308239	195	3	Map	Map	NNP
10_1101-2020_09_23_308239	195	4	,	,	,
10_1101-2020_09_23_308239	195	5	building	build	VBG
10_1101-2020_09_23_308239	195	6	a	a	DT
10_1101-2020_09_23_308239	195	7	computational	computational	JJ
10_1101-2020_09_23_308239	195	8	repository	repository	NN
10_1101-2020_09_23_308239	195	9	of	of	IN
10_1101-2020_09_23_308239	195	10	SARS	SARS	NNP
10_1101-2020_09_23_308239	195	11	-	-	HYPH
10_1101-2020_09_23_308239	195	12	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	195	13	virus	virus	NN
10_1101-2020_09_23_308239	195	14	-	-	HYPH
10_1101-2020_09_23_308239	195	15	host	host	NN
10_1101-2020_09_23_308239	195	16	interaction	interaction	NN
10_1101-2020_09_23_308239	195	17	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	195	18	.	.	.
10_1101-2020_09_23_308239	196	1	Scientific	scientific	JJ
10_1101-2020_09_23_308239	196	2	data	datum	NNS
10_1101-2020_09_23_308239	196	3	,	,	,
10_1101-2020_09_23_308239	196	4	7(1	7(1	NNP
10_1101-2020_09_23_308239	196	5	)	)	-RRB-
10_1101-2020_09_23_308239	196	6	,	,	,
10_1101-2020_09_23_308239	196	7	1	1	CD
10_1101-2020_09_23_308239	196	8	-	-	SYM
10_1101-2020_09_23_308239	196	9	4	4	CD
10_1101-2020_09_23_308239	196	10	.	.	.
10_1101-2020_09_23_308239	197	1	9	9	CD
10_1101-2020_09_23_308239	197	2	Domingo	Domingo	NNP
10_1101-2020_09_23_308239	197	3	-	-	HYPH
10_1101-2020_09_23_308239	197	4	Fernandez	Fernandez	NNP
10_1101-2020_09_23_308239	197	5	,	,	,
10_1101-2020_09_23_308239	197	6	D.	D.	NNP
10_1101-2020_09_23_308239	197	7	et	et	NNP
10_1101-2020_09_23_308239	197	8	al	al	NNP
10_1101-2020_09_23_308239	197	9	.	.	.
10_1101-2020_09_23_308239	198	1	COVID-19	COVID-19	:
10_1101-2020_09_23_308239	198	2	Knowledge	Knowledge	NNP
10_1101-2020_09_23_308239	198	3	Graph	Graph	NNP
10_1101-2020_09_23_308239	198	4	:	:	:
10_1101-2020_09_23_308239	198	5	a	a	DT
10_1101-2020_09_23_308239	198	6	computable	computable	JJ
10_1101-2020_09_23_308239	198	7	,	,	,
10_1101-2020_09_23_308239	198	8	multi	multi	JJ
10_1101-2020_09_23_308239	198	9	-	-	NN
10_1101-2020_09_23_308239	198	10	modal	modal	JJ
10_1101-2020_09_23_308239	198	11	,	,	,
10_1101-2020_09_23_308239	198	12	cause	cause	NN
10_1101-2020_09_23_308239	198	13	-	-	HYPH
10_1101-2020_09_23_308239	198	14	and	and	CC
10_1101-2020_09_23_308239	198	15	-	-	HYPH
10_1101-2020_09_23_308239	198	16	effect	effect	NN
10_1101-2020_09_23_308239	198	17	knowledge	knowledge	NN
10_1101-2020_09_23_308239	198	18	model	model	NN
10_1101-2020_09_23_308239	198	19	of	of	IN
10_1101-2020_09_23_308239	198	20	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	198	21	pathophysiology	pathophysiology	NN
10_1101-2020_09_23_308239	198	22	.	.	.
10_1101-2020_09_23_308239	199	1	Bioinformatics	bioinformatic	NNS
10_1101-2020_09_23_308239	199	2	.	.	.
10_1101-2020_09_23_308239	200	1	btaa834	btaa834	NNP
10_1101-2020_09_23_308239	200	2	(	(	-LRB-
10_1101-2020_09_23_308239	200	3	2020	2020	CD
10_1101-2020_09_23_308239	200	4	)	)	-RRB-
10_1101-2020_09_23_308239	200	5	.	.	.
10_1101-2020_09_23_308239	201	1	10	10	CD
10_1101-2020_09_23_308239	201	2	Gysi	Gysi	NNP
10_1101-2020_09_23_308239	201	3	,	,	,
10_1101-2020_09_23_308239	201	4	D.	D.	NNP
10_1101-2020_09_23_308239	201	5	M.	M.	NNP
10_1101-2020_09_23_308239	201	6	,	,	,
10_1101-2020_09_23_308239	201	7	Valle	Valle	NNP
10_1101-2020_09_23_308239	201	8	,	,	,
10_1101-2020_09_23_308239	201	9	Í.	Í.	NNP
10_1101-2020_09_23_308239	201	10	D.	D.	NNP
10_1101-2020_09_23_308239	201	11	,	,	,
10_1101-2020_09_23_308239	201	12	Zitnik	Zitnik	NNP
10_1101-2020_09_23_308239	201	13	,	,	,
10_1101-2020_09_23_308239	201	14	M.	M.	NNP
10_1101-2020_09_23_308239	201	15	,	,	,
10_1101-2020_09_23_308239	201	16	Ameli	Ameli	NNP
10_1101-2020_09_23_308239	201	17	,	,	,
10_1101-2020_09_23_308239	201	18	A.	a.	NN
10_1101-2020_09_23_308239	201	19	,	,	,
10_1101-2020_09_23_308239	201	20	Gan	Gan	NNP
10_1101-2020_09_23_308239	201	21	,	,	,
10_1101-2020_09_23_308239	201	22	X.	X.	NNP
10_1101-2020_09_23_308239	201	23	,	,	,
10_1101-2020_09_23_308239	201	24	Varol	Varol	NNP
10_1101-2020_09_23_308239	201	25	,	,	,
10_1101-2020_09_23_308239	201	26	O.	O.	NNP
10_1101-2020_09_23_308239	201	27	,	,	,
10_1101-2020_09_23_308239	201	28	...	...	.
10_1101-2020_09_23_308239	201	29	&	&	CC
10_1101-2020_09_23_308239	201	30	Barabási	Barabási	NNP
10_1101-2020_09_23_308239	201	31	,	,	,
10_1101-2020_09_23_308239	201	32	A.	a.	NN
10_1101-2020_09_23_308239	201	33	L.	L.	NNP
10_1101-2020_09_23_308239	201	34	(	(	-LRB-
10_1101-2020_09_23_308239	201	35	2020	2020	CD
10_1101-2020_09_23_308239	201	36	)	)	-RRB-
10_1101-2020_09_23_308239	201	37	.	.	.
10_1101-2020_09_23_308239	202	1	Network	network	NN
10_1101-2020_09_23_308239	202	2	medicine	medicine	NN
10_1101-2020_09_23_308239	202	3	framework	framework	NN
10_1101-2020_09_23_308239	202	4	for	for	IN
10_1101-2020_09_23_308239	202	5	identifying	identify	VBG
10_1101-2020_09_23_308239	202	6	drug	drug	NN
10_1101-2020_09_23_308239	202	7	repurposing	repurpose	VBG
10_1101-2020_09_23_308239	202	8	opportunities	opportunity	NNS
10_1101-2020_09_23_308239	202	9	for	for	IN
10_1101-2020_09_23_308239	202	10	covid-19	covid-19	NNP
10_1101-2020_09_23_308239	202	11	.	.	.
10_1101-2020_09_23_308239	203	1	arXiv	arXiv	NNP
10_1101-2020_09_23_308239	203	2	preprint	preprint	NN
10_1101-2020_09_23_308239	203	3	arXiv:2004.07229	arXiv:2004.07229	NNP
10_1101-2020_09_23_308239	203	4	.	.	.
10_1101-2020_09_23_308239	204	1	11	11	CD
10_1101-2020_09_23_308239	204	2	Khan	Khan	NNP
10_1101-2020_09_23_308239	204	3	,	,	,
10_1101-2020_09_23_308239	204	4	J.	J.	NNP
10_1101-2020_09_23_308239	204	5	Y.	Y.	NNP
10_1101-2020_09_23_308239	204	6	,	,	,
10_1101-2020_09_23_308239	204	7	Khondaker	Khondaker	NNP
10_1101-2020_09_23_308239	204	8	,	,	,
10_1101-2020_09_23_308239	204	9	M.	M.	NNP
10_1101-2020_09_23_308239	204	10	,	,	,
10_1101-2020_09_23_308239	204	11	Islam	Islam	NNP
10_1101-2020_09_23_308239	204	12	,	,	,
10_1101-2020_09_23_308239	204	13	T.	T.	NNP
10_1101-2020_09_23_308239	204	14	,	,	,
10_1101-2020_09_23_308239	204	15	Hoque	Hoque	NNP
10_1101-2020_09_23_308239	204	16	,	,	,
10_1101-2020_09_23_308239	204	17	I.	I.	NNP
10_1101-2020_09_23_308239	204	18	T.	T.	NNP
10_1101-2020_09_23_308239	204	19	,	,	,
10_1101-2020_09_23_308239	204	20	Al	Al	NNP
10_1101-2020_09_23_308239	204	21	-	-	HYPH
10_1101-2020_09_23_308239	204	22	Absi	Absi	NNP
10_1101-2020_09_23_308239	204	23	,	,	,
10_1101-2020_09_23_308239	204	24	H.	H.	NNP
10_1101-2020_09_23_308239	204	25	,	,	,
10_1101-2020_09_23_308239	204	26	Rahman	Rahman	NNP
10_1101-2020_09_23_308239	204	27	,	,	,
10_1101-2020_09_23_308239	204	28	M.	M.	NNP
10_1101-2020_09_23_308239	204	29	S.	S.	NNP
10_1101-2020_09_23_308239	204	30	,	,	,
10_1101-2020_09_23_308239	204	31	...	...	.
10_1101-2020_09_23_308239	204	32	&	&	CC
10_1101-2020_09_23_308239	204	33	Rahman	Rahman	NNP
10_1101-2020_09_23_308239	204	34	,	,	,
10_1101-2020_09_23_308239	204	35	M.	M.	NNP
10_1101-2020_09_23_308239	204	36	S.	S.	NNP
10_1101-2020_09_23_308239	204	37	(	(	-LRB-
10_1101-2020_09_23_308239	204	38	2020	2020	CD
10_1101-2020_09_23_308239	204	39	)	)	-RRB-
10_1101-2020_09_23_308239	204	40	.	.	.
10_1101-2020_09_23_308239	205	1	COVID-19Base	covid-19base	LS
10_1101-2020_09_23_308239	205	2	:	:	:
10_1101-2020_09_23_308239	205	3	A	a	DT
10_1101-2020_09_23_308239	205	4	knowledgebase	knowledgebase	NN
10_1101-2020_09_23_308239	205	5	to	to	TO
10_1101-2020_09_23_308239	205	6	explore	explore	VB
10_1101-2020_09_23_308239	205	7	biomedical	biomedical	JJ
10_1101-2020_09_23_308239	205	8	entities	entity	NNS
10_1101-2020_09_23_308239	205	9	related	relate	VBN
10_1101-2020_09_23_308239	205	10	to	to	IN
10_1101-2020_09_23_308239	205	11	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	205	12	.	.	.
10_1101-2020_09_23_308239	206	1	arXiv	arXiv	NNP
10_1101-2020_09_23_308239	206	2	preprint	preprint	NN
10_1101-2020_09_23_308239	206	3	arXiv:2005.05954	arXiv:2005.05954	NNP
10_1101-2020_09_23_308239	206	4	.	.	.
10_1101-2020_09_23_308239	207	1	12	12	CD
10_1101-2020_09_23_308239	207	2	Kuperstein	Kuperstein	NNP
10_1101-2020_09_23_308239	207	3	,	,	,
10_1101-2020_09_23_308239	207	4	I.	I.	NNP
10_1101-2020_09_23_308239	207	5	,	,	,
10_1101-2020_09_23_308239	207	6	Bonnet	Bonnet	NNP
10_1101-2020_09_23_308239	207	7	,	,	,
10_1101-2020_09_23_308239	207	8	E.	E.	NNP
10_1101-2020_09_23_308239	207	9	,	,	,
10_1101-2020_09_23_308239	207	10	Nguyen	Nguyen	NNP
10_1101-2020_09_23_308239	207	11	,	,	,
10_1101-2020_09_23_308239	207	12	H.	H.	NNP
10_1101-2020_09_23_308239	207	13	A.	A.	NNP
10_1101-2020_09_23_308239	207	14	,	,	,
10_1101-2020_09_23_308239	207	15	Cohen	Cohen	NNP
10_1101-2020_09_23_308239	207	16	,	,	,
10_1101-2020_09_23_308239	207	17	D.	D.	NNP
10_1101-2020_09_23_308239	207	18	,	,	,
10_1101-2020_09_23_308239	207	19	Viara	Viara	NNP
10_1101-2020_09_23_308239	207	20	,	,	,
10_1101-2020_09_23_308239	207	21	E.	E.	NNP
10_1101-2020_09_23_308239	207	22	,	,	,
10_1101-2020_09_23_308239	207	23	Grieco	Grieco	NNP
10_1101-2020_09_23_308239	207	24	,	,	,
10_1101-2020_09_23_308239	207	25	L.	L.	NNP
10_1101-2020_09_23_308239	207	26	,	,	,
10_1101-2020_09_23_308239	207	27	...	...	.
10_1101-2020_09_23_308239	207	28	&	&	CC
10_1101-2020_09_23_308239	207	29	Dutreix	Dutreix	NNP
10_1101-2020_09_23_308239	207	30	,	,	,
10_1101-2020_09_23_308239	207	31	M.	M.	NNP
10_1101-2020_09_23_308239	207	32	(	(	-LRB-
10_1101-2020_09_23_308239	207	33	2015	2015	CD
10_1101-2020_09_23_308239	207	34	)	)	-RRB-
10_1101-2020_09_23_308239	207	35	.	.	.
10_1101-2020_09_23_308239	208	1	Atlas	Atlas	NNP
10_1101-2020_09_23_308239	208	2	of	of	IN
10_1101-2020_09_23_308239	208	3	Cancer	Cancer	NNP
10_1101-2020_09_23_308239	208	4	Signalling	Signalling	NNP
10_1101-2020_09_23_308239	208	5	Network	Network	NNP
10_1101-2020_09_23_308239	208	6	:	:	:
10_1101-2020_09_23_308239	208	7	a	a	DT
10_1101-2020_09_23_308239	208	8	systems	system	NNS
10_1101-2020_09_23_308239	208	9	biology	biology	NN
10_1101-2020_09_23_308239	208	10	resource	resource	NN
10_1101-2020_09_23_308239	208	11	for	for	IN
10_1101-2020_09_23_308239	208	12	integrative	integrative	JJ
10_1101-2020_09_23_308239	208	13	analysis	analysis	NN
10_1101-2020_09_23_308239	208	14	of	of	IN
10_1101-2020_09_23_308239	208	15	cancer	cancer	NN
10_1101-2020_09_23_308239	208	16	data	datum	NNS
10_1101-2020_09_23_308239	208	17	with	with	IN
10_1101-2020_09_23_308239	208	18	Google	Google	NNP
10_1101-2020_09_23_308239	208	19	Maps	Maps	NNPS
10_1101-2020_09_23_308239	208	20	.	.	.
10_1101-2020_09_23_308239	209	1	Oncogenesis	oncogenesis	NN
10_1101-2020_09_23_308239	209	2	,	,	,
10_1101-2020_09_23_308239	209	3	4(7	4(7	NN
10_1101-2020_09_23_308239	209	4	)	)	-RRB-
10_1101-2020_09_23_308239	209	5	,	,	,
10_1101-2020_09_23_308239	209	6	e160-e160	e160-e160	ADD
10_1101-2020_09_23_308239	209	7	.	.	.
10_1101-2020_09_23_308239	210	1	13	13	CD
10_1101-2020_09_23_308239	210	2	Kodamullil	Kodamullil	NNP
10_1101-2020_09_23_308239	210	3	,	,	,
10_1101-2020_09_23_308239	210	4	A.	a.	NN
10_1101-2020_09_23_308239	210	5	T.	T.	NNP
10_1101-2020_09_23_308239	210	6	,	,	,
10_1101-2020_09_23_308239	210	7	Younesi	Younesi	NNP
10_1101-2020_09_23_308239	210	8	,	,	,
10_1101-2020_09_23_308239	210	9	E.	E.	NNP
10_1101-2020_09_23_308239	210	10	,	,	,
10_1101-2020_09_23_308239	210	11	Naz	Naz	NNP
10_1101-2020_09_23_308239	210	12	,	,	,
10_1101-2020_09_23_308239	210	13	M.	M.	NNP
10_1101-2020_09_23_308239	210	14	,	,	,
10_1101-2020_09_23_308239	210	15	Bagewadi	Bagewadi	NNP
10_1101-2020_09_23_308239	210	16	,	,	,
10_1101-2020_09_23_308239	210	17	S.	S.	NNP
10_1101-2020_09_23_308239	210	18	,	,	,
10_1101-2020_09_23_308239	210	19	&	&	CC
10_1101-2020_09_23_308239	210	20	Hofmann	Hofmann	NNP
10_1101-2020_09_23_308239	210	21	-	-	HYPH
10_1101-2020_09_23_308239	210	22	Apitius	Apitius	NNP
10_1101-2020_09_23_308239	210	23	,	,	,
10_1101-2020_09_23_308239	210	24	M.	M.	NNP
10_1101-2020_09_23_308239	210	25	(	(	-LRB-
10_1101-2020_09_23_308239	210	26	2015	2015	CD
10_1101-2020_09_23_308239	210	27	)	)	-RRB-
10_1101-2020_09_23_308239	210	28	.	.	.
10_1101-2020_09_23_308239	211	1	Computable	computable	JJ
10_1101-2020_09_23_308239	211	2	cause	cause	NN
10_1101-2020_09_23_308239	211	3	-	-	HYPH
10_1101-2020_09_23_308239	211	4	and-	and-	NN
10_1101-2020_09_23_308239	211	5	effect	effect	NN
10_1101-2020_09_23_308239	211	6	models	model	NNS
10_1101-2020_09_23_308239	211	7	of	of	IN
10_1101-2020_09_23_308239	211	8	healthy	healthy	JJ
10_1101-2020_09_23_308239	211	9	and	and	CC
10_1101-2020_09_23_308239	211	10	Alzheimer	Alzheimer	NNP
10_1101-2020_09_23_308239	211	11	's	's	POS
10_1101-2020_09_23_308239	211	12	disease	disease	NN
10_1101-2020_09_23_308239	211	13	states	state	NNS
10_1101-2020_09_23_308239	211	14	and	and	CC
10_1101-2020_09_23_308239	211	15	their	-PRON-	PRP$
10_1101-2020_09_23_308239	211	16	mechanistic	mechanistic	JJ
10_1101-2020_09_23_308239	211	17	differential	differential	NN
10_1101-2020_09_23_308239	211	18	analysis	analysis	NN
10_1101-2020_09_23_308239	211	19	.	.	.
10_1101-2020_09_23_308239	212	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_23_308239	212	2	's	's	POS
10_1101-2020_09_23_308239	212	3	&	&	CC
10_1101-2020_09_23_308239	212	4	Dementia	Dementia	NNP
10_1101-2020_09_23_308239	212	5	,	,	,
10_1101-2020_09_23_308239	212	6	11(11	11(11	CD
10_1101-2020_09_23_308239	212	7	)	)	-RRB-
10_1101-2020_09_23_308239	212	8	,	,	,
10_1101-2020_09_23_308239	212	9	1329	1329	CD
10_1101-2020_09_23_308239	212	10	-	-	SYM
10_1101-2020_09_23_308239	212	11	1339	1339	CD
10_1101-2020_09_23_308239	212	12	.	.	.
10_1101-2020_09_23_308239	213	1	14	14	CD
10_1101-2020_09_23_308239	213	2	Fujita	Fujita	NNP
10_1101-2020_09_23_308239	213	3	,	,	,
10_1101-2020_09_23_308239	213	4	K.	K.	NNP
10_1101-2020_09_23_308239	213	5	A.	A.	NNP
10_1101-2020_09_23_308239	213	6	,	,	,
10_1101-2020_09_23_308239	213	7	Ostaszewski	Ostaszewski	NNP
10_1101-2020_09_23_308239	213	8	,	,	,
10_1101-2020_09_23_308239	213	9	M.	M.	NNP
10_1101-2020_09_23_308239	213	10	,	,	,
10_1101-2020_09_23_308239	213	11	Matsuoka	Matsuoka	NNP
10_1101-2020_09_23_308239	213	12	,	,	,
10_1101-2020_09_23_308239	213	13	Y.	Y.	NNP
10_1101-2020_09_23_308239	213	14	,	,	,
10_1101-2020_09_23_308239	213	15	Ghosh	Ghosh	NNP
10_1101-2020_09_23_308239	213	16	,	,	,
10_1101-2020_09_23_308239	213	17	S.	S.	NNP
10_1101-2020_09_23_308239	213	18	,	,	,
10_1101-2020_09_23_308239	213	19	Glaab	Glaab	NNP
10_1101-2020_09_23_308239	213	20	,	,	,
10_1101-2020_09_23_308239	213	21	E.	E.	NNP
10_1101-2020_09_23_308239	213	22	,	,	,
10_1101-2020_09_23_308239	213	23	Trefois	Trefois	NNP
10_1101-2020_09_23_308239	213	24	,	,	,
10_1101-2020_09_23_308239	213	25	C.	C.	NNP
10_1101-2020_09_23_308239	213	26	,	,	,
10_1101-2020_09_23_308239	213	27	...	...	.
10_1101-2020_09_23_308239	213	28	&	&	CC
10_1101-2020_09_23_308239	213	29	Diederich	Diederich	NNP
10_1101-2020_09_23_308239	213	30	,	,	,
10_1101-2020_09_23_308239	213	31	N.	N.	NNP
10_1101-2020_09_23_308239	213	32	(	(	-LRB-
10_1101-2020_09_23_308239	213	33	2014	2014	CD
10_1101-2020_09_23_308239	213	34	)	)	-RRB-
10_1101-2020_09_23_308239	213	35	.	.	.
10_1101-2020_09_23_308239	214	1	Integrating	integrate	VBG
10_1101-2020_09_23_308239	214	2	pathways	pathway	NNS
10_1101-2020_09_23_308239	214	3	of	of	IN
10_1101-2020_09_23_308239	214	4	Parkinson	Parkinson	NNP
10_1101-2020_09_23_308239	214	5	's	's	POS
10_1101-2020_09_23_308239	214	6	disease	disease	NN
10_1101-2020_09_23_308239	214	7	in	in	IN
10_1101-2020_09_23_308239	214	8	a	a	DT
10_1101-2020_09_23_308239	214	9	molecular	molecular	JJ
10_1101-2020_09_23_308239	214	10	interaction	interaction	NN
10_1101-2020_09_23_308239	214	11	map	map	NN
10_1101-2020_09_23_308239	214	12	.	.	.
10_1101-2020_09_23_308239	215	1	Molecular	molecular	JJ
10_1101-2020_09_23_308239	215	2	neurobiology	neurobiology	NN
10_1101-2020_09_23_308239	215	3	,	,	,
10_1101-2020_09_23_308239	215	4	49(1	49(1	CD
10_1101-2020_09_23_308239	215	5	)	)	-RRB-
10_1101-2020_09_23_308239	215	6	,	,	,
10_1101-2020_09_23_308239	215	7	88-	88-	NNP
10_1101-2020_09_23_308239	215	8	102	102	CD
10_1101-2020_09_23_308239	215	9	.	.	.
10_1101-2020_09_23_308239	216	1	15	15	CD
10_1101-2020_09_23_308239	216	2	Matsuoka	Matsuoka	NNP
10_1101-2020_09_23_308239	216	3	,	,	,
10_1101-2020_09_23_308239	216	4	Y.	Y.	NNP
10_1101-2020_09_23_308239	216	5	et	et	NNP
10_1101-2020_09_23_308239	216	6	al	al	NNP
10_1101-2020_09_23_308239	216	7	.	.	.
10_1101-2020_09_23_308239	217	1	A	a	DT
10_1101-2020_09_23_308239	217	2	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	217	3	map	map	NN
10_1101-2020_09_23_308239	217	4	of	of	IN
10_1101-2020_09_23_308239	217	5	the	the	DT
10_1101-2020_09_23_308239	217	6	influenza	influenza	NNP
10_1101-2020_09_23_308239	217	7	A	a	DT
10_1101-2020_09_23_308239	217	8	virus	virus	NN
10_1101-2020_09_23_308239	217	9	replication	replication	NN
10_1101-2020_09_23_308239	217	10	cycle	cycle	NN
10_1101-2020_09_23_308239	217	11	.	.	.
10_1101-2020_09_23_308239	218	1	BMC	BMC	NNP
10_1101-2020_09_23_308239	218	2	Syst	Syst	NNP
10_1101-2020_09_23_308239	218	3	.	.	.
10_1101-2020_09_23_308239	219	1	Biol	Biol	NNP
10_1101-2020_09_23_308239	219	2	.	.	.
10_1101-2020_09_23_308239	220	1	7	7	CD
10_1101-2020_09_23_308239	220	2	,	,	,
10_1101-2020_09_23_308239	220	3	97	97	CD
10_1101-2020_09_23_308239	220	4	(	(	-LRB-
10_1101-2020_09_23_308239	220	5	2013	2013	CD
10_1101-2020_09_23_308239	220	6	16	16	CD
10_1101-2020_09_23_308239	220	7	Khan	Khan	NNP
10_1101-2020_09_23_308239	220	8	,	,	,
10_1101-2020_09_23_308239	220	9	J.	J.	NNP
10_1101-2020_09_23_308239	220	10	Y.	Y.	NNP
10_1101-2020_09_23_308239	220	11	,	,	,
10_1101-2020_09_23_308239	220	12	Khondaker	Khondaker	NNP
10_1101-2020_09_23_308239	220	13	,	,	,
10_1101-2020_09_23_308239	220	14	M.	M.	NNP
10_1101-2020_09_23_308239	220	15	,	,	,
10_1101-2020_09_23_308239	220	16	Islam	Islam	NNP
10_1101-2020_09_23_308239	220	17	,	,	,
10_1101-2020_09_23_308239	220	18	T.	T.	NNP
10_1101-2020_09_23_308239	220	19	,	,	,
10_1101-2020_09_23_308239	220	20	Hoque	Hoque	NNP
10_1101-2020_09_23_308239	220	21	,	,	,
10_1101-2020_09_23_308239	220	22	I.	I.	NNP
10_1101-2020_09_23_308239	220	23	T.	T.	NNP
10_1101-2020_09_23_308239	220	24	,	,	,
10_1101-2020_09_23_308239	220	25	Al	Al	NNP
10_1101-2020_09_23_308239	220	26	-	-	HYPH
10_1101-2020_09_23_308239	220	27	Absi	Absi	NNP
10_1101-2020_09_23_308239	220	28	,	,	,
10_1101-2020_09_23_308239	220	29	H.	H.	NNP
10_1101-2020_09_23_308239	220	30	,	,	,
10_1101-2020_09_23_308239	220	31	Rahman	Rahman	NNP
10_1101-2020_09_23_308239	220	32	,	,	,
10_1101-2020_09_23_308239	220	33	M.	M.	NNP
10_1101-2020_09_23_308239	220	34	S.	S.	NNP
10_1101-2020_09_23_308239	220	35	,	,	,
10_1101-2020_09_23_308239	220	36	...	...	.
10_1101-2020_09_23_308239	220	37	&	&	CC
10_1101-2020_09_23_308239	220	38	Rahman	Rahman	NNP
10_1101-2020_09_23_308239	220	39	,	,	,
10_1101-2020_09_23_308239	220	40	M.	M.	NNP
10_1101-2020_09_23_308239	220	41	S.	S.	NNP
10_1101-2020_09_23_308239	220	42	(	(	-LRB-
10_1101-2020_09_23_308239	220	43	2020	2020	CD
10_1101-2020_09_23_308239	220	44	)	)	-RRB-
10_1101-2020_09_23_308239	220	45	.	.	.
10_1101-2020_09_23_308239	221	1	COVID-19Base	covid-19base	LS
10_1101-2020_09_23_308239	221	2	:	:	:
10_1101-2020_09_23_308239	221	3	A	a	DT
10_1101-2020_09_23_308239	221	4	knowledgebase	knowledgebase	NN
10_1101-2020_09_23_308239	221	5	to	to	TO
10_1101-2020_09_23_308239	221	6	explore	explore	VB
10_1101-2020_09_23_308239	221	7	biomedical	biomedical	JJ
10_1101-2020_09_23_308239	221	8	entities	entity	NNS
10_1101-2020_09_23_308239	221	9	related	relate	VBN
10_1101-2020_09_23_308239	221	10	to	to	IN
10_1101-2020_09_23_308239	221	11	COVID-19	COVID-19	NNP
10_1101-2020_09_23_308239	221	12	.	.	.
10_1101-2020_09_23_308239	222	1	arXiv	arXiv	NNP
10_1101-2020_09_23_308239	222	2	preprint	preprint	NN
10_1101-2020_09_23_308239	222	3	arXiv:2005.05954	arXiv:2005.05954	NNP
10_1101-2020_09_23_308239	222	4	.	.	.
10_1101-2020_09_23_308239	223	1	17	17	CD
10_1101-2020_09_23_308239	223	2	Ostaszewski	Ostaszewski	NNP
10_1101-2020_09_23_308239	223	3	,	,	,
10_1101-2020_09_23_308239	223	4	M.	M.	NNP
10_1101-2020_09_23_308239	223	5	,	,	,
10_1101-2020_09_23_308239	223	6	Mazein	Mazein	NNP
10_1101-2020_09_23_308239	223	7	,	,	,
10_1101-2020_09_23_308239	223	8	A.	A.	NNP
10_1101-2020_09_23_308239	223	9	,	,	,
10_1101-2020_09_23_308239	223	10	Gillespie	Gillespie	NNP
10_1101-2020_09_23_308239	223	11	,	,	,
10_1101-2020_09_23_308239	223	12	M.	M.	NNP
10_1101-2020_09_23_308239	223	13	E.	E.	NNP
10_1101-2020_09_23_308239	223	14	,	,	,
10_1101-2020_09_23_308239	223	15	Kuperstein	Kuperstein	NNP
10_1101-2020_09_23_308239	223	16	,	,	,
10_1101-2020_09_23_308239	223	17	I.	I.	NNP
10_1101-2020_09_23_308239	223	18	,	,	,
10_1101-2020_09_23_308239	223	19	Niarakis	Niarakis	NNP
10_1101-2020_09_23_308239	223	20	,	,	,
10_1101-2020_09_23_308239	223	21	A.	A.	NNP
10_1101-2020_09_23_308239	223	22	,	,	,
10_1101-2020_09_23_308239	223	23	Hermjakob	Hermjakob	NNP
10_1101-2020_09_23_308239	223	24	,	,	,
10_1101-2020_09_23_308239	223	25	H.	H.	NNP
10_1101-2020_09_23_308239	223	26	,	,	,
10_1101-2020_09_23_308239	223	27	...	...	NFP
10_1101-2020_09_23_308239	223	28	&	&	CC
10_1101-2020_09_23_308239	223	29	Schreiber	Schreiber	NNP
10_1101-2020_09_23_308239	223	30	,	,	,
10_1101-2020_09_23_308239	223	31	F.	F.	NNP
10_1101-2020_09_23_308239	223	32	(	(	-LRB-
10_1101-2020_09_23_308239	223	33	2020	2020	CD
10_1101-2020_09_23_308239	223	34	)	)	-RRB-
10_1101-2020_09_23_308239	223	35	.	.	.
10_1101-2020_09_23_308239	224	1	COVID-19	COVID-19	:
10_1101-2020_09_23_308239	224	2	Disease	Disease	NNP
10_1101-2020_09_23_308239	224	3	Map	Map	NNP
10_1101-2020_09_23_308239	224	4	,	,	,
10_1101-2020_09_23_308239	224	5	building	build	VBG
10_1101-2020_09_23_308239	224	6	a	a	DT
10_1101-2020_09_23_308239	224	7	computational	computational	JJ
10_1101-2020_09_23_308239	224	8	repository	repository	NN
10_1101-2020_09_23_308239	224	9	of	of	IN
10_1101-2020_09_23_308239	224	10	SARS	SARS	NNP
10_1101-2020_09_23_308239	224	11	-	-	HYPH
10_1101-2020_09_23_308239	224	12	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	224	13	virus	virus	NN
10_1101-2020_09_23_308239	224	14	-	-	HYPH
10_1101-2020_09_23_308239	224	15	host	host	NN
10_1101-2020_09_23_308239	224	16	interaction	interaction	NN
10_1101-2020_09_23_308239	224	17	mechanisms	mechanism	NNS
10_1101-2020_09_23_308239	224	18	.	.	.
10_1101-2020_09_23_308239	225	1	Scientific	scientific	JJ
10_1101-2020_09_23_308239	225	2	data	datum	NNS
10_1101-2020_09_23_308239	225	3	,	,	,
10_1101-2020_09_23_308239	225	4	7(1	7(1	NNP
10_1101-2020_09_23_308239	225	5	)	)	-RRB-
10_1101-2020_09_23_308239	225	6	,	,	,
10_1101-2020_09_23_308239	225	7	1	1	CD
10_1101-2020_09_23_308239	225	8	-	-	SYM
10_1101-2020_09_23_308239	225	9	4	4	CD
10_1101-2020_09_23_308239	225	10	.	.	.
10_1101-2020_09_23_308239	226	1	18	18	CD
10_1101-2020_09_23_308239	226	2	Blanco	Blanco	NNP
10_1101-2020_09_23_308239	226	3	-	-	HYPH
10_1101-2020_09_23_308239	226	4	Melo	Melo	NNP
10_1101-2020_09_23_308239	226	5	,	,	,
10_1101-2020_09_23_308239	226	6	D.	D.	NNP
10_1101-2020_09_23_308239	226	7	,	,	,
10_1101-2020_09_23_308239	226	8	Nilsson	Nilsson	NNP
10_1101-2020_09_23_308239	226	9	-	-	HYPH
10_1101-2020_09_23_308239	226	10	Payant	Payant	NNP
10_1101-2020_09_23_308239	226	11	,	,	,
10_1101-2020_09_23_308239	226	12	B.	B.	NNP
10_1101-2020_09_23_308239	226	13	E.	E.	NNP
10_1101-2020_09_23_308239	226	14	,	,	,
10_1101-2020_09_23_308239	226	15	Liu	Liu	NNP
10_1101-2020_09_23_308239	226	16	,	,	,
10_1101-2020_09_23_308239	226	17	W.	W.	NNP
10_1101-2020_09_23_308239	226	18	C.	C.	NNP
10_1101-2020_09_23_308239	226	19	,	,	,
10_1101-2020_09_23_308239	226	20	Uhl	Uhl	NNP
10_1101-2020_09_23_308239	226	21	,	,	,
10_1101-2020_09_23_308239	226	22	S.	S.	NNP
10_1101-2020_09_23_308239	226	23	,	,	,
10_1101-2020_09_23_308239	226	24	Hoagland	Hoagland	NNP
10_1101-2020_09_23_308239	226	25	,	,	,
10_1101-2020_09_23_308239	226	26	D.	D.	NNP
10_1101-2020_09_23_308239	226	27	,	,	,
10_1101-2020_09_23_308239	226	28	Møller	Møller	NNP
10_1101-2020_09_23_308239	226	29	,	,	,
10_1101-2020_09_23_308239	226	30	R.	R.	NNP
10_1101-2020_09_23_308239	226	31	,	,	,
10_1101-2020_09_23_308239	226	32	...	...	.
10_1101-2020_09_23_308239	226	33	&	&	CC
10_1101-2020_09_23_308239	226	34	Wang	Wang	NNP
10_1101-2020_09_23_308239	226	35	,	,	,
10_1101-2020_09_23_308239	226	36	T.	T.	NNP
10_1101-2020_09_23_308239	226	37	T.	t.	NN
10_1101-2020_09_23_308239	226	38	(	(	-LRB-
10_1101-2020_09_23_308239	226	39	2020	2020	CD
10_1101-2020_09_23_308239	226	40	)	)	-RRB-
10_1101-2020_09_23_308239	226	41	.	.	.
10_1101-2020_09_23_308239	227	1	Imbalanced	imbalanced	JJ
10_1101-2020_09_23_308239	227	2	host	host	NN
10_1101-2020_09_23_308239	227	3	response	response	NN
10_1101-2020_09_23_308239	227	4	to	to	IN
10_1101-2020_09_23_308239	227	5	SARS	SARS	NNP
10_1101-2020_09_23_308239	227	6	-	-	HYPH
10_1101-2020_09_23_308239	227	7	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	227	8	drives	drive	VBZ
10_1101-2020_09_23_308239	227	9	development	development	NN
10_1101-2020_09_23_308239	227	10	of	of	IN
10_1101-2020_09_23_308239	227	11	COVID-19	covid-19	CD
10_1101-2020_09_23_308239	227	12	.	.	.
10_1101-2020_09_23_308239	228	1	Cell	cell	NN
10_1101-2020_09_23_308239	228	2	.	.	.
10_1101-2020_09_23_308239	229	1	19	19	CD
10_1101-2020_09_23_308239	229	2	Gordon	Gordon	NNP
10_1101-2020_09_23_308239	229	3	,	,	,
10_1101-2020_09_23_308239	229	4	D.	D.	NNP
10_1101-2020_09_23_308239	229	5	E.	E.	NNP
10_1101-2020_09_23_308239	229	6	,	,	,
10_1101-2020_09_23_308239	229	7	Jang	Jang	NNP
10_1101-2020_09_23_308239	229	8	,	,	,
10_1101-2020_09_23_308239	229	9	G.	G.	NNP
10_1101-2020_09_23_308239	229	10	M.	M.	NNP
10_1101-2020_09_23_308239	229	11	,	,	,
10_1101-2020_09_23_308239	229	12	Bouhaddou	Bouhaddou	NNP
10_1101-2020_09_23_308239	229	13	,	,	,
10_1101-2020_09_23_308239	229	14	M.	M.	NNP
10_1101-2020_09_23_308239	229	15	,	,	,
10_1101-2020_09_23_308239	229	16	Xu	Xu	NNP
10_1101-2020_09_23_308239	229	17	,	,	,
10_1101-2020_09_23_308239	229	18	J.	J.	NNP
10_1101-2020_09_23_308239	229	19	,	,	,
10_1101-2020_09_23_308239	229	20	Obernier	Obernier	NNP
10_1101-2020_09_23_308239	229	21	,	,	,
10_1101-2020_09_23_308239	229	22	K.	K.	NNP
10_1101-2020_09_23_308239	229	23	,	,	,
10_1101-2020_09_23_308239	229	24	White	White	NNP
10_1101-2020_09_23_308239	229	25	,	,	,
10_1101-2020_09_23_308239	229	26	K.	K.	NNP
10_1101-2020_09_23_308239	229	27	M.	M.	NNP
10_1101-2020_09_23_308239	229	28	,	,	,
10_1101-2020_09_23_308239	229	29	...	...	.
10_1101-2020_09_23_308239	229	30	&	&	CC
10_1101-2020_09_23_308239	229	31	Tummino	Tummino	NNP
10_1101-2020_09_23_308239	229	32	,	,	,
10_1101-2020_09_23_308239	229	33	T.	t.	NN
10_1101-2020_09_23_308239	229	34	A.	a.	NN
10_1101-2020_09_23_308239	230	1	(	(	-LRB-
10_1101-2020_09_23_308239	230	2	2020	2020	CD
10_1101-2020_09_23_308239	230	3	)	)	-RRB-
10_1101-2020_09_23_308239	230	4	.	.	.
10_1101-2020_09_23_308239	231	1	A	a	DT
10_1101-2020_09_23_308239	231	2	SARS	SARS	NNP
10_1101-2020_09_23_308239	231	3	-	-	HYPH
10_1101-2020_09_23_308239	231	4	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	231	5	protein	protein	NNP
10_1101-2020_09_23_308239	231	6	interaction	interaction	NNP
10_1101-2020_09_23_308239	231	7	map	map	NNP
10_1101-2020_09_23_308239	231	8	reveals	reveal	VBZ
10_1101-2020_09_23_308239	231	9	targets	target	NNS
10_1101-2020_09_23_308239	231	10	for	for	IN
10_1101-2020_09_23_308239	231	11	drug	drug	NN
10_1101-2020_09_23_308239	231	12	repurposing	repurposing	NN
10_1101-2020_09_23_308239	231	13	.	.	.
10_1101-2020_09_23_308239	232	1	Nature	nature	NN
10_1101-2020_09_23_308239	232	2	,	,	,
10_1101-2020_09_23_308239	232	3	1	1	CD
10_1101-2020_09_23_308239	232	4	-	-	SYM
10_1101-2020_09_23_308239	232	5	13	13	CD
10_1101-2020_09_23_308239	232	6	.	.	.
10_1101-2020_09_23_308239	233	1	20	20	CD
10_1101-2020_09_23_308239	233	2	Bojkova	Bojkova	NNP
10_1101-2020_09_23_308239	233	3	,	,	,
10_1101-2020_09_23_308239	233	4	D.	D.	NNP
10_1101-2020_09_23_308239	233	5	,	,	,
10_1101-2020_09_23_308239	233	6	Klann	Klann	NNP
10_1101-2020_09_23_308239	233	7	,	,	,
10_1101-2020_09_23_308239	233	8	K.	K.	NNP
10_1101-2020_09_23_308239	233	9	,	,	,
10_1101-2020_09_23_308239	233	10	Koch	Koch	NNP
10_1101-2020_09_23_308239	233	11	,	,	,
10_1101-2020_09_23_308239	233	12	B.	B.	NNP
10_1101-2020_09_23_308239	233	13	,	,	,
10_1101-2020_09_23_308239	233	14	Widera	Widera	NNP
10_1101-2020_09_23_308239	233	15	,	,	,
10_1101-2020_09_23_308239	233	16	M.	M.	NNP
10_1101-2020_09_23_308239	233	17	,	,	,
10_1101-2020_09_23_308239	233	18	Krause	Krause	NNP
10_1101-2020_09_23_308239	233	19	,	,	,
10_1101-2020_09_23_308239	233	20	D.	D.	NNP
10_1101-2020_09_23_308239	233	21	,	,	,
10_1101-2020_09_23_308239	233	22	Ciesek	Ciesek	NNP
10_1101-2020_09_23_308239	233	23	,	,	,
10_1101-2020_09_23_308239	233	24	S.	S.	NNP
10_1101-2020_09_23_308239	233	25			NNP
10_1101-2020_09_23_308239	233	26			NNP
10_1101-2020_09_23_308239	233	27	,	,	,
10_1101-2020_09_23_308239	233	28	...	...	NFP
10_1101-2020_09_23_308239	233	29	&	&	CC
10_1101-2020_09_23_308239	233	30	Münch	Münch	NNP
10_1101-2020_09_23_308239	233	31	,	,	,
10_1101-2020_09_23_308239	233	32	C.	C.	NNP
10_1101-2020_09_23_308239	233	33	(	(	-LRB-
10_1101-2020_09_23_308239	233	34	2020	2020	CD
10_1101-2020_09_23_308239	233	35	)	)	-RRB-
10_1101-2020_09_23_308239	233	36	.	.	.
10_1101-2020_09_23_308239	234	1	Proteomics	Proteomics	NNP
10_1101-2020_09_23_308239	234	2	of	of	IN
10_1101-2020_09_23_308239	234	3	SARS	SARS	NNP
10_1101-2020_09_23_308239	234	4	-	-	HYPH
10_1101-2020_09_23_308239	234	5	CoV-2-	CoV-2-	NNS
10_1101-2020_09_23_308239	234	6	infected	infect	VBD
10_1101-2020_09_23_308239	234	7	host	host	NN
10_1101-2020_09_23_308239	234	8	cells	cell	NNS
10_1101-2020_09_23_308239	234	9	reveals	reveal	VBZ
10_1101-2020_09_23_308239	234	10	therapy	therapy	NN
10_1101-2020_09_23_308239	234	11	targets	target	NNS
10_1101-2020_09_23_308239	234	12	.	.	.
10_1101-2020_09_23_308239	235	1	Nature	nature	NN
10_1101-2020_09_23_308239	235	2	,	,	,
10_1101-2020_09_23_308239	235	3	1	1	CD
10_1101-2020_09_23_308239	235	4	-	-	SYM
10_1101-2020_09_23_308239	235	5	8	8	CD
10_1101-2020_09_23_308239	235	6	.	.	.
10_1101-2020_09_23_308239	236	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	236	2	-	-	:
10_1101-2020_09_23_308239	236	3	BY	by	IN
10_1101-2020_09_23_308239	236	4	-	-	HYPH
10_1101-2020_09_23_308239	236	5	NC	NC	NNP
10_1101-2020_09_23_308239	236	6	-	-	HYPH
10_1101-2020_09_23_308239	236	7	ND	ND	NNP
10_1101-2020_09_23_308239	236	8	4.0	4.0	CD
10_1101-2020_09_23_308239	236	9	International	international	JJ
10_1101-2020_09_23_308239	236	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	236	11	.	.	.
10_1101-2020_09_23_308239	237	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	237	2	is	be	VBZ
10_1101-2020_09_23_308239	237	3	made	make	VBN
10_1101-2020_09_23_308239	237	4	available	available	JJ
10_1101-2020_09_23_308239	237	5	under	under	IN
10_1101-2020_09_23_308239	237	6	a	a	DT
10_1101-2020_09_23_308239	237	7	preprint	preprint	NN
10_1101-2020_09_23_308239	237	8	(	(	-LRB-
10_1101-2020_09_23_308239	237	9	which	which	WDT
10_1101-2020_09_23_308239	237	10	was	be	VBD
10_1101-2020_09_23_308239	237	11	not	not	RB
10_1101-2020_09_23_308239	237	12	certified	certify	VBN
10_1101-2020_09_23_308239	237	13	by	by	IN
10_1101-2020_09_23_308239	237	14	peer	peer	NN
10_1101-2020_09_23_308239	237	15	review	review	NN
10_1101-2020_09_23_308239	237	16	)	)	-RRB-
10_1101-2020_09_23_308239	237	17	is	be	VBZ
10_1101-2020_09_23_308239	237	18	the	the	DT
10_1101-2020_09_23_308239	237	19	author	author	NN
10_1101-2020_09_23_308239	237	20	/	/	SYM
10_1101-2020_09_23_308239	237	21	funder	funder	NN
10_1101-2020_09_23_308239	237	22	,	,	,
10_1101-2020_09_23_308239	237	23	who	who	WP
10_1101-2020_09_23_308239	237	24	has	have	VBZ
10_1101-2020_09_23_308239	237	25	granted	grant	VBN
10_1101-2020_09_23_308239	237	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	237	27	a	a	DT
10_1101-2020_09_23_308239	237	28	license	license	NN
10_1101-2020_09_23_308239	237	29	to	to	TO
10_1101-2020_09_23_308239	237	30	display	display	VB
10_1101-2020_09_23_308239	237	31	the	the	DT
10_1101-2020_09_23_308239	237	32	preprint	preprint	NN
10_1101-2020_09_23_308239	237	33	in	in	IN
10_1101-2020_09_23_308239	237	34	The	the	DT
10_1101-2020_09_23_308239	237	35	copyright	copyright	NN
10_1101-2020_09_23_308239	237	36	holder	holder	NN
10_1101-2020_09_23_308239	237	37	for	for	IN
10_1101-2020_09_23_308239	237	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	237	39	version	version	NN
10_1101-2020_09_23_308239	237	40	posted	post	VBD
10_1101-2020_09_23_308239	237	41	February	February	NNP
10_1101-2020_09_23_308239	237	42	12	12	CD
10_1101-2020_09_23_308239	237	43	,	,	,
10_1101-2020_09_23_308239	237	44	2021	2021	CD
10_1101-2020_09_23_308239	237	45	.	.	.
10_1101-2020_09_23_308239	237	46	;	;	:
10_1101-2020_09_23_308239	237	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	237	48	:	:	:
10_1101-2020_09_23_308239	237	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	237	50	preprint	preprint	NN
10_1101-2020_09_23_308239	237	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	237	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2020_09_23_308239	237	53	25	25	CD
10_1101-2020_09_23_308239	237	54	21	21	CD
10_1101-2020_09_23_308239	237	55	Ashburn	Ashburn	NNP
10_1101-2020_09_23_308239	237	56	,	,	,
10_1101-2020_09_23_308239	237	57	T.	T.	NNP
10_1101-2020_09_23_308239	237	58	T.	T.	NNP
10_1101-2020_09_23_308239	237	59	,	,	,
10_1101-2020_09_23_308239	237	60	&	&	CC
10_1101-2020_09_23_308239	237	61	Thor	Thor	NNP
10_1101-2020_09_23_308239	237	62	,	,	,
10_1101-2020_09_23_308239	237	63	K.	K.	NNP
10_1101-2020_09_23_308239	237	64	B.	B.	NNP
10_1101-2020_09_23_308239	238	1	(	(	-LRB-
10_1101-2020_09_23_308239	238	2	2004	2004	CD
10_1101-2020_09_23_308239	238	3	)	)	-RRB-
10_1101-2020_09_23_308239	238	4	.	.	.
10_1101-2020_09_23_308239	239	1	Drug	drug	NN
10_1101-2020_09_23_308239	239	2	repositioning	repositioning	NN
10_1101-2020_09_23_308239	239	3	:	:	:
10_1101-2020_09_23_308239	239	4	identifying	identify	VBG
10_1101-2020_09_23_308239	239	5	and	and	CC
10_1101-2020_09_23_308239	239	6	developing	develop	VBG
10_1101-2020_09_23_308239	239	7	new	new	JJ
10_1101-2020_09_23_308239	239	8	uses	use	NNS
10_1101-2020_09_23_308239	239	9	for	for	IN
10_1101-2020_09_23_308239	239	10	existing	exist	VBG
10_1101-2020_09_23_308239	239	11	drugs	drug	NNS
10_1101-2020_09_23_308239	239	12	.	.	.
10_1101-2020_09_23_308239	240	1	Nature	nature	NN
10_1101-2020_09_23_308239	240	2	reviews	review	VBZ
10_1101-2020_09_23_308239	240	3	Drug	drug	NN
10_1101-2020_09_23_308239	240	4	discovery	discovery	NN
10_1101-2020_09_23_308239	240	5	,	,	,
10_1101-2020_09_23_308239	240	6	3(8	3(8	NNP
10_1101-2020_09_23_308239	240	7	)	)	-RRB-
10_1101-2020_09_23_308239	240	8	,	,	,
10_1101-2020_09_23_308239	240	9	673	673	CD
10_1101-2020_09_23_308239	240	10	-	-	SYM
10_1101-2020_09_23_308239	240	11	683	683	CD
10_1101-2020_09_23_308239	240	12	.	.	.
10_1101-2020_09_23_308239	241	1	22	22	CD
10_1101-2020_09_23_308239	241	2	Pushpakom	Pushpakom	NNP
10_1101-2020_09_23_308239	241	3	,	,	,
10_1101-2020_09_23_308239	241	4	S.	S.	NNP
10_1101-2020_09_23_308239	241	5	,	,	,
10_1101-2020_09_23_308239	241	6	Iorio	Iorio	NNP
10_1101-2020_09_23_308239	241	7	,	,	,
10_1101-2020_09_23_308239	241	8	F.	F.	NNP
10_1101-2020_09_23_308239	241	9	,	,	,
10_1101-2020_09_23_308239	241	10	Eyers	Eyers	NNP
10_1101-2020_09_23_308239	241	11	,	,	,
10_1101-2020_09_23_308239	241	12	P.	P.	NNP
10_1101-2020_09_23_308239	241	13	A.	A.	NNP
10_1101-2020_09_23_308239	241	14	,	,	,
10_1101-2020_09_23_308239	241	15	Escott	Escott	NNP
10_1101-2020_09_23_308239	241	16	,	,	,
10_1101-2020_09_23_308239	241	17	K.	K.	NNP
10_1101-2020_09_23_308239	241	18	J.	J.	NNP
10_1101-2020_09_23_308239	241	19	,	,	,
10_1101-2020_09_23_308239	241	20	Hopper	Hopper	NNP
10_1101-2020_09_23_308239	241	21	,	,	,
10_1101-2020_09_23_308239	241	22	S.	S.	NNP
10_1101-2020_09_23_308239	241	23	,	,	,
10_1101-2020_09_23_308239	241	24	Wells	Wells	NNP
10_1101-2020_09_23_308239	241	25	,	,	,
10_1101-2020_09_23_308239	241	26	A.	A.	NNP
10_1101-2020_09_23_308239	241	27	,	,	,
10_1101-2020_09_23_308239	241	28	...	...	NFP
10_1101-2020_09_23_308239	241	29	&	&	CC
10_1101-2020_09_23_308239	241	30	Norris	Norris	NNP
10_1101-2020_09_23_308239	241	31	,	,	,
10_1101-2020_09_23_308239	241	32	A.	a.	NN
10_1101-2020_09_23_308239	242	1	(	(	-LRB-
10_1101-2020_09_23_308239	242	2	2019	2019	CD
10_1101-2020_09_23_308239	242	3	)	)	-RRB-
10_1101-2020_09_23_308239	242	4	.	.	.
10_1101-2020_09_23_308239	243	1	Drug	drug	NN
10_1101-2020_09_23_308239	243	2	repurposing	repurposing	NN
10_1101-2020_09_23_308239	243	3	:	:	:
10_1101-2020_09_23_308239	243	4	progress	progress	NN
10_1101-2020_09_23_308239	243	5	,	,	,
10_1101-2020_09_23_308239	243	6	challenges	challenge	NNS
10_1101-2020_09_23_308239	243	7	and	and	CC
10_1101-2020_09_23_308239	243	8	recommendations	recommendation	NNS
10_1101-2020_09_23_308239	243	9	.	.	.
10_1101-2020_09_23_308239	244	1	Nature	nature	NN
10_1101-2020_09_23_308239	244	2	reviews	review	VBZ
10_1101-2020_09_23_308239	244	3	Drug	drug	NN
10_1101-2020_09_23_308239	244	4	discovery	discovery	NN
10_1101-2020_09_23_308239	244	5	,	,	,
10_1101-2020_09_23_308239	244	6	18(1	18(1	CD
10_1101-2020_09_23_308239	244	7	)	)	-RRB-
10_1101-2020_09_23_308239	244	8	,	,	,
10_1101-2020_09_23_308239	244	9	41	41	CD
10_1101-2020_09_23_308239	244	10	-	-	SYM
10_1101-2020_09_23_308239	244	11	58	58	CD
10_1101-2020_09_23_308239	244	12	.	.	.
10_1101-2020_09_23_308239	245	1	23	23	CD
10_1101-2020_09_23_308239	245	2	http://rdcu.be/qKdSKdSp://rdcu.be/qKdS	http://rdcu.be/qkdskdsp://rdcu.be/qkds	CD
10_1101-2020_09_23_308239	245	3	24	24	CD
10_1101-2020_09_23_308239	245	4	https://doi.org/10.1073/pnas.1810137115	https://doi.org/10.1073/pnas.1810137115	NN
10_1101-2020_09_23_308239	245	5	25	25	CD
10_1101-2020_09_23_308239	245	6	https://reframedb.org/assays/A00461	https://reframedb.org/assays/a00461	NN
10_1101-2020_09_23_308239	245	7	26	26	CD
10_1101-2020_09_23_308239	245	8	https://reframedb.org/assays/A00440	https://reframedb.org/assays/a00440	NN
10_1101-2020_09_23_308239	245	9	27	27	CD
10_1101-2020_09_23_308239	245	10	preprint	preprint	NN
10_1101-2020_09_23_308239	245	11	,	,	,
10_1101-2020_09_23_308239	245	12	DOI:.21203	DOI:.21203	''
10_1101-2020_09_23_308239	245	13	/	/	SYM
10_1101-2020_09_23_308239	245	14	rs.3.rs-23951	rs.3.rs-23951	NNP
10_1101-2020_09_23_308239	245	15	/	/	SYM
10_1101-2020_09_23_308239	245	16	v1	v1	NN
10_1101-2020_09_23_308239	245	17	28	28	CD
10_1101-2020_09_23_308239	245	18	Slater	Slater	NNP
10_1101-2020_09_23_308239	245	19	,	,	,
10_1101-2020_09_23_308239	245	20	T.	t.	NN
10_1101-2020_09_23_308239	245	21	(	(	-LRB-
10_1101-2020_09_23_308239	245	22	2014	2014	CD
10_1101-2020_09_23_308239	245	23	)	)	-RRB-
10_1101-2020_09_23_308239	245	24	.	.	.
10_1101-2020_09_23_308239	246	1	Recent	recent	JJ
10_1101-2020_09_23_308239	246	2	advances	advance	NNS
10_1101-2020_09_23_308239	246	3	in	in	IN
10_1101-2020_09_23_308239	246	4	modeling	modeling	NN
10_1101-2020_09_23_308239	246	5	languages	language	NNS
10_1101-2020_09_23_308239	246	6	for	for	IN
10_1101-2020_09_23_308239	246	7	pathway	pathway	JJ
10_1101-2020_09_23_308239	246	8	maps	map	NNS
10_1101-2020_09_23_308239	246	9	and	and	CC
10_1101-2020_09_23_308239	246	10	computable	computable	JJ
10_1101-2020_09_23_308239	246	11	biological	biological	JJ
10_1101-2020_09_23_308239	246	12	networks	network	NNS
10_1101-2020_09_23_308239	246	13	.	.	.
10_1101-2020_09_23_308239	247	1	Drug	drug	NN
10_1101-2020_09_23_308239	247	2	discovery	discovery	NN
10_1101-2020_09_23_308239	247	3	today	today	NN
10_1101-2020_09_23_308239	247	4	,	,	,
10_1101-2020_09_23_308239	247	5	19(2	19(2	NNP
10_1101-2020_09_23_308239	247	6	)	)	-RRB-
10_1101-2020_09_23_308239	247	7	,	,	,
10_1101-2020_09_23_308239	247	8	193	193	CD
10_1101-2020_09_23_308239	247	9	-	-	SYM
10_1101-2020_09_23_308239	247	10	198	198	CD
10_1101-2020_09_23_308239	247	11	.	.	.
10_1101-2020_09_23_308239	248	1	29	29	CD
10_1101-2020_09_23_308239	248	2	Domingo	Domingo	NNP
10_1101-2020_09_23_308239	248	3	-	-	HYPH
10_1101-2020_09_23_308239	248	4	Fernández	Fernández	NNP
10_1101-2020_09_23_308239	248	5	,	,	,
10_1101-2020_09_23_308239	248	6	D.	D.	NNP
10_1101-2020_09_23_308239	248	7	,	,	,
10_1101-2020_09_23_308239	248	8	Mubeen	Mubeen	NNP
10_1101-2020_09_23_308239	248	9	,	,	,
10_1101-2020_09_23_308239	248	10	S.	S.	NNP
10_1101-2020_09_23_308239	248	11	,	,	,
10_1101-2020_09_23_308239	248	12	Marín	Marín	NNPS
10_1101-2020_09_23_308239	248	13	-	-	HYPH
10_1101-2020_09_23_308239	248	14	Llaó	Llaó	NNP
10_1101-2020_09_23_308239	248	15	,	,	,
10_1101-2020_09_23_308239	248	16	J.	J.	NNP
10_1101-2020_09_23_308239	248	17	,	,	,
10_1101-2020_09_23_308239	248	18	Hoyt	Hoyt	NNP
10_1101-2020_09_23_308239	248	19	,	,	,
10_1101-2020_09_23_308239	248	20	C.	C.	NNP
10_1101-2020_09_23_308239	248	21	T.	T.	NNP
10_1101-2020_09_23_308239	248	22	,	,	,
10_1101-2020_09_23_308239	248	23	&	&	CC
10_1101-2020_09_23_308239	248	24	Hofmann	Hofmann	NNP
10_1101-2020_09_23_308239	248	25	-	-	HYPH
10_1101-2020_09_23_308239	248	26	Apitius	Apitius	NNP
10_1101-2020_09_23_308239	248	27	,	,	,
10_1101-2020_09_23_308239	248	28	M.	M.	NNP
10_1101-2020_09_23_308239	248	29	(	(	-LRB-
10_1101-2020_09_23_308239	248	30	2019	2019	CD
10_1101-2020_09_23_308239	248	31	)	)	-RRB-
10_1101-2020_09_23_308239	248	32	.	.	.
10_1101-2020_09_23_308239	249	1	PathMe	pathme	NN
10_1101-2020_09_23_308239	249	2	:	:	:
10_1101-2020_09_23_308239	249	3	Merging	merge	VBG
10_1101-2020_09_23_308239	249	4	and	and	CC
10_1101-2020_09_23_308239	249	5	exploring	explore	VBG
10_1101-2020_09_23_308239	249	6	mechanistic	mechanistic	JJ
10_1101-2020_09_23_308239	249	7	pathway	pathway	JJ
10_1101-2020_09_23_308239	249	8	knowledge	knowledge	NN
10_1101-2020_09_23_308239	249	9	.	.	.
10_1101-2020_09_23_308239	250	1	BMC	BMC	NNP
10_1101-2020_09_23_308239	250	2	bioinformatics	bioinformatics	NNP
10_1101-2020_09_23_308239	250	3	,	,	,
10_1101-2020_09_23_308239	250	4	20(1	20(1	CD
10_1101-2020_09_23_308239	250	5	)	)	-RRB-
10_1101-2020_09_23_308239	250	6	,	,	,
10_1101-2020_09_23_308239	250	7	243	243	CD
10_1101-2020_09_23_308239	250	8	.	.	.
10_1101-2020_09_23_308239	251	1	30	30	CD
10_1101-2020_09_23_308239	251	2	Domingo	Domingo	NNP
10_1101-2020_09_23_308239	251	3	-	-	HYPH
10_1101-2020_09_23_308239	251	4	Fernández	Fernández	NNP
10_1101-2020_09_23_308239	251	5	,	,	,
10_1101-2020_09_23_308239	251	6	D.	D.	NNP
10_1101-2020_09_23_308239	251	7	,	,	,
10_1101-2020_09_23_308239	251	8	Hoyt	Hoyt	NNP
10_1101-2020_09_23_308239	251	9	,	,	,
10_1101-2020_09_23_308239	251	10	C.	C.	NNP
10_1101-2020_09_23_308239	251	11	T.	T.	NNP
10_1101-2020_09_23_308239	251	12	,	,	,
10_1101-2020_09_23_308239	251	13	Bobis	Bobis	NNP
10_1101-2020_09_23_308239	251	14	-	-	HYPH
10_1101-2020_09_23_308239	251	15	Álvarez	Álvarez	NNP
10_1101-2020_09_23_308239	251	16	,	,	,
10_1101-2020_09_23_308239	251	17	C.	C.	NNP
10_1101-2020_09_23_308239	251	18	,	,	,
10_1101-2020_09_23_308239	251	19	Marín	Marín	NNPS
10_1101-2020_09_23_308239	251	20	-	-	HYPH
10_1101-2020_09_23_308239	251	21	Llaó	Llaó	NNP
10_1101-2020_09_23_308239	251	22	,	,	,
10_1101-2020_09_23_308239	251	23	J.	J.	NNP
10_1101-2020_09_23_308239	251	24	,	,	,
10_1101-2020_09_23_308239	251	25	&	&	CC
10_1101-2020_09_23_308239	251	26	Hofmann	Hofmann	NNP
10_1101-2020_09_23_308239	251	27	-	-	HYPH
10_1101-2020_09_23_308239	251	28	Apitius	Apitius	NNP
10_1101-2020_09_23_308239	251	29	,	,	,
10_1101-2020_09_23_308239	251	30	M.	M.	NNP
10_1101-2020_09_23_308239	251	31	(	(	-LRB-
10_1101-2020_09_23_308239	251	32	2018	2018	CD
10_1101-2020_09_23_308239	251	33	)	)	-RRB-
10_1101-2020_09_23_308239	251	34	.	.	.
10_1101-2020_09_23_308239	252	1	ComPath	ComPath	NNP
10_1101-2020_09_23_308239	252	2	:	:	:
10_1101-2020_09_23_308239	252	3	an	an	DT
10_1101-2020_09_23_308239	252	4	ecosystem	ecosystem	NN
10_1101-2020_09_23_308239	252	5	for	for	IN
10_1101-2020_09_23_308239	252	6	exploring	explore	VBG
10_1101-2020_09_23_308239	252	7	,	,	,
10_1101-2020_09_23_308239	252	8	analyzing	analyze	VBG
10_1101-2020_09_23_308239	252	9	,	,	,
10_1101-2020_09_23_308239	252	10	and	and	CC
10_1101-2020_09_23_308239	252	11	curating	curate	VBG
10_1101-2020_09_23_308239	252	12	mappings	mapping	NNS
10_1101-2020_09_23_308239	252	13	across	across	IN
10_1101-2020_09_23_308239	252	14	pathway	pathway	JJ
10_1101-2020_09_23_308239	252	15	databases	database	NNS
10_1101-2020_09_23_308239	252	16	.	.	.
10_1101-2020_09_23_308239	253	1	NPJ	npj	NN
10_1101-2020_09_23_308239	253	2	systems	system	NNS
10_1101-2020_09_23_308239	253	3	biology	biology	NN
10_1101-2020_09_23_308239	253	4	and	and	CC
10_1101-2020_09_23_308239	253	5	applications	application	NNS
10_1101-2020_09_23_308239	253	6	,	,	,
10_1101-2020_09_23_308239	253	7	4(1	4(1	NNP
10_1101-2020_09_23_308239	253	8	)	)	-RRB-
10_1101-2020_09_23_308239	253	9	,	,	,
10_1101-2020_09_23_308239	253	10	1	1	CD
10_1101-2020_09_23_308239	253	11	-	-	SYM
10_1101-2020_09_23_308239	253	12	8	8	CD
10_1101-2020_09_23_308239	253	13	.	.	.
10_1101-2020_09_23_308239	254	1	31	31	CD
10_1101-2020_09_23_308239	254	2	Astghik	Astghik	NNP
10_1101-2020_09_23_308239	254	3	,	,	,
10_1101-2020_09_23_308239	254	4	S.	S.	NNP
10_1101-2020_09_23_308239	254	5	et	et	NNP
10_1101-2020_09_23_308239	254	6	al	al	NNP
10_1101-2020_09_23_308239	254	7	.	.	NNP
10_1101-2020_09_23_308239	254	8	,	,	,
10_1101-2020_09_23_308239	254	9	submitted	submit	VBN
10_1101-2020_09_23_308239	254	10	,	,	,
10_1101-2020_09_23_308239	254	11	Bioinformatics	Bioinformatics	NNP
10_1101-2020_09_23_308239	254	12	Journal	Journal	NNP
10_1101-2020_09_23_308239	254	13	(	(	-LRB-
10_1101-2020_09_23_308239	254	14	OUP	OUP	NNP
10_1101-2020_09_23_308239	254	15	)	)	-RRB-
10_1101-2020_09_23_308239	254	16	32	32	CD
10_1101-2020_09_23_308239	254	17	Chua	Chua	NNP
10_1101-2020_09_23_308239	254	18	,	,	,
10_1101-2020_09_23_308239	254	19	R.	R.	NNP
10_1101-2020_09_23_308239	254	20	L.	L.	NNP
10_1101-2020_09_23_308239	254	21	,	,	,
10_1101-2020_09_23_308239	254	22	Lukassen	Lukassen	NNP
10_1101-2020_09_23_308239	254	23	,	,	,
10_1101-2020_09_23_308239	254	24	S.	S.	NNP
10_1101-2020_09_23_308239	254	25	,	,	,
10_1101-2020_09_23_308239	254	26	Trump	Trump	NNP
10_1101-2020_09_23_308239	254	27	,	,	,
10_1101-2020_09_23_308239	254	28	S.	S.	NNP
10_1101-2020_09_23_308239	254	29	,	,	,
10_1101-2020_09_23_308239	254	30	Hennig	Hennig	NNP
10_1101-2020_09_23_308239	254	31	,	,	,
10_1101-2020_09_23_308239	254	32	B.	B.	NNP
10_1101-2020_09_23_308239	254	33	P.	P.	NNP
10_1101-2020_09_23_308239	254	34	,	,	,
10_1101-2020_09_23_308239	254	35	Wendisch	Wendisch	NNP
10_1101-2020_09_23_308239	254	36	,	,	,
10_1101-2020_09_23_308239	254	37	D.	D.	NNP
10_1101-2020_09_23_308239	254	38	,	,	,
10_1101-2020_09_23_308239	254	39	Pott	Pott	NNP
10_1101-2020_09_23_308239	254	40	,	,	,
10_1101-2020_09_23_308239	254	41	F.,Debnath	F.,Debnath	NNP
10_1101-2020_09_23_308239	254	42	,	,	,
10_1101-2020_09_23_308239	254	43	O.	O.	NNP
10_1101-2020_09_23_308239	254	44	,	,	,
10_1101-2020_09_23_308239	254	45	Thürmann	Thürmann	NNP
10_1101-2020_09_23_308239	254	46	,	,	,
10_1101-2020_09_23_308239	254	47	L.	L.	NNP
10_1101-2020_09_23_308239	254	48	,	,	,
10_1101-2020_09_23_308239	254	49	Kurth	Kurth	NNP
10_1101-2020_09_23_308239	254	50	,	,	,
10_1101-2020_09_23_308239	254	51	F.	F.	NNP
10_1101-2020_09_23_308239	254	52	,	,	,
10_1101-2020_09_23_308239	254	53	Völker	Völker	NNP
10_1101-2020_09_23_308239	254	54	,	,	,
10_1101-2020_09_23_308239	254	55	M.T.	M.T.	NNP
10_1101-2020_09_23_308239	254	56	,	,	,
10_1101-2020_09_23_308239	254	57	Kazmierski	Kazmierski	NNP
10_1101-2020_09_23_308239	254	58	,	,	,
10_1101-2020_09_23_308239	254	59	J.	J.	NNP
10_1101-2020_09_23_308239	254	60	,	,	,
10_1101-2020_09_23_308239	254	61	Timmermann	Timmermann	NNP
10_1101-2020_09_23_308239	254	62	,	,	,
10_1101-2020_09_23_308239	254	63	B.	B.	NNP
10_1101-2020_09_23_308239	254	64	,	,	,
10_1101-2020_09_23_308239	254	65	Twardziok	Twardziok	NNP
10_1101-2020_09_23_308239	254	66	,	,	,
10_1101-2020_09_23_308239	254	67	S.	S.	NNP
10_1101-2020_09_23_308239	254	68	,	,	,
10_1101-2020_09_23_308239	254	69	Schneider	Schneider	NNP
10_1101-2020_09_23_308239	254	70	,	,	,
10_1101-2020_09_23_308239	254	71	S.	S.	NNP
10_1101-2020_09_23_308239	254	72	,	,	,
10_1101-2020_09_23_308239	254	73	Machleidt	Machleidt	NNP
10_1101-2020_09_23_308239	254	74	,	,	,
10_1101-2020_09_23_308239	254	75	F.	F.	NNP
10_1101-2020_09_23_308239	254	76	,	,	,
10_1101-2020_09_23_308239	254	77	Müller	Müller	NNP
10_1101-2020_09_23_308239	254	78	-	-	HYPH
10_1101-2020_09_23_308239	254	79	Redetzky	Redetzky	NNP
10_1101-2020_09_23_308239	254	80	,	,	,
10_1101-2020_09_23_308239	254	81	H.	H.	NNP
10_1101-2020_09_23_308239	254	82	,	,	,
10_1101-2020_09_23_308239	254	83	Maier	Maier	NNP
10_1101-2020_09_23_308239	254	84	,	,	,
10_1101-2020_09_23_308239	254	85	M.	M.	NNP
10_1101-2020_09_23_308239	254	86	,	,	,
10_1101-2020_09_23_308239	254	87	Krannich	Krannich	NNP
10_1101-2020_09_23_308239	254	88	,	,	,
10_1101-2020_09_23_308239	254	89	A.	A.	NNP
10_1101-2020_09_23_308239	254	90	,	,	,
10_1101-2020_09_23_308239	254	91	Schmidt	Schmidt	NNP
10_1101-2020_09_23_308239	254	92	,	,	,
10_1101-2020_09_23_308239	254	93	S.	S.	NNP
10_1101-2020_09_23_308239	254	94	,	,	,
10_1101-2020_09_23_308239	254	95	Balzer	Balzer	NNP
10_1101-2020_09_23_308239	254	96	,	,	,
10_1101-2020_09_23_308239	254	97	F.	F.	NNP
10_1101-2020_09_23_308239	254	98	,	,	,
10_1101-2020_09_23_308239	254	99	Liebig	Liebig	NNP
10_1101-2020_09_23_308239	254	100	,	,	,
10_1101-2020_09_23_308239	254	101	J.	J.	NNP
10_1101-2020_09_23_308239	254	102	,	,	,
10_1101-2020_09_23_308239	254	103	Loske	Loske	NNP
10_1101-2020_09_23_308239	254	104	,	,	,
10_1101-2020_09_23_308239	254	105	J.	J.	NNP
10_1101-2020_09_23_308239	254	106	,	,	,
10_1101-2020_09_23_308239	254	107	Suttorp	Suttorp	NNP
10_1101-2020_09_23_308239	254	108	,	,	,
10_1101-2020_09_23_308239	254	109	N.	N.	NNP
10_1101-2020_09_23_308239	254	110	,	,	,
10_1101-2020_09_23_308239	254	111	Eils	Eils	NNP
10_1101-2020_09_23_308239	254	112	,	,	,
10_1101-2020_09_23_308239	254	113	J.	J.	NNP
10_1101-2020_09_23_308239	254	114	,	,	,
10_1101-2020_09_23_308239	254	115	Ishaque	Ishaque	NNP
10_1101-2020_09_23_308239	254	116	,	,	,
10_1101-2020_09_23_308239	254	117	N.	N.	NNP
10_1101-2020_09_23_308239	254	118	,	,	,
10_1101-2020_09_23_308239	254	119	Liebert	Liebert	NNP
10_1101-2020_09_23_308239	254	120	,	,	,
10_1101-2020_09_23_308239	254	121	U.G.	U.G.	NNP
10_1101-2020_09_23_308239	254	122	,	,	,
10_1101-2020_09_23_308239	254	123	von	von	NNP
10_1101-2020_09_23_308239	254	124	Kalle	Kalle	NNP
10_1101-2020_09_23_308239	254	125	,	,	,
10_1101-2020_09_23_308239	254	126	C.	C.	NNP
10_1101-2020_09_23_308239	254	127	,	,	,
10_1101-2020_09_23_308239	254	128	Witzenrath	Witzenrath	NNP
10_1101-2020_09_23_308239	254	129	,	,	,
10_1101-2020_09_23_308239	254	130	M.	M.	NNP
10_1101-2020_09_23_308239	254	131	,	,	,
10_1101-2020_09_23_308239	254	132	Goffinet	Goffinet	NNP
10_1101-2020_09_23_308239	254	133	,	,	,
10_1101-2020_09_23_308239	254	134	C.	C.	NNP
10_1101-2020_09_23_308239	254	135	,	,	,
10_1101-2020_09_23_308239	254	136	Drosten	Drosten	NNP
10_1101-2020_09_23_308239	254	137	,	,	,
10_1101-2020_09_23_308239	254	138	C.	C.	NNP
10_1101-2020_09_23_308239	254	139	,	,	,
10_1101-2020_09_23_308239	254	140	Laudi	Laudi	NNP
10_1101-2020_09_23_308239	254	141	,	,	,
10_1101-2020_09_23_308239	254	142	S.	S.	NNP
10_1101-2020_09_23_308239	254	143	,	,	,
10_1101-2020_09_23_308239	254	144	Lehmann	Lehmann	NNP
10_1101-2020_09_23_308239	254	145	,	,	,
10_1101-2020_09_23_308239	254	146	I.	I.	NNP
10_1101-2020_09_23_308239	254	147	,	,	,
10_1101-2020_09_23_308239	254	148	Conrad	Conrad	NNP
10_1101-2020_09_23_308239	254	149	,	,	,
10_1101-2020_09_23_308239	254	150	C.	C.	NNP
10_1101-2020_09_23_308239	254	151	,	,	,
10_1101-2020_09_23_308239	254	152	Sander	Sander	NNP
10_1101-2020_09_23_308239	254	153	,	,	,
10_1101-2020_09_23_308239	254	154	L	L	NNP
10_1101-2020_09_23_308239	254	155	-	-	HYPH
10_1101-2020_09_23_308239	254	156	E.	E.	NNP
10_1101-2020_09_23_308239	254	157	and	and	CC
10_1101-2020_09_23_308239	254	158	Eils	Eils	NNP
10_1101-2020_09_23_308239	254	159	,	,	,
10_1101-2020_09_23_308239	254	160	R.	R.	NNP
10_1101-2020_09_23_308239	254	161	(	(	-LRB-
10_1101-2020_09_23_308239	254	162	2020	2020	CD
10_1101-2020_09_23_308239	254	163	)	)	-RRB-
10_1101-2020_09_23_308239	254	164	.	.	.
10_1101-2020_09_23_308239	255	1	COVID-19	COVID-19	,
10_1101-2020_09_23_308239	255	2	severity	severity	NN
10_1101-2020_09_23_308239	255	3	correlates	correlate	VBZ
10_1101-2020_09_23_308239	255	4	with	with	IN
10_1101-2020_09_23_308239	255	5	airway	airway	NN
10_1101-2020_09_23_308239	255	6	epithelium	epithelium	NN
10_1101-2020_09_23_308239	255	7	–	–	:
10_1101-2020_09_23_308239	255	8	immune	immune	JJ
10_1101-2020_09_23_308239	255	9	cell	cell	NN
10_1101-2020_09_23_308239	255	10	interactions	interaction	NNS
10_1101-2020_09_23_308239	255	11	identified	identify	VBN
10_1101-2020_09_23_308239	255	12	by	by	IN
10_1101-2020_09_23_308239	255	13	single	single	JJ
10_1101-2020_09_23_308239	255	14	-	-	HYPH
10_1101-2020_09_23_308239	255	15	cell	cell	NN
10_1101-2020_09_23_308239	255	16	analysis	analysis	NN
10_1101-2020_09_23_308239	255	17	.	.	.
10_1101-2020_09_23_308239	256	1	Nature	Nature	NNP
10_1101-2020_09_23_308239	256	2	Biotechnology	Biotechnology	NNP
10_1101-2020_09_23_308239	256	3	,	,	,
10_1101-2020_09_23_308239	256	4	38(8	38(8	CD
10_1101-2020_09_23_308239	256	5	)	)	-RRB-
10_1101-2020_09_23_308239	256	6	,	,	,
10_1101-2020_09_23_308239	256	7	970	970	CD
10_1101-2020_09_23_308239	256	8	-	-	SYM
10_1101-2020_09_23_308239	256	9	979	979	CD
10_1101-2020_09_23_308239	256	10	.	.	.
10_1101-2020_09_23_308239	257	1	33	33	CD
10_1101-2020_09_23_308239	257	2	Ravindra	Ravindra	NNP
10_1101-2020_09_23_308239	257	3	,	,	,
10_1101-2020_09_23_308239	257	4	N.	N.	NNP
10_1101-2020_09_23_308239	257	5	G.	G.	NNP
10_1101-2020_09_23_308239	257	6	,	,	,
10_1101-2020_09_23_308239	257	7	Alfajaro	Alfajaro	NNP
10_1101-2020_09_23_308239	257	8	,	,	,
10_1101-2020_09_23_308239	257	9	M.	M.	NNP
10_1101-2020_09_23_308239	257	10	M.	M.	NNP
10_1101-2020_09_23_308239	257	11	,	,	,
10_1101-2020_09_23_308239	257	12	Gasque	Gasque	NNP
10_1101-2020_09_23_308239	257	13	,	,	,
10_1101-2020_09_23_308239	257	14	V.	V.	NNP
10_1101-2020_09_23_308239	257	15	,	,	,
10_1101-2020_09_23_308239	257	16	Habet	Habet	NNP
10_1101-2020_09_23_308239	257	17	,	,	,
10_1101-2020_09_23_308239	257	18	V.	V.	NNP
10_1101-2020_09_23_308239	257	19	,	,	,
10_1101-2020_09_23_308239	257	20	Wei	Wei	NNP
10_1101-2020_09_23_308239	257	21	,	,	,
10_1101-2020_09_23_308239	257	22	J.	J.	NNP
10_1101-2020_09_23_308239	257	23	,	,	,
10_1101-2020_09_23_308239	257	24	Filler	Filler	NNP
10_1101-2020_09_23_308239	257	25	,	,	,
10_1101-2020_09_23_308239	257	26	R.	R.	NNP
10_1101-2020_09_23_308239	257	27	B.	B.	NNP
10_1101-2020_09_23_308239	257	28	,	,	,
10_1101-2020_09_23_308239	257	29	Huston	Huston	NNP
10_1101-2020_09_23_308239	257	30	,	,	,
10_1101-2020_09_23_308239	257	31	N.	N.	NNP
10_1101-2020_09_23_308239	257	32	C.	C.	NNP
10_1101-2020_09_23_308239	257	33	,	,	,
10_1101-2020_09_23_308239	257	34	Wan	Wan	NNP
10_1101-2020_09_23_308239	257	35	,	,	,
10_1101-2020_09_23_308239	257	36	H.	H.	NNP
10_1101-2020_09_23_308239	257	37	,	,	,
10_1101-2020_09_23_308239	257	38	Szigeti-	Szigeti-	NNP
10_1101-2020_09_23_308239	257	39	Buck	Buck	NNP
10_1101-2020_09_23_308239	257	40	,	,	,
10_1101-2020_09_23_308239	257	41	K.	K.	NNP
10_1101-2020_09_23_308239	257	42	,	,	,
10_1101-2020_09_23_308239	257	43	Wang	Wang	NNP
10_1101-2020_09_23_308239	257	44	,	,	,
10_1101-2020_09_23_308239	257	45	B.	B.	NNP
10_1101-2020_09_23_308239	257	46	,	,	,
10_1101-2020_09_23_308239	257	47	Wang	Wang	NNP
10_1101-2020_09_23_308239	257	48	,	,	,
10_1101-2020_09_23_308239	257	49	G.	G.	NNP
10_1101-2020_09_23_308239	257	50	,	,	,
10_1101-2020_09_23_308239	257	51	Montgomery	Montgomery	NNP
10_1101-2020_09_23_308239	257	52	,	,	,
10_1101-2020_09_23_308239	257	53	R.R.	R.R.	NNP
10_1101-2020_09_23_308239	257	54	,	,	,
10_1101-2020_09_23_308239	257	55	Eisenbarth	Eisenbarth	NNP
10_1101-2020_09_23_308239	257	56	,	,	,
10_1101-2020_09_23_308239	257	57	S.	S.	NNP
10_1101-2020_09_23_308239	257	58	C.	C.	NNP
10_1101-2020_09_23_308239	257	59	,	,	,
10_1101-2020_09_23_308239	257	60	Williams	Williams	NNP
10_1101-2020_09_23_308239	257	61	,	,	,
10_1101-2020_09_23_308239	257	62	A.	a.	NN
10_1101-2020_09_23_308239	257	63	,	,	,
10_1101-2020_09_23_308239	257	64	Pyle	Pyle	NNP
10_1101-2020_09_23_308239	257	65	,	,	,
10_1101-2020_09_23_308239	257	66	A.M.	A.M.	NNP
10_1101-2020_09_23_308239	257	67	,	,	,
10_1101-2020_09_23_308239	257	68	Iwasaki	Iwasaki	NNP
10_1101-2020_09_23_308239	257	69	,	,	,
10_1101-2020_09_23_308239	257	70	A.	a.	NN
10_1101-2020_09_23_308239	257	71	,	,	,
10_1101-2020_09_23_308239	257	72	Horvath	Horvath	NNP
10_1101-2020_09_23_308239	257	73	,	,	,
10_1101-2020_09_23_308239	257	74	T.L.	T.L.	NNP
10_1101-2020_09_23_308239	257	75	,	,	,
10_1101-2020_09_23_308239	257	76	Foxman	Foxman	NNP
10_1101-2020_09_23_308239	257	77	,	,	,
10_1101-2020_09_23_308239	257	78	E.F.	E.F.	NNP
10_1101-2020_09_23_308239	257	79	,	,	,
10_1101-2020_09_23_308239	257	80	Pierce	Pierce	NNP
10_1101-2020_09_23_308239	257	81	,	,	,
10_1101-2020_09_23_308239	257	82	R.W.	R.W.	NNP
10_1101-2020_09_23_308239	257	83	,	,	,
10_1101-2020_09_23_308239	257	84	van	van	NNP
10_1101-2020_09_23_308239	257	85	Dijk	Dijk	NNP
10_1101-2020_09_23_308239	257	86	,	,	,
10_1101-2020_09_23_308239	257	87	D.	D.	NNP
10_1101-2020_09_23_308239	257	88	,	,	,
10_1101-2020_09_23_308239	257	89	and	and	CC
10_1101-2020_09_23_308239	257	90	Wilen	Wilen	NNP
10_1101-2020_09_23_308239	257	91	,	,	,
10_1101-2020_09_23_308239	257	92	C.B.	C.B.	NNP
10_1101-2020_09_23_308239	258	1	(	(	-LRB-
10_1101-2020_09_23_308239	258	2	2020	2020	CD
10_1101-2020_09_23_308239	258	3	)	)	-RRB-
10_1101-2020_09_23_308239	258	4	.	.	.
10_1101-2020_09_23_308239	259	1	Single	single	JJ
10_1101-2020_09_23_308239	259	2	-	-	HYPH
10_1101-2020_09_23_308239	259	3	cell	cell	NN
10_1101-2020_09_23_308239	259	4	longitudinal	longitudinal	JJ
10_1101-2020_09_23_308239	259	5	analysis	analysis	NN
10_1101-2020_09_23_308239	259	6	of	of	IN
10_1101-2020_09_23_308239	259	7	SARS-	SARS-	NNP
10_1101-2020_09_23_308239	259	8	CoV-2	cov-2	POS
10_1101-2020_09_23_308239	259	9	infection	infection	NN
10_1101-2020_09_23_308239	259	10	in	in	IN
10_1101-2020_09_23_308239	259	11	human	human	JJ
10_1101-2020_09_23_308239	259	12	bronchial	bronchial	JJ
10_1101-2020_09_23_308239	259	13	epithelial	epithelial	JJ
10_1101-2020_09_23_308239	259	14	cells	cell	NNS
10_1101-2020_09_23_308239	259	15	.	.	.
10_1101-2020_09_23_308239	260	1	bioRxiv	biorxiv	NN
10_1101-2020_09_23_308239	260	2	.	.	.
10_1101-2020_09_23_308239	261	1	34	34	CD
10_1101-2020_09_23_308239	261	2	Kuleshov	Kuleshov	NNP
10_1101-2020_09_23_308239	261	3	MV	MV	NNP
10_1101-2020_09_23_308239	261	4	,	,	,
10_1101-2020_09_23_308239	261	5	Jones	Jones	NNP
10_1101-2020_09_23_308239	261	6	MR	MR	NNP
10_1101-2020_09_23_308239	261	7	,	,	,
10_1101-2020_09_23_308239	261	8	Rouillard	Rouillard	NNP
10_1101-2020_09_23_308239	261	9	AD	AD	NNP
10_1101-2020_09_23_308239	261	10	,	,	,
10_1101-2020_09_23_308239	261	11	et	et	NNP
10_1101-2020_09_23_308239	261	12	al	al	NNP
10_1101-2020_09_23_308239	261	13	.	.	.
10_1101-2020_09_23_308239	262	1	Enrichr	Enrichr	NNP
10_1101-2020_09_23_308239	262	2	:	:	:
10_1101-2020_09_23_308239	262	3	a	a	DT
10_1101-2020_09_23_308239	262	4	comprehensive	comprehensive	JJ
10_1101-2020_09_23_308239	262	5	gene	gene	NN
10_1101-2020_09_23_308239	262	6	set	set	NN
10_1101-2020_09_23_308239	262	7	enrichment	enrichment	NN
10_1101-2020_09_23_308239	262	8	analysis	analysis	NN
10_1101-2020_09_23_308239	262	9	web	web	NN
10_1101-2020_09_23_308239	262	10	server	server	NN
10_1101-2020_09_23_308239	262	11	2016	2016	CD
10_1101-2020_09_23_308239	262	12	update	update	NN
10_1101-2020_09_23_308239	262	13	.	.	.
10_1101-2020_09_23_308239	263	1	Nucleic	Nucleic	NNP
10_1101-2020_09_23_308239	263	2	Acids	Acids	NNPS
10_1101-2020_09_23_308239	263	3	Res	Res	NNP
10_1101-2020_09_23_308239	263	4	.	.	.
10_1101-2020_09_23_308239	264	1	2016;44(W1):W90-W97	2016;44(w1):w90-w97	CD
10_1101-2020_09_23_308239	264	2	.	.	.
10_1101-2020_09_23_308239	265	1	doi:10.1093	doi:10.1093	NNP
10_1101-2020_09_23_308239	265	2	/	/	SYM
10_1101-2020_09_23_308239	265	3	nar	nar	NNP
10_1101-2020_09_23_308239	265	4	/	/	SYM
10_1101-2020_09_23_308239	265	5	gkw377	gkw377	NNP
10_1101-2020_09_23_308239	265	6	35	35	CD
10_1101-2020_09_23_308239	265	7	https://pypi.org/project/gseapy/	https://pypi.org/project/gseapy/	NN
10_1101-2020_09_23_308239	265	8	36	36	CD
10_1101-2020_09_23_308239	265	9	Benjamini	Benjamini	NNP
10_1101-2020_09_23_308239	265	10	Y.	Y.	NNP
10_1101-2020_09_23_308239	265	11	Discovering	discover	VBG
10_1101-2020_09_23_308239	265	12	the	the	DT
10_1101-2020_09_23_308239	265	13	false	false	JJ
10_1101-2020_09_23_308239	265	14	discovery	discovery	NN
10_1101-2020_09_23_308239	265	15	rate	rate	NN
10_1101-2020_09_23_308239	265	16	:	:	:
10_1101-2020_09_23_308239	265	17	False	false	JJ
10_1101-2020_09_23_308239	265	18	Discovery	Discovery	NNP
10_1101-2020_09_23_308239	265	19	Rate	rate	NN
10_1101-2020_09_23_308239	265	20	.	.	.
10_1101-2020_09_23_308239	266	1	J.	J.	NNP
10_1101-2020_09_23_308239	266	2	R.	R.	NNP
10_1101-2020_09_23_308239	266	3	Stat	Stat	NNP
10_1101-2020_09_23_308239	266	4	.	.	.
10_1101-2020_09_23_308239	267	1	Soc	Soc	NNP
10_1101-2020_09_23_308239	267	2	.	.	.
10_1101-2020_09_23_308239	268	1	Ser	Ser	NNP
10_1101-2020_09_23_308239	268	2	.	.	.
10_1101-2020_09_23_308239	269	1	B	B	NNP
10_1101-2020_09_23_308239	269	2	Stat	Stat	NNP
10_1101-2020_09_23_308239	269	3	.	.	.
10_1101-2020_09_23_308239	270	1	Methodol	Methodol	NNP
10_1101-2020_09_23_308239	270	2	.	.	.
10_1101-2020_09_23_308239	271	1	2010;72(4):405–416	2010;72(4):405–416	LS
10_1101-2020_09_23_308239	271	2	.	.	.
10_1101-2020_09_23_308239	272	1	doi	doi	NNP
10_1101-2020_09_23_308239	272	2	:	:	:
10_1101-2020_09_23_308239	272	3	10.1111	10.1111	CD
10_1101-2020_09_23_308239	272	4	/	/	SYM
10_1101-2020_09_23_308239	272	5	j.1467	j.1467	NNP
10_1101-2020_09_23_308239	272	6	-	-	HYPH
10_1101-2020_09_23_308239	272	7	9868.2010.00746.x	9868.2010.00746.x	NNP
10_1101-2020_09_23_308239	272	8	.	.	.
10_1101-2020_09_23_308239	273	1	37	37	CD
10_1101-2020_09_23_308239	273	2	Hoehl	Hoehl	NNP
10_1101-2020_09_23_308239	273	3	,	,	,
10_1101-2020_09_23_308239	273	4	S.	S.	NNP
10_1101-2020_09_23_308239	273	5	,	,	,
10_1101-2020_09_23_308239	273	6	Rabenau	Rabenau	NNP
10_1101-2020_09_23_308239	273	7	,	,	,
10_1101-2020_09_23_308239	273	8	H.	H.	NNP
10_1101-2020_09_23_308239	273	9	,	,	,
10_1101-2020_09_23_308239	273	10	Berger	Berger	NNP
10_1101-2020_09_23_308239	273	11	,	,	,
10_1101-2020_09_23_308239	273	12	A.	A.	NNP
10_1101-2020_09_23_308239	273	13	,	,	,
10_1101-2020_09_23_308239	273	14	Kortenbusch	Kortenbusch	NNP
10_1101-2020_09_23_308239	273	15	,	,	,
10_1101-2020_09_23_308239	273	16	M.	M.	NNP
10_1101-2020_09_23_308239	273	17	,	,	,
10_1101-2020_09_23_308239	273	18	Cinatl	Cinatl	NNP
10_1101-2020_09_23_308239	273	19	,	,	,
10_1101-2020_09_23_308239	273	20	J.	J.	NNP
10_1101-2020_09_23_308239	273	21	,	,	,
10_1101-2020_09_23_308239	273	22	Bojkova	Bojkova	NNP
10_1101-2020_09_23_308239	273	23	,	,	,
10_1101-2020_09_23_308239	273	24	D.	D.	NNP
10_1101-2020_09_23_308239	273	25	,	,	,
10_1101-2020_09_23_308239	273	26	Behrens	Behrens	NNP
10_1101-2020_09_23_308239	273	27	,	,	,
10_1101-2020_09_23_308239	273	28	P.	P.	NNP
10_1101-2020_09_23_308239	273	29	,	,	,
10_1101-2020_09_23_308239	273	30	Böddinghaus	Böddinghaus	NNP
10_1101-2020_09_23_308239	273	31	,	,	,
10_1101-2020_09_23_308239	273	32	B.	B.	NNP
10_1101-2020_09_23_308239	273	33	,	,	,
10_1101-2020_09_23_308239	273	34	Götsch	Götsch	NNP
10_1101-2020_09_23_308239	273	35	,	,	,
10_1101-2020_09_23_308239	273	36	U.	U.	NNP
10_1101-2020_09_23_308239	273	37	,	,	,
10_1101-2020_09_23_308239	273	38	Naujoks	Naujoks	NNP
10_1101-2020_09_23_308239	273	39	,	,	,
10_1101-2020_09_23_308239	273	40	F.	F.	NNP
10_1101-2020_09_23_308239	273	41	,	,	,
10_1101-2020_09_23_308239	273	42	Neumann	Neumann	NNP
10_1101-2020_09_23_308239	273	43	,	,	,
10_1101-2020_09_23_308239	273	44	P.	P.	NNP
10_1101-2020_09_23_308239	273	45	,	,	,
10_1101-2020_09_23_308239	273	46	Schork	Schork	NNP
10_1101-2020_09_23_308239	273	47	,	,	,
10_1101-2020_09_23_308239	273	48	J.	J.	NNP
10_1101-2020_09_23_308239	273	49	,	,	,
10_1101-2020_09_23_308239	273	50	Tiarks	Tiarks	NNP
10_1101-2020_09_23_308239	273	51	-	-	HYPH
10_1101-2020_09_23_308239	273	52	Jungk	Jungk	NNP
10_1101-2020_09_23_308239	273	53	,	,	,
10_1101-2020_09_23_308239	273	54	P.	P.	NNP
10_1101-2020_09_23_308239	273	55	,	,	,
10_1101-2020_09_23_308239	273	56	Walczok	Walczok	NNP
10_1101-2020_09_23_308239	273	57	,	,	,
10_1101-2020_09_23_308239	273	58	A.	A.	NNP
10_1101-2020_09_23_308239	273	59	,	,	,
10_1101-2020_09_23_308239	273	60	Eickmann	Eickmann	NNP
10_1101-2020_09_23_308239	273	61	,	,	,
10_1101-2020_09_23_308239	273	62	M.	M.	NNP
10_1101-2020_09_23_308239	273	63	,	,	,
10_1101-2020_09_23_308239	273	64	Vehreschild	Vehreschild	NNP
10_1101-2020_09_23_308239	273	65	,	,	,
10_1101-2020_09_23_308239	273	66	M.	M.	NNP
10_1101-2020_09_23_308239	273	67	,	,	,
10_1101-2020_09_23_308239	273	68	Kann	Kann	NNP
10_1101-2020_09_23_308239	273	69	,	,	,
10_1101-2020_09_23_308239	273	70	G.,Wolf	G.,Wolf	NNP
10_1101-2020_09_23_308239	273	71	,	,	,
10_1101-2020_09_23_308239	273	72	T.,Gottschalk	T.,Gottschalk	NNP
10_1101-2020_09_23_308239	273	73	,	,	,
10_1101-2020_09_23_308239	273	74	R.	R.	NNP
10_1101-2020_09_23_308239	273	75	,	,	,
10_1101-2020_09_23_308239	273	76	&	&	CC
10_1101-2020_09_23_308239	273	77	Ciesek	Ciesek	NNP
10_1101-2020_09_23_308239	273	78	,	,	,
10_1101-2020_09_23_308239	273	79	S.	S.	NNP
10_1101-2020_09_23_308239	273	80	(	(	-LRB-
10_1101-2020_09_23_308239	273	81	2020	2020	CD
10_1101-2020_09_23_308239	273	82	)	)	-RRB-
10_1101-2020_09_23_308239	273	83	.	.	.
10_1101-2020_09_23_308239	274	1	Evidence	evidence	NN
10_1101-2020_09_23_308239	274	2	of	of	IN
10_1101-2020_09_23_308239	274	3	SARS	SARS	NNP
10_1101-2020_09_23_308239	274	4	-	-	HYPH
10_1101-2020_09_23_308239	274	5	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	274	6	infection	infection	NN
10_1101-2020_09_23_308239	274	7	in	in	IN
10_1101-2020_09_23_308239	274	8	returning	return	VBG
10_1101-2020_09_23_308239	274	9	travelers	traveler	NNS
10_1101-2020_09_23_308239	274	10	from	from	IN
10_1101-2020_09_23_308239	274	11	Wuhan	Wuhan	NNP
10_1101-2020_09_23_308239	274	12	,	,	,
10_1101-2020_09_23_308239	274	13	China	China	NNP
10_1101-2020_09_23_308239	274	14	.	.	.
10_1101-2020_09_23_308239	275	1	New	New	NNP
10_1101-2020_09_23_308239	275	2	England	England	NNP
10_1101-2020_09_23_308239	275	3	Journal	Journal	NNP
10_1101-2020_09_23_308239	275	4	of	of	IN
10_1101-2020_09_23_308239	275	5	Medicine	Medicine	NNP
10_1101-2020_09_23_308239	275	6	,	,	,
10_1101-2020_09_23_308239	275	7	382(13	382(13	LS
10_1101-2020_09_23_308239	275	8	)	)	-RRB-
10_1101-2020_09_23_308239	275	9	,	,	,
10_1101-2020_09_23_308239	275	10	1278	1278	CD
10_1101-2020_09_23_308239	275	11	-	-	SYM
10_1101-2020_09_23_308239	275	12	1280	1280	CD
10_1101-2020_09_23_308239	275	13	.	.	.
10_1101-2020_09_23_308239	276	1	38	38	CD
10_1101-2020_09_23_308239	276	2	Ellinger	Ellinger	NNP
10_1101-2020_09_23_308239	276	3	,	,	,
10_1101-2020_09_23_308239	276	4	B.	B.	NNP
10_1101-2020_09_23_308239	276	5	,	,	,
10_1101-2020_09_23_308239	276	6	Bojkova	Bojkova	NNP
10_1101-2020_09_23_308239	276	7	,	,	,
10_1101-2020_09_23_308239	276	8	D.	D.	NNP
10_1101-2020_09_23_308239	276	9	,	,	,
10_1101-2020_09_23_308239	276	10	Zaliani	Zaliani	NNP
10_1101-2020_09_23_308239	276	11	,	,	,
10_1101-2020_09_23_308239	276	12	A.	a.	NN
10_1101-2020_09_23_308239	276	13	,	,	,
10_1101-2020_09_23_308239	276	14	Cinatl	Cinatl	NNP
10_1101-2020_09_23_308239	276	15	,	,	,
10_1101-2020_09_23_308239	276	16	J.	J.	NNP
10_1101-2020_09_23_308239	276	17	,	,	,
10_1101-2020_09_23_308239	276	18	Claussen	Claussen	NNP
10_1101-2020_09_23_308239	276	19	,	,	,
10_1101-2020_09_23_308239	276	20	C.	C.	NNP
10_1101-2020_09_23_308239	276	21	,	,	,
10_1101-2020_09_23_308239	276	22	Westhaus	Westhaus	NNP
10_1101-2020_09_23_308239	276	23	,	,	,
10_1101-2020_09_23_308239	276	24	S.	S.	NNP
10_1101-2020_09_23_308239	276	25	,	,	,
10_1101-2020_09_23_308239	276	26	...	...	.
10_1101-2020_09_23_308239	276	27	&	&	CC
10_1101-2020_09_23_308239	276	28	Gribbon	Gribbon	NNP
10_1101-2020_09_23_308239	276	29	,	,	,
10_1101-2020_09_23_308239	276	30	P.	P.	NNP
10_1101-2020_09_23_308239	276	31	(	(	-LRB-
10_1101-2020_09_23_308239	276	32	2020	2020	CD
10_1101-2020_09_23_308239	276	33	)	)	-RRB-
10_1101-2020_09_23_308239	276	34	.	.	.
10_1101-2020_09_23_308239	277	1	Identification	identification	NN
10_1101-2020_09_23_308239	277	2	of	of	IN
10_1101-2020_09_23_308239	277	3	inhibitors	inhibitor	NNS
10_1101-2020_09_23_308239	277	4	of	of	IN
10_1101-2020_09_23_308239	277	5	SARS	SARS	NNP
10_1101-2020_09_23_308239	277	6	-	-	HYPH
10_1101-2020_09_23_308239	277	7	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	277	8	in	in	IN
10_1101-2020_09_23_308239	277	9	-	-	HYPH
10_1101-2020_09_23_308239	277	10	vitro	vitro	FW
10_1101-2020_09_23_308239	277	11	cellular	cellular	JJ
10_1101-2020_09_23_308239	277	12	toxicity	toxicity	NN
10_1101-2020_09_23_308239	277	13	in	in	IN
10_1101-2020_09_23_308239	277	14	human	human	NN
10_1101-2020_09_23_308239	277	15	(	(	-LRB-
10_1101-2020_09_23_308239	277	16	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	277	17	)	)	-RRB-
10_1101-2020_09_23_308239	277	18	cells	cell	NNS
10_1101-2020_09_23_308239	277	19	using	use	VBG
10_1101-2020_09_23_308239	277	20	a	a	DT
10_1101-2020_09_23_308239	277	21	large	large	JJ
10_1101-2020_09_23_308239	277	22	scale	scale	NN
10_1101-2020_09_23_308239	277	23	drug	drug	NN
10_1101-2020_09_23_308239	277	24	repurposing	repurposing	NN
10_1101-2020_09_23_308239	277	25	collection	collection	NN
10_1101-2020_09_23_308239	277	26	.	.	.
10_1101-2020_09_23_308239	278	1	manuscript	manuscript	NNP
10_1101-2020_09_23_308239	278	2	under	under	IN
10_1101-2020_09_23_308239	278	3	review	review	NN
10_1101-2020_09_23_308239	278	4	39	39	CD
10_1101-2020_09_23_308239	278	5	Bobrowski	Bobrowski	NNP
10_1101-2020_09_23_308239	278	6	,	,	,
10_1101-2020_09_23_308239	278	7	T.	T.	NNP
10_1101-2020_09_23_308239	278	8	,	,	,
10_1101-2020_09_23_308239	278	9	Chen	Chen	NNP
10_1101-2020_09_23_308239	278	10	,	,	,
10_1101-2020_09_23_308239	278	11	L.	L.	NNP
10_1101-2020_09_23_308239	278	12	,	,	,
10_1101-2020_09_23_308239	278	13	Eastman	Eastman	NNP
10_1101-2020_09_23_308239	278	14	,	,	,
10_1101-2020_09_23_308239	278	15	R.	R.	NNP
10_1101-2020_09_23_308239	278	16	T.	T.	NNP
10_1101-2020_09_23_308239	278	17	,	,	,
10_1101-2020_09_23_308239	278	18	Itkin	Itkin	NNP
10_1101-2020_09_23_308239	278	19	,	,	,
10_1101-2020_09_23_308239	278	20	Z.	Z.	NNP
10_1101-2020_09_23_308239	278	21	,	,	,
10_1101-2020_09_23_308239	278	22	Shinn	Shinn	NNP
10_1101-2020_09_23_308239	278	23	,	,	,
10_1101-2020_09_23_308239	278	24	P.	P.	NNP
10_1101-2020_09_23_308239	278	25	,	,	,
10_1101-2020_09_23_308239	278	26	Chen	Chen	NNP
10_1101-2020_09_23_308239	278	27	,	,	,
10_1101-2020_09_23_308239	278	28	C.	C.	NNP
10_1101-2020_09_23_308239	278	29	,	,	,
10_1101-2020_09_23_308239	278	30	Guo	Guo	NNP
10_1101-2020_09_23_308239	278	31	,	,	,
10_1101-2020_09_23_308239	278	32	H.	H.	NNP
10_1101-2020_09_23_308239	278	33	,	,	,
10_1101-2020_09_23_308239	278	34	Zheng	Zheng	NNP
10_1101-2020_09_23_308239	278	35	,	,	,
10_1101-2020_09_23_308239	278	36	W.	W.	NNP
10_1101-2020_09_23_308239	278	37	,	,	,
10_1101-2020_09_23_308239	278	38	Michael	Michael	NNP
10_1101-2020_09_23_308239	278	39	,	,	,
10_1101-2020_09_23_308239	278	40	S.	S.	NNP
10_1101-2020_09_23_308239	278	41	,	,	,
10_1101-2020_09_23_308239	278	42	Simeonov	Simeonov	NNP
10_1101-2020_09_23_308239	278	43	,	,	,
10_1101-2020_09_23_308239	278	44	A.	A.	NNP
10_1101-2020_09_23_308239	278	45	,	,	,
10_1101-2020_09_23_308239	278	46	Hall	Hall	NNP
10_1101-2020_09_23_308239	278	47	,	,	,
10_1101-2020_09_23_308239	278	48	M.	M.	NNP
10_1101-2020_09_23_308239	278	49	,	,	,
10_1101-2020_09_23_308239	278	50	Zakharov	Zakharov	NNP
10_1101-2020_09_23_308239	278	51	,	,	,
10_1101-2020_09_23_308239	278	52	A.V.	A.V.	NNP
10_1101-2020_09_23_308239	278	53	,	,	,
10_1101-2020_09_23_308239	278	54	and	and	CC
10_1101-2020_09_23_308239	278	55	Muratov	Muratov	NNP
10_1101-2020_09_23_308239	278	56	,	,	,
10_1101-2020_09_23_308239	278	57	E.N.	E.N.	NNP
10_1101-2020_09_23_308239	279	1	(	(	-LRB-
10_1101-2020_09_23_308239	279	2	2020	2020	CD
10_1101-2020_09_23_308239	279	3	)	)	-RRB-
10_1101-2020_09_23_308239	279	4	.	.	.
10_1101-2020_09_23_308239	280	1	Discovery	Discovery	NNP
10_1101-2020_09_23_308239	280	2	of	of	IN
10_1101-2020_09_23_308239	280	3	Synergistic	Synergistic	NNP
10_1101-2020_09_23_308239	280	4	and	and	CC
10_1101-2020_09_23_308239	280	5	Antagonistic	Antagonistic	NNP
10_1101-2020_09_23_308239	280	6	Drug	Drug	NNP
10_1101-2020_09_23_308239	280	7	Combinations	Combinations	NNPS
10_1101-2020_09_23_308239	280	8	against	against	IN
10_1101-2020_09_23_308239	280	9	SARS	SARS	NNP
10_1101-2020_09_23_308239	280	10	-	-	HYPH
10_1101-2020_09_23_308239	280	11	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	280	12	In	in	IN
10_1101-2020_09_23_308239	280	13	Vitro	Vitro	NNP
10_1101-2020_09_23_308239	280	14	.	.	.
10_1101-2020_09_23_308239	281	1	BioRxiv	biorxiv	NN
10_1101-2020_09_23_308239	281	2	.	.	.
10_1101-2020_09_23_308239	282	1	40	40	CD
10_1101-2020_09_23_308239	282	2	Bobrowski	Bobrowski	NNP
10_1101-2020_09_23_308239	282	3	,	,	,
10_1101-2020_09_23_308239	282	4	T.	T.	NNP
10_1101-2020_09_23_308239	282	5	,	,	,
10_1101-2020_09_23_308239	282	6	Chen	Chen	NNP
10_1101-2020_09_23_308239	282	7	,	,	,
10_1101-2020_09_23_308239	282	8	L.	L.	NNP
10_1101-2020_09_23_308239	282	9	,	,	,
10_1101-2020_09_23_308239	282	10	Eastman	Eastman	NNP
10_1101-2020_09_23_308239	282	11	,	,	,
10_1101-2020_09_23_308239	282	12	R.	R.	NNP
10_1101-2020_09_23_308239	282	13	T.	T.	NNP
10_1101-2020_09_23_308239	282	14	,	,	,
10_1101-2020_09_23_308239	282	15	Itkin	Itkin	NNP
10_1101-2020_09_23_308239	282	16	,	,	,
10_1101-2020_09_23_308239	282	17	Z.	Z.	NNP
10_1101-2020_09_23_308239	282	18	,	,	,
10_1101-2020_09_23_308239	282	19	Shinn	Shinn	NNP
10_1101-2020_09_23_308239	282	20	,	,	,
10_1101-2020_09_23_308239	282	21	P.	P.	NNP
10_1101-2020_09_23_308239	282	22	,	,	,
10_1101-2020_09_23_308239	282	23	Chen	Chen	NNP
10_1101-2020_09_23_308239	282	24	,	,	,
10_1101-2020_09_23_308239	282	25	C.	C.	NNP
10_1101-2020_09_23_308239	282	26	,	,	,
10_1101-2020_09_23_308239	282	27	Guo	Guo	NNP
10_1101-2020_09_23_308239	282	28	,	,	,
10_1101-2020_09_23_308239	282	29	H.	H.	NNP
10_1101-2020_09_23_308239	282	30	,	,	,
10_1101-2020_09_23_308239	282	31	Zheng	Zheng	NNP
10_1101-2020_09_23_308239	282	32	,	,	,
10_1101-2020_09_23_308239	282	33	W.	W.	NNP
10_1101-2020_09_23_308239	282	34	,	,	,
10_1101-2020_09_23_308239	282	35	Michael	Michael	NNP
10_1101-2020_09_23_308239	282	36	,	,	,
10_1101-2020_09_23_308239	282	37	S.	S.	NNP
10_1101-2020_09_23_308239	282	38	,	,	,
10_1101-2020_09_23_308239	282	39	Simeonov	Simeonov	NNP
10_1101-2020_09_23_308239	282	40	,	,	,
10_1101-2020_09_23_308239	282	41	A.	A.	NNP
10_1101-2020_09_23_308239	282	42	,	,	,
10_1101-2020_09_23_308239	282	43	Hall	Hall	NNP
10_1101-2020_09_23_308239	282	44	,	,	,
10_1101-2020_09_23_308239	282	45	M.	M.	NNP
10_1101-2020_09_23_308239	282	46	,	,	,
10_1101-2020_09_23_308239	282	47	Zakharov	Zakharov	NNP
10_1101-2020_09_23_308239	282	48	,	,	,
10_1101-2020_09_23_308239	282	49	A.V.	A.V.	NNP
10_1101-2020_09_23_308239	282	50	,	,	,
10_1101-2020_09_23_308239	282	51	and	and	CC
10_1101-2020_09_23_308239	282	52	Muratov	Muratov	NNP
10_1101-2020_09_23_308239	282	53	,	,	,
10_1101-2020_09_23_308239	282	54	E.N.	E.N.	NNP
10_1101-2020_09_23_308239	283	1	(	(	-LRB-
10_1101-2020_09_23_308239	283	2	2020	2020	CD
10_1101-2020_09_23_308239	283	3	)	)	-RRB-
10_1101-2020_09_23_308239	283	4	.	.	.
10_1101-2020_09_23_308239	284	1	Discovery	Discovery	NNP
10_1101-2020_09_23_308239	284	2	of	of	IN
10_1101-2020_09_23_308239	284	3	Synergistic	Synergistic	NNP
10_1101-2020_09_23_308239	284	4	and	and	CC
10_1101-2020_09_23_308239	284	5	Antagonistic	Antagonistic	NNP
10_1101-2020_09_23_308239	284	6	Drug	Drug	NNP
10_1101-2020_09_23_308239	284	7	Combinations	Combinations	NNPS
10_1101-2020_09_23_308239	284	8	against	against	IN
10_1101-2020_09_23_308239	284	9	SARS	SARS	NNP
10_1101-2020_09_23_308239	284	10	-	-	HYPH
10_1101-2020_09_23_308239	284	11	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	284	12	In	in	IN
10_1101-2020_09_23_308239	284	13	Vitro	Vitro	NNP
10_1101-2020_09_23_308239	284	14	.	.	.
10_1101-2020_09_23_308239	285	1	BioRxiv	biorxiv	NN
10_1101-2020_09_23_308239	285	2	.	.	.
10_1101-2020_09_23_308239	286	1	41	41	CD
10_1101-2020_09_23_308239	286	2	Ellinger	ellinger	NN
10_1101-2020_09_23_308239	286	3	,	,	,
10_1101-2020_09_23_308239	286	4	B	B	NNP
10_1101-2020_09_23_308239	286	5	et	et	NNP
10_1101-2020_09_23_308239	286	6	al	al	NNP
10_1101-2020_09_23_308239	286	7	.	.	.
10_1101-2020_09_23_308239	287	1	(	(	-LRB-
10_1101-2020_09_23_308239	287	2	2020	2020	CD
10_1101-2020_09_23_308239	287	3	)	)	-RRB-
10_1101-2020_09_23_308239	287	4	.	.	.
10_1101-2020_09_23_308239	288	1	Identification	identification	NN
10_1101-2020_09_23_308239	288	2	of	of	IN
10_1101-2020_09_23_308239	288	3	inhibitors	inhibitor	NNS
10_1101-2020_09_23_308239	288	4	of	of	IN
10_1101-2020_09_23_308239	288	5	SARS	SARS	NNP
10_1101-2020_09_23_308239	288	6	-	-	HYPH
10_1101-2020_09_23_308239	288	7	CoV-2	CoV-2	NNP
10_1101-2020_09_23_308239	288	8	in	in	IN
10_1101-2020_09_23_308239	288	9	-	-	HYPH
10_1101-2020_09_23_308239	288	10	vitro	vitro	FW
10_1101-2020_09_23_308239	288	11	cellular	cellular	JJ
10_1101-2020_09_23_308239	288	12	toxicity	toxicity	NN
10_1101-2020_09_23_308239	288	13	in	in	IN
10_1101-2020_09_23_308239	288	14	human	human	NN
10_1101-2020_09_23_308239	288	15	(	(	-LRB-
10_1101-2020_09_23_308239	288	16	Caco-2	Caco-2	NNP
10_1101-2020_09_23_308239	288	17	)	)	-RRB-
10_1101-2020_09_23_308239	288	18	cells	cell	NNS
10_1101-2020_09_23_308239	288	19	using	use	VBG
10_1101-2020_09_23_308239	288	20	a	a	DT
10_1101-2020_09_23_308239	288	21	large	large	JJ
10_1101-2020_09_23_308239	288	22	scale	scale	NN
10_1101-2020_09_23_308239	288	23	drug	drug	NN
10_1101-2020_09_23_308239	288	24	repurposing	repurposing	NN
10_1101-2020_09_23_308239	288	25	collection	collection	NN
10_1101-2020_09_23_308239	288	26	.	.	.
10_1101-2020_09_23_308239	289	1	Preprint	preprint	NN
10_1101-2020_09_23_308239	289	2	.	.	.
10_1101-2020_09_23_308239	290	1	https://doi.org/10.21203/rs.3.rs-23951/v1	https://doi.org/10.21203/rs.3.rs-23951/v1	UH
10_1101-2020_09_23_308239	290	2	.	.	.
10_1101-2020_09_23_308239	291	1	42	42	CD
10_1101-2020_09_23_308239	291	2	Yamamoto	yamamoto	NN
10_1101-2020_09_23_308239	291	3	,	,	,
10_1101-2020_09_23_308239	291	4	N.	N.	NNP
10_1101-2020_09_23_308239	291	5	,	,	,
10_1101-2020_09_23_308239	291	6	Yang	Yang	NNP
10_1101-2020_09_23_308239	291	7	,	,	,
10_1101-2020_09_23_308239	291	8	R.	R.	NNP
10_1101-2020_09_23_308239	291	9	,	,	,
10_1101-2020_09_23_308239	291	10	Yoshinaka	Yoshinaka	NNP
10_1101-2020_09_23_308239	291	11	,	,	,
10_1101-2020_09_23_308239	291	12	Y.	Y.	NNP
10_1101-2020_09_23_308239	291	13	,	,	,
10_1101-2020_09_23_308239	291	14	Amari	Amari	NNP
10_1101-2020_09_23_308239	291	15	,	,	,
10_1101-2020_09_23_308239	291	16	S.	S.	NNP
10_1101-2020_09_23_308239	291	17	,	,	,
10_1101-2020_09_23_308239	291	18	Nakano	Nakano	NNP
10_1101-2020_09_23_308239	291	19	,	,	,
10_1101-2020_09_23_308239	291	20	T.	T.	NNP
10_1101-2020_09_23_308239	291	21	,	,	,
10_1101-2020_09_23_308239	291	22	Cinatl	Cinatl	NNP
10_1101-2020_09_23_308239	291	23	,	,	,
10_1101-2020_09_23_308239	291	24	J.	J.	NNP
10_1101-2020_09_23_308239	291	25	,	,	,
10_1101-2020_09_23_308239	291	26	...	...	.
10_1101-2020_09_23_308239	291	27	&	&	CC
10_1101-2020_09_23_308239	291	28	Tamamura	Tamamura	NNP
10_1101-2020_09_23_308239	291	29	,	,	,
10_1101-2020_09_23_308239	291	30	H.	H.	NNP
10_1101-2020_09_23_308239	291	31	(	(	-LRB-
10_1101-2020_09_23_308239	291	32	2004	2004	CD
10_1101-2020_09_23_308239	291	33	)	)	-RRB-
10_1101-2020_09_23_308239	291	34	.	.	.
10_1101-2020_09_23_308239	292	1	HIV	HIV	NNP
10_1101-2020_09_23_308239	292	2	protease	protease	NN
10_1101-2020_09_23_308239	292	3	inhibitor	inhibitor	NN
10_1101-2020_09_23_308239	292	4	nelfinavir	nelfinavir	NN
10_1101-2020_09_23_308239	292	5	inhibits	inhibit	VBZ
10_1101-2020_09_23_308239	292	6	replication	replication	NN
10_1101-2020_09_23_308239	292	7	of	of	IN
10_1101-2020_09_23_308239	292	8	SARS	SARS	NNP
10_1101-2020_09_23_308239	292	9	-	-	HYPH
10_1101-2020_09_23_308239	292	10	associated	associate	VBN
10_1101-2020_09_23_308239	292	11	coronavirus	coronavirus	NNP
10_1101-2020_09_23_308239	292	12	.	.	.
10_1101-2020_09_23_308239	293	1	Biochemical	biochemical	JJ
10_1101-2020_09_23_308239	293	2	and	and	CC
10_1101-2020_09_23_308239	293	3	biophysical	biophysical	JJ
10_1101-2020_09_23_308239	293	4	research	research	NN
10_1101-2020_09_23_308239	293	5	communications	communication	NNS
10_1101-2020_09_23_308239	293	6	,	,	,
10_1101-2020_09_23_308239	293	7	318(3	318(3	CD
10_1101-2020_09_23_308239	293	8	)	)	-RRB-
10_1101-2020_09_23_308239	293	9	,	,	,
10_1101-2020_09_23_308239	293	10	719	719	CD
10_1101-2020_09_23_308239	293	11	-	-	SYM
10_1101-2020_09_23_308239	293	12	725	725	CD
10_1101-2020_09_23_308239	293	13	.	.	.
10_1101-2020_09_23_308239	294	1	43	43	CD
10_1101-2020_09_23_308239	294	2	Musarrat	Musarrat	NNP
10_1101-2020_09_23_308239	294	3	,	,	,
10_1101-2020_09_23_308239	294	4	F.	F.	NNP
10_1101-2020_09_23_308239	294	5	,	,	,
10_1101-2020_09_23_308239	294	6	Chouljenko	Chouljenko	NNP
10_1101-2020_09_23_308239	294	7	,	,	,
10_1101-2020_09_23_308239	294	8	V.	V.	NNP
10_1101-2020_09_23_308239	294	9	,	,	,
10_1101-2020_09_23_308239	294	10	Dahal	Dahal	NNP
10_1101-2020_09_23_308239	294	11	,	,	,
10_1101-2020_09_23_308239	294	12	A.	A.	NNP
10_1101-2020_09_23_308239	294	13	,	,	,
10_1101-2020_09_23_308239	294	14	Nabi	Nabi	NNP
10_1101-2020_09_23_308239	294	15	,	,	,
10_1101-2020_09_23_308239	294	16	R.	R.	NNP
10_1101-2020_09_23_308239	294	17	,	,	,
10_1101-2020_09_23_308239	294	18	Chouljenko	Chouljenko	NNP
10_1101-2020_09_23_308239	294	19	,	,	,
10_1101-2020_09_23_308239	294	20	T.	T.	NNP
10_1101-2020_09_23_308239	294	21	,	,	,
10_1101-2020_09_23_308239	294	22	Jois	Jois	NNP
10_1101-2020_09_23_308239	294	23	,	,	,
10_1101-2020_09_23_308239	294	24	S.	S.	NNP
10_1101-2020_09_23_308239	294	25	D.	D.	NNP
10_1101-2020_09_23_308239	294	26	,	,	,
10_1101-2020_09_23_308239	294	27	&	&	CC
10_1101-2020_09_23_308239	294	28	Kousoulas	Kousoulas	NNP
10_1101-2020_09_23_308239	294	29	,	,	,
10_1101-2020_09_23_308239	294	30	K.	K.	NNP
10_1101-2020_09_23_308239	294	31	G.	G.	NNP
10_1101-2020_09_23_308239	294	32	(	(	-LRB-
10_1101-2020_09_23_308239	294	33	2020	2020	CD
10_1101-2020_09_23_308239	294	34	)	)	-RRB-
10_1101-2020_09_23_308239	294	35	.	.	.
10_1101-2020_09_23_308239	295	1	The	the	DT
10_1101-2020_09_23_308239	295	2	anti‐	anti‐	NN
10_1101-2020_09_23_308239	295	3	HIV	HIV	NNP
10_1101-2020_09_23_308239	295	4	Drug	Drug	NNP
10_1101-2020_09_23_308239	295	5	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	295	6	Mesylate	Mesylate	NNP
10_1101-2020_09_23_308239	295	7	(	(	-LRB-
10_1101-2020_09_23_308239	295	8	Viracept	Viracept	NNP
10_1101-2020_09_23_308239	295	9	)	)	-RRB-
10_1101-2020_09_23_308239	295	10	is	be	VBZ
10_1101-2020_09_23_308239	295	11	a	a	DT
10_1101-2020_09_23_308239	295	12	Potent	potent	JJ
10_1101-2020_09_23_308239	295	13	Inhibitor	Inhibitor	NNP
10_1101-2020_09_23_308239	295	14	of	of	IN
10_1101-2020_09_23_308239	295	15	Cell	Cell	NNP
10_1101-2020_09_23_308239	295	16	Fusion	Fusion	NNP
10_1101-2020_09_23_308239	295	17	Caused	cause	VBN
10_1101-2020_09_23_308239	295	18	by	by	IN
10_1101-2020_09_23_308239	295	19	the	the	DT
10_1101-2020_09_23_308239	295	20	SARS‐CoV‐2	sars‐cov‐2	NN
10_1101-2020_09_23_308239	295	21	Spike	Spike	NNP
10_1101-2020_09_23_308239	295	22	(	(	-LRB-
10_1101-2020_09_23_308239	295	23	S	S	NNP
10_1101-2020_09_23_308239	295	24	)	)	-RRB-
10_1101-2020_09_23_308239	295	25	Glycoprotein	Glycoprotein	NNP
10_1101-2020_09_23_308239	295	26	Warranting	warrant	VBG
10_1101-2020_09_23_308239	295	27	further	further	JJ
10_1101-2020_09_23_308239	295	28	Evaluation	Evaluation	NNP
10_1101-2020_09_23_308239	295	29	as	as	IN
10_1101-2020_09_23_308239	295	30	an	an	DT
10_1101-2020_09_23_308239	295	31	Antiviral	Antiviral	NNP
10_1101-2020_09_23_308239	295	32	against	against	IN
10_1101-2020_09_23_308239	295	33	COVID‐19	COVID‐19	NNP
10_1101-2020_09_23_308239	295	34	infections	infection	NNS
10_1101-2020_09_23_308239	295	35	.	.	.
10_1101-2020_09_23_308239	296	1	Journal	Journal	NNP
10_1101-2020_09_23_308239	296	2	of	of	IN
10_1101-2020_09_23_308239	296	3	medical	medical	JJ
10_1101-2020_09_23_308239	296	4	virology	virology	NN
10_1101-2020_09_23_308239	296	5	.	.	.
10_1101-2020_09_23_308239	297	1	.CC	.CC	NFP
10_1101-2020_09_23_308239	297	2	-	-	:
10_1101-2020_09_23_308239	297	3	BY	by	IN
10_1101-2020_09_23_308239	297	4	-	-	HYPH
10_1101-2020_09_23_308239	297	5	NC	NC	NNP
10_1101-2020_09_23_308239	297	6	-	-	HYPH
10_1101-2020_09_23_308239	297	7	ND	ND	NNP
10_1101-2020_09_23_308239	297	8	4.0	4.0	CD
10_1101-2020_09_23_308239	297	9	International	international	JJ
10_1101-2020_09_23_308239	297	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	297	11	.	.	.
10_1101-2020_09_23_308239	298	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	298	2	is	be	VBZ
10_1101-2020_09_23_308239	298	3	made	make	VBN
10_1101-2020_09_23_308239	298	4	available	available	JJ
10_1101-2020_09_23_308239	298	5	under	under	IN
10_1101-2020_09_23_308239	298	6	a	a	DT
10_1101-2020_09_23_308239	298	7	preprint	preprint	NN
10_1101-2020_09_23_308239	298	8	(	(	-LRB-
10_1101-2020_09_23_308239	298	9	which	which	WDT
10_1101-2020_09_23_308239	298	10	was	be	VBD
10_1101-2020_09_23_308239	298	11	not	not	RB
10_1101-2020_09_23_308239	298	12	certified	certify	VBN
10_1101-2020_09_23_308239	298	13	by	by	IN
10_1101-2020_09_23_308239	298	14	peer	peer	NN
10_1101-2020_09_23_308239	298	15	review	review	NN
10_1101-2020_09_23_308239	298	16	)	)	-RRB-
10_1101-2020_09_23_308239	298	17	is	be	VBZ
10_1101-2020_09_23_308239	298	18	the	the	DT
10_1101-2020_09_23_308239	298	19	author	author	NN
10_1101-2020_09_23_308239	298	20	/	/	SYM
10_1101-2020_09_23_308239	298	21	funder	funder	NN
10_1101-2020_09_23_308239	298	22	,	,	,
10_1101-2020_09_23_308239	298	23	who	who	WP
10_1101-2020_09_23_308239	298	24	has	have	VBZ
10_1101-2020_09_23_308239	298	25	granted	grant	VBN
10_1101-2020_09_23_308239	298	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	298	27	a	a	DT
10_1101-2020_09_23_308239	298	28	license	license	NN
10_1101-2020_09_23_308239	298	29	to	to	TO
10_1101-2020_09_23_308239	298	30	display	display	VB
10_1101-2020_09_23_308239	298	31	the	the	DT
10_1101-2020_09_23_308239	298	32	preprint	preprint	NN
10_1101-2020_09_23_308239	298	33	in	in	IN
10_1101-2020_09_23_308239	298	34	The	the	DT
10_1101-2020_09_23_308239	298	35	copyright	copyright	NN
10_1101-2020_09_23_308239	298	36	holder	holder	NN
10_1101-2020_09_23_308239	298	37	for	for	IN
10_1101-2020_09_23_308239	298	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	298	39	version	version	NN
10_1101-2020_09_23_308239	298	40	posted	post	VBD
10_1101-2020_09_23_308239	298	41	February	February	NNP
10_1101-2020_09_23_308239	298	42	12	12	CD
10_1101-2020_09_23_308239	298	43	,	,	,
10_1101-2020_09_23_308239	298	44	2021	2021	CD
10_1101-2020_09_23_308239	298	45	.	.	.
10_1101-2020_09_23_308239	298	46	;	;	:
10_1101-2020_09_23_308239	298	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	298	48	:	:	:
10_1101-2020_09_23_308239	298	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	298	50	preprint	preprint	NN
10_1101-2020_09_23_308239	298	51	http://rdcu.be/qKdS	http://rdcu.be/qKdS	NNP
10_1101-2020_09_23_308239	298	52	http://rdcu.be/qKdS	http://rdcu.be/qKdS	NNP
10_1101-2020_09_23_308239	298	53	http://rdcu.be/qKdS	http://rdcu.be/qKdS	NNP
10_1101-2020_09_23_308239	298	54	https://doi.org/10.1073/pnas.1810137115	https://doi.org/10.1073/pnas.1810137115	NNP
10_1101-2020_09_23_308239	298	55	https://reframedb.org/assays/A00461	https://reframedb.org/assays/A00461	``
10_1101-2020_09_23_308239	298	56	https://reframedb.org/assays/A00440	https://reframedb.org/assays/a00440	ADD
10_1101-2020_09_23_308239	298	57	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	ADD
10_1101-2020_09_23_308239	298	58	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NNP
10_1101-2020_09_23_308239	298	59	a	a	DT
10_1101-2020_09_23_308239	298	60	b	b	NN
10_1101-2020_09_23_308239	298	61	.CC	.CC	:
10_1101-2020_09_23_308239	298	62	-	-	HYPH
10_1101-2020_09_23_308239	298	63	BY	by	IN
10_1101-2020_09_23_308239	298	64	-	-	HYPH
10_1101-2020_09_23_308239	298	65	NC	NC	NNP
10_1101-2020_09_23_308239	298	66	-	-	HYPH
10_1101-2020_09_23_308239	298	67	ND	ND	NNP
10_1101-2020_09_23_308239	298	68	4.0	4.0	CD
10_1101-2020_09_23_308239	298	69	International	international	JJ
10_1101-2020_09_23_308239	298	70	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	298	71	.	.	.
10_1101-2020_09_23_308239	299	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	299	2	is	be	VBZ
10_1101-2020_09_23_308239	299	3	made	make	VBN
10_1101-2020_09_23_308239	299	4	available	available	JJ
10_1101-2020_09_23_308239	299	5	under	under	IN
10_1101-2020_09_23_308239	299	6	a	a	DT
10_1101-2020_09_23_308239	299	7	preprint	preprint	NN
10_1101-2020_09_23_308239	299	8	(	(	-LRB-
10_1101-2020_09_23_308239	299	9	which	which	WDT
10_1101-2020_09_23_308239	299	10	was	be	VBD
10_1101-2020_09_23_308239	299	11	not	not	RB
10_1101-2020_09_23_308239	299	12	certified	certify	VBN
10_1101-2020_09_23_308239	299	13	by	by	IN
10_1101-2020_09_23_308239	299	14	peer	peer	NN
10_1101-2020_09_23_308239	299	15	review	review	NN
10_1101-2020_09_23_308239	299	16	)	)	-RRB-
10_1101-2020_09_23_308239	299	17	is	be	VBZ
10_1101-2020_09_23_308239	299	18	the	the	DT
10_1101-2020_09_23_308239	299	19	author	author	NN
10_1101-2020_09_23_308239	299	20	/	/	SYM
10_1101-2020_09_23_308239	299	21	funder	funder	NN
10_1101-2020_09_23_308239	299	22	,	,	,
10_1101-2020_09_23_308239	299	23	who	who	WP
10_1101-2020_09_23_308239	299	24	has	have	VBZ
10_1101-2020_09_23_308239	299	25	granted	grant	VBN
10_1101-2020_09_23_308239	299	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	299	27	a	a	DT
10_1101-2020_09_23_308239	299	28	license	license	NN
10_1101-2020_09_23_308239	299	29	to	to	TO
10_1101-2020_09_23_308239	299	30	display	display	VB
10_1101-2020_09_23_308239	299	31	the	the	DT
10_1101-2020_09_23_308239	299	32	preprint	preprint	NN
10_1101-2020_09_23_308239	299	33	in	in	IN
10_1101-2020_09_23_308239	299	34	The	the	DT
10_1101-2020_09_23_308239	299	35	copyright	copyright	NN
10_1101-2020_09_23_308239	299	36	holder	holder	NN
10_1101-2020_09_23_308239	299	37	for	for	IN
10_1101-2020_09_23_308239	299	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	299	39	version	version	NN
10_1101-2020_09_23_308239	299	40	posted	post	VBD
10_1101-2020_09_23_308239	299	41	February	February	NNP
10_1101-2020_09_23_308239	299	42	12	12	CD
10_1101-2020_09_23_308239	299	43	,	,	,
10_1101-2020_09_23_308239	299	44	2021	2021	CD
10_1101-2020_09_23_308239	299	45	.	.	.
10_1101-2020_09_23_308239	299	46	;	;	:
10_1101-2020_09_23_308239	299	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	299	48	:	:	:
10_1101-2020_09_23_308239	299	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	299	50	preprint	preprint	NN
10_1101-2020_09_23_308239	299	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	299	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	299	53	.CC	.CC	:
10_1101-2020_09_23_308239	299	54	-	-	HYPH
10_1101-2020_09_23_308239	299	55	BY	by	IN
10_1101-2020_09_23_308239	299	56	-	-	HYPH
10_1101-2020_09_23_308239	299	57	NC	NC	NNP
10_1101-2020_09_23_308239	299	58	-	-	HYPH
10_1101-2020_09_23_308239	299	59	ND	ND	NNP
10_1101-2020_09_23_308239	299	60	4.0	4.0	CD
10_1101-2020_09_23_308239	299	61	International	international	JJ
10_1101-2020_09_23_308239	299	62	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	299	63	.	.	.
10_1101-2020_09_23_308239	300	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	300	2	is	be	VBZ
10_1101-2020_09_23_308239	300	3	made	make	VBN
10_1101-2020_09_23_308239	300	4	available	available	JJ
10_1101-2020_09_23_308239	300	5	under	under	IN
10_1101-2020_09_23_308239	300	6	a	a	DT
10_1101-2020_09_23_308239	300	7	preprint	preprint	NN
10_1101-2020_09_23_308239	300	8	(	(	-LRB-
10_1101-2020_09_23_308239	300	9	which	which	WDT
10_1101-2020_09_23_308239	300	10	was	be	VBD
10_1101-2020_09_23_308239	300	11	not	not	RB
10_1101-2020_09_23_308239	300	12	certified	certify	VBN
10_1101-2020_09_23_308239	300	13	by	by	IN
10_1101-2020_09_23_308239	300	14	peer	peer	NN
10_1101-2020_09_23_308239	300	15	review	review	NN
10_1101-2020_09_23_308239	300	16	)	)	-RRB-
10_1101-2020_09_23_308239	300	17	is	be	VBZ
10_1101-2020_09_23_308239	300	18	the	the	DT
10_1101-2020_09_23_308239	300	19	author	author	NN
10_1101-2020_09_23_308239	300	20	/	/	SYM
10_1101-2020_09_23_308239	300	21	funder	funder	NN
10_1101-2020_09_23_308239	300	22	,	,	,
10_1101-2020_09_23_308239	300	23	who	who	WP
10_1101-2020_09_23_308239	300	24	has	have	VBZ
10_1101-2020_09_23_308239	300	25	granted	grant	VBN
10_1101-2020_09_23_308239	300	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	300	27	a	a	DT
10_1101-2020_09_23_308239	300	28	license	license	NN
10_1101-2020_09_23_308239	300	29	to	to	TO
10_1101-2020_09_23_308239	300	30	display	display	VB
10_1101-2020_09_23_308239	300	31	the	the	DT
10_1101-2020_09_23_308239	300	32	preprint	preprint	NN
10_1101-2020_09_23_308239	300	33	in	in	IN
10_1101-2020_09_23_308239	300	34	The	the	DT
10_1101-2020_09_23_308239	300	35	copyright	copyright	NN
10_1101-2020_09_23_308239	300	36	holder	holder	NN
10_1101-2020_09_23_308239	300	37	for	for	IN
10_1101-2020_09_23_308239	300	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	300	39	version	version	NN
10_1101-2020_09_23_308239	300	40	posted	post	VBD
10_1101-2020_09_23_308239	300	41	February	February	NNP
10_1101-2020_09_23_308239	300	42	12	12	CD
10_1101-2020_09_23_308239	300	43	,	,	,
10_1101-2020_09_23_308239	300	44	2021	2021	CD
10_1101-2020_09_23_308239	300	45	.	.	.
10_1101-2020_09_23_308239	300	46	;	;	:
10_1101-2020_09_23_308239	300	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	300	48	:	:	:
10_1101-2020_09_23_308239	300	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	300	50	preprint	preprint	NN
10_1101-2020_09_23_308239	300	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	300	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	300	53	a	a	DT
10_1101-2020_09_23_308239	300	54	b	b	NN
10_1101-2020_09_23_308239	300	55	.CC	.CC	:
10_1101-2020_09_23_308239	300	56	-	-	HYPH
10_1101-2020_09_23_308239	300	57	BY	by	IN
10_1101-2020_09_23_308239	300	58	-	-	HYPH
10_1101-2020_09_23_308239	300	59	NC	NC	NNP
10_1101-2020_09_23_308239	300	60	-	-	HYPH
10_1101-2020_09_23_308239	300	61	ND	ND	NNP
10_1101-2020_09_23_308239	300	62	4.0	4.0	CD
10_1101-2020_09_23_308239	300	63	International	international	JJ
10_1101-2020_09_23_308239	300	64	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	300	65	.	.	.
10_1101-2020_09_23_308239	301	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	301	2	is	be	VBZ
10_1101-2020_09_23_308239	301	3	made	make	VBN
10_1101-2020_09_23_308239	301	4	available	available	JJ
10_1101-2020_09_23_308239	301	5	under	under	IN
10_1101-2020_09_23_308239	301	6	a	a	DT
10_1101-2020_09_23_308239	301	7	preprint	preprint	NN
10_1101-2020_09_23_308239	301	8	(	(	-LRB-
10_1101-2020_09_23_308239	301	9	which	which	WDT
10_1101-2020_09_23_308239	301	10	was	be	VBD
10_1101-2020_09_23_308239	301	11	not	not	RB
10_1101-2020_09_23_308239	301	12	certified	certify	VBN
10_1101-2020_09_23_308239	301	13	by	by	IN
10_1101-2020_09_23_308239	301	14	peer	peer	NN
10_1101-2020_09_23_308239	301	15	review	review	NN
10_1101-2020_09_23_308239	301	16	)	)	-RRB-
10_1101-2020_09_23_308239	301	17	is	be	VBZ
10_1101-2020_09_23_308239	301	18	the	the	DT
10_1101-2020_09_23_308239	301	19	author	author	NN
10_1101-2020_09_23_308239	301	20	/	/	SYM
10_1101-2020_09_23_308239	301	21	funder	funder	NN
10_1101-2020_09_23_308239	301	22	,	,	,
10_1101-2020_09_23_308239	301	23	who	who	WP
10_1101-2020_09_23_308239	301	24	has	have	VBZ
10_1101-2020_09_23_308239	301	25	granted	grant	VBN
10_1101-2020_09_23_308239	301	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	301	27	a	a	DT
10_1101-2020_09_23_308239	301	28	license	license	NN
10_1101-2020_09_23_308239	301	29	to	to	TO
10_1101-2020_09_23_308239	301	30	display	display	VB
10_1101-2020_09_23_308239	301	31	the	the	DT
10_1101-2020_09_23_308239	301	32	preprint	preprint	NN
10_1101-2020_09_23_308239	301	33	in	in	IN
10_1101-2020_09_23_308239	301	34	The	the	DT
10_1101-2020_09_23_308239	301	35	copyright	copyright	NN
10_1101-2020_09_23_308239	301	36	holder	holder	NN
10_1101-2020_09_23_308239	301	37	for	for	IN
10_1101-2020_09_23_308239	301	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	301	39	version	version	NN
10_1101-2020_09_23_308239	301	40	posted	post	VBD
10_1101-2020_09_23_308239	301	41	February	February	NNP
10_1101-2020_09_23_308239	301	42	12	12	CD
10_1101-2020_09_23_308239	301	43	,	,	,
10_1101-2020_09_23_308239	301	44	2021	2021	CD
10_1101-2020_09_23_308239	301	45	.	.	.
10_1101-2020_09_23_308239	301	46	;	;	:
10_1101-2020_09_23_308239	301	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	301	48	:	:	:
10_1101-2020_09_23_308239	301	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	301	50	preprint	preprint	NN
10_1101-2020_09_23_308239	301	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	301	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	301	53	a	a	DT
10_1101-2020_09_23_308239	301	54	b	b	NN
10_1101-2020_09_23_308239	301	55	c	c	NN
10_1101-2020_09_23_308239	301	56	.CC	.CC	:
10_1101-2020_09_23_308239	301	57	-	-	:
10_1101-2020_09_23_308239	301	58	BY	by	IN
10_1101-2020_09_23_308239	301	59	-	-	HYPH
10_1101-2020_09_23_308239	301	60	NC	NC	NNP
10_1101-2020_09_23_308239	301	61	-	-	HYPH
10_1101-2020_09_23_308239	301	62	ND	ND	NNP
10_1101-2020_09_23_308239	301	63	4.0	4.0	CD
10_1101-2020_09_23_308239	301	64	International	international	JJ
10_1101-2020_09_23_308239	301	65	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	301	66	.	.	.
10_1101-2020_09_23_308239	302	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	302	2	is	be	VBZ
10_1101-2020_09_23_308239	302	3	made	make	VBN
10_1101-2020_09_23_308239	302	4	available	available	JJ
10_1101-2020_09_23_308239	302	5	under	under	IN
10_1101-2020_09_23_308239	302	6	a	a	DT
10_1101-2020_09_23_308239	302	7	preprint	preprint	NN
10_1101-2020_09_23_308239	302	8	(	(	-LRB-
10_1101-2020_09_23_308239	302	9	which	which	WDT
10_1101-2020_09_23_308239	302	10	was	be	VBD
10_1101-2020_09_23_308239	302	11	not	not	RB
10_1101-2020_09_23_308239	302	12	certified	certify	VBN
10_1101-2020_09_23_308239	302	13	by	by	IN
10_1101-2020_09_23_308239	302	14	peer	peer	NN
10_1101-2020_09_23_308239	302	15	review	review	NN
10_1101-2020_09_23_308239	302	16	)	)	-RRB-
10_1101-2020_09_23_308239	302	17	is	be	VBZ
10_1101-2020_09_23_308239	302	18	the	the	DT
10_1101-2020_09_23_308239	302	19	author	author	NN
10_1101-2020_09_23_308239	302	20	/	/	SYM
10_1101-2020_09_23_308239	302	21	funder	funder	NN
10_1101-2020_09_23_308239	302	22	,	,	,
10_1101-2020_09_23_308239	302	23	who	who	WP
10_1101-2020_09_23_308239	302	24	has	have	VBZ
10_1101-2020_09_23_308239	302	25	granted	grant	VBN
10_1101-2020_09_23_308239	302	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	302	27	a	a	DT
10_1101-2020_09_23_308239	302	28	license	license	NN
10_1101-2020_09_23_308239	302	29	to	to	TO
10_1101-2020_09_23_308239	302	30	display	display	VB
10_1101-2020_09_23_308239	302	31	the	the	DT
10_1101-2020_09_23_308239	302	32	preprint	preprint	NN
10_1101-2020_09_23_308239	302	33	in	in	IN
10_1101-2020_09_23_308239	302	34	The	the	DT
10_1101-2020_09_23_308239	302	35	copyright	copyright	NN
10_1101-2020_09_23_308239	302	36	holder	holder	NN
10_1101-2020_09_23_308239	302	37	for	for	IN
10_1101-2020_09_23_308239	302	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	302	39	version	version	NN
10_1101-2020_09_23_308239	302	40	posted	post	VBD
10_1101-2020_09_23_308239	302	41	February	February	NNP
10_1101-2020_09_23_308239	302	42	12	12	CD
10_1101-2020_09_23_308239	302	43	,	,	,
10_1101-2020_09_23_308239	302	44	2021	2021	CD
10_1101-2020_09_23_308239	302	45	.	.	.
10_1101-2020_09_23_308239	302	46	;	;	:
10_1101-2020_09_23_308239	302	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	302	48	:	:	:
10_1101-2020_09_23_308239	302	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	302	50	preprint	preprint	NN
10_1101-2020_09_23_308239	302	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	302	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	302	53	.CC	.CC	:
10_1101-2020_09_23_308239	302	54	-	-	HYPH
10_1101-2020_09_23_308239	302	55	BY	by	IN
10_1101-2020_09_23_308239	302	56	-	-	HYPH
10_1101-2020_09_23_308239	302	57	NC	NC	NNP
10_1101-2020_09_23_308239	302	58	-	-	HYPH
10_1101-2020_09_23_308239	302	59	ND	ND	NNP
10_1101-2020_09_23_308239	302	60	4.0	4.0	CD
10_1101-2020_09_23_308239	302	61	International	international	JJ
10_1101-2020_09_23_308239	302	62	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	302	63	.	.	.
10_1101-2020_09_23_308239	303	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	303	2	is	be	VBZ
10_1101-2020_09_23_308239	303	3	made	make	VBN
10_1101-2020_09_23_308239	303	4	available	available	JJ
10_1101-2020_09_23_308239	303	5	under	under	IN
10_1101-2020_09_23_308239	303	6	a	a	DT
10_1101-2020_09_23_308239	303	7	preprint	preprint	NN
10_1101-2020_09_23_308239	303	8	(	(	-LRB-
10_1101-2020_09_23_308239	303	9	which	which	WDT
10_1101-2020_09_23_308239	303	10	was	be	VBD
10_1101-2020_09_23_308239	303	11	not	not	RB
10_1101-2020_09_23_308239	303	12	certified	certify	VBN
10_1101-2020_09_23_308239	303	13	by	by	IN
10_1101-2020_09_23_308239	303	14	peer	peer	NN
10_1101-2020_09_23_308239	303	15	review	review	NN
10_1101-2020_09_23_308239	303	16	)	)	-RRB-
10_1101-2020_09_23_308239	303	17	is	be	VBZ
10_1101-2020_09_23_308239	303	18	the	the	DT
10_1101-2020_09_23_308239	303	19	author	author	NN
10_1101-2020_09_23_308239	303	20	/	/	SYM
10_1101-2020_09_23_308239	303	21	funder	funder	NN
10_1101-2020_09_23_308239	303	22	,	,	,
10_1101-2020_09_23_308239	303	23	who	who	WP
10_1101-2020_09_23_308239	303	24	has	have	VBZ
10_1101-2020_09_23_308239	303	25	granted	grant	VBN
10_1101-2020_09_23_308239	303	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	303	27	a	a	DT
10_1101-2020_09_23_308239	303	28	license	license	NN
10_1101-2020_09_23_308239	303	29	to	to	TO
10_1101-2020_09_23_308239	303	30	display	display	VB
10_1101-2020_09_23_308239	303	31	the	the	DT
10_1101-2020_09_23_308239	303	32	preprint	preprint	NN
10_1101-2020_09_23_308239	303	33	in	in	IN
10_1101-2020_09_23_308239	303	34	The	the	DT
10_1101-2020_09_23_308239	303	35	copyright	copyright	NN
10_1101-2020_09_23_308239	303	36	holder	holder	NN
10_1101-2020_09_23_308239	303	37	for	for	IN
10_1101-2020_09_23_308239	303	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	303	39	version	version	NN
10_1101-2020_09_23_308239	303	40	posted	post	VBD
10_1101-2020_09_23_308239	303	41	February	February	NNP
10_1101-2020_09_23_308239	303	42	12	12	CD
10_1101-2020_09_23_308239	303	43	,	,	,
10_1101-2020_09_23_308239	303	44	2021	2021	CD
10_1101-2020_09_23_308239	303	45	.	.	.
10_1101-2020_09_23_308239	303	46	;	;	:
10_1101-2020_09_23_308239	303	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	303	48	:	:	:
10_1101-2020_09_23_308239	303	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	303	50	preprint	preprint	NN
10_1101-2020_09_23_308239	303	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	303	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2020_09_23_308239	303	53	-9	-9	:
10_1101-2020_09_23_308239	303	54	-8	-8	NNP
10_1101-2020_09_23_308239	303	55	-7	-7	:
10_1101-2020_09_23_308239	303	56	-6	-6	FW
10_1101-2020_09_23_308239	303	57	-5	-5	FW
10_1101-2020_09_23_308239	303	58	-4	-4	:
10_1101-2020_09_23_308239	303	59	-50	-50	NN
10_1101-2020_09_23_308239	303	60	0	0	CD
10_1101-2020_09_23_308239	303	61	50	50	CD
10_1101-2020_09_23_308239	303	62	100	100	CD
10_1101-2020_09_23_308239	303	63	150	150	CD
10_1101-2020_09_23_308239	303	64	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	65	DRC	drc	NN
10_1101-2020_09_23_308239	303	66	in	in	IN
10_1101-2020_09_23_308239	303	67	presence	presence	NN
10_1101-2020_09_23_308239	303	68	of	of	IN
10_1101-2020_09_23_308239	303	69	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	70	log	log	NN
10_1101-2020_09_23_308239	303	71	c	c	NN
10_1101-2020_09_23_308239	303	72	(	(	-LRB-
10_1101-2020_09_23_308239	303	73	M	m	NN
10_1101-2020_09_23_308239	303	74	)	)	-RRB-
10_1101-2020_09_23_308239	303	75	%	%	NN
10_1101-2020_09_23_308239	303	76	In	in	IN
10_1101-2020_09_23_308239	303	77	hi	hi	UH
10_1101-2020_09_23_308239	303	78	bi	bi	NNP
10_1101-2020_09_23_308239	303	79	tio	tio	NNP
10_1101-2020_09_23_308239	303	80	n	n	NNP
10_1101-2020_09_23_308239	303	81	0.25	0.25	CD
10_1101-2020_09_23_308239	303	82	µM	µM	NNP
10_1101-2020_09_23_308239	303	83	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	84	0.08	0.08	CD
10_1101-2020_09_23_308239	303	85	µM	µM	NNP
10_1101-2020_09_23_308239	303	86	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	87	0.03	0.03	CD
10_1101-2020_09_23_308239	303	88	µM	µM	NNP
10_1101-2020_09_23_308239	303	89	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	90	0.01	0.01	CD
10_1101-2020_09_23_308239	303	91	µM	µM	NNP
10_1101-2020_09_23_308239	303	92	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	93	-9	-9	NNP
10_1101-2020_09_23_308239	303	94	-8	-8	NNP
10_1101-2020_09_23_308239	303	95	-7	-7	:
10_1101-2020_09_23_308239	303	96	-6	-6	FW
10_1101-2020_09_23_308239	303	97	-5	-5	FW
10_1101-2020_09_23_308239	303	98	-4	-4	:
10_1101-2020_09_23_308239	303	99	-50	-50	NN
10_1101-2020_09_23_308239	303	100	0	0	CD
10_1101-2020_09_23_308239	303	101	50	50	CD
10_1101-2020_09_23_308239	303	102	100	100	CD
10_1101-2020_09_23_308239	303	103	150	150	CD
10_1101-2020_09_23_308239	303	104	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	105	DRC	drc	NN
10_1101-2020_09_23_308239	303	106	in	in	IN
10_1101-2020_09_23_308239	303	107	presence	presence	NN
10_1101-2020_09_23_308239	303	108	of	of	IN
10_1101-2020_09_23_308239	303	109	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	110	log	log	NN
10_1101-2020_09_23_308239	303	111	c	c	NN
10_1101-2020_09_23_308239	303	112	(	(	-LRB-
10_1101-2020_09_23_308239	303	113	M	m	NN
10_1101-2020_09_23_308239	303	114	)	)	-RRB-
10_1101-2020_09_23_308239	303	115	%	%	NN
10_1101-2020_09_23_308239	303	116	In	in	IN
10_1101-2020_09_23_308239	303	117	hi	hi	UH
10_1101-2020_09_23_308239	303	118	bi	bi	NNP
10_1101-2020_09_23_308239	303	119	tio	tio	NNP
10_1101-2020_09_23_308239	303	120	n	n	CC
10_1101-2020_09_23_308239	303	121	20	20	CD
10_1101-2020_09_23_308239	303	122	µM	µM	NNP
10_1101-2020_09_23_308239	303	123	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	124	6.67	6.67	CD
10_1101-2020_09_23_308239	303	125	µM	µM	NNP
10_1101-2020_09_23_308239	303	126	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	127	2.22	2.22	CD
10_1101-2020_09_23_308239	303	128	µM	µM	NNP
10_1101-2020_09_23_308239	303	129	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	130	0.74	0.74	CD
10_1101-2020_09_23_308239	303	131	µM	µM	NNP
10_1101-2020_09_23_308239	303	132	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	133	0.25	0.25	CD
10_1101-2020_09_23_308239	303	134	µM	µM	NNP
10_1101-2020_09_23_308239	303	135	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	136	0.08	0.08	CD
10_1101-2020_09_23_308239	303	137	µM	µM	NNP
10_1101-2020_09_23_308239	303	138	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	139	0.03	0.03	CD
10_1101-2020_09_23_308239	303	140	µM	µM	NNP
10_1101-2020_09_23_308239	303	141	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	142	0.01	0.01	CD
10_1101-2020_09_23_308239	303	143	µM	µM	NNP
10_1101-2020_09_23_308239	303	144	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	145	-9	-9	NNP
10_1101-2020_09_23_308239	303	146	-8	-8	NNP
10_1101-2020_09_23_308239	303	147	-7	-7	:
10_1101-2020_09_23_308239	303	148	-6	-6	FW
10_1101-2020_09_23_308239	303	149	-5	-5	FW
10_1101-2020_09_23_308239	303	150	-4	-4	:
10_1101-2020_09_23_308239	303	151	-50	-50	NN
10_1101-2020_09_23_308239	303	152	0	0	CD
10_1101-2020_09_23_308239	303	153	50	50	CD
10_1101-2020_09_23_308239	303	154	100	100	CD
10_1101-2020_09_23_308239	303	155	150	150	CD
10_1101-2020_09_23_308239	303	156	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	157	DRC	drc	NN
10_1101-2020_09_23_308239	303	158	in	in	IN
10_1101-2020_09_23_308239	303	159	presence	presence	NN
10_1101-2020_09_23_308239	303	160	of	of	IN
10_1101-2020_09_23_308239	303	161	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	162	log	log	NN
10_1101-2020_09_23_308239	303	163	c	c	NN
10_1101-2020_09_23_308239	303	164	(	(	-LRB-
10_1101-2020_09_23_308239	303	165	M	m	NN
10_1101-2020_09_23_308239	303	166	)	)	-RRB-
10_1101-2020_09_23_308239	303	167	%	%	NN
10_1101-2020_09_23_308239	303	168	In	in	IN
10_1101-2020_09_23_308239	303	169	hi	hi	UH
10_1101-2020_09_23_308239	303	170	bi	bi	NNP
10_1101-2020_09_23_308239	303	171	tio	tio	NNP
10_1101-2020_09_23_308239	303	172	n	n	NNP
10_1101-2020_09_23_308239	303	173	20	20	CD
10_1101-2020_09_23_308239	303	174	µM	µM	NNP
10_1101-2020_09_23_308239	303	175	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	176	6.67	6.67	CD
10_1101-2020_09_23_308239	303	177	µM	µM	NNP
10_1101-2020_09_23_308239	303	178	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	179	2.22	2.22	CD
10_1101-2020_09_23_308239	303	180	µM	µM	NNP
10_1101-2020_09_23_308239	303	181	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	182	0.74	0.74	CD
10_1101-2020_09_23_308239	303	183	µM	µM	NNP
10_1101-2020_09_23_308239	303	184	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	185	0.25	0.25	CD
10_1101-2020_09_23_308239	303	186	µM	µM	NNP
10_1101-2020_09_23_308239	303	187	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	188	0.08	0.08	CD
10_1101-2020_09_23_308239	303	189	µM	µM	NNP
10_1101-2020_09_23_308239	303	190	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	191	0.03	0.03	CD
10_1101-2020_09_23_308239	303	192	µM	µM	NNP
10_1101-2020_09_23_308239	303	193	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	194	0.01	0.01	CD
10_1101-2020_09_23_308239	303	195	µM	µM	NNP
10_1101-2020_09_23_308239	303	196	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	197	-9	-9	NNP
10_1101-2020_09_23_308239	303	198	-8	-8	NNP
10_1101-2020_09_23_308239	303	199	-7	-7	:
10_1101-2020_09_23_308239	303	200	-6	-6	FW
10_1101-2020_09_23_308239	303	201	-5	-5	FW
10_1101-2020_09_23_308239	303	202	-4	-4	:
10_1101-2020_09_23_308239	303	203	-50	-50	NN
10_1101-2020_09_23_308239	303	204	0	0	CD
10_1101-2020_09_23_308239	303	205	50	50	CD
10_1101-2020_09_23_308239	303	206	100	100	CD
10_1101-2020_09_23_308239	303	207	150	150	CD
10_1101-2020_09_23_308239	303	208	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	209	DRC	drc	NN
10_1101-2020_09_23_308239	303	210	in	in	IN
10_1101-2020_09_23_308239	303	211	presence	presence	NN
10_1101-2020_09_23_308239	303	212	of	of	IN
10_1101-2020_09_23_308239	303	213	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	214	log	log	NN
10_1101-2020_09_23_308239	303	215	c	c	NN
10_1101-2020_09_23_308239	303	216	(	(	-LRB-
10_1101-2020_09_23_308239	303	217	M	m	NN
10_1101-2020_09_23_308239	303	218	)	)	-RRB-
10_1101-2020_09_23_308239	303	219	%	%	NN
10_1101-2020_09_23_308239	303	220	In	in	IN
10_1101-2020_09_23_308239	303	221	hi	hi	UH
10_1101-2020_09_23_308239	303	222	bi	bi	NNP
10_1101-2020_09_23_308239	303	223	tio	tio	NNP
10_1101-2020_09_23_308239	303	224	n	n	CC
10_1101-2020_09_23_308239	303	225	20	20	CD
10_1101-2020_09_23_308239	303	226	µM	µM	NNP
10_1101-2020_09_23_308239	303	227	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	228	6.67	6.67	CD
10_1101-2020_09_23_308239	303	229	µM	µM	NNP
10_1101-2020_09_23_308239	303	230	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	231	2.22	2.22	CD
10_1101-2020_09_23_308239	303	232	µM	µM	NNP
10_1101-2020_09_23_308239	303	233	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	234	0.74	0.74	CD
10_1101-2020_09_23_308239	303	235	µM	µM	NNP
10_1101-2020_09_23_308239	303	236	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	237	0.25	0.25	CD
10_1101-2020_09_23_308239	303	238	µM	µM	NNP
10_1101-2020_09_23_308239	303	239	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	240	0.08	0.08	CD
10_1101-2020_09_23_308239	303	241	µM	µM	NNP
10_1101-2020_09_23_308239	303	242	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	243	0.03	0.03	CD
10_1101-2020_09_23_308239	303	244	µM	µM	NNP
10_1101-2020_09_23_308239	303	245	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	246	0.01	0.01	CD
10_1101-2020_09_23_308239	303	247	µM	µM	NNP
10_1101-2020_09_23_308239	303	248	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	249	-9	-9	NNP
10_1101-2020_09_23_308239	303	250	-8	-8	NNP
10_1101-2020_09_23_308239	303	251	-7	-7	:
10_1101-2020_09_23_308239	303	252	-6	-6	FW
10_1101-2020_09_23_308239	303	253	-5	-5	FW
10_1101-2020_09_23_308239	303	254	-4	-4	:
10_1101-2020_09_23_308239	303	255	-50	-50	NN
10_1101-2020_09_23_308239	303	256	0	0	CD
10_1101-2020_09_23_308239	303	257	50	50	CD
10_1101-2020_09_23_308239	303	258	100	100	CD
10_1101-2020_09_23_308239	303	259	150	150	CD
10_1101-2020_09_23_308239	303	260	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	261	DRC	drc	NN
10_1101-2020_09_23_308239	303	262	in	in	IN
10_1101-2020_09_23_308239	303	263	presence	presence	NN
10_1101-2020_09_23_308239	303	264	of	of	IN
10_1101-2020_09_23_308239	303	265	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	266	log	log	NN
10_1101-2020_09_23_308239	303	267	c	c	NN
10_1101-2020_09_23_308239	303	268	(	(	-LRB-
10_1101-2020_09_23_308239	303	269	M	m	NN
10_1101-2020_09_23_308239	303	270	)	)	-RRB-
10_1101-2020_09_23_308239	303	271	%	%	NN
10_1101-2020_09_23_308239	303	272	In	in	IN
10_1101-2020_09_23_308239	303	273	hi	hi	UH
10_1101-2020_09_23_308239	303	274	bi	bi	NNP
10_1101-2020_09_23_308239	303	275	tio	tio	NNP
10_1101-2020_09_23_308239	303	276	n	n	NNP
10_1101-2020_09_23_308239	303	277	0.25	0.25	CD
10_1101-2020_09_23_308239	303	278	µM	µM	NNP
10_1101-2020_09_23_308239	303	279	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	280	0.08	0.08	CD
10_1101-2020_09_23_308239	303	281	µM	µM	NNP
10_1101-2020_09_23_308239	303	282	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	283	0.03	0.03	CD
10_1101-2020_09_23_308239	303	284	µM	µM	NNP
10_1101-2020_09_23_308239	303	285	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	286	0.01	0.01	CD
10_1101-2020_09_23_308239	303	287	µM	µM	NNP
10_1101-2020_09_23_308239	303	288	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	289	-9	-9	NNP
10_1101-2020_09_23_308239	303	290	-8	-8	NNP
10_1101-2020_09_23_308239	303	291	-7	-7	:
10_1101-2020_09_23_308239	303	292	-6	-6	FW
10_1101-2020_09_23_308239	303	293	-5	-5	FW
10_1101-2020_09_23_308239	303	294	-4	-4	:
10_1101-2020_09_23_308239	303	295	-50	-50	NN
10_1101-2020_09_23_308239	303	296	0	0	CD
10_1101-2020_09_23_308239	303	297	50	50	CD
10_1101-2020_09_23_308239	303	298	100	100	CD
10_1101-2020_09_23_308239	303	299	150	150	CD
10_1101-2020_09_23_308239	303	300	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	301	DRC	drc	NN
10_1101-2020_09_23_308239	303	302	in	in	IN
10_1101-2020_09_23_308239	303	303	presence	presence	NN
10_1101-2020_09_23_308239	303	304	of	of	IN
10_1101-2020_09_23_308239	303	305	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	306	log	log	NN
10_1101-2020_09_23_308239	303	307	c	c	NN
10_1101-2020_09_23_308239	303	308	(	(	-LRB-
10_1101-2020_09_23_308239	303	309	M	m	NN
10_1101-2020_09_23_308239	303	310	)	)	-RRB-
10_1101-2020_09_23_308239	303	311	%	%	NN
10_1101-2020_09_23_308239	303	312	In	in	IN
10_1101-2020_09_23_308239	303	313	hi	hi	UH
10_1101-2020_09_23_308239	303	314	bi	bi	NNP
10_1101-2020_09_23_308239	303	315	tio	tio	NNP
10_1101-2020_09_23_308239	303	316	n	n	CC
10_1101-2020_09_23_308239	303	317	20	20	CD
10_1101-2020_09_23_308239	303	318	µM	µM	NNP
10_1101-2020_09_23_308239	303	319	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	320	6.67	6.67	CD
10_1101-2020_09_23_308239	303	321	µM	µM	NNP
10_1101-2020_09_23_308239	303	322	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	323	2.22	2.22	CD
10_1101-2020_09_23_308239	303	324	µM	µM	NNP
10_1101-2020_09_23_308239	303	325	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	326	0.74	0.74	CD
10_1101-2020_09_23_308239	303	327	µM	µM	NNP
10_1101-2020_09_23_308239	303	328	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	329	0.25	0.25	CD
10_1101-2020_09_23_308239	303	330	µM	µM	NNP
10_1101-2020_09_23_308239	303	331	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	332	0.08	0.08	CD
10_1101-2020_09_23_308239	303	333	µM	µM	NNP
10_1101-2020_09_23_308239	303	334	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	335	0.03	0.03	CD
10_1101-2020_09_23_308239	303	336	µM	µM	NNP
10_1101-2020_09_23_308239	303	337	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	338	0.01	0.01	CD
10_1101-2020_09_23_308239	303	339	µM	µM	NNP
10_1101-2020_09_23_308239	303	340	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	341	-9	-9	NNP
10_1101-2020_09_23_308239	303	342	-8	-8	NNP
10_1101-2020_09_23_308239	303	343	-7	-7	:
10_1101-2020_09_23_308239	303	344	-6	-6	FW
10_1101-2020_09_23_308239	303	345	-5	-5	FW
10_1101-2020_09_23_308239	303	346	-4	-4	:
10_1101-2020_09_23_308239	303	347	-50	-50	NN
10_1101-2020_09_23_308239	303	348	0	0	CD
10_1101-2020_09_23_308239	303	349	50	50	CD
10_1101-2020_09_23_308239	303	350	100	100	CD
10_1101-2020_09_23_308239	303	351	150	150	CD
10_1101-2020_09_23_308239	303	352	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	353	DRC	drc	NN
10_1101-2020_09_23_308239	303	354	in	in	IN
10_1101-2020_09_23_308239	303	355	presence	presence	NN
10_1101-2020_09_23_308239	303	356	of	of	IN
10_1101-2020_09_23_308239	303	357	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	358	log	log	NN
10_1101-2020_09_23_308239	303	359	c	c	NN
10_1101-2020_09_23_308239	303	360	(	(	-LRB-
10_1101-2020_09_23_308239	303	361	M	m	NN
10_1101-2020_09_23_308239	303	362	)	)	-RRB-
10_1101-2020_09_23_308239	303	363	%	%	NN
10_1101-2020_09_23_308239	303	364	In	in	IN
10_1101-2020_09_23_308239	303	365	hi	hi	UH
10_1101-2020_09_23_308239	303	366	bi	bi	NNP
10_1101-2020_09_23_308239	303	367	tio	tio	NNP
10_1101-2020_09_23_308239	303	368	n	n	NNP
10_1101-2020_09_23_308239	303	369	20	20	CD
10_1101-2020_09_23_308239	303	370	µM	µM	NNP
10_1101-2020_09_23_308239	303	371	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	372	6.67	6.67	CD
10_1101-2020_09_23_308239	303	373	µM	µM	NNP
10_1101-2020_09_23_308239	303	374	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	375	2.22	2.22	CD
10_1101-2020_09_23_308239	303	376	µM	µM	NNP
10_1101-2020_09_23_308239	303	377	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	378	0.74	0.74	CD
10_1101-2020_09_23_308239	303	379	µM	µM	NNP
10_1101-2020_09_23_308239	303	380	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	381	0.25	0.25	CD
10_1101-2020_09_23_308239	303	382	µM	µM	NNP
10_1101-2020_09_23_308239	303	383	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	384	0.08	0.08	CD
10_1101-2020_09_23_308239	303	385	µM	µM	NNP
10_1101-2020_09_23_308239	303	386	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	387	0.03	0.03	CD
10_1101-2020_09_23_308239	303	388	µM	µM	NNP
10_1101-2020_09_23_308239	303	389	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	390	0.01	0.01	CD
10_1101-2020_09_23_308239	303	391	µM	µM	NNP
10_1101-2020_09_23_308239	303	392	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	393	-9	-9	NNP
10_1101-2020_09_23_308239	303	394	-8	-8	NNP
10_1101-2020_09_23_308239	303	395	-7	-7	:
10_1101-2020_09_23_308239	303	396	-6	-6	FW
10_1101-2020_09_23_308239	303	397	-5	-5	FW
10_1101-2020_09_23_308239	303	398	-4	-4	:
10_1101-2020_09_23_308239	303	399	-50	-50	NN
10_1101-2020_09_23_308239	303	400	0	0	CD
10_1101-2020_09_23_308239	303	401	50	50	CD
10_1101-2020_09_23_308239	303	402	100	100	CD
10_1101-2020_09_23_308239	303	403	150	150	CD
10_1101-2020_09_23_308239	303	404	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	405	DRC	drc	NN
10_1101-2020_09_23_308239	303	406	in	in	IN
10_1101-2020_09_23_308239	303	407	presence	presence	NN
10_1101-2020_09_23_308239	303	408	of	of	IN
10_1101-2020_09_23_308239	303	409	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	410	log	log	NN
10_1101-2020_09_23_308239	303	411	c	c	NN
10_1101-2020_09_23_308239	303	412	(	(	-LRB-
10_1101-2020_09_23_308239	303	413	M	m	NN
10_1101-2020_09_23_308239	303	414	)	)	-RRB-
10_1101-2020_09_23_308239	303	415	%	%	NN
10_1101-2020_09_23_308239	303	416	In	in	IN
10_1101-2020_09_23_308239	303	417	hi	hi	UH
10_1101-2020_09_23_308239	303	418	bi	bi	NNP
10_1101-2020_09_23_308239	303	419	tio	tio	NNP
10_1101-2020_09_23_308239	303	420	n	n	CC
10_1101-2020_09_23_308239	303	421	20	20	CD
10_1101-2020_09_23_308239	303	422	µM	µM	NNP
10_1101-2020_09_23_308239	303	423	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	424	6.67	6.67	CD
10_1101-2020_09_23_308239	303	425	µM	µM	NNP
10_1101-2020_09_23_308239	303	426	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	427	2.22	2.22	CD
10_1101-2020_09_23_308239	303	428	µM	µM	NNP
10_1101-2020_09_23_308239	303	429	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	430	0.74	0.74	CD
10_1101-2020_09_23_308239	303	431	µM	µM	NNP
10_1101-2020_09_23_308239	303	432	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	433	0.25	0.25	CD
10_1101-2020_09_23_308239	303	434	µM	µM	NNP
10_1101-2020_09_23_308239	303	435	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	436	0.08	0.08	CD
10_1101-2020_09_23_308239	303	437	µM	µM	NNP
10_1101-2020_09_23_308239	303	438	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	439	0.03	0.03	CD
10_1101-2020_09_23_308239	303	440	µM	µM	NNP
10_1101-2020_09_23_308239	303	441	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	442	0.01	0.01	CD
10_1101-2020_09_23_308239	303	443	µM	µM	NNP
10_1101-2020_09_23_308239	303	444	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	445	-9	-9	NNP
10_1101-2020_09_23_308239	303	446	-8	-8	NNP
10_1101-2020_09_23_308239	303	447	-7	-7	:
10_1101-2020_09_23_308239	303	448	-6	-6	FW
10_1101-2020_09_23_308239	303	449	-5	-5	FW
10_1101-2020_09_23_308239	303	450	-4	-4	:
10_1101-2020_09_23_308239	303	451	-50	-50	NN
10_1101-2020_09_23_308239	303	452	0	0	CD
10_1101-2020_09_23_308239	303	453	50	50	CD
10_1101-2020_09_23_308239	303	454	100	100	CD
10_1101-2020_09_23_308239	303	455	150	150	CD
10_1101-2020_09_23_308239	303	456	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	457	DRC	drc	NN
10_1101-2020_09_23_308239	303	458	in	in	IN
10_1101-2020_09_23_308239	303	459	presence	presence	NN
10_1101-2020_09_23_308239	303	460	of	of	IN
10_1101-2020_09_23_308239	303	461	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	462	log	log	NN
10_1101-2020_09_23_308239	303	463	c	c	NN
10_1101-2020_09_23_308239	303	464	(	(	-LRB-
10_1101-2020_09_23_308239	303	465	M	m	NN
10_1101-2020_09_23_308239	303	466	)	)	-RRB-
10_1101-2020_09_23_308239	303	467	%	%	NN
10_1101-2020_09_23_308239	303	468	In	in	IN
10_1101-2020_09_23_308239	303	469	hi	hi	UH
10_1101-2020_09_23_308239	303	470	bi	bi	NNP
10_1101-2020_09_23_308239	303	471	tio	tio	NNP
10_1101-2020_09_23_308239	303	472	n	n	NNP
10_1101-2020_09_23_308239	303	473	0.25	0.25	CD
10_1101-2020_09_23_308239	303	474	µM	µM	NNP
10_1101-2020_09_23_308239	303	475	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	476	0.08	0.08	CD
10_1101-2020_09_23_308239	303	477	µM	µM	NNP
10_1101-2020_09_23_308239	303	478	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	479	0.03	0.03	CD
10_1101-2020_09_23_308239	303	480	µM	µM	NNP
10_1101-2020_09_23_308239	303	481	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	482	0.01	0.01	CD
10_1101-2020_09_23_308239	303	483	µM	µM	NNP
10_1101-2020_09_23_308239	303	484	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	485	-9	-9	NNP
10_1101-2020_09_23_308239	303	486	-8	-8	NNP
10_1101-2020_09_23_308239	303	487	-7	-7	:
10_1101-2020_09_23_308239	303	488	-6	-6	FW
10_1101-2020_09_23_308239	303	489	-5	-5	FW
10_1101-2020_09_23_308239	303	490	-4	-4	:
10_1101-2020_09_23_308239	303	491	-50	-50	NN
10_1101-2020_09_23_308239	303	492	0	0	CD
10_1101-2020_09_23_308239	303	493	50	50	CD
10_1101-2020_09_23_308239	303	494	100	100	CD
10_1101-2020_09_23_308239	303	495	150	150	CD
10_1101-2020_09_23_308239	303	496	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	497	DRC	drc	NN
10_1101-2020_09_23_308239	303	498	in	in	IN
10_1101-2020_09_23_308239	303	499	presence	presence	NN
10_1101-2020_09_23_308239	303	500	of	of	IN
10_1101-2020_09_23_308239	303	501	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	502	log	log	NN
10_1101-2020_09_23_308239	303	503	c	c	NN
10_1101-2020_09_23_308239	303	504	(	(	-LRB-
10_1101-2020_09_23_308239	303	505	M	m	NN
10_1101-2020_09_23_308239	303	506	)	)	-RRB-
10_1101-2020_09_23_308239	303	507	%	%	NN
10_1101-2020_09_23_308239	303	508	In	in	IN
10_1101-2020_09_23_308239	303	509	hi	hi	UH
10_1101-2020_09_23_308239	303	510	bi	bi	NNP
10_1101-2020_09_23_308239	303	511	tio	tio	NNP
10_1101-2020_09_23_308239	303	512	n	n	CC
10_1101-2020_09_23_308239	303	513	20	20	CD
10_1101-2020_09_23_308239	303	514	µM	µM	NNP
10_1101-2020_09_23_308239	303	515	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	516	6.67	6.67	CD
10_1101-2020_09_23_308239	303	517	µM	µM	NNP
10_1101-2020_09_23_308239	303	518	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	519	2.22	2.22	CD
10_1101-2020_09_23_308239	303	520	µM	µM	NNP
10_1101-2020_09_23_308239	303	521	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	522	0.74	0.74	CD
10_1101-2020_09_23_308239	303	523	µM	µM	NNP
10_1101-2020_09_23_308239	303	524	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	525	0.25	0.25	CD
10_1101-2020_09_23_308239	303	526	µM	µM	NNP
10_1101-2020_09_23_308239	303	527	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	528	0.08	0.08	CD
10_1101-2020_09_23_308239	303	529	µM	µM	NNP
10_1101-2020_09_23_308239	303	530	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	531	0.03	0.03	CD
10_1101-2020_09_23_308239	303	532	µM	µM	NNP
10_1101-2020_09_23_308239	303	533	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	534	0.01	0.01	CD
10_1101-2020_09_23_308239	303	535	µM	µM	NNP
10_1101-2020_09_23_308239	303	536	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	537	-9	-9	NNP
10_1101-2020_09_23_308239	303	538	-8	-8	NNP
10_1101-2020_09_23_308239	303	539	-7	-7	:
10_1101-2020_09_23_308239	303	540	-6	-6	FW
10_1101-2020_09_23_308239	303	541	-5	-5	FW
10_1101-2020_09_23_308239	303	542	-4	-4	:
10_1101-2020_09_23_308239	303	543	-50	-50	NN
10_1101-2020_09_23_308239	303	544	0	0	CD
10_1101-2020_09_23_308239	303	545	50	50	CD
10_1101-2020_09_23_308239	303	546	100	100	CD
10_1101-2020_09_23_308239	303	547	150	150	CD
10_1101-2020_09_23_308239	303	548	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	549	DRC	drc	NN
10_1101-2020_09_23_308239	303	550	in	in	IN
10_1101-2020_09_23_308239	303	551	presence	presence	NN
10_1101-2020_09_23_308239	303	552	of	of	IN
10_1101-2020_09_23_308239	303	553	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	554	log	log	NN
10_1101-2020_09_23_308239	303	555	c	c	NN
10_1101-2020_09_23_308239	303	556	(	(	-LRB-
10_1101-2020_09_23_308239	303	557	M	m	NN
10_1101-2020_09_23_308239	303	558	)	)	-RRB-
10_1101-2020_09_23_308239	303	559	%	%	NN
10_1101-2020_09_23_308239	303	560	In	in	IN
10_1101-2020_09_23_308239	303	561	hi	hi	UH
10_1101-2020_09_23_308239	303	562	bi	bi	NNP
10_1101-2020_09_23_308239	303	563	tio	tio	NNP
10_1101-2020_09_23_308239	303	564	n	n	NNP
10_1101-2020_09_23_308239	303	565	20	20	CD
10_1101-2020_09_23_308239	303	566	µM	µM	NNP
10_1101-2020_09_23_308239	303	567	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	568	6.67	6.67	CD
10_1101-2020_09_23_308239	303	569	µM	µM	NNP
10_1101-2020_09_23_308239	303	570	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	571	2.22	2.22	CD
10_1101-2020_09_23_308239	303	572	µM	µM	NNP
10_1101-2020_09_23_308239	303	573	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	574	0.74	0.74	CD
10_1101-2020_09_23_308239	303	575	µM	µM	NNP
10_1101-2020_09_23_308239	303	576	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	577	0.25	0.25	CD
10_1101-2020_09_23_308239	303	578	µM	µM	NNP
10_1101-2020_09_23_308239	303	579	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	580	0.08	0.08	CD
10_1101-2020_09_23_308239	303	581	µM	µM	NNP
10_1101-2020_09_23_308239	303	582	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	583	0.03	0.03	CD
10_1101-2020_09_23_308239	303	584	µM	µM	NNP
10_1101-2020_09_23_308239	303	585	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	586	0.01	0.01	CD
10_1101-2020_09_23_308239	303	587	µM	µM	NNP
10_1101-2020_09_23_308239	303	588	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	589	-9	-9	NNP
10_1101-2020_09_23_308239	303	590	-8	-8	NNP
10_1101-2020_09_23_308239	303	591	-7	-7	:
10_1101-2020_09_23_308239	303	592	-6	-6	FW
10_1101-2020_09_23_308239	303	593	-5	-5	FW
10_1101-2020_09_23_308239	303	594	-4	-4	:
10_1101-2020_09_23_308239	303	595	-50	-50	NN
10_1101-2020_09_23_308239	303	596	0	0	CD
10_1101-2020_09_23_308239	303	597	50	50	CD
10_1101-2020_09_23_308239	303	598	100	100	CD
10_1101-2020_09_23_308239	303	599	150	150	CD
10_1101-2020_09_23_308239	303	600	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	601	DRC	drc	NN
10_1101-2020_09_23_308239	303	602	in	in	IN
10_1101-2020_09_23_308239	303	603	presence	presence	NN
10_1101-2020_09_23_308239	303	604	of	of	IN
10_1101-2020_09_23_308239	303	605	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	606	log	log	NN
10_1101-2020_09_23_308239	303	607	c	c	NN
10_1101-2020_09_23_308239	303	608	(	(	-LRB-
10_1101-2020_09_23_308239	303	609	M	m	NN
10_1101-2020_09_23_308239	303	610	)	)	-RRB-
10_1101-2020_09_23_308239	303	611	%	%	NN
10_1101-2020_09_23_308239	303	612	In	in	IN
10_1101-2020_09_23_308239	303	613	hi	hi	UH
10_1101-2020_09_23_308239	303	614	bi	bi	NNP
10_1101-2020_09_23_308239	303	615	tio	tio	NNP
10_1101-2020_09_23_308239	303	616	n	n	CC
10_1101-2020_09_23_308239	303	617	20	20	CD
10_1101-2020_09_23_308239	303	618	µM	µM	NNP
10_1101-2020_09_23_308239	303	619	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	620	6.67	6.67	CD
10_1101-2020_09_23_308239	303	621	µM	µM	NNP
10_1101-2020_09_23_308239	303	622	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	623	2.22	2.22	CD
10_1101-2020_09_23_308239	303	624	µM	µM	NNP
10_1101-2020_09_23_308239	303	625	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	626	0.74	0.74	CD
10_1101-2020_09_23_308239	303	627	µM	µM	NNP
10_1101-2020_09_23_308239	303	628	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	629	0.25	0.25	CD
10_1101-2020_09_23_308239	303	630	µM	µM	NNP
10_1101-2020_09_23_308239	303	631	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	632	0.08	0.08	CD
10_1101-2020_09_23_308239	303	633	µM	µM	NNP
10_1101-2020_09_23_308239	303	634	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	635	0.03	0.03	CD
10_1101-2020_09_23_308239	303	636	µM	µM	NNP
10_1101-2020_09_23_308239	303	637	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	638	0.01	0.01	CD
10_1101-2020_09_23_308239	303	639	µM	µM	NNP
10_1101-2020_09_23_308239	303	640	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	641	-9	-9	NNP
10_1101-2020_09_23_308239	303	642	-8	-8	NNP
10_1101-2020_09_23_308239	303	643	-7	-7	:
10_1101-2020_09_23_308239	303	644	-6	-6	FW
10_1101-2020_09_23_308239	303	645	-5	-5	FW
10_1101-2020_09_23_308239	303	646	-4	-4	:
10_1101-2020_09_23_308239	303	647	-50	-50	NN
10_1101-2020_09_23_308239	303	648	0	0	CD
10_1101-2020_09_23_308239	303	649	50	50	CD
10_1101-2020_09_23_308239	303	650	100	100	CD
10_1101-2020_09_23_308239	303	651	150	150	CD
10_1101-2020_09_23_308239	303	652	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	653	DRC	drc	NN
10_1101-2020_09_23_308239	303	654	in	in	IN
10_1101-2020_09_23_308239	303	655	presence	presence	NN
10_1101-2020_09_23_308239	303	656	of	of	IN
10_1101-2020_09_23_308239	303	657	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	658	log	log	NN
10_1101-2020_09_23_308239	303	659	c	c	NN
10_1101-2020_09_23_308239	303	660	(	(	-LRB-
10_1101-2020_09_23_308239	303	661	M	m	NN
10_1101-2020_09_23_308239	303	662	)	)	-RRB-
10_1101-2020_09_23_308239	303	663	%	%	NN
10_1101-2020_09_23_308239	303	664	In	in	IN
10_1101-2020_09_23_308239	303	665	hi	hi	UH
10_1101-2020_09_23_308239	303	666	bi	bi	NNP
10_1101-2020_09_23_308239	303	667	tio	tio	NNP
10_1101-2020_09_23_308239	303	668	n	n	NNP
10_1101-2020_09_23_308239	303	669	0.25	0.25	CD
10_1101-2020_09_23_308239	303	670	µM	µM	NNP
10_1101-2020_09_23_308239	303	671	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	672	0.08	0.08	CD
10_1101-2020_09_23_308239	303	673	µM	µM	NNP
10_1101-2020_09_23_308239	303	674	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	675	0.03	0.03	CD
10_1101-2020_09_23_308239	303	676	µM	µM	NNP
10_1101-2020_09_23_308239	303	677	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	678	0.01	0.01	CD
10_1101-2020_09_23_308239	303	679	µM	µM	NNP
10_1101-2020_09_23_308239	303	680	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	681	-9	-9	NNP
10_1101-2020_09_23_308239	303	682	-8	-8	NNP
10_1101-2020_09_23_308239	303	683	-7	-7	:
10_1101-2020_09_23_308239	303	684	-6	-6	FW
10_1101-2020_09_23_308239	303	685	-5	-5	FW
10_1101-2020_09_23_308239	303	686	-4	-4	:
10_1101-2020_09_23_308239	303	687	-50	-50	NN
10_1101-2020_09_23_308239	303	688	0	0	CD
10_1101-2020_09_23_308239	303	689	50	50	CD
10_1101-2020_09_23_308239	303	690	100	100	CD
10_1101-2020_09_23_308239	303	691	150	150	CD
10_1101-2020_09_23_308239	303	692	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	693	DRC	drc	NN
10_1101-2020_09_23_308239	303	694	in	in	IN
10_1101-2020_09_23_308239	303	695	presence	presence	NN
10_1101-2020_09_23_308239	303	696	of	of	IN
10_1101-2020_09_23_308239	303	697	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	698	log	log	NN
10_1101-2020_09_23_308239	303	699	c	c	NN
10_1101-2020_09_23_308239	303	700	(	(	-LRB-
10_1101-2020_09_23_308239	303	701	M	m	NN
10_1101-2020_09_23_308239	303	702	)	)	-RRB-
10_1101-2020_09_23_308239	303	703	%	%	NN
10_1101-2020_09_23_308239	303	704	In	in	IN
10_1101-2020_09_23_308239	303	705	hi	hi	UH
10_1101-2020_09_23_308239	303	706	bi	bi	NNP
10_1101-2020_09_23_308239	303	707	tio	tio	NNP
10_1101-2020_09_23_308239	303	708	n	n	CC
10_1101-2020_09_23_308239	303	709	20	20	CD
10_1101-2020_09_23_308239	303	710	µM	µM	NNP
10_1101-2020_09_23_308239	303	711	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	712	6.67	6.67	CD
10_1101-2020_09_23_308239	303	713	µM	µM	NNP
10_1101-2020_09_23_308239	303	714	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	715	2.22	2.22	CD
10_1101-2020_09_23_308239	303	716	µM	µM	NNP
10_1101-2020_09_23_308239	303	717	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	718	0.74	0.74	CD
10_1101-2020_09_23_308239	303	719	µM	µM	NNP
10_1101-2020_09_23_308239	303	720	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	721	0.25	0.25	CD
10_1101-2020_09_23_308239	303	722	µM	µM	NNP
10_1101-2020_09_23_308239	303	723	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	724	0.08	0.08	CD
10_1101-2020_09_23_308239	303	725	µM	µM	NNP
10_1101-2020_09_23_308239	303	726	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	727	0.03	0.03	CD
10_1101-2020_09_23_308239	303	728	µM	µM	NNP
10_1101-2020_09_23_308239	303	729	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	730	0.01	0.01	CD
10_1101-2020_09_23_308239	303	731	µM	µM	NNP
10_1101-2020_09_23_308239	303	732	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	733	-9	-9	NNP
10_1101-2020_09_23_308239	303	734	-8	-8	NNP
10_1101-2020_09_23_308239	303	735	-7	-7	:
10_1101-2020_09_23_308239	303	736	-6	-6	FW
10_1101-2020_09_23_308239	303	737	-5	-5	FW
10_1101-2020_09_23_308239	303	738	-4	-4	:
10_1101-2020_09_23_308239	303	739	-50	-50	NN
10_1101-2020_09_23_308239	303	740	0	0	CD
10_1101-2020_09_23_308239	303	741	50	50	CD
10_1101-2020_09_23_308239	303	742	100	100	CD
10_1101-2020_09_23_308239	303	743	150	150	CD
10_1101-2020_09_23_308239	303	744	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	745	DRC	drc	NN
10_1101-2020_09_23_308239	303	746	in	in	IN
10_1101-2020_09_23_308239	303	747	presence	presence	NN
10_1101-2020_09_23_308239	303	748	of	of	IN
10_1101-2020_09_23_308239	303	749	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	750	log	log	NN
10_1101-2020_09_23_308239	303	751	c	c	NN
10_1101-2020_09_23_308239	303	752	(	(	-LRB-
10_1101-2020_09_23_308239	303	753	M	m	NN
10_1101-2020_09_23_308239	303	754	)	)	-RRB-
10_1101-2020_09_23_308239	303	755	%	%	NN
10_1101-2020_09_23_308239	303	756	In	in	IN
10_1101-2020_09_23_308239	303	757	hi	hi	UH
10_1101-2020_09_23_308239	303	758	bi	bi	NNP
10_1101-2020_09_23_308239	303	759	tio	tio	NNP
10_1101-2020_09_23_308239	303	760	n	n	NNP
10_1101-2020_09_23_308239	303	761	20	20	CD
10_1101-2020_09_23_308239	303	762	µM	µM	NNP
10_1101-2020_09_23_308239	303	763	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	764	6.67	6.67	CD
10_1101-2020_09_23_308239	303	765	µM	µM	NNP
10_1101-2020_09_23_308239	303	766	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	767	2.22	2.22	CD
10_1101-2020_09_23_308239	303	768	µM	µM	NNP
10_1101-2020_09_23_308239	303	769	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	770	0.74	0.74	CD
10_1101-2020_09_23_308239	303	771	µM	µM	NNP
10_1101-2020_09_23_308239	303	772	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	773	0.25	0.25	CD
10_1101-2020_09_23_308239	303	774	µM	µM	NNP
10_1101-2020_09_23_308239	303	775	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	776	0.08	0.08	CD
10_1101-2020_09_23_308239	303	777	µM	µM	NNP
10_1101-2020_09_23_308239	303	778	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	779	0.03	0.03	CD
10_1101-2020_09_23_308239	303	780	µM	µM	NNP
10_1101-2020_09_23_308239	303	781	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	782	0.01	0.01	CD
10_1101-2020_09_23_308239	303	783	µM	µM	NNP
10_1101-2020_09_23_308239	303	784	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	785	-9	-9	NNP
10_1101-2020_09_23_308239	303	786	-8	-8	NNP
10_1101-2020_09_23_308239	303	787	-7	-7	:
10_1101-2020_09_23_308239	303	788	-6	-6	FW
10_1101-2020_09_23_308239	303	789	-5	-5	FW
10_1101-2020_09_23_308239	303	790	-4	-4	:
10_1101-2020_09_23_308239	303	791	-50	-50	NN
10_1101-2020_09_23_308239	303	792	0	0	CD
10_1101-2020_09_23_308239	303	793	50	50	CD
10_1101-2020_09_23_308239	303	794	100	100	CD
10_1101-2020_09_23_308239	303	795	150	150	CD
10_1101-2020_09_23_308239	303	796	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	797	DRC	drc	NN
10_1101-2020_09_23_308239	303	798	in	in	IN
10_1101-2020_09_23_308239	303	799	presence	presence	NN
10_1101-2020_09_23_308239	303	800	of	of	IN
10_1101-2020_09_23_308239	303	801	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	802	log	log	NN
10_1101-2020_09_23_308239	303	803	c	c	NN
10_1101-2020_09_23_308239	303	804	(	(	-LRB-
10_1101-2020_09_23_308239	303	805	M	m	NN
10_1101-2020_09_23_308239	303	806	)	)	-RRB-
10_1101-2020_09_23_308239	303	807	%	%	NN
10_1101-2020_09_23_308239	303	808	In	in	IN
10_1101-2020_09_23_308239	303	809	hi	hi	UH
10_1101-2020_09_23_308239	303	810	bi	bi	NNP
10_1101-2020_09_23_308239	303	811	tio	tio	NNP
10_1101-2020_09_23_308239	303	812	n	n	CC
10_1101-2020_09_23_308239	303	813	20	20	CD
10_1101-2020_09_23_308239	303	814	µM	µM	NNP
10_1101-2020_09_23_308239	303	815	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	816	6.67	6.67	CD
10_1101-2020_09_23_308239	303	817	µM	µM	NNP
10_1101-2020_09_23_308239	303	818	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	819	2.22	2.22	CD
10_1101-2020_09_23_308239	303	820	µM	µM	NNP
10_1101-2020_09_23_308239	303	821	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	822	0.74	0.74	CD
10_1101-2020_09_23_308239	303	823	µM	µM	NNP
10_1101-2020_09_23_308239	303	824	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	825	0.25	0.25	CD
10_1101-2020_09_23_308239	303	826	µM	µM	NNP
10_1101-2020_09_23_308239	303	827	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	828	0.08	0.08	CD
10_1101-2020_09_23_308239	303	829	µM	µM	NNP
10_1101-2020_09_23_308239	303	830	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	831	0.03	0.03	CD
10_1101-2020_09_23_308239	303	832	µM	µM	NNP
10_1101-2020_09_23_308239	303	833	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	834	0.01	0.01	CD
10_1101-2020_09_23_308239	303	835	µM	µM	NNP
10_1101-2020_09_23_308239	303	836	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	837	-9	-9	NNP
10_1101-2020_09_23_308239	303	838	-8	-8	NNP
10_1101-2020_09_23_308239	303	839	-7	-7	:
10_1101-2020_09_23_308239	303	840	-6	-6	FW
10_1101-2020_09_23_308239	303	841	-5	-5	FW
10_1101-2020_09_23_308239	303	842	-4	-4	:
10_1101-2020_09_23_308239	303	843	-50	-50	NN
10_1101-2020_09_23_308239	303	844	0	0	CD
10_1101-2020_09_23_308239	303	845	50	50	CD
10_1101-2020_09_23_308239	303	846	100	100	CD
10_1101-2020_09_23_308239	303	847	150	150	CD
10_1101-2020_09_23_308239	303	848	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	849	DRC	drc	NN
10_1101-2020_09_23_308239	303	850	in	in	IN
10_1101-2020_09_23_308239	303	851	presence	presence	NN
10_1101-2020_09_23_308239	303	852	of	of	IN
10_1101-2020_09_23_308239	303	853	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	854	log	log	NN
10_1101-2020_09_23_308239	303	855	c	c	NN
10_1101-2020_09_23_308239	303	856	(	(	-LRB-
10_1101-2020_09_23_308239	303	857	M	m	NN
10_1101-2020_09_23_308239	303	858	)	)	-RRB-
10_1101-2020_09_23_308239	303	859	%	%	NN
10_1101-2020_09_23_308239	303	860	In	in	IN
10_1101-2020_09_23_308239	303	861	hi	hi	UH
10_1101-2020_09_23_308239	303	862	bi	bi	NNP
10_1101-2020_09_23_308239	303	863	tio	tio	NNP
10_1101-2020_09_23_308239	303	864	n	n	NNP
10_1101-2020_09_23_308239	303	865	0.25	0.25	CD
10_1101-2020_09_23_308239	303	866	µM	µM	NNP
10_1101-2020_09_23_308239	303	867	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	868	0.08	0.08	CD
10_1101-2020_09_23_308239	303	869	µM	µM	NNP
10_1101-2020_09_23_308239	303	870	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	871	0.03	0.03	CD
10_1101-2020_09_23_308239	303	872	µM	µM	NNP
10_1101-2020_09_23_308239	303	873	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	874	0.01	0.01	CD
10_1101-2020_09_23_308239	303	875	µM	µM	NNP
10_1101-2020_09_23_308239	303	876	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	877	-9	-9	NNP
10_1101-2020_09_23_308239	303	878	-8	-8	NNP
10_1101-2020_09_23_308239	303	879	-7	-7	:
10_1101-2020_09_23_308239	303	880	-6	-6	FW
10_1101-2020_09_23_308239	303	881	-5	-5	FW
10_1101-2020_09_23_308239	303	882	-4	-4	:
10_1101-2020_09_23_308239	303	883	-50	-50	NN
10_1101-2020_09_23_308239	303	884	0	0	CD
10_1101-2020_09_23_308239	303	885	50	50	CD
10_1101-2020_09_23_308239	303	886	100	100	CD
10_1101-2020_09_23_308239	303	887	150	150	CD
10_1101-2020_09_23_308239	303	888	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	889	DRC	drc	NN
10_1101-2020_09_23_308239	303	890	in	in	IN
10_1101-2020_09_23_308239	303	891	presence	presence	NN
10_1101-2020_09_23_308239	303	892	of	of	IN
10_1101-2020_09_23_308239	303	893	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	894	log	log	NN
10_1101-2020_09_23_308239	303	895	c	c	NN
10_1101-2020_09_23_308239	303	896	(	(	-LRB-
10_1101-2020_09_23_308239	303	897	M	m	NN
10_1101-2020_09_23_308239	303	898	)	)	-RRB-
10_1101-2020_09_23_308239	303	899	%	%	NN
10_1101-2020_09_23_308239	303	900	In	in	IN
10_1101-2020_09_23_308239	303	901	hi	hi	UH
10_1101-2020_09_23_308239	303	902	bi	bi	NNP
10_1101-2020_09_23_308239	303	903	tio	tio	NNP
10_1101-2020_09_23_308239	303	904	n	n	CC
10_1101-2020_09_23_308239	303	905	20	20	CD
10_1101-2020_09_23_308239	303	906	µM	µM	NNP
10_1101-2020_09_23_308239	303	907	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	908	6.67	6.67	CD
10_1101-2020_09_23_308239	303	909	µM	µM	NNP
10_1101-2020_09_23_308239	303	910	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	911	2.22	2.22	CD
10_1101-2020_09_23_308239	303	912	µM	µM	NNP
10_1101-2020_09_23_308239	303	913	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	914	0.74	0.74	CD
10_1101-2020_09_23_308239	303	915	µM	µM	NNP
10_1101-2020_09_23_308239	303	916	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	917	0.25	0.25	CD
10_1101-2020_09_23_308239	303	918	µM	µM	NNP
10_1101-2020_09_23_308239	303	919	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	920	0.08	0.08	CD
10_1101-2020_09_23_308239	303	921	µM	µM	NNP
10_1101-2020_09_23_308239	303	922	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	923	0.03	0.03	CD
10_1101-2020_09_23_308239	303	924	µM	µM	NNP
10_1101-2020_09_23_308239	303	925	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	926	0.01	0.01	CD
10_1101-2020_09_23_308239	303	927	µM	µM	NNP
10_1101-2020_09_23_308239	303	928	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	929	-9	-9	NNP
10_1101-2020_09_23_308239	303	930	-8	-8	NNP
10_1101-2020_09_23_308239	303	931	-7	-7	:
10_1101-2020_09_23_308239	303	932	-6	-6	FW
10_1101-2020_09_23_308239	303	933	-5	-5	FW
10_1101-2020_09_23_308239	303	934	-4	-4	:
10_1101-2020_09_23_308239	303	935	-50	-50	NN
10_1101-2020_09_23_308239	303	936	0	0	CD
10_1101-2020_09_23_308239	303	937	50	50	CD
10_1101-2020_09_23_308239	303	938	100	100	CD
10_1101-2020_09_23_308239	303	939	150	150	CD
10_1101-2020_09_23_308239	303	940	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	941	DRC	drc	NN
10_1101-2020_09_23_308239	303	942	in	in	IN
10_1101-2020_09_23_308239	303	943	presence	presence	NN
10_1101-2020_09_23_308239	303	944	of	of	IN
10_1101-2020_09_23_308239	303	945	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	946	log	log	NN
10_1101-2020_09_23_308239	303	947	c	c	NN
10_1101-2020_09_23_308239	303	948	(	(	-LRB-
10_1101-2020_09_23_308239	303	949	M	m	NN
10_1101-2020_09_23_308239	303	950	)	)	-RRB-
10_1101-2020_09_23_308239	303	951	%	%	NN
10_1101-2020_09_23_308239	303	952	In	in	IN
10_1101-2020_09_23_308239	303	953	hi	hi	UH
10_1101-2020_09_23_308239	303	954	bi	bi	NNP
10_1101-2020_09_23_308239	303	955	tio	tio	NNP
10_1101-2020_09_23_308239	303	956	n	n	NNP
10_1101-2020_09_23_308239	303	957	20	20	CD
10_1101-2020_09_23_308239	303	958	µM	µM	NNP
10_1101-2020_09_23_308239	303	959	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	960	6.67	6.67	CD
10_1101-2020_09_23_308239	303	961	µM	µM	NNP
10_1101-2020_09_23_308239	303	962	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	963	2.22	2.22	CD
10_1101-2020_09_23_308239	303	964	µM	µM	NNP
10_1101-2020_09_23_308239	303	965	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	966	0.74	0.74	CD
10_1101-2020_09_23_308239	303	967	µM	µM	NNP
10_1101-2020_09_23_308239	303	968	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	969	0.25	0.25	CD
10_1101-2020_09_23_308239	303	970	µM	µM	NNP
10_1101-2020_09_23_308239	303	971	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	972	0.08	0.08	CD
10_1101-2020_09_23_308239	303	973	µM	µM	NNP
10_1101-2020_09_23_308239	303	974	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	975	0.03	0.03	CD
10_1101-2020_09_23_308239	303	976	µM	µM	NNP
10_1101-2020_09_23_308239	303	977	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	978	0.01	0.01	CD
10_1101-2020_09_23_308239	303	979	µM	µM	NNP
10_1101-2020_09_23_308239	303	980	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	981	-9	-9	NNP
10_1101-2020_09_23_308239	303	982	-8	-8	NNP
10_1101-2020_09_23_308239	303	983	-7	-7	:
10_1101-2020_09_23_308239	303	984	-6	-6	FW
10_1101-2020_09_23_308239	303	985	-5	-5	FW
10_1101-2020_09_23_308239	303	986	-4	-4	:
10_1101-2020_09_23_308239	303	987	-50	-50	NN
10_1101-2020_09_23_308239	303	988	0	0	CD
10_1101-2020_09_23_308239	303	989	50	50	CD
10_1101-2020_09_23_308239	303	990	100	100	CD
10_1101-2020_09_23_308239	303	991	150	150	CD
10_1101-2020_09_23_308239	303	992	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	993	DRC	drc	NN
10_1101-2020_09_23_308239	303	994	in	in	IN
10_1101-2020_09_23_308239	303	995	presence	presence	NN
10_1101-2020_09_23_308239	303	996	of	of	IN
10_1101-2020_09_23_308239	303	997	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	998	log	log	NN
10_1101-2020_09_23_308239	303	999	c	c	NN
10_1101-2020_09_23_308239	303	1000	(	(	-LRB-
10_1101-2020_09_23_308239	303	1001	M	m	NN
10_1101-2020_09_23_308239	303	1002	)	)	-RRB-
10_1101-2020_09_23_308239	303	1003	%	%	NN
10_1101-2020_09_23_308239	303	1004	In	in	IN
10_1101-2020_09_23_308239	303	1005	hi	hi	UH
10_1101-2020_09_23_308239	303	1006	bi	bi	NNP
10_1101-2020_09_23_308239	303	1007	tio	tio	NNP
10_1101-2020_09_23_308239	303	1008	n	n	CC
10_1101-2020_09_23_308239	303	1009	20	20	CD
10_1101-2020_09_23_308239	303	1010	µM	µM	NNP
10_1101-2020_09_23_308239	303	1011	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1012	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1013	µM	µM	NNP
10_1101-2020_09_23_308239	303	1014	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1015	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1016	µM	µM	NNP
10_1101-2020_09_23_308239	303	1017	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1018	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1019	µM	µM	NNP
10_1101-2020_09_23_308239	303	1020	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1021	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1022	µM	µM	NNP
10_1101-2020_09_23_308239	303	1023	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1024	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1025	µM	µM	NNP
10_1101-2020_09_23_308239	303	1026	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1027	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1028	µM	µM	NNP
10_1101-2020_09_23_308239	303	1029	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1030	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1031	µM	µM	NNP
10_1101-2020_09_23_308239	303	1032	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1033	-9	-9	NNP
10_1101-2020_09_23_308239	303	1034	-8	-8	NNP
10_1101-2020_09_23_308239	303	1035	-7	-7	:
10_1101-2020_09_23_308239	303	1036	-6	-6	FW
10_1101-2020_09_23_308239	303	1037	-5	-5	FW
10_1101-2020_09_23_308239	303	1038	-4	-4	:
10_1101-2020_09_23_308239	303	1039	-50	-50	NN
10_1101-2020_09_23_308239	303	1040	0	0	CD
10_1101-2020_09_23_308239	303	1041	50	50	CD
10_1101-2020_09_23_308239	303	1042	100	100	CD
10_1101-2020_09_23_308239	303	1043	150	150	CD
10_1101-2020_09_23_308239	303	1044	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1045	DRC	drc	NN
10_1101-2020_09_23_308239	303	1046	in	in	IN
10_1101-2020_09_23_308239	303	1047	presence	presence	NN
10_1101-2020_09_23_308239	303	1048	of	of	IN
10_1101-2020_09_23_308239	303	1049	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1050	log	log	NN
10_1101-2020_09_23_308239	303	1051	c	c	NN
10_1101-2020_09_23_308239	303	1052	(	(	-LRB-
10_1101-2020_09_23_308239	303	1053	M	m	NN
10_1101-2020_09_23_308239	303	1054	)	)	-RRB-
10_1101-2020_09_23_308239	303	1055	%	%	NN
10_1101-2020_09_23_308239	303	1056	In	in	IN
10_1101-2020_09_23_308239	303	1057	hi	hi	UH
10_1101-2020_09_23_308239	303	1058	bi	bi	NNP
10_1101-2020_09_23_308239	303	1059	tio	tio	NNP
10_1101-2020_09_23_308239	303	1060	n	n	NNP
10_1101-2020_09_23_308239	303	1061	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1062	µM	µM	NNP
10_1101-2020_09_23_308239	303	1063	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1064	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1065	µM	µM	NNP
10_1101-2020_09_23_308239	303	1066	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1067	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1068	µM	µM	NNP
10_1101-2020_09_23_308239	303	1069	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1070	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1071	µM	µM	NNP
10_1101-2020_09_23_308239	303	1072	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1073	-9	-9	NNP
10_1101-2020_09_23_308239	303	1074	-8	-8	NNP
10_1101-2020_09_23_308239	303	1075	-7	-7	:
10_1101-2020_09_23_308239	303	1076	-6	-6	FW
10_1101-2020_09_23_308239	303	1077	-5	-5	FW
10_1101-2020_09_23_308239	303	1078	-4	-4	:
10_1101-2020_09_23_308239	303	1079	-50	-50	NN
10_1101-2020_09_23_308239	303	1080	0	0	CD
10_1101-2020_09_23_308239	303	1081	50	50	CD
10_1101-2020_09_23_308239	303	1082	100	100	CD
10_1101-2020_09_23_308239	303	1083	150	150	CD
10_1101-2020_09_23_308239	303	1084	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	1085	DRC	drc	NN
10_1101-2020_09_23_308239	303	1086	in	in	IN
10_1101-2020_09_23_308239	303	1087	presence	presence	NN
10_1101-2020_09_23_308239	303	1088	of	of	IN
10_1101-2020_09_23_308239	303	1089	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1090	log	log	NN
10_1101-2020_09_23_308239	303	1091	c	c	NN
10_1101-2020_09_23_308239	303	1092	(	(	-LRB-
10_1101-2020_09_23_308239	303	1093	M	m	NN
10_1101-2020_09_23_308239	303	1094	)	)	-RRB-
10_1101-2020_09_23_308239	303	1095	%	%	NN
10_1101-2020_09_23_308239	303	1096	In	in	IN
10_1101-2020_09_23_308239	303	1097	hi	hi	UH
10_1101-2020_09_23_308239	303	1098	bi	bi	NNP
10_1101-2020_09_23_308239	303	1099	tio	tio	NNP
10_1101-2020_09_23_308239	303	1100	n	n	CC
10_1101-2020_09_23_308239	303	1101	20	20	CD
10_1101-2020_09_23_308239	303	1102	µM	µM	NNP
10_1101-2020_09_23_308239	303	1103	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1104	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1105	µM	µM	NNP
10_1101-2020_09_23_308239	303	1106	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1107	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1108	µM	µM	NNP
10_1101-2020_09_23_308239	303	1109	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1110	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1111	µM	µM	NNP
10_1101-2020_09_23_308239	303	1112	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1113	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1114	µM	µM	NNP
10_1101-2020_09_23_308239	303	1115	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1116	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1117	µM	µM	NNP
10_1101-2020_09_23_308239	303	1118	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1119	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1120	µM	µM	NNP
10_1101-2020_09_23_308239	303	1121	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1122	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1123	µM	µM	NNP
10_1101-2020_09_23_308239	303	1124	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1125	-9	-9	NNP
10_1101-2020_09_23_308239	303	1126	-8	-8	NNP
10_1101-2020_09_23_308239	303	1127	-7	-7	:
10_1101-2020_09_23_308239	303	1128	-6	-6	FW
10_1101-2020_09_23_308239	303	1129	-5	-5	FW
10_1101-2020_09_23_308239	303	1130	-4	-4	:
10_1101-2020_09_23_308239	303	1131	-50	-50	NN
10_1101-2020_09_23_308239	303	1132	0	0	CD
10_1101-2020_09_23_308239	303	1133	50	50	CD
10_1101-2020_09_23_308239	303	1134	100	100	CD
10_1101-2020_09_23_308239	303	1135	150	150	CD
10_1101-2020_09_23_308239	303	1136	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1137	DRC	drc	NN
10_1101-2020_09_23_308239	303	1138	in	in	IN
10_1101-2020_09_23_308239	303	1139	presence	presence	NN
10_1101-2020_09_23_308239	303	1140	of	of	IN
10_1101-2020_09_23_308239	303	1141	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1142	log	log	NN
10_1101-2020_09_23_308239	303	1143	c	c	NN
10_1101-2020_09_23_308239	303	1144	(	(	-LRB-
10_1101-2020_09_23_308239	303	1145	M	m	NN
10_1101-2020_09_23_308239	303	1146	)	)	-RRB-
10_1101-2020_09_23_308239	303	1147	%	%	NN
10_1101-2020_09_23_308239	303	1148	In	in	IN
10_1101-2020_09_23_308239	303	1149	hi	hi	UH
10_1101-2020_09_23_308239	303	1150	bi	bi	NNP
10_1101-2020_09_23_308239	303	1151	tio	tio	NNP
10_1101-2020_09_23_308239	303	1152	n	n	NNP
10_1101-2020_09_23_308239	303	1153	20	20	CD
10_1101-2020_09_23_308239	303	1154	µM	µM	NNP
10_1101-2020_09_23_308239	303	1155	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1156	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1157	µM	µM	NNP
10_1101-2020_09_23_308239	303	1158	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1159	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1160	µM	µM	NNP
10_1101-2020_09_23_308239	303	1161	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1162	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1163	µM	µM	NNP
10_1101-2020_09_23_308239	303	1164	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1165	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1166	µM	µM	NNP
10_1101-2020_09_23_308239	303	1167	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1168	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1169	µM	µM	NNP
10_1101-2020_09_23_308239	303	1170	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1171	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1172	µM	µM	NNP
10_1101-2020_09_23_308239	303	1173	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1174	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1175	µM	µM	NNP
10_1101-2020_09_23_308239	303	1176	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1177	-9	-9	NNP
10_1101-2020_09_23_308239	303	1178	-8	-8	NNP
10_1101-2020_09_23_308239	303	1179	-7	-7	:
10_1101-2020_09_23_308239	303	1180	-6	-6	FW
10_1101-2020_09_23_308239	303	1181	-5	-5	FW
10_1101-2020_09_23_308239	303	1182	-4	-4	:
10_1101-2020_09_23_308239	303	1183	-50	-50	NN
10_1101-2020_09_23_308239	303	1184	0	0	CD
10_1101-2020_09_23_308239	303	1185	50	50	CD
10_1101-2020_09_23_308239	303	1186	100	100	CD
10_1101-2020_09_23_308239	303	1187	150	150	CD
10_1101-2020_09_23_308239	303	1188	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1189	DRC	drc	NN
10_1101-2020_09_23_308239	303	1190	in	in	IN
10_1101-2020_09_23_308239	303	1191	presence	presence	NN
10_1101-2020_09_23_308239	303	1192	of	of	IN
10_1101-2020_09_23_308239	303	1193	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1194	log	log	NN
10_1101-2020_09_23_308239	303	1195	c	c	NN
10_1101-2020_09_23_308239	303	1196	(	(	-LRB-
10_1101-2020_09_23_308239	303	1197	M	m	NN
10_1101-2020_09_23_308239	303	1198	)	)	-RRB-
10_1101-2020_09_23_308239	303	1199	%	%	NN
10_1101-2020_09_23_308239	303	1200	In	in	IN
10_1101-2020_09_23_308239	303	1201	hi	hi	UH
10_1101-2020_09_23_308239	303	1202	bi	bi	NNP
10_1101-2020_09_23_308239	303	1203	tio	tio	NNP
10_1101-2020_09_23_308239	303	1204	n	n	CC
10_1101-2020_09_23_308239	303	1205	20	20	CD
10_1101-2020_09_23_308239	303	1206	µM	µM	NNP
10_1101-2020_09_23_308239	303	1207	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1208	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1209	µM	µM	NNP
10_1101-2020_09_23_308239	303	1210	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1211	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1212	µM	µM	NNP
10_1101-2020_09_23_308239	303	1213	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1214	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1215	µM	µM	NNP
10_1101-2020_09_23_308239	303	1216	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1217	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1218	µM	µM	NNP
10_1101-2020_09_23_308239	303	1219	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1220	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1221	µM	µM	NNP
10_1101-2020_09_23_308239	303	1222	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1223	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1224	µM	µM	NNP
10_1101-2020_09_23_308239	303	1225	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1226	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1227	µM	µM	NNP
10_1101-2020_09_23_308239	303	1228	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1229	-9	-9	NNP
10_1101-2020_09_23_308239	303	1230	-8	-8	NNP
10_1101-2020_09_23_308239	303	1231	-7	-7	:
10_1101-2020_09_23_308239	303	1232	-6	-6	FW
10_1101-2020_09_23_308239	303	1233	-5	-5	FW
10_1101-2020_09_23_308239	303	1234	-4	-4	:
10_1101-2020_09_23_308239	303	1235	-50	-50	NN
10_1101-2020_09_23_308239	303	1236	0	0	CD
10_1101-2020_09_23_308239	303	1237	50	50	CD
10_1101-2020_09_23_308239	303	1238	100	100	CD
10_1101-2020_09_23_308239	303	1239	150	150	CD
10_1101-2020_09_23_308239	303	1240	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1241	DRC	drc	NN
10_1101-2020_09_23_308239	303	1242	in	in	IN
10_1101-2020_09_23_308239	303	1243	presence	presence	NN
10_1101-2020_09_23_308239	303	1244	of	of	IN
10_1101-2020_09_23_308239	303	1245	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1246	log	log	NN
10_1101-2020_09_23_308239	303	1247	c	c	NN
10_1101-2020_09_23_308239	303	1248	(	(	-LRB-
10_1101-2020_09_23_308239	303	1249	M	m	NN
10_1101-2020_09_23_308239	303	1250	)	)	-RRB-
10_1101-2020_09_23_308239	303	1251	%	%	NN
10_1101-2020_09_23_308239	303	1252	In	in	IN
10_1101-2020_09_23_308239	303	1253	hi	hi	UH
10_1101-2020_09_23_308239	303	1254	bi	bi	NNP
10_1101-2020_09_23_308239	303	1255	tio	tio	NNP
10_1101-2020_09_23_308239	303	1256	n	n	NNP
10_1101-2020_09_23_308239	303	1257	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1258	µM	µM	NNP
10_1101-2020_09_23_308239	303	1259	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1260	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1261	µM	µM	NNP
10_1101-2020_09_23_308239	303	1262	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1263	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1264	µM	µM	NNP
10_1101-2020_09_23_308239	303	1265	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1266	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1267	µM	µM	NNP
10_1101-2020_09_23_308239	303	1268	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1269	-9	-9	NNP
10_1101-2020_09_23_308239	303	1270	-8	-8	NNP
10_1101-2020_09_23_308239	303	1271	-7	-7	:
10_1101-2020_09_23_308239	303	1272	-6	-6	FW
10_1101-2020_09_23_308239	303	1273	-5	-5	FW
10_1101-2020_09_23_308239	303	1274	-4	-4	:
10_1101-2020_09_23_308239	303	1275	-50	-50	NN
10_1101-2020_09_23_308239	303	1276	0	0	CD
10_1101-2020_09_23_308239	303	1277	50	50	CD
10_1101-2020_09_23_308239	303	1278	100	100	CD
10_1101-2020_09_23_308239	303	1279	150	150	CD
10_1101-2020_09_23_308239	303	1280	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	1281	DRC	drc	NN
10_1101-2020_09_23_308239	303	1282	in	in	IN
10_1101-2020_09_23_308239	303	1283	presence	presence	NN
10_1101-2020_09_23_308239	303	1284	of	of	IN
10_1101-2020_09_23_308239	303	1285	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1286	log	log	NN
10_1101-2020_09_23_308239	303	1287	c	c	NN
10_1101-2020_09_23_308239	303	1288	(	(	-LRB-
10_1101-2020_09_23_308239	303	1289	M	m	NN
10_1101-2020_09_23_308239	303	1290	)	)	-RRB-
10_1101-2020_09_23_308239	303	1291	%	%	NN
10_1101-2020_09_23_308239	303	1292	In	in	IN
10_1101-2020_09_23_308239	303	1293	hi	hi	UH
10_1101-2020_09_23_308239	303	1294	bi	bi	NNP
10_1101-2020_09_23_308239	303	1295	tio	tio	NNP
10_1101-2020_09_23_308239	303	1296	n	n	CC
10_1101-2020_09_23_308239	303	1297	20	20	CD
10_1101-2020_09_23_308239	303	1298	µM	µM	NNP
10_1101-2020_09_23_308239	303	1299	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1300	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1301	µM	µM	NNP
10_1101-2020_09_23_308239	303	1302	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1303	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1304	µM	µM	NNP
10_1101-2020_09_23_308239	303	1305	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1306	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1307	µM	µM	NNP
10_1101-2020_09_23_308239	303	1308	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1309	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1310	µM	µM	NNP
10_1101-2020_09_23_308239	303	1311	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1312	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1313	µM	µM	NNP
10_1101-2020_09_23_308239	303	1314	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1315	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1316	µM	µM	NNP
10_1101-2020_09_23_308239	303	1317	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1318	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1319	µM	µM	NNP
10_1101-2020_09_23_308239	303	1320	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1321	-9	-9	NNP
10_1101-2020_09_23_308239	303	1322	-8	-8	NNP
10_1101-2020_09_23_308239	303	1323	-7	-7	:
10_1101-2020_09_23_308239	303	1324	-6	-6	FW
10_1101-2020_09_23_308239	303	1325	-5	-5	FW
10_1101-2020_09_23_308239	303	1326	-4	-4	:
10_1101-2020_09_23_308239	303	1327	-50	-50	NN
10_1101-2020_09_23_308239	303	1328	0	0	CD
10_1101-2020_09_23_308239	303	1329	50	50	CD
10_1101-2020_09_23_308239	303	1330	100	100	CD
10_1101-2020_09_23_308239	303	1331	150	150	CD
10_1101-2020_09_23_308239	303	1332	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1333	DRC	drc	NN
10_1101-2020_09_23_308239	303	1334	in	in	IN
10_1101-2020_09_23_308239	303	1335	presence	presence	NN
10_1101-2020_09_23_308239	303	1336	of	of	IN
10_1101-2020_09_23_308239	303	1337	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1338	log	log	NN
10_1101-2020_09_23_308239	303	1339	c	c	NN
10_1101-2020_09_23_308239	303	1340	(	(	-LRB-
10_1101-2020_09_23_308239	303	1341	M	m	NN
10_1101-2020_09_23_308239	303	1342	)	)	-RRB-
10_1101-2020_09_23_308239	303	1343	%	%	NN
10_1101-2020_09_23_308239	303	1344	In	in	IN
10_1101-2020_09_23_308239	303	1345	hi	hi	UH
10_1101-2020_09_23_308239	303	1346	bi	bi	NNP
10_1101-2020_09_23_308239	303	1347	tio	tio	NNP
10_1101-2020_09_23_308239	303	1348	n	n	NNP
10_1101-2020_09_23_308239	303	1349	20	20	CD
10_1101-2020_09_23_308239	303	1350	µM	µM	NNP
10_1101-2020_09_23_308239	303	1351	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1352	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1353	µM	µM	NNP
10_1101-2020_09_23_308239	303	1354	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1355	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1356	µM	µM	NNP
10_1101-2020_09_23_308239	303	1357	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1358	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1359	µM	µM	NNP
10_1101-2020_09_23_308239	303	1360	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1361	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1362	µM	µM	NNP
10_1101-2020_09_23_308239	303	1363	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1364	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1365	µM	µM	NNP
10_1101-2020_09_23_308239	303	1366	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1367	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1368	µM	µM	NNP
10_1101-2020_09_23_308239	303	1369	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1370	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1371	µM	µM	NNP
10_1101-2020_09_23_308239	303	1372	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1373	-9	-9	NNP
10_1101-2020_09_23_308239	303	1374	-8	-8	NNP
10_1101-2020_09_23_308239	303	1375	-7	-7	:
10_1101-2020_09_23_308239	303	1376	-6	-6	FW
10_1101-2020_09_23_308239	303	1377	-5	-5	FW
10_1101-2020_09_23_308239	303	1378	-4	-4	:
10_1101-2020_09_23_308239	303	1379	-50	-50	NN
10_1101-2020_09_23_308239	303	1380	0	0	CD
10_1101-2020_09_23_308239	303	1381	50	50	CD
10_1101-2020_09_23_308239	303	1382	100	100	CD
10_1101-2020_09_23_308239	303	1383	150	150	CD
10_1101-2020_09_23_308239	303	1384	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1385	DRC	drc	NN
10_1101-2020_09_23_308239	303	1386	in	in	IN
10_1101-2020_09_23_308239	303	1387	presence	presence	NN
10_1101-2020_09_23_308239	303	1388	of	of	IN
10_1101-2020_09_23_308239	303	1389	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1390	log	log	NN
10_1101-2020_09_23_308239	303	1391	c	c	NN
10_1101-2020_09_23_308239	303	1392	(	(	-LRB-
10_1101-2020_09_23_308239	303	1393	M	m	NN
10_1101-2020_09_23_308239	303	1394	)	)	-RRB-
10_1101-2020_09_23_308239	303	1395	%	%	NN
10_1101-2020_09_23_308239	303	1396	In	in	IN
10_1101-2020_09_23_308239	303	1397	hi	hi	UH
10_1101-2020_09_23_308239	303	1398	bi	bi	NNP
10_1101-2020_09_23_308239	303	1399	tio	tio	NNP
10_1101-2020_09_23_308239	303	1400	n	n	CC
10_1101-2020_09_23_308239	303	1401	20	20	CD
10_1101-2020_09_23_308239	303	1402	µM	µM	NNP
10_1101-2020_09_23_308239	303	1403	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1404	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1405	µM	µM	NNP
10_1101-2020_09_23_308239	303	1406	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1407	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1408	µM	µM	NNP
10_1101-2020_09_23_308239	303	1409	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1410	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1411	µM	µM	NNP
10_1101-2020_09_23_308239	303	1412	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1413	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1414	µM	µM	NNP
10_1101-2020_09_23_308239	303	1415	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1416	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1417	µM	µM	NNP
10_1101-2020_09_23_308239	303	1418	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1419	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1420	µM	µM	NNP
10_1101-2020_09_23_308239	303	1421	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1422	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1423	µM	µM	NNP
10_1101-2020_09_23_308239	303	1424	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1425	-9	-9	NNP
10_1101-2020_09_23_308239	303	1426	-8	-8	NNP
10_1101-2020_09_23_308239	303	1427	-7	-7	:
10_1101-2020_09_23_308239	303	1428	-6	-6	FW
10_1101-2020_09_23_308239	303	1429	-5	-5	FW
10_1101-2020_09_23_308239	303	1430	-4	-4	:
10_1101-2020_09_23_308239	303	1431	-50	-50	NN
10_1101-2020_09_23_308239	303	1432	0	0	CD
10_1101-2020_09_23_308239	303	1433	50	50	CD
10_1101-2020_09_23_308239	303	1434	100	100	CD
10_1101-2020_09_23_308239	303	1435	150	150	CD
10_1101-2020_09_23_308239	303	1436	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1437	DRC	drc	NN
10_1101-2020_09_23_308239	303	1438	in	in	IN
10_1101-2020_09_23_308239	303	1439	presence	presence	NN
10_1101-2020_09_23_308239	303	1440	of	of	IN
10_1101-2020_09_23_308239	303	1441	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1442	log	log	NN
10_1101-2020_09_23_308239	303	1443	c	c	NN
10_1101-2020_09_23_308239	303	1444	(	(	-LRB-
10_1101-2020_09_23_308239	303	1445	M	m	NN
10_1101-2020_09_23_308239	303	1446	)	)	-RRB-
10_1101-2020_09_23_308239	303	1447	%	%	NN
10_1101-2020_09_23_308239	303	1448	In	in	IN
10_1101-2020_09_23_308239	303	1449	hi	hi	UH
10_1101-2020_09_23_308239	303	1450	bi	bi	NNP
10_1101-2020_09_23_308239	303	1451	tio	tio	NNP
10_1101-2020_09_23_308239	303	1452	n	n	NNP
10_1101-2020_09_23_308239	303	1453	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1454	µM	µM	NNP
10_1101-2020_09_23_308239	303	1455	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1456	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1457	µM	µM	NNP
10_1101-2020_09_23_308239	303	1458	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1459	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1460	µM	µM	NNP
10_1101-2020_09_23_308239	303	1461	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1462	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1463	µM	µM	NNP
10_1101-2020_09_23_308239	303	1464	Thioguanosine	Thioguanosine	NNP
10_1101-2020_09_23_308239	303	1465	-9	-9	NNP
10_1101-2020_09_23_308239	303	1466	-8	-8	NNP
10_1101-2020_09_23_308239	303	1467	-7	-7	:
10_1101-2020_09_23_308239	303	1468	-6	-6	FW
10_1101-2020_09_23_308239	303	1469	-5	-5	FW
10_1101-2020_09_23_308239	303	1470	-4	-4	:
10_1101-2020_09_23_308239	303	1471	-50	-50	NN
10_1101-2020_09_23_308239	303	1472	0	0	CD
10_1101-2020_09_23_308239	303	1473	50	50	CD
10_1101-2020_09_23_308239	303	1474	100	100	CD
10_1101-2020_09_23_308239	303	1475	150	150	CD
10_1101-2020_09_23_308239	303	1476	Nelfinavir	Nelfinavir	NNP
10_1101-2020_09_23_308239	303	1477	DRC	drc	NN
10_1101-2020_09_23_308239	303	1478	in	in	IN
10_1101-2020_09_23_308239	303	1479	presence	presence	NN
10_1101-2020_09_23_308239	303	1480	of	of	IN
10_1101-2020_09_23_308239	303	1481	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1482	log	log	NN
10_1101-2020_09_23_308239	303	1483	c	c	NN
10_1101-2020_09_23_308239	303	1484	(	(	-LRB-
10_1101-2020_09_23_308239	303	1485	M	m	NN
10_1101-2020_09_23_308239	303	1486	)	)	-RRB-
10_1101-2020_09_23_308239	303	1487	%	%	NN
10_1101-2020_09_23_308239	303	1488	In	in	IN
10_1101-2020_09_23_308239	303	1489	hi	hi	UH
10_1101-2020_09_23_308239	303	1490	bi	bi	NNP
10_1101-2020_09_23_308239	303	1491	tio	tio	NNP
10_1101-2020_09_23_308239	303	1492	n	n	CC
10_1101-2020_09_23_308239	303	1493	20	20	CD
10_1101-2020_09_23_308239	303	1494	µM	µM	NNP
10_1101-2020_09_23_308239	303	1495	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1496	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1497	µM	µM	NNP
10_1101-2020_09_23_308239	303	1498	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1499	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1500	µM	µM	NNP
10_1101-2020_09_23_308239	303	1501	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1502	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1503	µM	µM	NNP
10_1101-2020_09_23_308239	303	1504	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1505	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1506	µM	µM	NNP
10_1101-2020_09_23_308239	303	1507	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1508	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1509	µM	µM	NNP
10_1101-2020_09_23_308239	303	1510	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1511	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1512	µM	µM	NNP
10_1101-2020_09_23_308239	303	1513	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1514	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1515	µM	µM	NNP
10_1101-2020_09_23_308239	303	1516	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1517	-9	-9	NNP
10_1101-2020_09_23_308239	303	1518	-8	-8	NNP
10_1101-2020_09_23_308239	303	1519	-7	-7	:
10_1101-2020_09_23_308239	303	1520	-6	-6	FW
10_1101-2020_09_23_308239	303	1521	-5	-5	FW
10_1101-2020_09_23_308239	303	1522	-4	-4	:
10_1101-2020_09_23_308239	303	1523	-50	-50	NN
10_1101-2020_09_23_308239	303	1524	0	0	CD
10_1101-2020_09_23_308239	303	1525	50	50	CD
10_1101-2020_09_23_308239	303	1526	100	100	CD
10_1101-2020_09_23_308239	303	1527	150	150	CD
10_1101-2020_09_23_308239	303	1528	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1529	DRC	drc	NN
10_1101-2020_09_23_308239	303	1530	in	in	IN
10_1101-2020_09_23_308239	303	1531	presence	presence	NN
10_1101-2020_09_23_308239	303	1532	of	of	IN
10_1101-2020_09_23_308239	303	1533	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1534	log	log	NN
10_1101-2020_09_23_308239	303	1535	c	c	NN
10_1101-2020_09_23_308239	303	1536	(	(	-LRB-
10_1101-2020_09_23_308239	303	1537	M	m	NN
10_1101-2020_09_23_308239	303	1538	)	)	-RRB-
10_1101-2020_09_23_308239	303	1539	%	%	NN
10_1101-2020_09_23_308239	303	1540	In	in	IN
10_1101-2020_09_23_308239	303	1541	hi	hi	UH
10_1101-2020_09_23_308239	303	1542	bi	bi	NNP
10_1101-2020_09_23_308239	303	1543	tio	tio	NNP
10_1101-2020_09_23_308239	303	1544	n	n	NNP
10_1101-2020_09_23_308239	303	1545	20	20	CD
10_1101-2020_09_23_308239	303	1546	µM	µM	NNP
10_1101-2020_09_23_308239	303	1547	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1548	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1549	µM	µM	NNP
10_1101-2020_09_23_308239	303	1550	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1551	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1552	µM	µM	NNP
10_1101-2020_09_23_308239	303	1553	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1554	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1555	µM	µM	NNP
10_1101-2020_09_23_308239	303	1556	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1557	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1558	µM	µM	NNP
10_1101-2020_09_23_308239	303	1559	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1560	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1561	µM	µM	NNP
10_1101-2020_09_23_308239	303	1562	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1563	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1564	µM	µM	NNP
10_1101-2020_09_23_308239	303	1565	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1566	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1567	µM	µM	NNP
10_1101-2020_09_23_308239	303	1568	Anisomycin	Anisomycin	NNP
10_1101-2020_09_23_308239	303	1569	-9	-9	NNP
10_1101-2020_09_23_308239	303	1570	-8	-8	NNP
10_1101-2020_09_23_308239	303	1571	-7	-7	:
10_1101-2020_09_23_308239	303	1572	-6	-6	FW
10_1101-2020_09_23_308239	303	1573	-5	-5	FW
10_1101-2020_09_23_308239	303	1574	-4	-4	:
10_1101-2020_09_23_308239	303	1575	-50	-50	NN
10_1101-2020_09_23_308239	303	1576	0	0	CD
10_1101-2020_09_23_308239	303	1577	50	50	CD
10_1101-2020_09_23_308239	303	1578	100	100	CD
10_1101-2020_09_23_308239	303	1579	150	150	CD
10_1101-2020_09_23_308239	303	1580	Remdesivir	Remdesivir	NNP
10_1101-2020_09_23_308239	303	1581	DRC	drc	NN
10_1101-2020_09_23_308239	303	1582	in	in	IN
10_1101-2020_09_23_308239	303	1583	presence	presence	NN
10_1101-2020_09_23_308239	303	1584	of	of	IN
10_1101-2020_09_23_308239	303	1585	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1586	log	log	NN
10_1101-2020_09_23_308239	303	1587	c	c	NN
10_1101-2020_09_23_308239	303	1588	(	(	-LRB-
10_1101-2020_09_23_308239	303	1589	M	m	NN
10_1101-2020_09_23_308239	303	1590	)	)	-RRB-
10_1101-2020_09_23_308239	303	1591	%	%	NN
10_1101-2020_09_23_308239	303	1592	In	in	IN
10_1101-2020_09_23_308239	303	1593	hi	hi	UH
10_1101-2020_09_23_308239	303	1594	bi	bi	NNP
10_1101-2020_09_23_308239	303	1595	tio	tio	NNP
10_1101-2020_09_23_308239	303	1596	n	n	CC
10_1101-2020_09_23_308239	303	1597	20	20	CD
10_1101-2020_09_23_308239	303	1598	µM	µM	NNP
10_1101-2020_09_23_308239	303	1599	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1600	6.67	6.67	CD
10_1101-2020_09_23_308239	303	1601	µM	µM	NNP
10_1101-2020_09_23_308239	303	1602	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1603	2.22	2.22	CD
10_1101-2020_09_23_308239	303	1604	µM	µM	NNP
10_1101-2020_09_23_308239	303	1605	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1606	0.74	0.74	CD
10_1101-2020_09_23_308239	303	1607	µM	µM	NNP
10_1101-2020_09_23_308239	303	1608	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1609	0.25	0.25	CD
10_1101-2020_09_23_308239	303	1610	µM	µM	NNP
10_1101-2020_09_23_308239	303	1611	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1612	0.08	0.08	CD
10_1101-2020_09_23_308239	303	1613	µM	µM	NNP
10_1101-2020_09_23_308239	303	1614	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1615	0.03	0.03	CD
10_1101-2020_09_23_308239	303	1616	µM	µM	NNP
10_1101-2020_09_23_308239	303	1617	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1618	0.01	0.01	CD
10_1101-2020_09_23_308239	303	1619	µM	µM	NNP
10_1101-2020_09_23_308239	303	1620	Raloxifene	Raloxifene	NNP
10_1101-2020_09_23_308239	303	1621	a	a	DT
10_1101-2020_09_23_308239	303	1622	c	c	NN
10_1101-2020_09_23_308239	303	1623	b	b	NN
10_1101-2020_09_23_308239	303	1624	d	d	NN
10_1101-2020_09_23_308239	303	1625	.CC	.CC	:
10_1101-2020_09_23_308239	303	1626	-	-	HYPH
10_1101-2020_09_23_308239	303	1627	BY	by	IN
10_1101-2020_09_23_308239	303	1628	-	-	HYPH
10_1101-2020_09_23_308239	303	1629	NC	NC	NNP
10_1101-2020_09_23_308239	303	1630	-	-	HYPH
10_1101-2020_09_23_308239	303	1631	ND	ND	NNP
10_1101-2020_09_23_308239	303	1632	4.0	4.0	CD
10_1101-2020_09_23_308239	303	1633	International	international	JJ
10_1101-2020_09_23_308239	303	1634	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_23_308239	303	1635	.	.	.
10_1101-2020_09_23_308239	304	1	It	-PRON-	PRP
10_1101-2020_09_23_308239	304	2	is	be	VBZ
10_1101-2020_09_23_308239	304	3	made	make	VBN
10_1101-2020_09_23_308239	304	4	available	available	JJ
10_1101-2020_09_23_308239	304	5	under	under	IN
10_1101-2020_09_23_308239	304	6	a	a	DT
10_1101-2020_09_23_308239	304	7	preprint	preprint	NN
10_1101-2020_09_23_308239	304	8	(	(	-LRB-
10_1101-2020_09_23_308239	304	9	which	which	WDT
10_1101-2020_09_23_308239	304	10	was	be	VBD
10_1101-2020_09_23_308239	304	11	not	not	RB
10_1101-2020_09_23_308239	304	12	certified	certify	VBN
10_1101-2020_09_23_308239	304	13	by	by	IN
10_1101-2020_09_23_308239	304	14	peer	peer	NN
10_1101-2020_09_23_308239	304	15	review	review	NN
10_1101-2020_09_23_308239	304	16	)	)	-RRB-
10_1101-2020_09_23_308239	304	17	is	be	VBZ
10_1101-2020_09_23_308239	304	18	the	the	DT
10_1101-2020_09_23_308239	304	19	author	author	NN
10_1101-2020_09_23_308239	304	20	/	/	SYM
10_1101-2020_09_23_308239	304	21	funder	funder	NN
10_1101-2020_09_23_308239	304	22	,	,	,
10_1101-2020_09_23_308239	304	23	who	who	WP
10_1101-2020_09_23_308239	304	24	has	have	VBZ
10_1101-2020_09_23_308239	304	25	granted	grant	VBN
10_1101-2020_09_23_308239	304	26	bioRxiv	biorxiv	IN
10_1101-2020_09_23_308239	304	27	a	a	DT
10_1101-2020_09_23_308239	304	28	license	license	NN
10_1101-2020_09_23_308239	304	29	to	to	TO
10_1101-2020_09_23_308239	304	30	display	display	VB
10_1101-2020_09_23_308239	304	31	the	the	DT
10_1101-2020_09_23_308239	304	32	preprint	preprint	NN
10_1101-2020_09_23_308239	304	33	in	in	IN
10_1101-2020_09_23_308239	304	34	The	the	DT
10_1101-2020_09_23_308239	304	35	copyright	copyright	NN
10_1101-2020_09_23_308239	304	36	holder	holder	NN
10_1101-2020_09_23_308239	304	37	for	for	IN
10_1101-2020_09_23_308239	304	38	thisthis	thisthis	DT
10_1101-2020_09_23_308239	304	39	version	version	NN
10_1101-2020_09_23_308239	304	40	posted	post	VBD
10_1101-2020_09_23_308239	304	41	February	February	NNP
10_1101-2020_09_23_308239	304	42	12	12	CD
10_1101-2020_09_23_308239	304	43	,	,	,
10_1101-2020_09_23_308239	304	44	2021	2021	CD
10_1101-2020_09_23_308239	304	45	.	.	.
10_1101-2020_09_23_308239	304	46	;	;	:
10_1101-2020_09_23_308239	304	47	https://doi.org/10.1101/2020.09.23.308239doi	https://doi.org/10.1101/2020.09.23.308239doi	LS
10_1101-2020_09_23_308239	304	48	:	:	:
10_1101-2020_09_23_308239	304	49	bioRxiv	biorxiv	VB
10_1101-2020_09_23_308239	304	50	preprint	preprint	NN
10_1101-2020_09_23_308239	304	51	https://doi.org/10.1101/2020.09.23.308239	https://doi.org/10.1101/2020.09.23.308239	VBZ
10_1101-2020_09_23_308239	304	52	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN